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Decisions about health policy and services are, in part, informed by research.  In this 
thesis, I argue health research and the systems which generate and then use it, fail to 
consider marginalised populations.  As a consequence, decision-makers in service 
and policy settings lack appropriate information to address health inequity and in 
fact contribute to it through their regard for these marginalised populations. 
To support this argument, I draw on a range of empirical work. I review public 
records for evidence of marginalised groups’ inclusion in research and the activities 
that use research to decide policy or service provision.  I then examine the role of 
ethics committees in reviewing justice and the systems and structures that 
researchers who work with marginalised populations navigate. Using this 
information, I then look at reasons and potential solutions to this injustice. 
I scrutinised public records for representation of three case populations considered 
marginalised in Aotearoa New Zealand (NZ) in evidence-generating activities and 
evidence-using activities to establish a lack of inclusion.  Based on the data available, 
representation was found to be lacking.  
In NZ, approved ethics committees have the task of ethically assessing health 
research that has the potential to create evidence.  The National Ethical Advisory 
Committee (NEAC) of NZ sets out what justice entails in the review and practice of 
research.  I surveyed committee members to understand their views on justice 
requirements and their review of them.  The survey response rate was too low to be 
representative but provided starting points for discussion. 
Using an institutional ethnographic method, I analysed interviews with senior 
researchers (informants) who work with marginalised populations alongside 
institutional texts to understand informants work and how it sits within the larger 
system of health research.  I theorise that the marketisation of the university and 
health system within a neoliberal knowledge economy, along with an emphasis on 
the biomedical, direct research practices in ways counter-intuitive and counter-
productive to those working with marginalised groups.  Not only that but these 
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research systems create what Miranda Fricker calls an ‘epistemic injustice’ by their 
privileging of certain kinds of research work over others.  
Moving from the empirical, the thread of epistemic injustice is then taken up and 
elaborated. Epistemologies in health research– their foundations, the information 
they provide, and their limitations are laid out.  I argue that the privileging of one 
kind of knowing is in part based on our established theory of justice narrowing our 
perspective (especially within a neoliberal environment).  Then, I put forward the 
claim that a shift in justice theory to a Capabilities Approach (CA) that reframes the 
questions that we need to address and therefore the methods needed to address 
them, might be more effective in acknowledging health inequity and creating a fairer 
health research environment.   
Sen’s CA takes as its foundation the equalising of people’s capabilities to achieve their 
preferred functionings, recognising the diversity of these functionings and does this 
on the basis of public discourse and decision-making.  This approach to justice in 
health research requires a more inclusive and patient-centered framework than the 
current model which in practice is often disease-centric and generalising. I argue a CA 
framework is likely to not only change the informational environment required to 
make decisions but liable to improve inequity because it more explicitly asks us to 
notice it.  
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Chapter 1: Introduction 
“The world as we have created it is a process of our thinking. It cannot be changed without 
changing our thinking.” 
Albert Einstein 
1. Background 
This thesis grew out of intuitions in practice.  While working in research 
governance, I became aware that those people who took part in trials were always 
quite similar. The literature that informed funding applications often described trial 
cohorts (if articles reported demographics beyond age) as quite homogenous. 
Furthermore, the people I knew that worked with those who suffered the most 
health inequity, always seemed to struggle to get their research funded, approved, 
and recognised.  This lack of inclusion of both particular populations in individual 
projects and projects of interest to these communities in the greater research 
landscape seemed wrong to me.  I wanted to know if it was a national problem in 
Aotearoa New Zealand and if so what factors contributed to the phenomenon so 
that change can happen.   
 
This thesis presents a new way of thinking about the problem; connecting issues 
previously dealt with separately. The core idea here is that the way we think about 
health and health inequity determines our ability to affect and change it. Justice 
theories require an informational base; a defined space in which to evaluate 
options. Our epistemologies determine, what is ‘information’ in that space. The 
dominant ideas about what is fair (justice) and what is evidence (epistemology) in 
their current combination funnel our problem-solving and thinking into an effective 
dead-end.  This dead-end forces us to: 
- think of people generically, creating a mismatch between theory and reality; 
- think mainly of health from a disease-centric perspective, which fails to 
inform interventions adequately for all. 
We have set up structures and practices that consistently reinforce this thinking and 




In this chapter, I describe health inequity and make the connection between health 
inequity and health research inequity, before explaining the objective and aims of 
the work in this thesis. 
1.1. Health Inequity 
The New Zealand Public Health and Disability Act clearly states that the purpose of 
the Act is to ensure provision of funding, services and the creation of organisations 
with the objective (amongst others) of reducing disparities (NZ Public Health & 
Disability Act 2000).  Health Research Council Annual Reports and various 
documents from the Ministry of Health continue this thought – describing health 
equity as a goal.   
 
Health inequity2 is a dire and immediate problem globally, both across and within 
nations. Health inequity is multi-causal and complex (Chandrasekhar, 2009; Preda & 
Voigt, 2015; Smith, Bambra, & Hill, 2016).  The definition of health inequity is an 
unfair inequality; that is, a difference in health that occurs because of practices or 
circumstances that are unjust towards a specific group based on that group’s social 
characteristics (Braveman & Gruskin, 2003; Braveman, 2006; Smith et al., 2016). 
These inequities can be due to a complex interplay of social conditions and service 
access or delivery. Social conditions are the fundamental conditions for health, 
including but not limited to clean water, shelter, food and education.  Access is the 
direct ability to receive healthcare. Delivery specifies the acceptability of its form 
(Smith et al., 2016).   
 
Health inequity in Aotearoa New Zealand (NZ) is a very real phenomenon. For 
example, amenable mortality rates (i.e. avoidable deaths before the age of 75) vary 
considerably between different groups of the population. Amenable mortality rates 
are three times as high for Māori, twice as high for Pasifika peoples, and there are 
significant differences related to deprivation status. These rates are mainly 
attributable to diabetes and cardiovascular disease (McCormack, Yeh, Braybrook, & 
Clyne, 2012; Talamaivao et al., 2010).   This thesis aims to provide a foundational 
                                                        
2 Inequity and disparities are seen as moral terms referencing justice, whereas inequality is seen as 
simple difference.(Carter-Pokras & Baquet, 2002)  These three terms can be used interchangeable in 
different settings based on the common usage within that setting (i.e. North America can differ from 
Europe). For this thesis, inequity is used as an indicator of unfair circumstances. 
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argument for change.  The work draws on interdisciplinary knowledge and research 
across economics, politics, policy analysis, data management, bioethics, and more.  
 
Health equity is a complex goal to obtain and is influenced by healthcare policy, 
provision, research, and social conditions (Braveman, 2006; Kawachi, Subramanian, 
& Almeida-Filho, 2002; Smith et al., 2016).   Evidence-based policy and provision 
(services) depend on health research to provide the necessary “evidence” for 
decision-making.  Current health research does not inform policy and services 
appropriately or adequately to change health inequity dramatically.  Various factors 
influence the research endeavour and thereby distort evidence. These factors are in 
the selection of what research we fund and prioritise, as well as how we 
conceptualise issues and how relevant research is to real life and its diversity.  To 
better understand health inequity and improve it, a shift in focus is needed to 
change research processes and the resultant information that feeds into decision-
making.  
 
In this thesis, the focus is on health research and health research practice, i.e. the 
means of informing decision-making. I will not be discussing the socio-economic 
factors that influence health in any depth, nor the social reform that may be 
necessary to ‘even the playing field’ (Kawachi et al., 2002; Marmot, 2007), although 
these issues arise periodically in setting context and deliberating forms and types of 
changes. I will also not touch on institutional/structural racism, even though this is 
a very real factor in the Aotearoa New Zealand health environment (Harris et al., 
2006). Structural racism is a macro-level phenomenon that shapes civil society in 
such a way as to be discriminatory, although not overtly so, through institutional 
philosophies, policies, and practices (Gee & Ford, 2011).  This kind of racism (as 
well as overt racism) affects the indigenous population of NZ, despite NZ’s Treaty 
with Māori guaranteeing certain rights and defining obligations on the part of the 
Crown (Harris et al., 2006; Kearns, Moewaka-Barnes, & McCreanor, 2009; Human 
Rights Commission, 2012; Came, 2014).  However, it also affects populations who 
identify ethnically with the Pacific, Asia, the Middle East and Africa (Human Rights 
Commission, 2012).  It is my belief that the problem addressed in this thesis is 
broader than structural racism as it affects other groups not only those ethnically-
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defined.  By this, I mean to say that structural racism, can explain some of the 
disparity, but not all, and equally, if we were to fix the issues outlined in this thesis, 
it may not fully eliminate this type of discrimination.  
 
While many an argument abounds about means and ends and their relative worth to 
each other, this work takes as its point of interest means, based on the assumption 
that the end of health equity is agreed (Daniels, 2007; Riddle, 2017).3  These means, 
i.e. health research and all the associated, intertwined practices and mechanisms 
that foster and support it, should be changed for their sake, as well as achieving the 
desired end.  This reform is desirable and necessary because the changes proposed 
aim to make research more efficient and effective (Cochrane, 1972), which in and of 
itself is a matter of social justice given the massive public investment carrying the 
health research endeavour directly and indirectly (projects, institutions, and 
infrastructure). 
 
Current health services and policy are ill-equipped to deal with a person’s 
individuality, and this would be the case whether the social determinants of health 
in society were addressed or not. Health research practice provides evidence for 
interventions about indeterminate masses.  Evidence takes a broad scatter gun 
approach. The assumption is that because this works for a large part of one group 
(the trial cohort), it will work for a large proportion of another group (the 
population). Little work is done after this initial step to consider the variety of 
people and situations in which any given intervention needs to be effective.  Our 
frameworks fail to think about, how we may better design and target interventions 
to those affected, seeing them as people with characteristics and contexts that 
require attention.  At present health practitioners are left to address the specific 
needs of a wide variety of patients in practice, adapting evidence ad hoc to suit 
patients. Health professionals do not have any apparent tools to do this in a robust 
way.  This adaptation in practice ignores two important factors. Firstly, a health 
                                                        
3 Norman Daniels, among others, has noted that health holds a special place in our considerations of 
priorities and is crucial for wellbeing in other domains. It is this recognition that underpins such 
things as “Health in all Policies” (Pinto, Molnar, Shankardass, O’Campo, & Bayoumi, 2015) and why 




practitioner other than through experience or self-teaching is not automatically 
prepared to deal with the complexities of various people’s social, cultural, economic, 
educational or other influences on their health. Secondly, necessary interventions or 
ways to manage within certain circumstances are not even in existence because of 
the perceived difficulty in researching them under current conditions. 
1.1.1. Relationship between research and inequity 
Little work has been done exploring the relationships between health inequity and 
health research practices in comparison to the work done for other causes of 
injustice. 
 
Prominent indigenous researchers have written extensively on the lack of 
consideration for indigenous worldviews and knowledge in conducting research 
generally, and more specifically for health (Durie, 1985; Dyck & Kearns, 1995; 
Guillemin et al., 2016; Hudson & Russell, 2009, 2009; Smith, 1999; Walter & 
Andersen, 2013).4 Overlooking indigeneity is evident in the lack of consideration of 
cultural safety or appropriateness when designing research projects and 
interventions or services. It is also apparent in the dismissal of indigenous health 
and medical knowledge (Cram, Smith, & Johnstone, 2003; Durie, 1985; Hudson, 
2004).  Compounding this issue is a (historical) narrative of exploitation or abuse in 
research (Smith, 1999). Stories of researchers “researching on” rather than for, or 
with indigenous communities are common, and examples across both indigenous 
communities and other marginalised groups contribute to a sense of distrust in an 
environment where “authority” is mostly not responsive to needs.  
 
Echoes of this fraught relationship also exist in the disability community. The 
community voices their need for disability specific outcome measures and research, 
where this means both considerations of what research is needed, how research is 
designed considering people with disability, and what outcomes measures are valid. 
(Andresen, 2000; Björnsdóttir & Svensdóttir, 2008; Charman & Campbell, 1997; 
Cohen & Marino, 2000; Leeder & Dominello, 2005; Pendo, 2016; Shakespeare, 
                                                        
4 These are but a selection of references for the Māori perspective but excellent texts exist from all 
over the world exploring the ways in which indigenous and aboriginal world views are silenced in 
the defining of health and healing (Bartlett, Madariaga-Vignudo, O’Neil, & Kuhnlein, 2007; 
Humphery, 2001; Turton, 1997; Waldram, Herring, & Young, 2006)  
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1996). Again as a community, people with disabilities (both physical and learning 
disabilities) have had a difficult relationship with institutions and research groups.  
These groups and organisations have failed to acknowledge people with disabilities 
as equal. Authorities whether research organisations or not often consider disability 
as an inferior state. Alternatively, they classify people with disability as vulnerable 
by definition rather than by situation (Bickenbach, 2013; Borsay, 2005; Gustafson & 
Brunger, 2014; Horner‐Johnson & Drum, 2006; Longmore, Gallagher, Lane, Tyor, & 
Bell, 1987; Melbøe et al., 2016).  
Others have written about the lack of representation in studies. Trial populations 
are often white and male (Bartlett et al., 2003; Burchard et al., 2003; Oh et al., 2015; 
Rogers, 2004b; Rogers & Ballantyne, 2009). As we will see in Chapter 5, this is 
problematic.  It means that the research that tests diagnostic parameters, disease 
characteristics, interventions and outcome measures, uses samples that lack 
representation.  Evidence, on which we then base decisions, is only evidence of 
illness presentation or interventional effect as it applies to one group within the 
population.   The differences between a generic trial cohort (which might be white, 
middle-aged males for example) and other groups can be remarkable. These 
differences can include genetics (Mays, Ponce, Washington, & Cochran, 2003; 
Pearce, Foliaki, Sporle, & Cunningham, 2004), metabolic variation (in relation to 
medications)(Burroughs, Maxey, & Levy, 2002; Kalow, 2012), characteristics of 
disease presentation (Chaturvedi, 2003; Collins, Vitale, Spoletini, & Barbaro, 2011; 
Shavers, Harlan, & Stevens, 2003), or other things such as acceptability of 
intervention. We use best evidence for one group and assume that the differences 
between groups will not be so significant. The reasons for this homogeneity are 
discussed further in Chapters 4 and 5.  Homogeneity is caused partly by: 
-  the evidence environment, i.e. regarding what we can and cannot count as 
evidence;  
- the research environment, due to funding, performance measures, 
incentives; and  
- the way researchers run trials, including recruitment methods, intervention 
ancillaries related to intervention delivery, service environment, staffing and 
the like.  
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There are not only problems of representation in the sense of trial participants but 
also representation in the disease and interventions that are chosen to investigate 
in the first place.  Research activity rarely focuses on the issues that concern those 
marginalised groups in society.  The exception to this is when the disease creates 
severe consequences, and this is still not necessarily sufficient, or the disease 
creates a significant economic burden.   
Rheumatic fever would be an obvious example in NZ of a condition with severe 
consequences that received attention.  However, the prominence of rheumatic fever 
in health policy (Ministry of Health, n.d.-j) is in large part due to the advocacy of 
then Associate Minister Tariana Turia (Māori Party) in the Ministry of Health. This 
prominence was not due to general recognition by the Ministry of Health of the 
problem and its ethical implications. By this I mean, that it is not clear that this 
funding/strategy would be in place without the advocacy of M. Turia (O’Sullivan, 
2015).  
Economic burden, as a reason for attention, rarely occurs for something that solely 
affects a marginalised or minority population. Therefore, when such a disease 
becomes the focus, interventions are not necessarily designed with these 
populations in mind. Interventions are not planned considering their needs, and 
trials do not necessarily recruit relevant subgroups.  Exceptions of course exist, but 
there are noticeable examples that confirm this case, diabetes and cardiovascular 
disease being the obvious ones.   
1.2. Research Questions and Aims 
As mentioned, this thesis began in observed practice, a practice that was limited in 
scope.  Therefore, the growing intuition that a problem of injustice might be 
occurring on a larger scale required verification, if the problem was to be solved.  
The questions I, therefore, set out to address, in their simplest form were:  
Q1: Is the principle of justice, defined as (at minimum) both the fair distribution of 
benefits and harms and fair representation, evident in the Aotearoa New Zealand 
health research environment? 
Q2: If not, why not?  
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Q3: What can we do about it? 
To answer these questions, I required information about the reality of the NZ 
situation, and from that information, I could identify where problems lie and 
consider solutions.  The aims of this thesis, therefore, were to:  
Aims 1 Seek information on the representation of marginalised groups in 
health research and explore what information decision-makers use. 
Aim 2  Seek information on the review of justice at ethics committees 
Aim 3  Seek information about conducting research with marginalised 
groups 
Aim 4 Use the information from Aims 1-3, to theoretically explore the 
problem and potential solutions 
1.3. Chapter Outline 
As indicated, I needed empirical as well as theoretical work to address these goals. 
In Chapter 2, a description of three case populations is given, as well as a scoping of 
their representation in public records.   The three case populations, Māori, Pasifika 
and the learning disabled5, are described demographically and in terms of the 
health inequity they suffer.  I explain the justification for this selection and then 
provide a survey of their representation in public records, which included clinical 
trial registry data, ethics committee data, and Health Research Council records 
(primary NZ health research funder).  This review of public documentation for 
representation is the first of its kind in New Zealand and while limited to three case 
populations provides new information on research equity. There is an indication of 
non-proportional representation of all three groups in all sources, comparative to 
their population size within the limitations of information available; and this 
despite the fact that their need is greater and so representation should conceivably 
be higher.  I also undertook a further survey of representation in guideline 
documents for the conditions causing the largest degree of morbidity and mortality 
                                                        
5 The term used up until 2014 was intellectual disability, but based on the advocacy of People First 
NZ (a New Zealand non-governmental organisation advocating for those with learning disabilities) 
this has now been changed to learning disability. 
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for these groups.  This review was to understand the extent to which guidelines 
include relevant evidence, research or expert opinion for three case populations. 
Again, representation was relatively weak. Finding a lack of representation in this 
sort of documentation further supports the work of Dr Heather Came who reviewed 
public health policy documents between 2009-2011 for Māori scholarship and input 
and found a similar dearth of material (Came, 2014). Came theorises this as 
institutional racism and suppression of Māori knowledge within a model that 
favours the epidemiological and biomedical without acknowledging and acting on 
the commitments the Crown has to Māori as Tangata Whenua6 (Came, 2012, 2014). 
My work adds to this, by showing that the lack of representation occurs much more 
widely (i.e. in other types of documentation and activity) and the focus on the 
epidemiological and biomedical is not only disadvantaging Māori but also other 
groups within society. 
Part of ethics committees’ remit is to review justice, which in the NZ context (and 
more widely) includes reference to not only the fair distribution of benefits and 
risks but also representation (NEAC, 2012a, 2012b).  It, therefore, seemed necessary 
to question how committees understand and review justice, as no-one has done this 
work yet in NZ. In Chapter 3, I report on a survey of accredited NZ ethics 
committees.7 This study did not reach a high enough response rate to be conclusive.  
Questions took the form of both quantitative Likert scales and tick-box formats, but 
also asked for comments on some issues. The limited responses provided a mixed 
picture of the understanding of the guidelines that prescribe justice review, as well 
as differing opinions on ethics committees’ role in the consideration of justice.  The 
survey included questions regarding research methodologies and practices that are 
thought to be able to help address some issues of health inequity.  Again from the 
small sample, that responded, views on these matters were mixed.  
                                                        
6 Indigenous population, translated as “People of the Land” 
7 Approved ethics committees are those who met the criteria of robust ethics committees as judged 
by the Health Research Council of New Zealand under its mandate in the Health Research ACT 1990 
to approve ethics committees. This is explained in full in Chapter 3.  
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After finding a lack of representation in the research activity within the reference 
period (2006-2013)8, and exploring the role of ethics committees in promoting 
justice, an understanding of the research environment was necessary to be able to 
draw conclusions about what the likely causes of this research inequity might be. I 
explored a new avenue of enquiry to achieve this. Using an institutional 
ethnographic method, I talked to researchers working with marginalised 
populations.  In Chapter 4, I report on these interviews with senior researchers and 
their experiences which I analysed alongside the institutional texts that are part of 
their research environment. This institutional ethnographic method aims to find the 
“ruling relations” of a given problematic; this being the context or setting in which 
the informants9 experience their “everyday”, in our case senior researchers for 
marginalised populations (Smith, 1987).  A research environment ruled by 
neoliberal educational policy and managerialism10 combined with a biomedical bias, 
served to marginalise the researchers themselves and I argue, creates an epistemic 
injustice.   
The underlying cause of the epistemic injustice that occurs for marginalised 
researchers is a two-part problem. On the one hand, it is a failure of the prevailing 
theory of justice in health, that fails to value topics addressing marginalised 
populations when weighing priorities. On the other, it is a problem of epistemology, 
with the current dominant epistemology dismissing types of research (those often 
used with marginalised populations) based on a conflation of objectivity in theory 
and objectivity in practice (Chapter 5).  This application of epistemic injustice is 
entirely novel.  Others have explored epistemic injustice within the academy (Wylie, 
2011) or have related it to evidence-based medicine in the healthcare setting (Ho, 
2011; Hutchison & Rogers, 2012; Kidd & Carel, 2016; Carel & Kidd, 2014; Loughlin 
et al., 2015; Wardrope, 2015) but no-one has examined how an evidence-based 
                                                        
8 This period was chosen as this was the period available within the Health Research Council funding 
records. All other sources were then searched between this period even though some had greater 
reference periods for record-keeping. 
9 This is the terminology of an institutional ethnography – informants are the experts within the 
problematic, i.e. those living that particular reality. Triangulating their reports of their experience 
with institutional texts and discourses provide the material for analysis (M. Campbell, 2002). 
10 Is also described in Chapter 4, but is: a professional practice and ideology that through the use of 
management tools and techniques removes decision-making power from all other parties (owners, 
workers, civil society) other than management by arguing for the superior knowledge/ability of 
managers to run any kind of organisation based on management knowledge rather than 
organisation-specific expertise. (Klikauer, 2013).  
11 
 
health research environment affects researchers working in health research and 
specifically those working with marginalised populations. 
In Chapter 6, I put forward the original argument that a shift in justice theory is 
needed to reform the evidence and research environment linking the informational 
base of a justice theory to the epistemological environment. The Capabilities 
Approach (CA) as described by Amartya Sen provides a framework that connects 
well with the issues raised and is, I suggest, a solution to the problems identified.  
Sen’s CA is a framework that evaluates justice by determining people’s actual well-
being and freedom by focusing on the capabilities they have to achieve valuable 
functionings that they have reason to value (Sen, 1992). Key elements of the CA are 
its person-centredness, the focus on intrinsic goods, and use of democratic public 
discourse. I argue that a CA in health would require a broader informational base 
for decision-making while ensuring an emphasis on freedom and well-being when 
addressing capability deficits. All justice theories have an informational base (Sen, 
2011).  This informational base is the space in which one evaluates options as fair, 
based on the information about the effects of various options measured, i.e. option x 
increases capabilities or utilities, for example, over option y.  
Finally, in Chapter 7, I summarise the new information gleaned from the empirical 
work along with the original argument made in the theoretical work in the context 
of the NZ research environment. Likewise, I outline the limitations of the work, as 
well as put forwards what future work, would be of interest; specifically around 
funding frameworks, research evaluation exercises, ethics committee standards and 
review processes, and big and open data practices. I argue that this thesis adds to 
the NZ research setting by providing information not previously available and 
making a case for the reform of the research and evidence environment using Sen’s 
Capabilities Approach.  
These chapters together make the argument that: 
1) Representation of marginalised groups in information that determines 
health policy and services is poor, where that information is sourced from 
research and service data. 
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a. Research shows a lack of representation of marginalised groups in 
overall research topics and general research sub-analysis. 
b. Data from services, etc. is lacking in representation due to both less 
service use by marginalised groups and poor data classification and 
collection methods according to literature. 
2) Representation in research is not easily supported or reviewed by ethics 
committees (definitive statements cannot be made) and their views of 
potential big data/open data practices as well as co-design/engagement 
models are not clear. 
3) Researchers working with marginalised populations experience the system 
in a way that suggests an epistemic injustice occurs. 
4) This epistemic injustice is related to the evidence-based medicine 
epistemology and related evidence-based frameworks in policy and decision-
making settings (within a neoliberal political environment), creating a 
narrow informational base for decision-making.  
a. This narrow informational base necessarily creates an injustice for 
marginalised populations by restricting the ability of decision-making 
to be responsive to diverse needs.  
5) To change this injustice, a framework for justice using Sen’s Capabilities 
Approach (CA), which requires a broadening of the informational base, 
public deliberation, and prioritising those with the least well-being and 
freedom is put forward. 
This CA-related extension of the informational base and need for public 
deliberation, prioritising those with the greatest capability deficits will require new 
processes, systems, and tools.  I make some suggestions as to the change needed, 
which includes changes to prioritisation exercises in research, policy, and services, 
data practices, the academic environment,  health research funding and ethics 
committees. 
By describing the problem, addressing why we should care and what particular 
form that care should take (justice), refocusing what evidence is required to address 
health inequity (informational base – what counts) and identifying what reform 
might require in Aotearoa New Zealand, this thesis provides a new approach to 
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improving a contributing factor of health inequity from the bottom up, i.e. through 
the research that informs both policy and practice. 
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Chapter 2: Representation in Aotearoa New Zealand Health Research 
Activity  
 
The best way to show that a stick is crooked is not to argue about it or to spend time 
denouncing it, but to lay a straight stick alongside it.”  
D. L. Moody (1894) 
2.1. Introduction 
The disparity in health experienced by particular groups in Aotearoa New Zealand 
(NZ) is blatant.  One can easily compare the straight stick of the general population’s 
health statistics (life expectancy, morbidity/mortality) to the crooked stick of 
marginalised groups, and observe the deviations (Blakely, Soeberg, & Sarfati, 2012; 
Hill, Sarfati, Robson, & Blakely, 2013; Jeffreys et al., 2009; Linton, Maskill, & Wright, 
2011; McCormack et al., 2012; Talamaivao et al., 2010). The factors that go together 
to create these deviations, however, are not as obvious and require something more 
than a superficial comparison.  
Certain causal factors of inequity are socially determined; these are poverty and the 
associated poor housing, or education and access to healthy food and services to 
name a few (Chandrasekhar, 2009; Preda & Voigt, 2015).  These are the social 
determinants of health (Chandrasekhar, 2009; Preda & Voigt, 2015) and they exist 
in NZ.  These factors tell only one part of the story (Marmot, 2007; Neckerman & 
Torche, 2007; Rogers, 2004a). This thesis is an exploration of the existence and 
magnitude of structural causes of health inequity in the ways the system currently 
prioritises, conducts, and utilises health research; arguing that this is another 




Figure 1 - Relationships between research, policy, services and equity 
Research is one of the elements in a complex environment that informs health 
policy and service decision-making, which then affects health (Figure1): if the 
research used to make decisions ignores the complex reality in which people strive 
for health, then it hampers our ability to make truly relevant and applicable 
decisions about the systems that support the achievement of health.11 Structural 
inattention to complexity and context have the potential to worsen health inequity.  
This potential for worse inequity is especially urgent given the phenomena of 
growing income inequality (Piketty, 2014; Stiglitz, 2012), chronic and multi-disease 
(Agborsangaya, Ngwakongnwi, Lahtinen, Cooke, & Johnson, 2013; Caughey, Vitry, 
Gilbert, & Roughead, 2008) and ageing populations (Beard et al., 2016). As these 
three things collide in the 21st century, they will increasingly create more complex 
needs. 
                                                        
11 It is acknowledged that research could ignore complexity, if complexity was considered in the 
decision-making itself in conjunction with the research evidence. It will be explained in Chapter 5 & 6 




This chapter describes health inequity in the context of NZ and explores the inequity 
in research evidence. Health inequity in NZ is seen most starkly in the management 
of cardiovascular disease and diabetes. For some these conditions can mean death 
before retirement age and severe morbidity, while for others, these are conditions 
to be managed well into their late 70s or 80s (Chen, Eggleston, Li, Shah, & Wang, 
2014; Talamaivao et al., 2010). Similarly, cancer rates (Jeffreys et al.,2009; Blakely, 
Soeberg, and Sarfati 2012; Hill et al.,2012), mental illness management (Gone, 2015; 
Ministry of Health, 2013), and public health issues (Blakely et al., 2011; El-
Khorazaty et al., 2007) show disparities between some groups and the general 
population. It is not easy to pinpoint the cause of these differences to a lack of 
service access or specific social determinants. As we will see, differences between 
some groups and the general population even exist when controlling for socio-
economic status (Hill et al., 2010, 2013). 
I described the distinction between health inequalities and health inequities in 
Chapter 1. Health inequalities are differences in health outcomes that occur without 
unjust causes, such as breast cancer rates by sex.12 Health inequities or disparities 
are differences in clinical outcomes based on an unfair distribution of the means of 
health (in their broadest sense), such as differences in breast cancer survival based 
on ethnicity (Hofrichter, 2003; Marmot, 2010). The latter indicates at minimum 
some form of inaction; some passivity to the needs of those suffering the inequity 
and this is what is unjust.  At maximum some action that leads to worse outcomes 
for one group over another based either on a lack of knowledge or lack of 
consideration, which is unjust. The distribution of the means of health in this 
broadest sense addresses not only accessibility but acceptability and applicability of 
healthcare options. What does this mean? Prohibitive costs of accessing some 
services and complying with interventions (such as the ongoing cost of medication 
or travel for treatments) are not the only causes of health inequity.  Inequity occurs 
because of the absence of fit between interventions and people, where those with 
access to the social determinants of health have more options to benefit from 
healthcare, and those with less struggle to convert health services into well-being.   
                                                        





The argument in this part of the thesis is that the foundations of our systems 
(concerning both epistemology and justice) that generate health evidence from 
research, which then informs policy and services, create implicit injustice and this 
injustice is manifest in three specific ways: 
1) Evidence used for decision-making is not generalizable to those that are 
marginalised.  
2) Research addressing the needs of those who are marginalised is relatively 
rare or is of a type that is unlikely to meet the grade of “evidence” and 
therefore be included in decision-making processes. 
3) The mechanisms by which decisions are made, priorities set (including 
research priorities), are largely circular, i.e. are informed by the research and 
data13 generated by the epistemology and practices mentioned in 1) and 2) 
and therefore closed. Politics and advocacy can sometimes push these 
beyond their narrow purview, but in general, they are unavailable or beyond 
the scope of influence of those who suffer health inequity and their 
advocates. 
Certain terms in this analysis require clarification.  Firstly, “marginalised” and 
“disadvantaged”14, within the context of this thesis, will be used interchangeably to 
describe those who suffer health inequities.  These “marginalised” people can be 
different groups within various discussions, i.e. a group identified by culture, socio-
economic status or conditions, for example, and where this is the case, this will be 
made explicit. In general, they are any group, who based on a particular 
characteristic(s), recognising that people are more than one specific identifying 
characteristic and that the intersection of different characteristics can be further 
marginalising, fare worse than others. They fare worse in disease manifestation, 
outcomes, or health status, in a way that is considered unjust (Hofrichter, 2003).  
                                                        
13 Data from systems that are underutilised by certain groups fails to adequately capture the realities 
of those groups’ health and well-being, i.e. primary care use, etc. Not only that, but research has 
shown that ethnicity data for example, collected within the system is not always accurate (Bramley & 
Latimer, 2007; Swan, Lillis, & Simmons, 2006). 
14 The term vulnerable population has been avoided, as I wanted to place the emphasis of these 
groups’ disadvantage on something that is being actively done to them; vulnerable as a word, does 
not impart this. While vulnerability has in recent times been discussed as social process rather than 
necessarily a group or individual characteristic (people are not inherently vulnerable, social factors 
and situations create vulnerability for different people based on their characteristics (Fineman, 
2008; Mechanic & Tanner, 2007), it still remains somewhat passive in its description. 
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“Evidence” will be used throughout this thesis to denote information ranked as 
useful within the dominant epistemology. This dominant epistemology is promoted 
through the Evidence-Based Medicine (EBM) hierarchy of evidence and similarly in 
policy-making exercises through the use of grading tables and the Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE) tool.15 
Within these ranking exercises, valuable evidence is the information gained from 
randomised controlled trials and systematic reviews. A discussion of the validity of 
this ranking forms part of the conversation in Chapter 5, but for clarity, I use the 
term “evidence” to represent information graded as strong or robust evidence in 
typical grading exercises. It is of note, that epidemiological and some 
pathophysiological research can also be used as evidence, which is beyond the 
scope of “evidence-based” in its traditional form and this is part of the expansion of 
the term of “evidence-based” and its sphere of influence discussed in Chapter 5. 
Policy and services are in part determined by research evidence.  Research evidence 
informs the identification and understanding of the problem, as well as the scoping 
and evaluation of solutions (regarding efficacy, effectiveness, and cost-
effectiveness) (Figure 2) (Andermann, Pang, Newton, Davis, & Panisset, 2016; 
Majone, 1989; Oliver, Innvar, Lorenc, Woodman, & Thomas, 2014; Samson, van 
Katwyk, Fröling, & Ndoro, 2015). For policy, this may be about what a government 
will or will not fund, for services it may be what is best practice or considered the 
usual standard of care.  Research alone does not inform decisions, but within an 
evidence-based decision-making and practice framework, research evidence is a 
crucial factor in identifying issues and justifying an argument for or against 
something. Arguments for a particular decision are also made based on the values of 
the group making them, their constraints (financial or otherwise) and their goals 




                                                        
15 The most popular form of this is GRADE which helps policy-makers, guideline creators and those 





Figure 2 - Elements influencing process of policy & service setting 
If the research used within these frameworks is not representative of the society, 
they are meant to serve, and especially not representative of those who fare worst 
then this is an injustice. If no additional work is done to address the information gap 
between the non-representational research and the real world need for the 
diversity of people present in society, then this is an injustice. This gap means that 
we are failing to make informed decisions for all people and especially those who 
need it most. Failing to make relevant decisions for all is a compounded injustice.  
By this I mean, that this situation marginalises people, i.e. those who cannot either 
adapt or overcome the lack of applicability research (and therefore policy/services) 
has to them. This disadvantage is further exaggerated by the fact that it occurs to 
people who are often already disadvantaged within society based on geography, 
culture, socio-economic position for example. 
The outcomes of the three premises above would suggest that interventions are 
therefore not designed with those who need them most in mind and may be less 
effective or potentially harmful depending on the nature of the intervention. This 
lack of appropriate or responsive interventions means that their health status is 
unlikely to improve or equal the wider population, maintaining the current 
injustice. Even if the social determinants that affect their health were to improve 
without addressing this problem, and consequently, their health status improved; 










lack of representation and consideration within the evidence-generating system is 
still problematic.  
Three groups are used here as valuable test cases within the NZ context to consider 
this issue: Māori, Pasifika peoples, and those who have a learning disability.  These 
groups are representative of health inequity in NZ. Each suffers worse outcomes 
across most health domains. Each is the subject of some attention, and therefore 
some statistics and information are collected and reported by the government on 
the health status of these three groups. Each suffers health inequity for reasons that 
are complex and in some ways similar, though in other ways distinctly different.  
The aim of this chapter is, therefore, to: 
1) State the current degree of health inequity for three groups identified. 
2) Relate this inequity to the premises listed above by: 
a. Surveying representation in funding, trial registry, and ethics records. 
Providing an overview of inclusion in the research conducted in NZ 
most likely to feed into decision-making. 
b. Describing the evidence used to make policy and guidelines for 
disease/conditions where the three groups are known to suffer poor 
outcomes. 
This review then sets the scene in such a way as to allow critical reflection on where 
the gaps occur – these deficiencies are between the ideal and the reality (policy), 
theory and practice (research), and planning and implementation (service). They 
occur both on the micro- and macro-level insofar as problems are not 
conceptualised adequately, investigated effectively, and implemented appropriately 








In this section, I outline inequalities for Māori, Pasifika and learning disabled groups 
based on Ministry of Health reporting.  
2.2.2. Māori 
Māori are the indigenous population of NZ.  There is a long and tragic history, 
mirrored in many other countries with indigenous peoples, of the effects of 
colonisation on their cultural, economic, and social sovereignty. Māori are a 
heterogeneous ethnic group, being comprised of many iwi/hapu (tribes/families) 
that have different cultural practices (Tikanga) and dialects (Te Reo Māori) as part 
of their world view or Māori world (Te Ao Māori16). Recognition of this Te Ao Māori 
is relatively new within the social and health systems, and responsiveness to it is 
still developing or missing.  
There are approximately 700,000 Māori living in NZ (Ministry of Health, n.d.-k).  
More than 50% of Māori live in the lowest (most deprived) three deciles of social 
deprivation (total of ten deciles), compared to only 24% of non-Māori (Ministry of 
Health, n.d.-h). Regarding health literacy, 80% of Māori males and over 70% of 
Māori females had a “poor” health literacy score (Talamaivao et al., 2010.).  Māori 
reported a higher rate of having an unmet need to see their GP in the past 12 
months, despite the fact that their rates of having a usual health practitioner, and 
having seen a general practitioner (GP) in the last twelve months were equivalent or 
similar to non-Māori  (Ministry of Health, n.d.-h).  The most cited reason for not 
seeing a GP was cost (Ministry of Health, n.d.-h).  Māori were also twice as likely to 
have uncollected prescriptions due to cost than non- Māori (Ministry of Health, n.d.-
h). 
Māori statistics for hospitalisation and mortality were worse than those of non-
Māori for all diseases noted. These disparities were present for cardiovascular 
disease, cancer, respiratory disease, diabetes, infectious disease and mental health 
(Gillies, Tomlin, Dovey, & Tilyard, 2013; Hill et al., 2010, 2013; Ministry of Health, 
n.d.-g).  Overall life expectancy at birth for Māori is around seven years less than 
non-Māori for both males and females (Ministry of Health, n.d.-e). Leading causes of 
                                                        
16 Te Ao Māori – means “Māori world” which generally encompasses three main things: Te Reo Māori 
(the language), Tikanga (protocols and practices) and the Treaty of Waitangi. However, more broadly 
it includes whānau, hapū, iwi (familial and tribal connections) and the Marae (the community focal 
point), whakapapa (genealogy) and Waahi Tapu (sites of importance) 
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death for Māori are different to non-Māori.  For Māori ischaemic heart disease, lung 
cancer, diabetes, cerebrovascular disease, chronic obstructive pulmonary disease 
(COPD), suicide, and motor vehicle accidents are the leading causes of death 
(Ministry of Health, n.d.-f). The reports do not list diabetes as one of the leading 
causes of death for non-Māori; COPD is also not listed (breast cancer and colorectal 
cancer replace these in the list for non-Māori) (Ministry of Health, n.d.-f). 
When examining diseases individually within the data provided by the Ministry of 
Health, the pattern is often of higher prevalence, but also much higher rates of poor 
outcomes. For example, diabetes prevalence was twice as high for Māori as for non-
Māori, but related renal failure was five times as high (Ministry of Health, n.d.-d). 
Māori also had poorer outcomes for cancer, total cancer registrations for Māori 
were 503.6 per 100,000, while those for non-Māori were 405.8 per 100,000 and yet 
mortality was closer to twice the ratio: 215.6 per 100,000 for Māori and 120.3 for 
non-Māori (Ministry of Health, n.d.-a). The same kind of disparities exists across 
other conditions reported (Ministry of Health, n.d.-g). 
The picture we get from this information allows us to draw inferences on how to 
address health inequity. Management of chronic disease is poorer for Māori than 
non-Māori, hence the higher rates of hospitalisation and mortality for Māori, 
especially when bearing diabetes in mind. This inequity is obviously in part due to 
healthcare access, i.e. costs of GP visits and prescriptions.  However, other factors 
must also play a role, including health literacy, but also research for each disease 
regarding treatment design/delivery, adherence, and acceptability, as well as work 
mitigating the effects of living in social deprivation and public health measures.    
2.2.3. Pasifika Peoples 
The Pasifika population in NZ initially began emigrating here after World War 2 but 
were encouraged to emigrate during the 1960s and 1970s to address worker 
shortages (Hill, 2010). Today the population consists of 1st, 2nd, and 3rd+ 
generation immigrants.  The population much like Māori is heterogeneous having 
originated from many Pacific Nations, with various languages and cultures. Their 
history in NZ is similarly one that includes racism and oppression: when the need 
for extra workers passed, their welcome in New Zealand waned. Stories of the 
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“Dawn Raids” in the mid-70s (Anae, 1997; Pearson, 2005) are prevalent in popular 
culture where “over-stayers” were forcibly removed from their family homes in the 
early hours of the morning, causing distress and terror in the community. There is 
some recognition of Pasifika peoples’ cultural and social needs within health 
services, systems, and research, but much like the situation for Māori, it is often, 
underdeveloped, minimal, and sporadic. 
Tupu Ola Moui- Pacific Health Chart Book 2012 states that 7% of the population of 
NZ identify as Pacific Islander (in comparison to 15% Māori (Ministry of Health, 
n.d.-k)) and of these more than 50% live in the two lowest deciles of social 
deprivation (McCormack et al.,2012). Nearly 90% of Pasifika peoples have poor 
health literacy (McCormack et al.,2012). Life expectancy was slightly better for 
Pasifika peoples when compared to Māori, but rates of independent living (i.e. free 
of functional limitation) were lower in comparison to the total population 
(McCormack et al.,2012).  Again, while the rates for having seen a GP in the last 
twelve months were equivalent to the total population, rates of having an unmet 
need for seeing a GP in the past 12 months were higher (McCormack et al.,2012).  
Primary reasons for visiting a Pacific Health Provider17 were the need for having 
someone who understood their culture, then, the proximity of provider, and cost; in 
contrast to Māori, where cost was a primary reason for visiting a Māori Health 
Provider (McCormack et al.,2012).   
As with Māori, rates of hospitalisation and mortality for cerebrovascular disease, 
ischaemic heart disease, diabetes, and asthma, among others were higher than for 
the total population (McCormack et al.,2012).  Unlike, Māori whose primary reason 
for unintentional injury was road accidents (McCormack et al.,2012), for Pasifika 
peoples, the leading causes of unintentional injury are entirely different.  Leading 
causes of unintentional injury for Pasifika peoples were split between falls and 
“drug, medicaments and biological substance causing adverse effects in therapeutic 
use* - * assigned for adverse effects of drugs properly administered (e.g. allergic 
reactions)” (p54, McCormack et al.,2012).  This cause of injury is curious, as this is 
potentially a sign of the lack of transferability of general pharmaceutical 
                                                        
17 Pacific Health Providers and Māori Health Providers are health practitioners who generally also 
identify as Pasifika or Māori (not always the case for all staff in a given centre), who provide care in a 
culturally more responsive fashion.  
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interventions to this specific population or the need for ancillary elements to the 
encounter apart from the standard prescription and application of a general 
remedy.   
Again, we can infer from this picture what might be fruitful directions for 
investigations to improve health inequity for the Pasifika population.  Chronic 
disease management, health literacy, culturally-appropriate healthcare and 
suitability of treatments are obvious avenues of inquiry.  
2.2.4. People with Learning (Intellectual) Disabilities  
People with learning disabilities represent another population for whom health is 
poor and research attention is minimal. Unlike Māori and Pasifika peoples, who may 
be included in “mainstream” research and have some targeted funding, those with a 
learning disability are unlikely to be included in clinical trials at all and have less 
research and funding focused on their needs.   
Based on a report written for the Ministry of Health only 0.7%18 of the population 
has a learning disability (Linton, Maskill, and Wright, 2011). However, this group 
incurred almost three times as many costs in primary/secondary healthcare than 
the general population (not counting non-health related care, such as in-home help, 
or educational support) (Linton et al., 2011). This group is more likely to be 
enrolled with a primary healthcare organisation, more likely to visit their GP within 
a three month period, and their health practitioners are more likely to prescribe 
twice as many drugs than the total population (Linton et al., 2011).  Again, those 
with a learning disability were highly represented in the most socially deprived 
deciles (more than 50% in points 4 & 5 on a 5-point scale, where 1 is least deprived 
and 5 is most deprived)(Linton et al., 2011). Their life expectancy is lower than not 
only the total population but each of the groups considered so far, with a gap of 18 
and 23 years for females and males respectively to the total population (Linton et 
al., 2011).   
For the chronic conditions, coronary heart disease, respiratory disease, diabetes, 
kidney disease, cancer and morbid obesity, the learning disabled had higher rates 
                                                        
18 This figure is however presumed an underestimation due to issues of classification and recording 
both in the report itself (Linton, Maskill, and Wright, 2011) and in the community. 
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across the board (Linton et al., 2011).  Those with learning disability showed lower 
numbers in participating in screening for both breast and cervical cancers (Linton et 
al., 2011).  They were also more than four times more likely to have an avoidable 
hospital discharge (i.e. avoidable injury, or something that could have been 
prevented by a primary health intervention, or public health measures) (Linton et 
al., 2011). These disparities exist, although the learning disabled are more likely to 
access healthcare regularly (Linton et al., 2011).  
Again, we see the same issues related to the management of chronic disease 
(regardless of higher contact with health professionals), health literacy, and 
speculatively the suitability of treatments to their specific situations.19  
2.2.5. Other Groups 
Why are other groups not chosen for these case studies? The simple answer is that 
for other groups the ability to map their disadvantage is limited. NZ has no 
mandatory reporting in trial research of ethnicity data, socioeconomic status or 
education level, unlike for example, the NIH, which requires at least ethnicity data 
(on top of sex and age) (National Institutes of Health, n.d.). Also, reporting of some 
of these factors is not necessarily routinely collected in health services data 
(Douglas, Dawes, Holden, & Mack, 2015; The use of routine healthcare data in New 
Zealand, Gurney, 2012).   Data collection within the New Zealand health system is 
limited (Bramley & Latimer, 2007; Swan, Lillis, & Simmons, 2006) and so the ability 
to even take stock of where certain groups with vulnerability within the population 
might be regarding their health is difficult.  The Ministry of Health commissions 
reports for various groups as they become priorities.  Reports for some other 
groups exist such those for the Asian population (Ministry of Health, 2006a) and the 
elderly (Ministry of Health, 2006b). 20   The Ministry does not update these reports 
on a regular cycle while tracking their measures over extended periods of time, to 
establish a true picture of the health of particular groups. In addition to the groups 
                                                        
19 It is noted that people with some learning disabilities have shorter life expectancy due to the 
condition that causes their learning disability.  However, much of the data presented in the Linton 
report (Linton, et al.,2011) available in NZ showed that much of their disparity in mortality is related 
specifically to chronic disease management and an averseness to screening, and therefore amenable 
– their life expectancy and quality of life can be improved. This is confirmed by work in the UK 
(Bittles et al., 2002). 
20 There are also a variety of reports from different times regarding young people and specifically 
Māori or Pasifika young people. These can be found at: http://www.health.govt.nz/publications  
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mentioned, groups that would be of interest are those in the lowest social deciles for 
example or those suffering mental health issues.  In the literature, there is 
speculation that these groups fare worse in their encounters with health services 
and much like the case populations struggle to manage their chronic illnesses 
(Ashworth, Medina, & Morgan, 2008; Cabassa, Siantz, Nicasio, Guarnaccia, & Lewis-
Fernández, 2014; Kawachi & Kennedy, 1999; Stafford & Marmot, 2003).  
2.2.6.  Why is there a difference? 
What all of these group descriptions suggest is that there is something outside of the 
general biomedical view of health that influences health outcomes.  Why is this 
conclusion drawn? Because for those people who are not Māori, Pasifika, or do not 
have a learning disability, life expectancy and hospitalisations for the same 
conditions are more favourable, and mortality is not related to things that are 
avoidable or at least manageable (like diabetes).  This discrepancy in outcomes 
means that interventions are working for some.  We can see that aside from social 
deprivation; other factors are influencing the health outcomes for these groups, 
which means that addressing health inequity is not just a matter of improving 
access (regarding individual financial barriers).  For example, avoidable injury, in 
the form of adverse drug reactions, (noted in Pasifika peoples) is not likely to be 
reduced by providing free access to primary healthcare and cheaper prescriptions.  
Those with learning disabilities have access to healthcare, and yet, the management 
of their chronic illnesses is still poor. 
This chapter will explore the representation of these groups in research activity to 
try and understand these disparities.  Research activity informs what we know 
about health conditions and the people that suffer from them and helps us to decide 
what to do for people. If we do not have knowledge of these groups and their needs, 
then the services we design and provide are potentially unhelpful for some groups.  
2.3. Representation in Health Research Council of New Zealand Funding  
Health research funding was an obvious place to start this exploration of 
representation. How are the case populations represented in the activity that the 
government pays for to improve the health of those living in Aotearoa New Zealand? 
The Health Research Council of New Zealand (HRC) is NZ’s major health funder, 
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similar to the Medical Research Council (MRC) in the United Kingdom, the National 
Health and Medical Research Council (NHMRC) in Australia and the National 
Institutes of Health (NIH) in the United States of America. I chose the HRC records, 
because 1) they were public, 2) they are NZ’s largest health funder, and 3) they are 
the funder specifically mandated by the government under the Health Research 
Council Act of 1990 to fund research that contributes to the health of New 
Zealanders.   
The HRC has an annual funding round that calls for investigator-led proposals.  
These proposals can be Feasibility Studies (limit $150,000 over two years), Project 
grants (limit $1.2 million over three years maximum) and Programme Grants (limit 
approx. $5million over five years maximum, although applications for extensions 
are an option through the annual process). In addition to this round, HRC has 
multiple career awards for various levels of career achievement (Summer 
Studentships, Masters, PhD and Postdoctoral grants). There are targeted career 
award categories such as Māori and Pasifika, but also awards aimed at specific types 
of researchers (for example clinicians, those interested in health policy, or delivery). 
There was previously a Disability Placement scholarship programme, but this was 
discontinued. The HRC also funds partnership programmes which are not 
investigator-led but driven by a specific government priority or sector need. These 
require partners in the health sector that will ensure the successful translation or 
implementation of the research results into policy or practice.21  
Other funders naturally exist. For example, the Lottery Health Grant round funded 
by lottery income and managed by the Department of Internal Affairs is more 
community focused.  However the full details of Lottery Health grants are not 
publicly available, and their funding is limited both in terms of duration (no more 
than two years) and budgets (no more than $120,000).22  These budgets do not 
include overheads, like the HRC, making their budgets even more limiting.23 These 
                                                        
21 Information on HRC funding opportunities can be found here: http://www.hrc.govt.nz/funding-
opportunities  
22 Information on Lottery Health grants can be found here: 
http://www.communitymatters.govt.nz/Funding-and-grants---Lottery-grants---Lottery-Health-
Research  
23 Overheads are a line within a budget, generally based on percentage of the staffing budget within 
the grant that recognises the infrastructure cost of running any particular project.  Few grant bodies 
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restrictive funding opportunities mean that what research is possible with a 
community focus is limited and less financially attractive to tertiary institutions 
(due to the lack of overheads). Disease or cause-based funders, such as the Heart 
Foundation, Neurological Foundation, Arthritis New Zealand also exist. The Royal 
Society of New Zealand offers Marsden grants, but these are with the express 
purpose of supporting “blue skies” research, and so any health research projects 
awarded under this scheme are often lab-based or at a purely theoretical level.    
The HRC as the funder with the explicit mandate of contributing to the health of 
New Zealanders was the clear choice for this review.  
The records available were limiting, in that they only provided a title for 
investigation. Titles were checked for descriptions of Māori, Pasifika, or learning 









Table 1 - Summary of Research Funding by Case Groups 










1 Total $ $618,182,308 $53,232,138 $7,449,037 $2,025,241 $10,469,653 
                                                                                                                                                                    
in New Zealand offer overheads, other than the HRC grants, the Ministry of Business, Innovation and 
Entrepreneurship grants, and any private research funding contracts with industry.   
24 A full description of methodology used is available in Appendix A along with a full list of the 
applications selected for inclusion. 
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 (8.6%) (1.2%) (0.3%) (1.7%) 








3 Average $ $751,133 $405,981 $180,639 $337,540 $697,977 
























































8 Average Duration 29.8 months 27.1 months 14.1 
months 
19 months 23.3 months 














As can be seen, the representation of the case groups in the total funding pool is not 
proportional to their representation in society (Table 1 - row 1) despite there being 
a specific Investment Stream for Māori research and specific career awards.25 Māori 
and people with learning disabilities do reach some degree of proportional 
representation in the total number of grants awarded (i.e. 15% and 0.7% 
respectively), but Pasifika barely reach half (Table 1 - row 2). This discrepancy 
between the amount funded and the number of grants awarded, is discussed further 
                                                        
25 The HRC asks applicants to align their projects within four Investment Streams in the Annual 
Funding round (Health and Well-being in New Zealand, Improving Outcomes for Chronic Conditions, 
Health Service Delivery, and Rangahau Hauora Māori) 
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in Chapter 4, where researchers explain the perception of having to limit the money 
they ask for so that they can get funding. One can see clearly (Table 1 – row 3) that 
the per-grant-cost across the groups is quite different from the total group average. 
It is not immediately clear why clinical projects for marginalised populations would 
cost less, in fact, they are likely to cost more given the geographical spread of small 
populations within the country.  Therefore, the assumption is that these projects 
with less funding are unlikely to be either technically sophisticated (requiring 
expensive laboratory equipment) or clinical interventions (requiring sample sizes 
sufficient to power studies). This assumption is explored further within this chapter 
and Chapter 4. Rows 4-5 (Table 1) show the degree to which career awards 
represent the share of funding that each group receives. Career awards are 
necessary for workforce development but are also limited in the scope of what they 
can achieve – Masters’ projects and summer studentships are unlikely to lead to 
immediately translatable knowledge or evidence.  Of the 111 grants under 
$100,000, the three case groups combined received 55% of them. These smaller 
grants represented a significant portion of the case groups’ overall grant lists 
(especially for Pasifika – 62.5%) (Table 1 – Row 6). Grants under 12 months also 
represented a significant proportion of these case groups funding success (i.e. case 
groups received 41% combined of all grants under 12months) (Table 1 – row 7). 
This prevalence of shorter and smaller grants shows that the work done with these 
case groups is of a different nature.  The average duration of each groups’ grants 
was significantly less than that of the total group average except for Māori (27.1 
months versus total group average of 29.8 months).  There were 101 grants of 
$1.3.million or more, which are generally programme grants but can also be 
partnership grants. Of the 101 grants that were larger than $1.3million in funding, 
so those grants that represent a significant investment over a longer period, only 
four were for the case groups of interest (combined), and not one of these was for 
people with learning disabilities.  
I cannot speak to the numbers of grants submitted. For example, an objection might 
be that no-one has ever submitted grants to the Health Research Council within the 
programme grant section for the people with learning disabilities.  Part of the 
criteria for applying for a Programme Grant is that you have already been successful 
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in HRC funding to a certain extent before your application to receive programme 
funding.  Given the low numbers of grants awarded to learning disability projects in 
these records and the years of those grants, none of the investigators working with 
people with learning disabilities are eligible for programme funding. Furthermore, 
no new investigators would be eligible to apply without showing equivalent level 
experience somewhere else. In other words, the lack of representation for research 
for people with learning disabilities at the programme level is a direct reflection of 
their lack of representation at project level, despite informants (in Chapter 4) 
reporting that grants have been submitted at the project level annually.   
As mentioned above there are some limitations to this analysis. I cannot compare 
what was submitted, and its evaluation to those projects that the HRC funded.  The 
review of titles alone does not guarantee that efforts were not made within funded 
projects to recruit or consider diverse populations. Moreover, some information is 
missing from the publically available list, based on a researcher’s ability to embargo 
their publication.  This embargoing of information is more likely to occur for 
commercially sensitive research rather than the research that occurs for 
marginalised populations, however.  
Overall, what this information points to is that there is significant support for 
research workforce development by earmarking career awards for Māori and 
Pasifika, and there is a specific Investment Stream for Māori. However, grant 
funding for the health needs of populations that suffer the greatest health 
disparities are lower than their representation in society and arguably than their 
need, and this is especially the case for the people with learning disabilities.  
Funding records from the HRC do not provide a full picture of health research 
activity occurring in NZ. Therefore other sources were necessary.  The use of clinical 
trial registries (described below) is growing in NZ (Jull, Wills, Scoggins, & Rodgers, 
2005; Currie & Jull, 2012) and the information is publically available, so these too, 
seemed like a useful source of information.  
2.4. Representation in Trial Registries  
2.4.1. A Brief History of Trial Registration  
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Efforts on both sides of the Atlantic in the 1970s led to the creation of the first 
clinical trial registries.  In the United States of America (USA), Nixon’s “War on 
Cancer” and the resultant National Cancer Act (Steinbrook, 2004) specified the need 
for sharing of trial information to speed up efforts to address research gaps and 
avoid publication bias.  Similarly, in the U.K., Iain Chalmers, an ardent follower of 
Archibald Cochrane26 and later creator of the Cochrane Collaboration and Library, 
helped advocate for and set-up a perinatal medicine registry (Chalmers et al., 1986). 
Advocates of registries saw a key factor impeding progress in research development 
was the lack of information sharing, in particular for trials that had not been 
published (Chalmers et al., 1986; Chalmers, Gray, & Sheldon, 1995; Simes, 1986; 
Steinbrook, 2004). Trial registries were designed to not only provide a way of 
knowing what activity was occurring but also to provide a way of sharing the 
outcomes of activity regardless of whether the research was published in academic 
journals or not.  In the USA, legislation in 1997 required the NIH to create a 
database for trial registration (FDA Modernisation Act of 1997).  This database 
came to fruition in 2000, when NIH created the ClinicalTrials.gov registry. Efforts 
were occurring globally, albeit without coordination, to create trial registries. In 
2004, at a Ministerial Summit on Health Research, the WHO was asked to monitor 
this activity and provide access to it, to make the use of registries more amenable 
(WHO, n.d.-a).  
The WHO created standards for clinical trial registry creators and administrators, 
the clinical trial registry data set, and a portal for searching all trials registries 
classified as primary (i.e. meeting WHO criteria)(WHO, n.d.-b). The WHO Trial 
Registry Data Set (TRDS) specifies what a registration must include to meet their 
standards of reporting (WHO, n.d.-c). These reporting standards include 
specification of funders, sponsors, inclusion/exclusion criteria, primary outcome 
measures, study type, among others (20 items in all).  
Also in 2005, the International Committee of Medical Journal Editors (ICMJE) 
released a statement saying that they would only publish research that had been 
registered in a clinical trial database (De Angelis et al., 2004). This policy was 
                                                        
26 Archibald Cochrane called for randomised controlled trials in medicine post World War 2 to bring 
methodological rigour to health research.   
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supposed to provide motivation to researchers to prospectively register their work 
in accordance with what was considered best practice.  
Despite all these efforts, many trials are still not being registered prospectively, and 
many of the registrations are incomplete and/or inaccurate (Currie & Jull, 2012; 
Goldacre, 2012; Jull et al., 2005; Mathieu, Boutron, Moher, Altman, & Ravaud, 2009; 
Wood, 2009). 
2.4.2. Trial Registrations and Our Premises 
Given that trial registration was introduced in 1997, endorsed by the International 
Committee of Medical Journal Editors (ICMJE) initially in 2005, and embedded in 
their policies in 2007, registries were thought to be a good source of information for 
further establishing the premises of this project, namely that: 
 the majority of research conducted is not for, or generalizable to 
various subgroups in the population 
While the HRC data provided in the previous sections shows what work and types of 
work are funded (from the main health research funder in NZ), this by no means 
provides a complete picture of research activity and provides little information on 
methodologies used. It was therefore thought prudent to investigate trial registries 
relevant to the NZ context to examine:  
1. What research has been/or is being undertaken for the three case groups 
identified in this work as examples of those suffering health inequity (Māori, 
Pasifika, and people with learning disabilities)? This question concerns both 
research specifically with these groups in mind, and research in areas of 
particular interest to these groups (i.e. based on disease prevalence or poor 
outcomes for example)  
2. For all research, what kinds of subgroup analyses have been/or are being 
done and how was/is external validity considered, as this would make the 
work more likely to be generalizable across the population?   
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I chose the ClinicalTrials.gov, Australia New Zealand Clinical Trial Registry 
(ANZCTR) and ISCRTN27 Registry as sources of information likely to contain the 
majority of registered interventional and observational studies occurring in NZ. 
This choice was related to the fact that previous work by Jull examining the 
increasing use of trial registries by NZ researchers in two studies (Currie & Jull, 
2012; Jull et al., 2005) included these registries. 
Our general search criteria to get an initial list of interest28 from each registry were:  
Table 2 - Search criteria across all three registries 
Factor Search Value Reason 
Time period 01/01/2006-31/12/2013 To align with the data used from the HRC 
Trial Status Completed This criterion would increase the 
likelihood of information regarding 
publication or results being available for 
earlier studies within the group (i.e. 
those registered from 2010 onwards, 
depending on their duration would be 
unlikely to include publications). 
Location of data 
collection 
New Zealand This criterion definition could mean 
either as a main site of collection or as an 
“arm” of an international trial.  This was 
chosen to identify trials that had chosen 
a New Zealand population as relevant. 
 
A search of each of the three sites resulted in the identification of 646 relevant trials. 
These relevant trials were spread across the sources as follows:  
                                                        
27 ISCRTN is not spelt out as its original definition as 'International Standard Randomised Controlled 
Trial Number' is stated on the registry website as no longer applying because the scope has 
broadened, so they just use the acronym. 
28 The list of interest was a list of all research being conducted during the reference period that may 
include projects that either directly or in subgroup analysis focused on the case populations.  More 




Figure 3 - Search Results by Source 
It is important to note that the trial registries were not as complete or as 
informative as anticipated.  As outlined above, trial registries were designed to 
provide transparency and information to the public and professionals on clinical 
research work being conducted at any given time (Chalmers et al., 1986; Steinbrook, 
2004; Wood, 2009). By posting detailed and accurate accounts of protocols and 
research activity people can investigate researchers and hold them accountable for 
what they said they would do and what they then later publish.   
The ANZCTR specifies that it meets the data requirements of the WHO. However, 
information that could have led to an analysis of how externally valid a trial was, 
was largely not available and information regarding internal validity was varying in 
its standards in the records found. Best practice which includes prospective 
registration and full and clear descriptions within entries in the registries was not 
evident, based on the following factors: 
1) Retrospective registrations    
Trials are ideally registered before the commencement of work so that the 
intended outcomes to be measured and the analysis are recorded and 
researchers cannot change these after they have collected data.  There is 
evidence in the literature of the switching of the secondary and primary 





















et al., 2009). This switching is problematic: most studies are powered29 off 
the primary outcome and so generally have insufficient numbers to assess 
the efficacy/effectiveness of the secondary outcome.  Retrospective 
registration while not necessarily the result of wilful misdirection 
undermines the purposes of the registry (as outlined above).  Less than half 
of the trials meeting our search criteria were registered prospectively in the 
ANZCTR (98 of 231, 42.42%) or ISRCTN (6/20, 30.0%) (see Figure 4), while 
the ClinicalTrials.gov registry showed somewhat better practices (275/395, 
69.62%, Figure 4). 
 
Figure 4 - Registration Timing 
2) Minimalist descriptions of outcomes 
Descriptions of outcomes in the registries ranged from detailed descriptors 
that included considerations of minimally important clinical difference 
(MICD) or clinical significance measures, to those that simply stated a 
category of outcome such as “pain”.  What this vague specification of 
outcomes means is that researchers can, if they feel pressure to, redefine 
what a significant outcome is in their trial after the fact. Others have done 
research scoping the size of this issue. (Chan, Hróbjartsson, Haahr, Gøtzsche, 
                                                        
29 To power a study, is to complete a calculation that informs you how many participants you need to 
be able to make statements about the significance of results, given the variables identified.  Power 
calculations can vary depending on your statistical preferences and are dependent on the outcome 
measure you have chosen and the size of change you need in that outcome for it to be classed as 
significant.  
ANZCTR ClinicalTrials.gov ISRCTN
Prospective 133 122 6
Retrospective 98 268 14
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& Altman, 2004; Goldacre, 2012; Mathieu et al., 2009; Prayle, Hurley, & 
Smyth, 2012).  The switching of outcome measures after analysis is 
comparable to taking a test and deciding what the passing grade is after you 
know your grade. What is also worrying about the lack of detailed 
information in this category is that to calculate correct sample sizes requires 
specific outcomes measures. If therefore, trial teams have not determined 
specific outcomes measures, they cannot calculate robust sample sizes. 
Alternatively, if the teams have calculated specific outcome measures, why 
are they not being shared?  Interestingly, the WHO TRDS (WHO, n.d.-c) does 
not make explicit the level of detail required and has “accredited” the 
ClinicalTrials.gov registry, ISRCTN, and the ANZCTR through their inclusion 
in the primary registries group. So, despite the serious problems just 
described, it could be claimed that these practices are “acceptable” according 
to current WHO requirements. 
3) Incomplete records (no description of statistical analysis) 
All trial records had insufficient information about the statistical analyses 
used to determine their sample or to analyse their outcomes.  For example, of 
the 231 records matching our criteria in the ANZCTR, only 19 specified their 
statistical methods (Figure 5).30 Most users provided no information, and 
where information was provided it varied in detail.  Again, while WHO TRDS 
does not specify the level of detail (WHO, n.d.-c), this lack of information 
clearly undermines the purposes of the registry. Sample size calculations are 
powered from the primary and sometimes also the secondary outcome. 
Deciding what a significant difference in outcome might be is used to 
calculate sample sizes. Researchers should have determined this significant 
difference and the sample size to proceed with a trial, meaning that the 
information should be available. Therefore, where this omission occurs in 
the registry, the information is either a) available and the researcher is not 
providing it; or b) it is not available in which case the researcher is 
conducting a trial without a scientifically valid sample size.   
                                                        
30  Less than 10% specified an intention-to-treat analysis. An intention-to-treat analysis is one where statistical 
analysis is done on the whole cohort including drop-outs.  This allows for an analysis that can make claims about 
treatment adherence, as well as efficacy of intervention and is therefore more externally valid in its claims, 
because one could presume if adherence is low in a trial situation; it is likely to be lower still in a “real life” 





Figure 5 - No. of Trial Registrations with Statistical Methods Section 
What this shows is that trial registries are at present only partly fulfilling their 
purpose in providing accountability. While they do allow clinicians, researchers, the 
public, and other interested parties to find out what work is going on to some 
degree (insofar as researchers use them), they do not consistently provide enough 
information to ensure research conduct (for this particular aspect) is acceptable.  
To investigate how much work is done specifically for or with the groups identified 
in our work as disadvantaged, we searched our results for the occurrence of the 
case groups within protocols. We did this for each trial registry separately given the 
differences in their formats and search functions. 
The following search terms were used to identify population-specific work: 
 
Table 3- Population Search Terms31 
Māori “Māori”, “indigenous”, “Tangata Whenua”, 
“whanau”, “hauora” 
Pasifika “Pasifika”, “Pacific Islander”, “Tongan”, 
                                                        
31 For all three categories terms were used that cast the net wide (i.e. Pac* or disability) to ensure a 
comprehensive search; this resulted naturally in more results than were relevant – irrelevant results were 
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“Samoan”, “Cook Islander”,  “Cook Island 
Māori” “Fijian”, “Niuean”, “Rarotongan”, 
“other Pacific Peoples”, “Pas*”, “Pac*.” 
Intellectually Disabled32 “intellectual disab*”, “Downs syndrome”, 
“Prada-Willi syndrome”, “f* alcohol 
syndrome”, “FAD” also “disability” and 
“development” were included 
  
In the ANZCTR, the research summary and inclusion/exclusion criteria sections 
provided the information regarding target population. I found subgroup analysis 
information in inclusion/exclusion criteria, secondary outcomes measures, 
randomization process (specification of stratification by subgroup) and statistical 
methods (where these were complete) sections. The results provided in Figure 6 
regarding subgroup analysis could, in fact, be larger, though we cannot confirm this 
due to the incompleteness of records.   
 
                                                        
32 This terminology was used in the search as it pre-dated the use of learning disability. The search terms, do not 
provide a full profile of the learning disabled population and underestimation of population size is an ongoing 
issue for this group based on classification and diagnosis issues (Leeder & Dominello, 2005; Linton et al., 2011).  
Added to this, we excluded SOTOS (generally considered an intellectual disability) due to its rarity.  After the 
change of name from intellectual to learning, other disorders such as dyslexia, could have been included, but 
were not based on adhering to the chronologically accurate definition. 
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Figure 6 - ANZCTR Registered Trials with Target Group or Subgroup Analysis of Target Group 
In the ClinicalTrials.gov registry, as with ANZCTR, target group information was 
found in the research summary and inclusion/exclusion criteria sections. However, 
for the subgroup analysis, two methods were used. Of the 395 trials that met the 
search criteria on ClinicalTrials.gov, 120 had study results available. These results 
include a “baseline measures” section where registrants specify their baseline 
measures for each participant including demographic details.  For the 120 trials 
with results, I checked their baselines measures for a specification of ethnicity/race 
data collected. For the remaining 275 trials, I checked their inclusion/exclusion 
criteria, secondary outcome measures and any publications listed. Of the 275, none 
specified anything related to relevant subgroup analysis. As with ANZCTR however, 
this could mean the 275 collected ethnicity/race data but did not report it. No 
studies targeted any of our groups specifically and only 39 of 395 trials reported the 
collection of ethnicity data (Figure 7). 
 
Figure 7 - ClinicalTrials.gov Trials with Target Group or which specified collection of ethnicity and 
included NZ relevant categories 
It is significant that of the 120 studies with results in the ClinicalTrial.gov registry, 
the 14 that collected New Zealand specific data included one study that had the 
category “Māori” and thirteen studies with the category “Hawaiian/Pacific Islander”.  
Of these 14, none had recruited anyone to those categories, i.e. in their study results, 





















lead to changes in services or policy33 none could report the inclusion of a single 
participant of Māori or Pasifika ethnicity. This lack of participation by the case 
groups speaks to the premise that evidence generation is not generalizable or 
externally valid to our setting. 
Based on the Māori Health Chartbook (Talamaivao et al., 2010), I also decided to 
investigate the research activity around the leading causes of death in this 
population. The “Pasifika Health Chartbook” and “Health Indicators for Intellectually 
Disabled New Zealanders” did not specify leading causes of death (Linton et al., 
2011; McCormack et al., 2012) and so an equivalent analysis could not be 
undertaken. Of the 231 trials found on the ANZCTR, the following studies related to 
leading causes of death for Māori (Total: 60/231) (Figure 8). 
 
Figure 8 - Major Causes of Death, Māori Health Chartbook (2010) 
Given the trials sourced in the ClinicalTrials.gov registry only listed New Zealand as 
a secondary site for research and rarely collected ethnicity data relevant to our 
population, I did not complete a similar analysis of disease type in this registry.   
The ISRCTN registry sample covered cancer (breast, gastro-intestinal, colorectal, 
gynaecological) (7), kidney disease, flu vaccinations, blood pressure during 
pregnancy, cardio- pulmonary or vascular related interventions (5), faecal 
incontinence, pelvic floor prolapse, patient reassurance intervention, infantile 
spasms and traumatic brain injury.  
                                                        
33 It acknowledged that a trial’s ability to affect services or policy depends on the outcomes of the 
trial, its dissemination, and the implications. 
Suicide Diabetes Lung Cancer COPD Heart Disease Stroke









ANZCTR Completed Trials 2006-2013 -  No. of 
Trials for Major Causes of Death (Māori) 
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Of the 20 trials in the ISRCTN, six primarily recruited in New Zealand.  Of these, 
three had information on ethnicity data: 
- one trial recruited one participant; 
- one trial had two ethnicity categories, “European” or “Other”, and in the 
“Other” category recruited 29 participants; 
- one trial collected full ethnicity data and recruited 41 Māori participants and 
19 Pasifika participants in a total participant pool of 113.  
None of the trials registered in the ISRCTN specifically targeted Māori, Pasifika, or 
people with learning disabilities.  
Regarding this inquiry, what do these findings mean for representation? While 
research activity relating to diseases of interest to the case populations is occurring 
(Figure 8), little research is being done specifically for them (Figure 6).  I cannot 
conclude that much work is being done to recruit or undertake subgroup analyses 
within the research activity recorded (Figures 7) keeping the limitations of the 
information described above in mind.  
Information provided in trial registries was more limited than expected.  
Representation appeared superficially to be weak. This weak representation was 
both in relation to numbers of trials registered where Māori, Pasifika or people with 
learning disabilities were the main focus, but also regarding subgroup analysis and 
recruitment of Māori or Pasifika participants.  Subgroup analysis for people with 
learning disabilities is not specified and people with learning disabilities are very 
rarely included in trials that are not specifically for them (McDonald & Keys, 2008; 
Puyalto, Pallisera, Fullana, & Vilà, 2015).  There are barriers to recruiting people 
with learning disabilities into research (and especially research directed to the 
wider public).  On the one hand, designing recruitment activities, research 
procedures and interventions that are user-friendly for those with learning 
disabilities requires more care and consideration so that information is conveyed 
appropriately, interventions are suitable and practicable, and processes include 
guardians where necessary (Iacono, 2006; Iacono & Murray, 2003; Lennox et al., 
2005). On the other hand, ethics committee review can be more challenging and 
lengthy (Lennox et al., 2005) with some committees’ attitudes being classed as 
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overprotective (this also is mentioned in Chapter 4). Both of these factors require 
time which researchers sometimes perceive to be lacking. Knowing that people with 
learning disabilities are not generally recruited into total population trials means 
that these results for this group specifically can be taken at face value, i.e. if they are 
not the primary focus of the trial then they are unlikely to have been included at all.  
For Māori and Pasifika peoples, we can assume that reporting may well have been 
lower than practice and that therefore, aside from research directed towards them 
specifically, and the research where we found some subgroup analysis, figures for 
this subgroup analysis are probably somewhat higher.   Overall, however, 
representation was still not proportional to either demographic representation or 
need.  
Given the use of registries was not 100%, a review of a further source of research 
activity made sense.  
2.5. Representation in Ethics Committee Records 
Health researchers in NZ complete ethical review for their work and therefore 
ethics committee records provided another avenue for investigation. Actual 
regulation in New Zealand is somewhat odd, in that no one piece of legislation 
prescribes ethical review, but a collection of legislation ensures the rights of 
participations/patients, these include: Protection of Personal and Property Rights 
Act 1988, New Zealand Bill of Rights Act 1990, Privacy Act 1993, Health and 
Disability Commissioner Act 1994, Accident Compensation Act 2001, Human Tissue 
Act 2008, and the Treaty of Waitangi.  The HRC stipulates that ethics review is 
compulsory for funding, and universities enforce a compulsory ethics approval for 
research undertaken, as do hospitals. There are however gaps in this system for 
research undertaken outside of universities that do not involve hospitals or patients 
recruited from hospitals. 
An approved ethics committee is one that has been through the HRC process for 
accreditation34. The HRC is the main funding body for health research in New 
Zealand, and under the Health Research Act (1996) is mandated to accredit ethics 
                                                        
34 The approval process asks committees to demonstrate their members mix (in terms of 
gender/ethnicity), their expertise (capability to robustly review) and annual training, their 




committees on the basis that it cannot award funding to an investigator who has not 
undertaken robust ethical review. In addition, to the HRC, there is a National Ethics 
Advisory Committee (NEAC). This committee creates reports and guideline 
documents for clinical and research ethics matters but has no oversight 
responsibilities for research ethics review.   Accredited committees are currently of 
two kinds: Health and Disability Ethics Committees (HDECs) and various 
Institutional Ethics Committees.   
HDECs are Ministerial Committees (Ministry of Health) tasked with the review of all 
health and disability research. Their scope was restricted and their structure 
changed in 2012, to minimise review times within committees and make them more 
efficient, in the hopes of making the clinical trial environment more welcoming and 
productive (Tolich & Smith, 2015).35  All clinical (interventional, all risk; 
observational, high risk) research is supposed to be assessed by an HDEC. Where a 
researcher requires approval from an accredited ethics committee as part of their 
funding arrangements, but their projects falls outside of this HDEC scope, they 
would apply to an appropriate accredited Institutional Ethics Committee. Some 
universities and polytechnics have applied to have their Institutional Ethics 
Committees accredited and these committees review research work of all levels and 
kinds at the institution that fall outside of the scope of HDEC review. Other 
Institutional Ethics Committees at universities and polytechnics are non-accredited 
and largely assess student work of a non-health nature (i.e. sociological research for 
example). District Health Boards36, where they have their committees, still require 
HDEC approval, but their committee will approve the research to go ahead within 
their facilities specifically. The New Zealand Ethics Committee is non-accredited 
independent/private committee reviewing non-clinical research from the 
government/third sector/industry and is not related to our inquiry. Historically, NZ 
also had one accredited industry committee.  This committee was a committee at a 
                                                        
35 While Tolich and Smith discuss this reform, full documentation regarding the enquiry and the 
various submissions made by pharmaceutical companies, concerned citizens, ethics committee 
chairs, academics, the Law Foundation, Women’s Health Aotearoa, and many more can be found 
here: https://www.parliament.nz/en/pb/sc/submissions-and-
advice/document/49SCHE_ADV_00DBSCH_INQ_9752_1_A146217/summary-of-submissions 
36 District Health Boards are regional governance and service structures for the provision of 
secondary and tertiary care and public health in NZ, which also distribute funding through Primary 
Health Organisations to primary care. 
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Drug-Trial Company that trialled generics.  This committee is no longer in existence 




Figure 9 - Ethics Committees in Aotearoa New Zealand 
For this analysis, I took the records of HDECS, which are publically available, as a 
representation of clinical research work occurring in NZ, i.e. work likely to generate 
‘evidence’.  Records before 2012 are more comprehensive in that their review scope 
was broader at that time and therefore more diverse kinds of research were 
considered by the committees. Records post-2012 are less comprehensive of the 
total view of health research occurring in NZ but can be seen as more relevant in 
that the work reviewed is much more likely to be work that leads to ‘evidence’ 
within current ranking/evaluation systems.  This difference post-2012 is based on 
the 2012 reforms which limited the committees’ review scope, but in doing so 
focused it more clearly on clinical work (likely to be classed as evidence).   
A limitation of this study was that I had to rely solely on the project title and this 
may not have accurately reflected the content of the project as a whole. I and one 
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Māori, Pasifika, or learning disability projects, as well as projects that referred to 
multiple ethnicities, comparisons or disparities.37 
 
Table 4 - Breakdown by year total for all Health and Disability Ethics Committee applications and 
proportion for groups of interest 
                                                        
37 A full description of methodology used is available in Appendix A-2 along with a full list of the 
applications selected for inclusion. 
  2005 % 2006 % 2007 % 2008 % 2009 % 
Total no. of 
applications 
848 939 1186 1176 1035 
Withdrawn 14 25 15 20 11 
Declined 9 11 24 18 18 
Total no. of 
applications 
considered 825 903 1147 1138 1006 
Combined - case 
populations 47 5.70 42 4.65 40 3.49 52 4.57 43 4.27 
Māori 24 2.91 20 2.21 10 0.87 24 2.11 20 1.99 
Pasifika 8 0.97 8 0.89 13 1.13 18 1.58 3 0.30 
Learning/Intellectual 
disability 2 0.24 6 0.66 8 0.70 4 0.35 5 0.50 
Ethnicity/Disparities 13 1.58 8 0.89 9 0.78 6 0.53 15 1.49 
  2010 % 2011 % 2012a % 2012b % 2013 % 
Total no. of 
applications 1322 1409 578 262 562 
Withdrawn 15 10 3 1 0 
Declined 14 13 2 6 16 
Total no. of 
applications 
considered 1293 1386 573 255 546 
Combined - case 






Table 5 -Summary of HDEC Application Numbers 2005-2013 (inclusive) and proportion of applications 
for groups of interest 
  Total % 
Total no. of applications 9317 
Withdrawn 114 
Declined 131 
Total no. of applications considered 9072 
Combined - case populations 419 4.62 
Māori 187 2.06 
Pasifika 74 0.82 
Learning/Intellectual disability 46 0.51 
Ethnicity/Disparities 112 1.23 
 
As with the trial registries, it is apparent that based on research titles alone less 
than 5% of research is conducted with our case populations combined.  
Numbers before 2012, when the HDEC review was regional38 show no difference in 
representation despite  Māori and Pasifika populations being larger in some 
regions, such as Central Regional Ethics Committee, Northern X and Northern Y.  
To be clear, the information available in the ethics committee reports does not 
provide information as to a researcher’s intention to conduct subgroup analysis. 
However, it is fair to assume none completed subgroup analysis specifically for 
                                                        
38  post-2012, while each committee has a name identifying it geographically, applications are 
submitted through a portal and then distributed to committees based on monthly capaicity to review  
Māori 34 2.63 30 2.16 14 2.44 6 2.35 5 0.92 
Pasifika 9 0.70 8 0.58 3 0.52 1 0.39 3 0.55 
Learning/Intellectual 
disability 4 0.31 10 0.72 1 0.17 1 0.39 5 0.92 
Ethnicity/Disparities 22 1.70 20 1.44 9 1.57 3 1.18 7 1.28 
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those with learning disabilities as this is not common practice in NZ and most trials 
would exclude those without the capacity to consent independently.  
2.6. Representation in Government Strategies and Guidelines 
2.6.1. What Evidence?   
It is important to understand what information is used to guide decision-making in 
health. To this end, I collected all relevant guidelines from the Ministry of Health 
website and discussion documents for Health Technology Assessment in NZ. These 
are two areas of decision-making that have open documentation available for 
scrutiny, one relating to healthcare delivery and the other to its provision.  
Guidelines for conditions that the three case populations fare worst in based on the 
health statistics in 2.1 of this thesis were the obvious choice.  These guidelines 
especially should take account of the case populations based on their need.  I used 
guidelines that included either a specific reference to evidence grading, expert 
review or included a full reference list.  Guidelines for each condition were not 
available, but guidelines for related management were included (this included the 
Primary Care Handbook). I then reviewed each guideline for the following, where 
available: 
1) Specific sections for Māori, Pasifika or learning disabled populations 
2) Specific inclusion of Māori, Pasifika or learning disabled experts on the 
review or advisory panels 
3) Grading of evidence in recommendations specifically related to Māori, 
Pasifika or learning disabled populations  
4) Number of references included for Māori, Pasifika or learning disabled 
populations.39  
Table 6 - Government documents for the major causes of mortality and morbidity40 








No information provided.  
                                                        
39 Appendix A-3 includes full lists of the references referred to. 
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This table shows that guidelines and strategies include little in the way of high-
quality evidence as judged on the GRADE scale to support the case populations with 
some guidelines specifically stating the difficulty in making recommendations due 
to lack of available health data or research evidence (Ministry of Health, 2009). This 
lack of relevant evidence for the case groups is further emphasised by Collings and 
Beautris when referring to suicide, who state: 
“Unfortunately, in regard to individual risk factors there is no published 
research that rigorously compares the profiles of Māori and non-Māori. Neither 
is there robust research that examines risk and protective factor profiles 
among Māori with the same explanatory power as has been used in studies of 
the wider population.” (Collings & Beautrais, 2005)  
Where the guidelines do reference relevant research, it is mostly epidemiological or 
theoretical, and only refers to Māori and Pasifika peoples, those with a learning 
disability being entirely invisible. Most of the intervention studies listed in 
reference lists were completed internationally and so the generalisability to Māori 
and Pasifika groups, and even the NZ population is unknown. The Suicide 
guideline41 in the table above makes specific reference to including broader types of 
research in the generation of guidelines: “There is an urgent need to increase and 
build on existing evidence-based research relating to Māori suicidal behaviour, and 
the inclusion of other forms of evidence is seen as critical by Māori.”(Ministry of 
Health, 2006c), something we will discuss further in Chapter 5. 
Guidelines were one source of information, which relate to service delivery. Health 
Technology Assessments (HTAs) undertaken by governments determine health 
service provision. The National Health Committee (NHC) of New Zealand (recently 
made defunct) was the main body that undertook HTA in NZ.  These kinds of 
assessments inform governments on appropriate services to fund (or more rarely 
de-fund) when determining the limits of the health budget. The other government 
agencies that currently undertake these kinds of assessment are PHARMAC42 which 
                                                        
41 An excellent Suicide Prevention Toolkit for DHBs has also been created (Ministry of Health, 2015). 
This document references Māori and Māori resources specifically and includes a section for 
consideration of diverse populations.   




does them solely for pharmaceutical products, although the government has 
recently added medical devices to its remit; and the Accident & Compensation 
Corporation (ACC)43, which is NZ’s no fault injury insurance.44 
HTAs undertaken by the NHC that are publicly available are those for aortic stenosis 
and low back pain management. Aortic stenosis is not highly prevalent in the Māori 
population according to the documents related to this HTA. Of note, however, is the 
Tier 2 and 3 assessments documents as well as the decision paper which includes 
more than 140 references, one of these references relates to Māori, and none relate 
to the other populations (National Health Committee, n.d.-c). The low back pain 
document is similarly sparse (one mention of obesity in Māori in the text, no 
references unique to Māori in the list of 76 references). The omission of relevant 
work is despite the fact that prevalence of low back pain in New Zealanders is high 
(1 in 3 as quoted in the document), and the prevalence of potential causes of low 
back pain are higher in the Māori populations (National Health Committee, n.d.-a).   
I acknowledge that an argument can be made that these technical documents do not 
need to consider diversity, as they simply weigh efficacy against cost.  However, 
these discussions of funding often focus on cut-off points for care that are mostly to 
do with age45 or quality of life46 (as well as the ability to benefit). Factors such as life 
expectancy and cultural awareness amongst others, then become highly relevant. 
Authors of these documents and those making related service provision decisions 
should acknowledge this relevance in discussions of funding, given the “the legal 
and moral obligation to reduce health inequalities” as explained in the Chronic 
Condition document (National Health Committee, n.d.-b).  
There are also problems with using health data sets or national surveys where 
service utilisation (due to lower service use) or response rates may not be 
representative for subgroups of the population (Bramley & Latimer, 2007; Swan et 
                                                        
43 This is NZ’s no-fault accident insurance provide to all based on taxation and levies. For more 
information, see: http://www.acc.co.nz/  
44 HTAs are likely also undertaken by individual DHBs on an ad hoc basis and there are some 
academic HTAs, but these three agencies were the main users of HTA up until recently.  
45 If life expectancy is lower for a group, or morbidity begins earlier, care caps for these groups could 
be lower than for the general population if we were addressing equity.  This is of course, contentious 
and will be discussed further in Chapter 6.  
46 Research exists that outlines this problem (Chamberlain, 1985), but no reference to this is made, in 
any of the documents at any time.   
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al., 2006).47 Another document created by the NHC regarding chronic conditions 
and their management is comprehensive.  It makes explicit statements about the 
lack of evidence in certain areas related to culturally appropriate care and the need 
for government to fill this gap, but also makes clear statements about the 
importance of culturally sensitive care, considerations of inequalities in designing 
care, patient-centric management and so on (National Health Committee, n.d.-b).   A 
statement that best typifies this document is: “Any effort to limit the impact of 
chronic conditions should ensure that outcomes for groups at greatest disadvantage 
improve earliest and most significantly”(National Health Committee, n.d.-b). 
However, this document is much older than the other NHC documents available 
(2006, versus 2015). It is probable that the stark difference in tone reflects the 
change of government in New Zealand.48  
PHARMAC HTAs (eculizumab and Herceptin) and ACC HTAs that were available 
online similarly lacked reference to inequalities or specific groups such as Māori. 
However, PHARMAC has a section of their website that listed some Māori research 
references and a section of their website addresses Māori issues.49 The ACC website, 
which has a publication section for their evidence-based reviews, procurement 
reports, guidelines, and research project outcomes, has one document that is 
specifically about Māori (ACC, 2016).  The NHC Chronic Condition document (the 
described more favourably above) is the only one to mention Pasifika and no HTA 
documents mention people with learning disabilities anywhere.  
This lack of reference to the three case groups in these kinds of documentation and 
tools is important because within the health system and policy settings, guidelines, 
prediction rules, cost-benefit analyses, and the like, are becoming fundamental to 
                                                        
47 To be clear, data sets from census or mortality data is likely to be accurate, but this is only very 
specific information.  Various prevalence and service use data, as well as data from surveys, may be 
less reliable. 
48 The National government, which would be described as centrist-right/right took over government 
from a three-term Labour government.  It is generally acknowledged that during that Labour period 
great headway was made in terms of disparities in New Zealand, and this in part was due to various 
health policies that were underpinned by the tagline “Better Health For All”. The National 
governments initial health policies had taglines and titles such as “Better, Sooner, More Convenient”. 
49 PHARMAC have also recently launched new “factors for consideration” which are their decision-
making criteria and these include specific reference to inequalities and Māori outcomes. These new 
factors are still in the process of implementation and the degree to which they are weighted is not 
clear. This question of weighting was specifically asked at an AABHL Conference in 2015 of a 
presenter from PHARMAC introducing these factors, who stated there currently were no weights 
assigned to individual factors and how they would be traded off against each was not yet clear. 
54 
 
healthcare and healthcare decision-making.  These tools are essential in a system 
marked by economic-targets, standardisation, and managerialism (Adams & 
Leveson, 2012; Bill Doolin & Stewart Lawrence, 1997; Maddock & Morgan, 1998; 
McCloskey & Diers, 2005). Where these decisions and tools are created using 
research that lacks external validity to the setting and population, there is the risk of 
disadvantaging people further, by failing to address their needs and alienating them 
from the healthcare system. 
The Ministry of Health developed a tool “Health Equity Assessment Tool” in 2008 
(Signal, Martin, Cram, & Robson, 2008) to help those designing services, 
programmes, guidelines and policies to incorporate health equity considerations.  
The tool outlines a step-by-step process for understanding health inequities by 
identifying determinants and addressing them in your setting.  Again this document 
predates the current government, and the degree to which it is being used is 
unclear.  Interestingly, it does require that work using the tool is evidence-based, 
but calls for the inclusion of evidence from grey literature, qualitative work, as well 
as key informants (in addition to the general evidence definition).  None of the 
documents sourced referenced this tool. 
2.7. Research for the Case Populations 
From the previous sections, we can see that there is relatively little clinical work or 
‘evidence’ generation done specifically for the groups chosen to represent 
disadvantage.  It is important, however, to confirm what work people are doing 
outside of these main settings. 
2.7.1. Māori Research 
Te Puna Kokiri is a government funded organisation that provides advice to 
government on all matters Māori.50 They also conduct trials to test policy (not solely 
health related).  One of their most significant portfolios is the Whānau Ora 
programme51, a programme championed by the Māori Party52 that uses an 
innovative model to improve Māori well-being across multiple domains (i.e. health, 
                                                        
50 For more information on Te Puna Kokiri, please see: https://www.tpk.govt.nz/en/  
51 It is important to note here that while the Whānau Ora services are a Māori-led model, and were 
originally only for Māori it can now be accessed by, any New Zealander, irrespective of ethnicity. 
52 The Māori Party is a New Zealand political party that specifically advocates for and supports Māori 




education, housing).  Te Puna Kokiri and the Ministry of Social Development fund it 
as a joint initiative.53 While Te Puna Kokiri does not have a specific health research 
remit or stream, Whānau Ora has a Whānau Ora Research page embedded within 
the Community Research (Tangata Whenua, Community & Voluntary Sector 
Research Centre, a registered charity and incorporated society focusing on 
collecting, disseminating and promoting community research)54 website.  This 
webpage collects research on “Whānau Ora, communities, and whānau” and shares 
this openly while providing a space for discussion and networking.55 
In this repository, 38 projects are listed and provide information on a wide variety 
of topics. These topics include models of health; frameworks for undertaking health 
interventions, research, or evaluations of Whānau Ora; what is appropriate 
evidence; discussions of Tino Rangatiratanga (sovereignty) in relation to well-being; 
best practice guides; service tools; and implementation research. The majority of 
this research is about understanding how to conduct research or provide services or 
measures outcomes in a way that is responsive to Māori and does this through 
theoretical or empirical work.56 
Another source of research information for Māori is the Māori edition of the 
“Research Reviews”.  A private company employs recognised experts in various 
fields to collate and comment on recent research in a given area to create each 
review, which are distributed via email to those who subscribe.57  One of these 
expert areas is Māori Health.  Currently, there are 61 reviews available online.  
These reviews include a mixture of epidemiological research, national and 
international research that includes Māori or is of relevance to Māori. Interventional 
work is mostly international (and therefore does not include Māori in the sampling). 
Reviews also contain local studies and qualitative work on occasion. 
Each University has a Māori research unit of some form, i.e. Auckland and Otago 
have specific health research units, Victoria has a Treaty of Waitangi unit, Waikato 
                                                        
53 For more information, see: https://www.tpk.govt.nz/en/whakamahia/whanau-ora/  
54 For more information, see: http://www.communityresearch.org.nz/  
55 For more information, see: http://whanauoraresearch.co.nz/about-whanau-ora-research/  
56 A full list is available here: http://whanauoraresearch.co.nz/browse/all/  
57 For more information see: http://www.researchreview.co.nz/nz/About-Us.aspx  
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has a unit with a psychology focus, AUT has a Māori Health Team, and so some 
dedicated resources and funding are being allocated to research for Māori.  
There is, therefore, reason to believe that information exists that could provide a 
broader picture in decision-making if used. However, this information may not 
reach grading standards if evaluated based on evidence-based hierarchies.  It is 
important to remember that such hierarchies only measure information against one 
dimension of validity (efficacy); ignoring information that might provide other 
useful material (this is discussed fully in Chapter 5).  
Māori have representatives on most formal government committees from those that 
sit in the Ministry of Health to those sitting on ethics committees or grant funding 
panels, and other organisational committees.  Working parties may not have specific 
representation, but they may ask for advice on policy and documents.  While Māori 
representation is somewhat more formalised and protected through NZ’s Treaty58 
with Māori, there is an indication in Chapter 4 that there are questions as to the 
quality of this representation. 
2.7.2. Pasifika Research 
Pasifika peoples have a Ministry of Pacific Peoples much like Te Puna Kokiri (but 
smaller) that provides policy advice to government and supports Pasifika peoples’ 
flourishing in NZ through a variety of initiatives.59 There is no equivalent Whānau 
Ora programme for well-being or health but after changes to Whānau Ora any 
person of any ethnicity could access the programme.  There is no dedicated website 
to the dissemination of Pacific Health research.  Some universities do have Pacific 
Health Research units; these exist at AUT and Auckland.  Other Universities have a 
research stream within other health research units, such as at Massey or Otago.   
The “Research Reviews” organisation also has an expert review in Pacific Health, 
although this has not been available as long (only 24 reviews are online) as the one 
                                                        
58 The Treaty of Waitangi (Tiriti o Waitangi) is the constitutional document that establishes the 
relationship between the Tangata Whenua (People of the Land) and the Crown.  The document is 
controversial, insofar as it is argued that the English and Māori translations did not marry up, and so 
Māori believed they were signing something else (it is also of note that not all iwi (tribes) 
representatives signed the Treaty).  The Treaty is used in modern times, to underpin Māori self-
determination and rights, and for Māori to make claims of compensation. For more information see: 
http://www.teara.govt.nz/en/treaty-of-waitangi  
59 For more information, see http://www.mpp.govt.nz/what-we-do/  
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described above for Māori.60 Again, as with the Māori Health Research Reviews, 
much of the work included is epidemiological where it specifically applies to 
Pasifika Peoples, intervention studies in the reviews were mixed regarding their 
inclusion of Pasifika peoples, and some qualitative or theoretical work was present.  
Representation in decision-making processes that directly affect Pasifika peoples is 
not enshrined in policy as it is for Māori.  Therefore, representation for Pasifika 
relies on individual organisations’ philosophy regarding representation and 
consultation.61  
2.7.3. People with Learning Disabilities Research 
The Office of Disability Issues is the government department tasked with providing 
advice for policy and services that affect the disabled, and this includes people with 
learning disabilities, but people with learning disabilities are not their sole focus. 
The Donald Beasley Institute (a not-for-profit organisation) is the only dedicated 
research organisation or unit for people with learning disabilities, although 
individual researchers at Auckland, AUT, Massey, Victoria and Otago do conduct 
research for and with people with learning disabilities.  There is no Research 
Review for people with learning disabilities. There is no dedicated funding, as was 
mentioned for Māori and Pasifika in Section 3.3. of this chapter. There is no 
dedicated representation on general health service committees that make decisions 
that will impact their lives, although some committees and  services specifically for 
this group will consult, and some (advocacy) organisations are committed to 
ensuring people with learning disabilities have a voice and are considered (like the 
Donald Beasley Institute, IHC or  People First, to name but a few). 62  
People with learning disabilities, while being a very small percentage of the 
population, fare the worst in health outcomes (life expectancy at birth of 59.7/59.5 
years for males and females respectively, well below the global average of 71.4 
                                                        
60For more information see: http://www.pacifichealthreview.co.nz/ph/Pages/Recent-Reviews.aspx  
61 And the advocacy and activism of Pasifika health champions who argue for appropriate 
representation. 
62 The Office of Disability Issues has recently undergone a major consultation process as it is 
updating the current disability strategy. The Office is very good at providing ways for all to 
participate in this kind of consultation allowing various forms of submission from recorded to 
written, open forums, support those making submissions and so forth.  (Personal communication 
with Donald Beasley Institute). 
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years)(Linton et al., 2011; WHO, n.d.-d) with little research support to change that 
outcome.63 
2.8 Data for the Case Populations 
Big Data is the use and combination of large datasets collected by various 
government organisations. Within this context, those organisations are government 
organisations providing health and social services, although Big Data is also possible 
in commercial settings.  
Big Data is put forward as a solution to data scarcity for minority populations 
(Raghupathi & Raghupathi, 2014), insofar as those populations not taking part in 
research will have accessed services and so decision-makers can use information 
regarding their access use as a proxy.  Māori and Pasifika health service data is 
dependent on ethnicity reporting, while learning disability data is much harder to 
collect. 
The reporting of ethnicity data is variable (Swan et al., 2006; Bramley & Latimer, 
2007). Efforts are being made to improve this. 
While reviewing all 20 District Health Board Māori Health Plans for 2013/2014 for 
information regarding District Health Board decision-making, it was found that all 
included the priority of improving ethnicity data collection (specifically for Māori).  
The Ministry of Health also introduced a Primary Care Ethnicity Data Audit Toolkit64 
in 2013 to support DHBs in improving their ethnicity data collection.  
Statistics New Zealand created a framework for Māori statistics (Statistics New 
Zealand, 2002) discussion document recognising the need for measures and data 
collection that was reflective and responsive to Te Ao Māori (the Māori world view). 
It is not clear how well things have improved or how well this framework has been 
adopted. Statistics New Zealand also recently created the Integrated Data 
Infrastructure65 combining large sets of government data across ministries which 
researchers can access on approval (anonymised datasets), but there is no specific 
                                                        
63 One could argue that due to their smaller proportion in society that funding and attention is 
currently adequate, but this claim will be investigated further in Chapter 6. 
64 Available from: http://www.health.govt.nz/publication/primary-care-ethnicity-data-audit-toolkit  




mention on their website as to how Māori (or any other group is being considered 
appropriately in this work).  
For people with learning disabilities and those seeking to make their lives better, 
data availability is even direr. As noted in the Linton report above (Linton et al., 
2011) there are issues of classification, under-diagnosis, and under- and 
misreporting, meaning that quantification or identification of the population is in 
and of itself an issue, before seeking data on service use.  
In addition to Big Data, open data is a term for the sharing of raw research data 
between researchers. Open data, which also presents a means of reducing the 
research burden on minority populations and a way of making up for research data 
scarcity (by using and combining already existing datasets), rests on researchers 
inclusion and reporting of detailed demographic data.  As presented earlier in this 
chapter, that reporting is variable and arguably insufficient.  
2.9. Summary 
In this chapter, I have provided a description of health disparities that exist for 
three case populations; Māori, Pasifika, and people with learning disabilities. These 
differences showed poorer outcomes for these groups, especially for chronic 
conditions, but also for injury-related illness (such as falls, motor accidents, and 
suicides).  
While others have investigated the incorporation of Māori scholarship in public 
health documentation (Came, 2012, 2014) or the use of trial registries in NZ (Currie 
& Jull, 2012; Jull et al.,2005), this work is the first of its kind to try and establish 
representation of those who suffer health inequity in research activity and the 
processes that use research in decision-making. Based on the limited information 
available in funding, trial registry and ethics committee records, there is an 
indication that representation in research activity for these groups is weak.  
Documentation that signifies decision-making within the health system showed 
poor reference to all three of the case populations (although Māori were somewhat 
better represented).  
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Not only is the dearth of research used in decision-making troubling, but the lack of 
overall research for each group is problematic, as advocates who wish to draw 
attention to a specific population and problem, require evidence to move 
governments to take action.  Governments determine what work they will prioritise 
based on proof of a problem. This proof includes research.  There is, therefore, a 
circular barrier to addressing inequalities, when the only way to be prioritised is 
through research that shows evidence of disparities, but research itself is 
inequitable. 
Ethics committees should review representation based on the definition of justice 
within ethics guidelines in NZ.   In Chapter 3, I move to ethics committee review as 
means of understanding why representation is lacking and if committee review is 




Chapter 3: Justice and Ethics committees 
An important point of evaluation, when deciding whether the research we conduct 
is just, is ethics committee review. Ethics committees are responsible for ensuring 
researchers and their projects meet ethical standards. One of those ethical 
standards is the principle of justice within the Aotearoa New Zealand (NZ) (and 
most Western) frameworks (Beauchamp & Childress, 2001; NEAC, 2012a, 2012b; 
The National Health and Medical Research Council, 2015). Justice in ethical review 
is included to protect those who have vulnerability, in regards to not only their 
participation but also their exclusion (Bismark & Morris, 2014; Emanuel, Wendler, 
Killen, & Grady, 2004; Pieper & Thomson, 2013; Ryan, 1978). What is meant by 
justice, how committees review justice and what recommendations they make, is 
problematic, given that guidance explicitly states that researchers must incorporate 
justice into research design, yet we ask for no real accounting of it. Nor is it evident 
in practice based on the work outlined in Chapter 2.   If we see the lack of 
representation both within individual trials, as well as the lack of representation 
across all possible trials as an injustice, then this prompts questions of who is 
responsible for ensuring representation as a form of justice. How are ethics 
committees tasked with addressing justice, if at all? How do ethics committees 
understand and enact this duty?  
3.1. Background 
In NZ, some but not all ethics committees are accredited. The Health Research 
Council (HRC) of New Zealand provides accreditation based on their mandate as set 
out in the Health Research Council Act of 1990. The HRC Ethics Committee only 
provides this accreditation to committees on the submission of evidence of a 
committee’s ability to provide a fair and robust review. The guidelines created by 
the HRC ask for evidence of this ability to review (HRC-NZ, 2012).  Ability to review 
is measured based on evidence of processes for the review of applications; annual 
training; an appropriate mix of gender, ethnicity, lay and expert perspectives; and a 
full and safe procedure for record-keeping and annual reporting (HRC-NZ, 2012). If 
a committee provides sufficient evidence, the HRC grants accreditation.  
Accreditation provides a committee with: 
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1) Reputational Confidence – i.e. people can trust that they have met 
government standards of practice as a committee. 
2) Only research approved by an accredited committee can receive HRC 
funding.  
3) Only research approved by an accredited committee has coverage under the 
Injury Prevention, Rehabilitation and Compensation Act 2001, meaning 
those injured in any way during a research process have access to Accident 
and Compensation Corporation services, rather than an individual 
institution’s indemnity insurance.66 (HRC-NZ, 2012) 
 
Of note, the types of accredited committees fall into three categories: 
1) Health and Disability Ethics Committee (run by the Ministry of Health) 
2) Institutional Ethics Committees (run by Universities and Polytechnics) 
3) Private Sector Committees (such as Zentech’ s committee, now defunct) 
 
The Health and Disability Ethics Committees (HDECS)67 are charged with reviewing 
any research that involves human participants in their capacity as consumers of 
health and disability support services (or their relatives/caregivers), human 
participants in their capacity as volunteers in clinical trials (including 
bioequivalence/bioavailability studies), any project involving human tissue (with 
some exceptions) and any project using health data (with some exceptions).  They 
do not review low-risk medical device projects, low-risk observational studies, 
audits, or student projects (unless they are an intervention and at PhD level). 
Institutional Ethics Committees review work that does not meet the minimum 
threshold for HDEC review. 
Approved ethics committees have some guideline documents they can and should 
take direction from in their operations: 
1) Ethical Guidelines for Intervention Studies. National Ethics Advisory 
Committee (2012).  
2) Ethical Guidelines for Observational Studies: Observational Research, Audits, 
and Related Activities. National Ethics Advisory Committee (2012).  
                                                        
66 There are some caveats specific to commercial endeavours 
67 See: http://ethics.health.govt.nz/applying-review  
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3) Good Clinical Research Practice Guideline (Part 11 of the Guideline on the 
Regulation of Therapeutic Products in New Zealand). Medsafe, Ministry of 
Health (2011).  
4) Guidelines for Researchers on Health Research Involving Māori. Health 
Research Council of New Zealand (2010 version 2)  
5) HRC Guidance Notes on Research Ethics 6 Guidelines for the Use of Human 
Tissue for Future Unspecified Research Purposes. Ministry of Health (2007). 
6) Guidelines for Using Cells from Established Human Embryonic Stem Cell 
Lines for Research. Ministry of Health (2006).  
7) Health and Disability Commissioner (Code of Health and Disability Services 
Consumers’ Rights) Regulations 1996. Health Information Privacy Code 
1994. HRC Guidelines for Approval of Ethics Committees. Health Research 
Council of New Zealand (2012).  
8) Non-Therapeutic use of Human Tissue NZS 8135:2009. Standards New 
Zealand (2009).  
9) Pacific Health Research Guidelines. Health Research Council of New Zealand 
(2014)  
10) Te Ara Tika: Guidelines for Māori Research Ethics: A framework for 
researchers and ethics committee members. Pūtaiora Writing Group (2010). 
 
Documents 1) and 2) pertain to most health research, while 5) and 6) for example 
are only used in very specific fields. One would hope 4), 9), and 10) are read widely 
used, but there is no way of knowing this at present.68  The first two documents are 
guidelines that those assessing and designing clinical research should be aware of 
and they have very specific justice requirements (see Figure 10). Given the findings 
in Chapter 2 of a lack of representation, it is important to understand who is 
considering representation as an element of justice in the process of generating 
evidence and how, so that we can address the failing. Ethics committees would seem 
an obvious starting point given the NEAC guidelines (Figure 10). 
                                                        
68 Document 1 and 2 are also the only documents to set all aspects of ethical review, except for 
documents 9) and 10) which relate indigenous perspectives and Pasifika perspectives to research 




Figure 10 - Section on Justice, NEAC Guidelines for Interventional Studies (NEAC, 2012a, 2012b) 
These justice requirements cover both a micro and macro-level of justice and make 
clear our obligations to the Tangata Whenua. 
How is this micro/macro distinction being used here? Justice directed towards 
individuals is micro-justice: is each participant within a research study treated 
justly? Macro-justice is external to the research study; it relates to population(s) in 
society or society as a whole, who are advantaged or disadvantaged by the research 
study.  So 4.5 (Figure 10) includes both micro-justice (balance of burdens and 
benefits for the individual) and macro-justice (fair distribution) whereas 4.6 would 
address macro-justice, 4.7-4.10 are a mixture of both.   
It is interesting that some prescriptions set out in this section of the guidelines 
include qualifiers, such as “where applicable” (4.7 – Figure 10), but the guidelines 
give no further explanation. What constitutes applicability?  When does a study 
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meet the requirement for incorporating Treaty principles – what is the bar at which 
Treaty principles need to be incorporated and below which they do not? Direct 
impact is an obvious answer, but what of indirect impact and what level of impact, 
what of potential participation of Māori, without necessarily being the primary 
focus?   To switch this around for further clarity, what are the characteristics of 
studies, where no consideration of Treaty principles is required? Laboratory 
studies? Phase 1 Pharmaceutical studies? These too can impact on Māori lives. 
Moreover, as we saw in the preceding chapter for Pasifika peoples, genetic variation 
can make a significant difference in drug safety (McCormack et al., 2012). 
Researcher recognition of applicability cannot be taken as a given.  
Furthermore, these statements are all phrased imperatively – guiding action, even if 
differently detailed in that guidance, except 4.10 which simply makes a statement.  
How committees can assess an application against these prescriptions is less clear 
and especially so for those points that address macro-justice. I interpret 4.6 to mean 
that all studies should consider ways in which they can reduce inequalities through 
the choice of their study questions and processes in their given area of interest. 
What is not clear, however, is how a committee has evaluated this point or directed 
applicants to change protocols or processes based on this point (more to this later 
in the chapter).  
Therefore in trying to understand fair representation in research, 4.5 and 4.6 are of 
particular interest (addressing inequity/inequality more globally), but also 4.7-4.10 
are equally important given that these address Tangata Whenua, to whom NZ has 
distinct obligations based on the Treaty. 
I felt it was important to understand: 
- whether committee members agreed with these definitions and principles;  
- whether they felt that they had the mandate/power to request changes to a 
project in relation to these statements; 
- whether they did ask applicants to address these statements in their 
projects; and 




These items are necessary for the greater project because they inform an analysis of 
where justice could be considered fully in the research process. As was shown, in 
Chapter 2, representation is currently not just. Given the mandate of ethics 
committees (Figure 10), I felt it was vital to understand whether committees do not 
agree with the definition of justice, are unable to review it, or unable to enforce it.  
This information would help inform recommendations for future practice change.  
For example, if committees agree with the definitions of justice and agree that they 
are the point at which to evaluate it, but do not feel able to do so, then this requires 
a different approach, than the problem of committees not agreeing with the 
definition or not agreeing it should be their responsibility to review justice. 
 
In addition to these fundamental questions regarding justice, I thought that 
questioning ethics committees regarding two potential avenues of increasing health 
equity in research, based on arguments in the literature was appropriate. These 
were: 
1) Big & Open Data usage69 
2) Stakeholder Engagement & Collaborative Partnerships70 
 
Data is the “new frontier” in research with many promises made as to what it can 
deliver (Doll & Patel, 2015; Kisely, 2016; Mittelstadt & Floridi, 2015; Raghupathi & 
Raghupathi, 2014; Reardon, 2014; The use of routine healthcare data in New 
Zealand, Gurney, 2012).  Equally, data use raises its own questions, with literature 
citing worries around its accuracy, safety, and privacy (Bramley & Latimer, 2007; 
Iorio, Carinci, & Oderkirk, 2014; Jepson, 2014; Mittelstadt & Floridi, 2015; Swan et 
al., 2006). As noted in Chapter 2, data usage could be useful for marginalised 
populations if decision-makers can use data already available in the various systems 
that exist where research data is lacking. However, if the data is also deficient (due 
to poor data practices and inappropriate classification categories) and is analysed 
using dominant perspectives with no consideration of marginalised views, then data 
holds no further promises for these groups. Ethics committees would seem like an 
                                                        
69 See Appendix B-1 
70 See Appendix B-1 
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obvious place to promote and support good practice; I wanted to know if they 
agreed. 
Engagement practices that include communities and participants in the decision-
making of research are not new and people have been advocating for them for some 
time (Barkhordarian et al., 2015; Hunt, Gogognon, & Ridde, 2014; MacQueen et al., 
2015; O¿Mara-Eves et al., 2015; Sarrami-Foroushani, Travaglia, Debono, & 
Braithwaite, 2014; Shakespeare, 1996; van Bekkum, Fergie, & Hilton, 2016; 
Varvasovszky & Brugha, 2000). These practices which can vary in type, duration 
and frequency of input are dependent on researchers and their professional 
practice and commitment to relationship development.  People engage in various 
ways whether a one-off meeting with the major stakeholders to determine an issue 
or get input on intervention design, or the commitment to co-design 
(participants/community as co-researchers). The evidence, however, would suggest 
that researchers can engage perfunctorily or with little understanding of what 
proper engagement is supposed to mean (Deverka et al., 2012; S. R. Oliver et al., 
2008; Wright, Foster, Amir, Elliott, & Wilson, 2010).  Again stakeholder practices 
and more involved collaborative partnerships raise ethical concerns related to 
managing relationships and power.  Collaborative partnerships which involve co-
ownership and shared responsibility can be particularly challenging given they do 
not neatly fit into our ideas of informed consent, research objectivity, and  
intellectual property for example (Beebeejaun, Durose, Rees, Richardson, & 
Richardson, 2015; Goodyear-Smith, Jackson, & Greenhalgh, 2015; Hunt et al., 2014; 
MacQueen et al., 2015). It, therefore, seemed prudent to ask ethics committees what 
they understand by these terms; how useful they might be in addressing equity; and 
how problematic (if at all) they might be for ethics committees to review.  
3.2. Aim 
Given the larger project examining research practices and health equity, within this 
sub-project, the aims were to: 
1) Explore NZ Approved ethics committee member views of justice review in 
ethics: 
a. do they agree with the definition, 
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b. do they review aspects of justice within an application,  
c. do they make recommendations,  
d. do they want to make recommendations but feel they cannot, and  
e. are recommendations addressed? 
2) Explore NZ accredited ethics committee member views on the research 
practices proposed (data practices and engagement practices) and their 
usefulness for improving health equity and their implications for ethical 
review. 
3.3. Methodology 
3.3.1 Survey Development 
I designed a cross-sectional, descriptive online survey, using both quantitative 
(yes/no; Likert scales) and open text box responses, to explore aims as described.  
In choosing this method and combining both aims into one survey (versus two) I 
considered various factors: 
1) Choosing an online survey as the first point of contact seemed prudent given 
an awareness of ethics committee member workloads and the nature of 
committee commitment often being voluntary. A survey albeit a longer one 
in the norm of surveys (25-35mins) seemed like less of an imposition than a 
focus group or interviews. 
2) Choosing to complete one longer survey versus two short surveys was 
considered more likely to provide a positive response rate. There was a risk 
in separating the surveys that the first may have a good response rate, but 
the rate may have dropped when asked to complete the second survey. 
3) Contextually, it was also important to have both the discussion about justice 
and what practices may help improve elements of justice in the same 
“conversation”.  
 
Using accepted survey methodologies, I created the survey and planned a pre-test 
(Hunt, Sparkman Jr, & Wilcox, 1982; Andrews, Nonnecke, & Preece, 2003; Kelley, 
Clark, Brown, & Sitzia, 2003; Groves et al., 2011).  The survey included 31 questions 
(all optional). Part 1 covered the statements from the NEAC guidelines, asked 
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participants to rate their responses to different questions around the justice 
statements on 5-point Likert scales (plus “no comment” point; considered best 
practice) or provide open answers (see the full survey in Appendix B-1). Each 
question involving a Likert scale also provided an open text box for participants to 
make any further comments they may wish to make and in some cases had follow-
up questions with comment boxes. 
Questions built on each other, from: 
1. Do you agree with the statements (statements provided from guidelines)? 
2. How often do you receive applications that address these statements in their 
initial submission? 
3. How often does your committee make recommendations to applicants 
around these statements? 
4. How often have you felt your committee should make a recommendation 
around these statements, but has not? 
a. If you felt there were instances where matters of justice were not 
addressed, why do you think this was the case? 
5. How often has your committee made recommendations in relation to the 
following statements that were contested or opposed by the applicant? 
a. Where they were met with opposition, explain what you think the 
reasons for that opposition were? 
b. Where they were met with opposition, how was the situation 
resolved? 
6. How often has your committee made recommendations in relation to the 
following statements that were well received by applicants? 
7. Do you as a committee member ever omit recommendations in relation to 
justice that you would like to make? Why? 
 
These questions asked participants to report based on their recollection; this is a 
limitation of the methodology, but one that recognises constraints of the setting.71 I 
hypothesised that applications where participants felt some form of injustice or 
                                                        
71 The ability to assess each committees’ assessment of each application they reviewed was not 
possible within the limited resources of the project (i.e. some of these committees have open 
meetings, but to attend them all would mean travelling the country monthly). 
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discrepancy occurred were likely to stick out in their minds. A further triangulation 
of data was undertaken using committee minutes, and this is described in the 
limitations section 4.6. 
 
Between this first and second section of the survey, participants were asked to 
describe in what order they reviewed an ethics application. In the second part of the 
survey, I then used a similar methodology to the first section to elicit ethics 
committees’ views on the benefits and risks of, and their review role in: Big Data, 
Open Data, Stakeholder Engagement and Collaborative Partnerships. For each topic, 
participants were first asked to give an explanation of what they understand by a 
term, such as “Big Data”.  I then provided a definition of the term as is commonly 
accepted in the literature, before asking further questions rating statements around 
the use of the term in research. Questions addressed both the usefulness of a 
described term for health equity and how well an ethics committee can evaluate the 
practice related to the term (see Appendix B-1).  
I revised the draft survey with supervisory input before also pre-testing it with 
three purposively sampled members of non-approved ethics committees.72 These 
pre-test answers and respondent feedback of their survey experience resulted in 
the revision of wording of some questions (adding clarity).  
3.3.2 Māori Consultation and Ethical Approval 
I undertook Māori Consultation with Ngai Tahu through the University of Otago 
process.  Consultation lead to the inclusion of a demographic question, which I 
originally omitted given the small target cohort. I added this demographic question 
and amended the information sheet to make clear that I would make every effort to 
analyse and report on data in such a way as to minimise the risk of participant 
identification. Ethics approval was gained from the Otago University Human Ethics 
Committee (14/195) (Appendix B).  
3.3.3. Recruitment 
                                                        
72 Two members of the Otago Polytechnic Research Ethics Committee & two members of the New 
Zealand Ethics Committee were asked to voluntarily provide input. Three of the four volunteers 
asked agreed to provide feedback. Members of non-accredited committees were chose to pilot the 
survey so as to not reduce the potential pool of participants.  
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The Health Research Council website provided a list of accredited committees.  
From this, I searched the listed committees’ institutional/organisational websites 
for contact details.  An initial email was then sent to the administrator/Chair of each 
committee requesting their dissemination of the invitation to take part in the survey 
to their members. It also asked each committee to confirm the number of members 
that sat on their committee for response rate calculation. I sent reminder emails at 
two weeks and one month after the initial dissemination, and gave a survey end 
date. These emails, however, went through a “gatekeeper” in that I depended on 
either a committee administrator or Chair distributing the emails. This likely 
contributed to the response rate but was unavoidable. 
3.3.4. Analysis 
I undertook a descriptive analysis of quantitative data and open textbox answers 
were used to contextualise this data.  I added a very simple thematic analysis where 
sufficient participants provided full comments in textbox answers.73 
3.4. Results 
3.4.1. Response Rate 
I emailed an invitation and the survey to committee administrators and Chairs. 
Those that confirmed they had distributed it to their committees also provided the 
number of members who sat on their committees. 138 members of approved ethics 
committees received the email with 35 of these members taking part in the survey. 
This number of respondents provides a response rate of 25.36%. Of those 
responses, only 23 were complete (i.e. clicked through entire survey, did not 
necessarily complete all questions, given that none were compulsory). The 
completed survey response rate is therefore 16.67%.  This rate is inadequate to 
make any claims of representation.74 
3.4.2. Responses 
3.4.2.1. Demographics 
                                                        
73 It is accepted (Groves et al., 2011) that these types of surveys with complementary text boxes very 
rarely elicit full answers from participants that can provide sufficient material for thematic analysis, 
although they may provide contextually important qualifiers or explanations. 
74 To achieve a 95% confidence with +/-5% margin of error 102 response were required; even when 
increasing the margin of error to +/-10%, 57 responses were required. 
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The survey was specifically sent to approved ethics committees, however, to 
reiterate that this was the primary audience, the first question asked participants to 
confirm that they were approved ethics committee members (Figure 11). One non-
accredited committee member also appears to have opened the survey. They may 
have been a committee administrator or manager, and one participant skipped the 
question. 
 
Figure 11 - Question 1: Are you a member of an HRC Approved ethics committee in Aotearoa New 
Zealand? 
The second question of the survey asked people to report their ethnicity where they 
felt comfortable doing so.  The option was given to tick more than one category. 
Ethnicity categories were those used by NZ Statistics Census Data options. Results 






















































Figure 12 - Question 2: What ethnicity do you belong to? Tick all that apply75 
3.4.2.2. NEAC Guideline Statements 
As provided earlier in this document, the NEAC statements form the foundation of 
Questions 3-12.  Reported are number of responses as a count. Percentages were 
calculated but then abandoned due to the small numbers represented.  
To begin the questionnaire, we asked committee members whether they agreed 













Table 7 - Question3: Do you agree with these statements? 
                                                        




Responses show that participants overwhelmingly agreed with statements and in 
most cases strongly agreed with statements.  The weakest agreement and the one 
more evenly split between “Agree”/Strongly Agree”( 71.42%, even split 50:50 
between “agree”/”strongly agree”), was the statement  (4.6) about health 
inequalities and consideration of health inequity. Participants ranked most other as 
“strongly agree”. There was some disagreement with the statements, but this 
represented less than 10% of the participants for each statement (when 
disagree/strongly disagree were combined). 
Comments included the need for qualifications. Participants stated they would have 
agreed more strongly to individual statements if the wording had included 
qualifiers.  This comment included recommendations to add “where relevant” and 
other recommendations to be more prescriptive by using words such as “should” or 
“must”.  
Another participant commented that justice and Treaty issues were not well 
considered within ethics committees, as committees were mainly used to assess 
risk, protecting  “institution, researcher, and participants; roughly in that order”.76  I 
interpreted this as frustration, i.e. that they would like ethics committees to be 
doing more, but that they felt within their setting that this was not the case.  Equally, 
                                                        
76 All quotes in italics are from respondents’ survey comments 
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I could have interpreted this to mean that the participant felt that this was the way 
things should be.  
Participants were then asked to report how often they thought they received 
applications that addressed these statements when first submitted (i.e. before 
review recommendations).  
Table 8 - Question 4: How often do you receive applications that address these statements in their initial 
submission? 
 
Responses to this question showed that initial applications were mostly thought to 
address the statements “sometimes” or “often” (58% -80%). While I did not 
complete significance testing due to the response rate, it is worth noting: 
1) Statements 4.7-4.9 regarding the Treaty principles, due recognition of the 
Tangata Whenua and consultation were those that represented the highest 
percentage within the “very often” category.  
2) In the ‘Rarely’ category 4.10 (research informing Māori health priorities) and 
4.5 (fair distribution of burdens/benefits) received the highest percentages 




Where participants were asked to comment further on this section, many did. 
Comments showed that many committees had application forms, which asked 
people to be explicit around statements 4.7-4.10, but in the selection of statements 
from participants that follows, there was recognition of: 
a) Tokenism  “(…)'cut and paste' type answers that don't directly answer or 
engage in the question and show lack of thought or genuine insight” and “Most 
address the PPPs77 with a sense of reluctant compliance” 
b) Avoidance “Often researchers will avoid involving Māori participants if they 
can because anything Māori is perceived to be "hard work" (…).” 
c) Lack of knowledge “Applicants struggle with identifying how to apply the 
TOW78 principles in their work (if they recognize their relevance for their own 
study)” and “(…)many researchers accept the basic principles here, but have 
difficulty - unless they have connections into some Māori communities - in 
realising how these could be implemented (…)”79 
 
Other participants explained that their forms did not make it clear how applicants 
could express thinking in this area and that clear pathways for consultation did not 
exist in their setting.  
Only one participant commented on 4.5/4.6 relating to justice as fair 
distribution/representation, insofar as they felt justice was implicit. In this response 
it would seem justice, when applied to society, is implicit and only explicit when 
applied to Māori, based on the specific sections of committee forms requiring 
responses.  
I then asked participants how often their committees made recommendations to 
applicants in response to these statements, to qualify the previous questions 
regarding the frequency with which applications addressed them.  
 
Table 9 – Question 5: How often does your committee make recommendations to applicants in relation 
to these statements? 
                                                        
77 PPPs are the principles of the Treaty of Waitangi; these are partnership, protection, participation. 
78 TOW – used by participant as short form of Treaty of Waitangi principles. 




Participants mostly reported that they felt their committees responded to these 
statements “sometimes” – the spread of responses was relatively wide across the 
scale. What was of particular interest was that in Question 4,  32% of participants 
said that initial applications rarely addressed 4.10 (research informing Māori health 
priorities), yet this category also had the highest number of participants stating that 
they “rarely” made recommendations about this statement (45.45%).   
If the applicants are not addressing this element of justice (4.10) and the committee 
equally does not respond to it, then either its wording or content is failing to engage 
either party.  
Many comments to these questions referred again specifically to 4.7-4.10 stating 
that the application form specifically requests responses to justice and Māori 
communities. Therefore, recommendations were not necessary, or participants 
presumed that applicants would have had to resolve any issues in Māori 
consultation which they complete before submitting ethics. Evidence of this is in 




“There is also presumption and expectation that the Māori consultation 
component of the application and the actual consultation itself will have raised 
these issues and no recommendations will be made (unless Māori consultation 
has not been carried out or intended)” 
 
“(..)there is a section on the form pertaining to consultation so there is an 
expectation consultation has occurred with Māori, when there are Māori 
participants (…)” 
Only one comment related to 4.5 and 4.6 (fair distribution/representation and 
equity), stating that it would be useful to have more explicit statements or questions 
in the application form that addressed these. Some general comments indicated that 
much was implicit and committees always made recommendations where they 
found shortcomings. Participants also expressed the view that these statements 
were not always relevant. 
Following this question of how often committees made recommendations, it then 
made sense to ask whether there were times where participants felt the committee 
should have made recommendations but had not. I, therefore, asked participants to 











Table 10 - Question 6: How often have you felt that your committee should make a recommendation in 
relation to the following statements, but it hasn't? 
 
Most participants felt that their committees never failed to make recommendations 
they should make, with all statements ranked “Never” 60% of the time. The only 
statement below the 60% average was 4.6 (health equity), but this was only 
minimally so. It may be of note, that within the “often” category, 4.10 (research for 
Māori health priorities) was again the highest.  
I then asked participants to qualify their responses again with comments. Those 
that did respond reiterated that much was left to the Māori representative or 
presumed covered in Māori consultation rather than directly deliberated by the 
committee. It was re-emphasised by one participant that these matters of justice 
were not relevant to all research. 
One participant stated that their committee always passed all recommendations 
they made to researchers. While another participant expressed the view that 
projects they reviewed were of little import to justice and society and were largely 
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for the benefit of academic careers.  Once again, I interpreted this participant’s 
views as an expression of frustration. 
I asked participants to explain why they thought committees omitted 
recommendations if they had been. Responses largely seemed to indicate that a lack 
of recommendations around justice was either due to: 
- injustice not being apparent, or 
- justice was not a priority for review (e.g. risk was), or 
- the form itself did not link the review to “broader, overarching themes such as 
justice”.   
One participant felt that there was prioritisation of some interests over others, as 
they put it: “Fear of losing international investment in research (…)”. 
From this question, I then asked participants whether recommendations were 
contested or opposed by applicants.  
Table 11 - Question 8: How often has your committee made a recommendation in relation to the 
following statements that were contested or opposed by an applicant? 
 
Participants overwhelmingly stated that this “Never” occurred (68.18%-81.82% 
across statements). Within the “Rarely” category, statements with the highest 
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agreement were 4.5 (fair distribution), 4.6 (health inequalities/inequities) and 4.9 
(consultation) with all other statements having a singular agreement.   
Comments to further explain these responses showed that some participants did 
not encounter opposition to recommendations. Participants explained this lack of 
opposition to recommendations in multiple ways.  Either participants thought no 
opposition had arisen because they believed researchers had taken comments on 
board; or they were aware that opposition if it did exist, was managed by the Chair 
without further discussion at committee; or, as one participant described it, 
researchers choose: “(…) the path of least resistance and so instead of directly 
opposing, they provide, for example, token, tick box evidence of Māori consultation.” 
One participant also reported: 
“Contesting by applicants around these issues is rare but mostly occurs around 
the reluctance to modify protocols which are derived from reputable 
collaborative research groups for whom issues around justice of vulnerable 
people and indigenous people do not receive the same focus as here in NZ.” 
I asked participants about the reasons for opposition. Again for some, reasoning 
behind opposition was not transparent, because this information did not come back 
to the committee or it was not clear that opposition had occurred at all to their 
review. Others felt that opposition was often a matter of recommendations 
requiring more resourcing or time than was available, rather than a fundamental 
disagreement as to the principles underlying the recommendations. 
Those that had experienced more negative opposition felt that it showed an 
“Annoyance at being challenged about their study. Frustration, with different opinions 
(within and between committees) about what is required or appropriate” and that 
there was a “lack of thought” and meaningful engagement with Māori. 
I also asked them where they had experienced applicant opposition, how was it 
resolved. For those participants who had encountered opposition, comments 
described clarification and mediation processes, using discussion and identifying 
appropriate members on the committee to interact with different applicants.  One 
participant expressed frustration: 
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“(…), but as we see the same researchers putting forward applications with the issues 
repeated again, it obviously is not resolved in terms of changing thinking” 
 
From here, I then asked how often applicants receive ethics committee 
recommendations well. 
Table 12 - Question 11: How often has your committee made recommendations in relation to the 
following statements that were well received by applicants? 
  
Distribution of responses across the scale fell predominantly for all statements in 
the “Sometimes” and “No Comment” categories. 
It is evident from the comments that this question was not necessarily applicable to 
all participants in that the Chair did not necessarily communicate this kind of 
information to the committee, or as a participant had earlier commented, their 
committee did not make recommendations, or the question itself was thought to be 
unclear. Others responded that only bad feedback was reported back to the 
committee, while others stated that recommendations were often well received, but 
recommendations themselves were not often necessary.  
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One participant made a comprehensive comment relating that sometimes 
recommendations were made to researchers to better answer questions regarding 
the impact for Māori and their involvement and that this was normally done 
“without protest”.  Issues of justice and inequality were rarely raised by the 
committee, but were: “sometimes part of applicants’ presentation of their research 
projects, particularly in health-related research”. 
One participant made clear that within their committee’s recommendations to 
applicants, the committee provided helpful information:   
“I think it's a matter of knowing who to go to for consultation and support about 
Māori issues in research, and just not sending them off to deal with yet another 
faceless bureaucracy.” 
To understand whether in-committee dynamics might play a role, I then asked 
participants whether they had ever omitted questions they wanted to make about 
justice while sitting on their committee. 
 
Figure 13 - Question 12: Do you as a member of your committee ever omit recommendations in relation 




Participants overwhelmingly said that they “Never” omitted recommendations they 
wanted to make (84%). When asked to comment on their answers here to provide 
more information, participants explained that their committees allowed for robust 
discussion and openness, with high levels of knowledge and expertise, allowing all 
to have a say and voice concerns. They noted the importance of raising issues and 
working collaboratively as a committee. 
For others, they did not see recommendations around justice as part of their role: 
“I believe the issue of justice is more of an institutional responsibility. The primary 
work of ethics committees should be to mitigate participants from harm resulting 
from participating in the research.” 
It was also reported that sometimes other considerations override individual 
recommendations, such as:  
a) Primacy of other ethical issues that are perceived to have a greater import, 
“Sometimes larger ethical issues take up the ‘air time’ for a particular review 
(…)” 
b) Importance of review consistency within committees, therefore, 
recommendations omitted that may have contradicted previous decisions, 
“(…) consistency is desired.” 
c) Primacy of priorities – when research is part of an international study “(…) 
the benefits of knowledge outweigh smaller regional concerns.” 
 
One participant also mentioned that their committee discussed the bigger question 
of why researchers were not doing more research for health inequalities but that 
this was beyond the review of an individual application.  
3.4.2.3. Review Order 
This last question concluded the section on the NEAC statements. Before moving to 
Section 2 of the questionnaire, participants were asked to describe the process by 
which they reviewed an ethics application. This question was designed to provide 
information as to what sections/elements of an application provide the information 
ethics committee members want to understand, to assess an applications ethical 
practice. Twenty participants described their process. 
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Participants fell into two groups, those that read the form in the order presented 
and those who went about it in an alternative manner (9 in order; 7 out of order; 4 
not explicitly stated). Those reviewing in a different order favoured reading the 
Patient Information Sheet and Consent Forms first, or methodology before going 
back through the document to then further understand the project.  
Participants reported picking and choosing what information to scrutinise most 
based on their expertise and the expectation that others with different roles and 
skills would do the same (i.e. and therefore pick up their particular gaps).   
Risk/safety came through as the element most investigated in undertaking a review 
where this involved both direct risk and risk to privacy/confidentiality and safety of 
data/samples.  Multiple participants commented on the need to consider the project 
from multiple viewpoints including the “(…) participant, researcher, University, 
General Public.” and “Focus on 'safety' in its broadest sense - for and between 
populations, communities, organisations, family groups and individuals”. 
Participants described very involved and thorough processes for review including 
the notation of questions to ask the applicant when they presented at the committee 
meeting. Others also reported that time constraints could affect their level of 
review, prioritising some elements over others to get work done.  
It was clear that participants wanted to see a demonstration of the applicant’s 
processes and understanding of ethical practice and cultural sensitivity about their 
work and the use of appropriate codes of conduct, guideline documents, or advice. 
Justice was only mentioned by participants insofar as they reported that forms did 
not include it and therefore it was not prioritised; participants reported that 
pressures of reviewing the volume of applications that the committees dealt with 
precluded the promotion of justice; or that when issues of justice did arise they 
came up after other considerations. 
This section ended with participants being prompted to provide any further 
comments they might have to this first section. 
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One participant pointed out that the survey itself was dependent on the recollection 
of those responding. I was aware of this as explained and justified in the 
“Methodology" section above.  
Another participant raised some very valid questions regarding the differentiation 
of health research and social science review; the compliance cost of ethical review 
across disciplines; why ethics committee members with no special status or training 
have the role of “judge or censor” over others and the implications for academic 
freedom. These were all valid and highly interesting questions to the researcher, but 
beyond the remit of the current project.  
3.4.2.4. Data  
The survey then switched to a discussion around potential research practices/ 
methodologies that may be beneficial in reducing health inequities. This section 
began by asking participants what they thought the term “Big Data” meant.  Twenty 
participants provided answers to this question.  
Nine participants stated that they were not familiar with the term or that their 
committee did not use the term. The remaining eleven participants demonstrated 
good knowledge of the term. The low response rate to the survey and then the more 
limited response to this question precludes the drawing of any conclusions, but the 
fact that almost 50% of those responding to this question were not familiar with the 
term would suggest that further work in the data space is necessary. 
I then provided a definition of Big Data80 before asking participants questions 
related to it, to ensure that all participants had a clear understanding of what was 
meant by “Big Data” within the context of the survey. Participants then completed 
questions about how much they agreed/disagreed with the following statements, 




                                                        
80 See Appendix B-1 
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The expanded use of health/government data for research purposes is critical to addressing 
health issues in the 21st century. 
 
The expanded use of health/government data for research purposes can aid in addressing 
issues of health inequity. 
 
The expanded use of health/government data for research purposes carries a high risk. 
 
Oversight of the use of health/government data can safeguard against risk and ensure proper 
use. 
 
Ethics Committees are best placed to provide oversight for use of health/government data. 
Figure 14 - Statements used in Question 16 
Participants answered as follows: 
Table 13 - Question 16: How much do you agree with the following statements about "Big Data" 
initiatives? 
 
Participants did not strongly disagree/disagree with these statements, except for 
two who felt that ethics committees were not the appropriate providers of oversight 
for Big Data. Over 70% “agreed” or “strongly agreed” that the expanded use of Big 
Data could aid issues of health inequity and nearly 60% “agreed” or “strongly 
agreed” that appropriate oversight could be used to safeguard against any risks 
involved in using Big Data. There was much ambivalence within this response with 
nearly a third of participants ranking most statements as “Neither Disagree, Nor 
Agree”, which in all likelihood represents those participants who were not familiar 
with the term.  
As with other questions, participants had the opportunity to provide further 
comment, 14 of which did so.  
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Some expressed a need for more clarity in the question and its relationship to ethics 
committees. Half the participants (7) who made comments expressed concern that 
committees did not have the specific expertise available to provide careful oversight 
of data management appropriate to “Big Data” sets.  Being mindful of the limitations 
of the response rate, this concern is interesting given that only four participants 
disagreed that the committees were the proper body for monitoring – implying that 
some believe it is the appropriate body, but that they require more 
resourcing/expertise to do so.81  Others suggested that other governance bodies 
would be better placed to provide oversight or that a case-by-case approach was 
warranted.  
Participants raised the concern that while people can manage datasets, this does not 
necessarily mean that “(…) privacy and confidentiality.” could be guaranteed given 
that “(…) unforeseen risks may be the major issue (…)” for data, meaning that the 
assessment of risk may not be adequate.  One participant thought a collaborative 
approach between the ethics committee and another body might be the answer due 
to the ethics committee’s limitations:  
“Ethics committees can be part of the process, however (…) (and the standard 
application process) aren't currently configured for good consideration of the 
issues specific to secondary data use, data matching etc. informational risk, 
dignitary harm etc. are writ large for big data.” 
Participants were then asked to describe what they thought the term “Open Data” 
meant. Of the 19 participants that responded to this question, five were not familiar 
with the term, and the remaining 14 rightly described it as research data sets that 
are de-identified and shared freely.  The accepted definition was provided to 
participants before they were then asked to rank their agreement with the following 
statements: 
The compulsory sharing of research data is critical to addressing health issues in the 21st 
century. 
 
The compulsory sharing of research data can aid in addressing issues of health inequity. 
 
                                                        
81 Naturally, all statements of this kind pointing to interesting findings, take into account the lack of 
response rate, and therefore the inability to make any kind of definitive statement. 
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The compulsory sharing of research data carries a high risk. 
 
Oversight of the sharing of research data can safeguard against risk and ensure proper use. 
 
Ethics Committees are best placed to provide oversight for the sharing of research data. 
Figure 15 - Statements used in Question 17 
Given these statements included the word ‘compulsory’ Participants were slightly 
less equivocal about these statements:  
Table 14 - Question 18: How much do you agree with the following statements about Open Data 
initiatives? 
 
Agreement was higher for the statements that sharing carried high risk and that 
oversight could ensure proper use and a reduction in risk. Disagreement was 
highest (although still low) for the statement that ethics committees were best 
placed to provide oversight.  
When asked to provide further comment, opinions reiterated the lack of expertise 
within ethics committees to consider the technological aspects of Big and Open 
Data.  Participants made comments that sharing data made sense regarding the 
reduction inequalities/inequities, but other participants contradicted these 
comments because they felt that this should not be “open slather” but rather access 
for particular groups or felt:  “I do not believe anyone should be compelled to share 
their research data”. 
Others considered the question(s) was too broad to answer – different 
situations/cases called for various responses. The risk of loss of de-
identification/anonymisation was reiterated through multiple statements (with 
examples being provided) and the risk of misuse or misinformation was also raised, 
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with one participant articulating it, as: “(…) Once the genie is out of the bottle, not 
sure over-sight can protect against mis-use?” 
Another participant felt that oversight of the datasets would contradict the principle 
of open-access.  
No participant availed themselves of the opportunity to comment on the section as a 
whole.  
3.4.2.5. Collaborative Partnerships and Stakeholder Engagement 
From here Participants were then asked:  
“Please describe what you think is meant by the term ‘stakeholder 
engagement’ in research, including who stakeholders might be and what 
engagement might entail?” 
Fifteen Participants answered this question and described it as 
talking/discussing/consulting with “(…) people who will be affected by the research”, 
where “people” was defined as:  
“Communities, professional associations and individuals, advocacy groups, iwi and 
half, organisations - govt and not for profit” and “(…) e.g. Māori groups, advocacy or 
support groups relating to a particular condition being studied etc.” and “It very much 
depends on the type of research. It might range from very engaged research generated 
out of a community of interest itself, through to research like clinical trials that 
engage with clinician stakeholders but perhaps not patient stakeholders.”  
Participants stated that the description of stakeholder was project-dependent, but 
could be defined broadly as: ““Stakeholders are anyone who could benefit from the 
research, could participate in the research, could inform the research processes and 
conduct.” 
Responses described stakeholder engagement as a process that improved the 
chances of the project leading to more positive outcomes. While some participants 
described stakeholder engagement as consultation and talking to inform a project, 
others felt that it was something much more involved than this that should begin 
very early on: “Active engagement should begin in early stages of project design and 
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continue throughout. Engagement is more than 'consultation' or informing” and 
“Stakeholder engagement is the idea that people who are part of the research, have an 
interest in the outcomes of the research should be involved in the design of the 
research and the analysis or interpretation of the data.” 
Others commented on the need for researchers to be open and honest when 
engaging in stakeholder relationships ensuring things like the purpose of the 
project, project funders, conflicts of interest, and the like were known. 
From this question, they were then asked to do a similar task, describing their 
understanding of collaborative partnerships: 
 “Please describe what you think is meant by the term ‘collaborative 
partnerships’ in research, including who are the ‘partners’ in these 
relationships are and what activities such partnerships might entail.” 
Again 15 Participants answered this question.  
Participants recognised that collaborative partnerships included greater activity by 
partners in the research process.  However, whereas the literature conceives of 
collaborative partnerships in the community context, participants defined these 
collaborative partnerships more broadly in line with their definition of stakeholders 
(i.e. collaborative partnerships could include industry or other academic 
institutions, as well).  One participant described it fully:  
“This implies an active role where researchers and their partners undertake 
the whole research journey - what questions matter and need to be answered, 
how they should be answered, how the research should be undertaken and 
analysed and then how this should be presented back. Partners I would 
consider communities of interest e.g. ethnic groups, disease advocacy groups, 
patients.” 
Other participants found the term nonsense or the referred to concept unhelpful: 
“Collaborative partnership is a tautology.  A non-collaborative partnership is 




“Too theoretical a concept. Partners will vary depending upon the research. In 
many cases there will be no partners”. 
From here, I then asked participants whether these recommended relationships, 
present challenges for researchers and participants. 
 
Figure 16 - Question 22: Closer relationships with communities/groups that are the target of research is 
recommended. Do you feel that these relationships present challenges for the researcher and their 
participants? 
Twenty participants responded to this question, with the majority (70%) feeling 
that these relationships did present challenges.  Comments to this question were 
then separated based on people’s response. Those that answered “yes” were asked 
to explain what problems they felt arise.  
Responses to this question fell into a number categories:  
Time – challenges of time both for participants (burden) and researchers 
(restrictive timeframes set out from organisations that do not work with 
community engagement). Consultation and finding the right people to 
consult with takes time. 
Skill – engagement requires skill, understanding, a certain level of 




Conflict of Interests/Priorities – this was described not only between 
researcher and participants, but within communities that may be 
heterogeneous, or the difference between the representation of a community 
and the community itself (i.e. research participant wants to take part, 
community “group” does not want people to take part). Agreement between 
parties is not a given and requires negotiation. 
Research Outcome – some saw this as bettering the research outcome 
(even with increased time needs) other felt that it could create “issues with 
impartiality of research results”. 
Knowledge Barriers – this was presented in two forms; one in that 
community groups were not necessarily aware of ethical 
practices/principles and the related requirements, but secondly researchers 
privileging their knowledge over that of the consulting partners.  
For those that responded that they did not see issues, their comments showed that 
they thought relationships were “crucial” and that researchers have to manage 
these relationships. I interpreted these comments as meaning that problems arise 
but just need to be managed rather than that no issues arise per se. 
The survey was designed to probe this further. The next question, therefore, asked 
whether participants thought researchers could manage issues that result from 




Figure 17 - Question 25: Do you think the challenges that arise from closer relationships in research can 
be managed effectively by researchers? 
Participants’ responses were either agreement that researchers could (“Strongly 
Agree” and “Agree” category combined) or neutral (“Neither Disagree, Nor Agree”).  
Of the 19 participants, eight made further comment when offered the opportunity.  
Half of these stated that “it depends”, explaining that whether a researcher could 
manage it or not depended on the individual researchers, their expertise, 
institutional support, whom they were developing relationships with, and whether 
external factors played a role for example.  
While one participant pointed out that they were not clear that this question was 
meaningful: 
“Not sure what challenges you are referring to? All relationships with people 
involved can be challenging but generally they are not, rather they are 
empowering which is the purpose of stakeholder and collaborative 
relationships” 
Another thought that researchers were mostly well-intentioned and “often want to 
'do the right thing' but want guidance on how or what that might look like”.  
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One participant pointed out that: “It takes a skilled researcher - with networks - and 
working in a way that some researchers would see as foreign”.  
The final question in this section then asked whether participants had wanted to 
make recommendations regarding engagement, but had not.  
 
Figure 18 - Question 26: Do you as a member of your committee ever omit recommendations in relation 
to engagement that you would like to make? Why? 
Participants overwhelmingly said “Never” to this question (88.24%) with one 
participant choosing “Sometimes” and one choosing “No Comment”. Four qualified 
their response in this section, one of these however misunderstood the question, 
referring to those applying to ethics rather than themselves (i.e. if ethics applicants 
omit engagement). 
Another felt that engagement was not part of the “ethical remit”. The remaining two 
participants were supportive of engagement, one stating that it was the “most 
important thing a researcher can do” and the other explaining that while it was 
important, it is: 
“Often seen as the role of the Māori or Pacific members of the committee but 
sometimes feel that the tendency to rely on perfunctory consultation or 




There were then two further options for commenting on this section of the survey 
and commenting on the survey as a whole.  The majority of responses commented 
on the length of the survey and the fact that some participants felt that the 
questions asked would have been better answered in a focus group or interview 
setting rather than as a survey.  Participants also made a few positive comments, 
which were received gratefully.  
3.5. Discussion 
It is the task of ethics committees to review research protocols, and this review 
draws on the four principles in Western settings: beneficence, non-maleficence, 
justice and autonomy (these have been added to, but are the core of most 
guidelines)(Beauchamp & Childress, 2001).  This study specifically set out to 
examine how approved ethics committees (i.e. those more likely to be reviewing 
health projects) considered the consideration of justice within their work, whether 
they felt they could make recommendations based on justice, and what they thought 
of measures that may promote justice. Weijer (Weijer, 1999) and Rogers (Rogers, 
2004a; Rogers & Ballantyne, 2009) consider that justice at the very least must cover 
fair representation, while Emanuel et al (2004) also include fair distribution of 
benefit and risk.  Fair representation is thought to provide justice by ensuring that 
the generalisability of a trial is broad rather than directed at a particular group of 
people (those that are similar to the trial participants). Our guidelines here in NZ 
specify what is considered ‘just’ practice in health research in relation to 
distribution, representation and specific requirements concerning the Tangata 
Whenua.  
The results of this survey cannot be considered representative of approved ethics 
committee members’ views due to the low response rate. However, those that have 
responded have provided points for discussion. These points are summarised below 
and then addressed more fully in Chapter 7.  
3.5.1. What belongs in ethical review? 
There was a feeling from some participants that matters of justice were not always 
relevant to the review of projects, that they were less important than risk, or that 
the prevalence of injustices in research design was so small, as to hardly ever 
warrant consideration.  This perception is of interest given that justice is one of the 
97 
 
cornerstones of ethical review in the literature and the guidelines, and that work on 
this project that examined fair representation in research activity showed it to be 
lacking (Chapter 2).  It raises the question of whether justice and injustice are easily 
understood, recognisable and open to addressing through the ethical review 
process; is justice capable of being operationalised at the ethics committee level or 
should issues of justice be considered elsewhere – if elsewhere, where and how?  
3.5.2. What does justice mean in ethical review?  
What naturally follows from this study is a discussion of what is meant by ‘justice’ 
when reviewing a project. We can often quickly delineate risk when reviewing 
projects, more so for physical than psychological/emotional or professional/peer-
harm, but for risk, this identification is much simpler than the question of justice. 
Familiar examples of injustice discussed in ethics classes and the literature are 
researchers completing drug trials in low-income countries for drugs that will never 
be available/affordable within those countries (Emanuel et al., 2004), or vulnerable 
populations (such as prisoners or people with learning disabilities) needing 
protection from exploitation (Ryan, 1978).  What is lacking are relevant and more 
nuanced examples in the local setting. Examples that show the apparent injustice of 
under-representation as clearly as that of distribution.  It would seem that ethics 
committees implicitly make a distinction between micro-justice and macro-justice 
regarding their remit. 
Participants agreed with statements of the NEAC guidelines around the issues of 
health inequity the least, and one can only assume this is due to the perception of 
relevance, i.e. health inequity is not relevant to all research.82 It is clear that ethics 
committees are not in a position to ensure that there is a balance of representation 
across all research activity.  What they could be empowered to do, however, is 
ensure that individual studies address macro-justice through their design, 
processes, and engagement with appropriate populations.  In fact, there is some 
literature that argues that lack of representation in studies is not only based on 
minority populations distrusting researchers because of past research abuses. This 
literature puts forward the idea, that lack of representation rests on the absence of 
effort by researchers to recruit a diversity of people using activities such as 
                                                        
82 This is discussed further in Chapter 6 – is this assumption a fair one/accurate one?  
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outreach (Maghera et al., 2014; Symonds, Lord, Mitchell, & Raghavan, 2012; UyBico, 
Pavel, & Gross, 2007). Broader discussion and agreement is necessary to ensure 
macro-justice given such complex matters: distinctions between the obligations of 
commercial versus public research, the binding nature of ethics committee 
recommendations/ requirements that incur further costs, minimum standards 
versus desirable standards, and many others. 
At present ethics committee application forms do not provide information to assess 
these matters appropriately. A detailed description of the demographics of those 
affected by the condition/situation of interest and who fares worst within that 
population, would be an example of information required. At present inclusion and 
exclusion criteria are the only information sought, although many applicants would 
describe some demographics of their populations in the background sections of 
their application.  Currently, committees rely on the expertise and experience of 
their members to assess whether recruitment methods are fair and research 
designs implicitly exclude certain subgroups of any given population (as they do 
with other elements of the application). This reliance on individuals appears ad hoc 
in upholding justice within ethically sound research. Adjusting a form only works as 
a proxy for measuring true practice and understanding.  Some would argue (Smith, 
1999; Tolich & Smith, 2015), and it has been noted in responses to this survey, that 
current form requirements about Māori consultation, much like other cultural 
requirements and engagement, can be filled in, in a tokenistic fashion, rather than 
genuinely. 
What is more, Statement 4.10 (Figure 10) which reminds us that high-quality 
research can inform policy and empower Māori, fails to direct action as it places no 
requirement on researchers to ensure that this is indeed occurring.  Equally, one 
could argue that this statement should apply to more groups who are suffering 
disadvantage or marginalisation. It is unclear what the purpose of this statement is 
within the guidelines. Researchers are said to find ethical guidelines unhelpful 
(Stark, 2012; Tolich & Tumilty, 2013), and anecdotally researchers describe 
guideline-use as something at the point of applying for ethics, not at the point of 
research design itself, where such guidance would be informative.   
99 
 
Some participants repeatedly stated that matters of justice do not only apply to 
health research but also to other forms of research. I agree with this view, but given 
the scope of this work, I was only able to consider health research in this instance. 
What would be helpful in emphasising the need to consider justice across the scope 
of research would be guidelines from NEAC that addressed more than 
interventional/observational research projects, given that health research can often 
also utilise sociological rather than biomedical methodologies and that these also 
require ethical review. 
3.5.3. Demanding workloads 
Participants in some cases made mention of the workloads they dealt with on their 
committees and that this could affect their review of applications. There was also 
reference made to the demanding workload of researchers and the consequent 
restrictions on their ability to connect with populations affected by their work.  This 
connection to populations is often key in not only designing just research, but 
research with impact (Dunston, Lee, Boud, Brodie, & Chiarella, 2009; Faulkner & 
Thomas, 2002; Gillard, Simons, Turner, Lucock, & Edwards, 2012; Hewison, Gale, & 
Shapiro, 2012). Workload issues are an ongoing problem for both committees and 
academics.  
3.5.4. Tokenism 
There were comments made throughout of researchers “talking the talk” but not 
necessarily “walking the walk” and just doing what was necessary to get approval. 
Participants saw evidence of this for relationships and ethics requirements in 
general, but also more specifically for researchers and their commitment to Te Ao 
Māori and its tikanga and whenua (insofar as in some cases they saw no 
commitment).  Comments showed that this was due to a lack of understanding or 
knowledge and again, issues of time and resourcing.  
3.5.5. Big Data/Open Data 
It was of interest that most participants felt that data practices could affect health 
inequity and oversight was appropriate for data practices to minimise risk, but that 
this oversight might not be best provided by an ethics committee (or at least not in 
their current form).  It may be that committees could add a “data-tech” expert much 
like the previous inclusion of biostatisticians into HDECs. It could also be the case 
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that a separate system is more desirable that deals with all data management 
nationally. Issues around data persist, for example: 
- management of informed consent where researchers use data in multiple 
projects over extended periods of time; 
- the possibility of identification where multiple sets of data are combined; 
and 
- misuse of data for purposes that may be counter to participants’ values.  
An alternative model exists for Māori in some cases with Kaitiaki83 groups managing 
access to data (described further in Chapter 7) and some discussions have been had 
around cultural issues and biobanks or collective consent84 (Hudson, 2009; Beaton 
et al., 2016). Collective consent is controversial and often misunderstood.  The 
collective consent model proposed by Maui Hudson (2009) asks researchers to 
consult with iwi (tribe) and get consent from iwi prior to individual consent from 
participants within the tribe.  This prior iwi consent addresses questions of benefits 
and risks to the community, rather than individual.  Others have interpreted this to 
mean that collective consent trumps individual consent, but this is not the case.  
This kind of consultation is important especially for biobank data given the 
importance of whakapapa (bloodlines and heritage) in Māori culture and the fact 
that bodily products are tapu (sacred/taboo).   
Aside from these discussions regarding Māori however, little has been discussed 
regarding broader issues of inequity and other groups’ disadvantages in the 
consideration of data.  
Data practices require ongoing consideration and stakeholder discussion before we 
establish (national) systems and standards. I discuss big and open data further in 
Chapter 7, including its advantages and disadvantages in affecting health inequity. 
3.5.6. Engagement 
It is fair to say that most participants agreed engagement was worthwhile and 
necessary, but that it was also a very challenging and time-consuming process to get 
                                                        
83 “Kaitiaki” is translated as guardians and these groups manage who accesses data and for what 




right that required skill and expertise. Again, some comments reported tokenism in 
engagement practices described to committees, but there was also the provision of 
guidance from committees to researchers to help get it right. Engagement with 
Māori specifically was described as being a process that researchers struggle with, 
knowing whom to go to and with whom to establish relationships, and so some try 
to get ‘sign off’ on very superficial versions of engagement.  
It would seem from these comments that participants felt that they did make 
recommendations relating to justice where they identified them and that they felt 
there was an indirect enhancement of justice through the emphasis on Māori 
consultation and appropriate relationships. However, given the results of Chapter 2 
showing a lack of representation, specifically in NZ, it would be fair to say that 
researchers are not meeting justice requirements.  
What this work could point to is that ethics committees are not necessarily the best 
point at which to incorporate justice requirements into work where they are 
lacking. Ethics committees can only be the final stop gap for integrating justice. 
Justice would have to be explicitly incorporated somewhere much earlier in the 
process, and ethics committees would serve only as a final safety net to ensure 
nothing passed that did not meet our agreed and specified requirements of justice. 
Again matters of engagement are discussed more in-depth in Chapter 7.  
3.6. Limitations 
Aside from the low response rate, there was an awareness from the beginning that 
an online survey using Likert scales and text boxes does not provide as rich data as 
focus groups and interviews. Also, in this case, the survey itself was too long. The 
likely availability of research ethics committee members was a factor in choosing a 
survey, as mentioned earlier in this chapter.  An online survey was thought to be the 
least burdensome method to committee members of eliciting information while 
working within the resource constraints of the project (i.e. committees are spread 
geographically across all of NZ, and so interviews/focus groups would have 
required extensive travel). 
Feedback received from committee members both in email and in the survey shows 
that participant lacked engagement with material to some degree, insofar as the 
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questions evoked no strong responses, and in many cases were not fully 
completed.85 Lack of participation could have been avoided by socialisation to the 
material before its release or with an email which provided a richer explanation of 
the reasoning for the survey at the time of invitation.86 It was evident in some 
responses that participants felt by some that the survey was meant to show that 
ethics committees were not performing adequately in some way and this was not 
the intention at all. The purpose of the survey was not to show that they performed 
their role inadequately, but rather to gain an understanding of committee members’ 
views on their mandate and review of justice. Along with getting their opinion, on 
the challenges of reviewing applications in future that include very complex issues 
involving data practices or complex relationships between participants and 
researchers.  
To partially address limitations of self-reporting as noted in Section 4.3., I reviewed 
all committee minutes for 2014 (44 sets of minutes available on HDEC website).87 Of 
these minutes, 21 made some form of recommendation regarding either: 
- specification of cultural issues on participant information sheets (inclusion of 
information regarding culturally appropriate tissue disposal, the inclusion of 
information regarding cultural advocacy contacts, for example); 
- recommendations to include  information related to the consideration of 
ethnicity or inequalities in future applications (i.e. recommendations for 
explaining work when applying in the future, while approving the 
application under consideration), and 
- two made specifications regarding the provision of translators (these related 
to the provisions for translation already made, rather than a 
recommendation to add translation).88  
                                                        
85 Some very thoughtful answers were provided by participants, but many participants chose to 
answer very few questions, and more than 1/3 did not fully complete the survey. 
86 The author, in this case, made assumptions based on her own experience of sitting on ethics 
committees, and her own views as to the need for research about ethics committees in NZ. 
87Minutes are available from: http://ethics.health.govt.nz/about-committees/meeting-dates-venues-
minutes  
88 The list of minutes that made relevant recommendations are: NTA (May-14); NTB (Sept14); NTB 
(May14); CEN (full list 2014); STH (Feb, Mar, Apr, May, Sept, Oct, Nov, 14).  
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This review of minutes is also incomplete insofar, as access to applications is not 
available, and therefore the ability to judge whether committees always made 
recommendations when they should have is not possible. It would seem that the 
Central Ethics Committee whose documentation included reference to adding 
appropriate cultural information in the participant information sheet in every set of 
their minutes often for multiple applications (with further recommendations also 
present in some minutes) would seem to have a rule for checking for this 
specifically.  Other committees may not be this disciplined about adding cultural 
information to information sheets. Laura Stark has argued that Ethics Committee set 
their own “local precedents” meaning that each committee while working with the 
guidelines and standards, applies those edicts differently, based on their committee 
composition and various members’ strengths and personalities (Stark, 2012). This 
example from the Central Ethics Committee would seem to be a possible indication 
of a local precedent. 
These minutes and the survey provided a limited picture of the review of justice in 
approved ethics committees in NZ. 
3.7. Summary 
A survey of approved ethics committee members was undertaken to try to gain an 
understanding of their views of justice within review, their ability to request 
changes to projects for justice, and their thoughts on specific research practices that 
may increase health equity. This information does not currently exist in the 
literature and is needed to understand where justice in research is considered.  
The survey itself did not reach a high enough response rate to provide 
representational work. A review of approved ethics committee minutes in 2014 was 
also undertaken to support responses and provided a limited view of committees’ 
review of justice in applications. Minutes showed recommendations mostly dealt 
with appropriate information in Participant Information Sheets, relevant 
information for future applications, and some recommendations regarding 
accessibility of studies for participants (i.e. translators).  The limited survey 
responses combined with the findings from the minutes’ review would suggest that 
further work in understanding justice in ethics committee review in NZ is necessary. 
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What role ethics committees play in reviewing justice, what this review could or 
should look like, and where other responsibilities may lie in ensuring research 
practice is just is something I take up further in Chapter 7, after having further input 






Chapter 4: Institutional Ethnography of Researchers working with 
Marginalised populations 
 
It is not our role to speak to the people about our view of the world, nor to attempt to impose 
that view on them, but rather to dialogue with the people about their view and ours. – Paulo 
Friere 
In Chapter 1, I explained definitions and causes of health inequity and posed the 
question of whether one cause of inequity may be related to marginalised 
population representation in health research used for evidence-based medicine and 
policy. To answer this question, I went about seeking evidence of marginalised 
groups’ health inequity and their representation in evidence and knowledge-
generating activities.  Empirical data showed that their health inequity mirrors an 
inequity in research visibility, as well as potential under- or misrepresentation in 
government data (Chapter 2). In New Zealand accredited ethics committees have a 
responsibility to review justice (as defined in the NEAC guidelines) when 
considering health research ethics applications that potentially lead to evidence and 
knowledge generation and I, therefore, surveyed ethics committee member views 
on this responsibility and their ability to meet it (Chapter 3). The results of this 
survey were not substantive.  
This chapter diverges from the previous ones, shifting from a methodologically 
descriptive position to a political one. In this chapter I use an institutional 
ethnographic method; the aim of which is to reveal the ‘ruling relations’ (explained 
in 5.1) coordinating a group’s actions or practice (Smith, 1999, 2005). In this 
context, the ruling relations are those that create a health research space, more 
specifically a research space for researchers working with marginalised 
populations.   
The purpose of this shift is to understand how research for marginalised 
populations occurs and how the health research environment influences that 
activity. By doing this, I provide insight not previously available in NZ about 
research for, and researchers working with, marginalised populations.  
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An ethnography can be a large undertaking that is the sole purpose of a thesis. An 
institutional ethnography is somewhat different in that it can be both a grand 
undertaking, Ethnography with a capital “E”, but also an analytic method that 
purposefully sets out to explore conditions, from a particular perspective within a 
specified analytic frame.  More time, informants and analysis of government 
policies, documentation and more field work89, along with greater discussions of the 
political and sociological theory underpinning the concepts used, would provide an 
ethnographic undertaking of the larger scale. Such an endeavour would 
undoubtedly shed a more nuanced light on the ‘ruling relations’ as they exist for 
researchers working with marginalised populations. However, it is this latter 
version that I have used here based on the reasoning that the method and analytical 
frame were the most appropriate for answering the question at hand. Namely, “how 
do researchers working with marginalised populations do their work and what 
determines how they do that work?”. But also, because this is one piece of the 
puzzle rather than the sole question I am investigating.  
One discovers ruling relations through the analysis of informant experiences, which 
serve as entry points into the ‘problematic’ (Smith, 1999, 2005), investigated 
alongside the institutional texts and processes that help maintain the power of the 
ruling relations across time and place.  
This thematic shift explores not only the ruling relations. It makes possible an 
exploration of the researcher perspective when conducting research, which will 
contribute to the discussion of epistemology in Chapter 5.   The aim of this chapter 
is first to explain what an institutional ethnographic method is and why I chose it 
for this stage of the research programme, which is then followed by the 
ethnographic work itself. A full description of the methodology, sampling, analysis 
and limitations of the study are available in Appendix C-1.  
In this chapter through informant testimony, I discover the problematic as an 
environment that is full of contradiction.  Researchers struggle with relationships 
that provide them both with the ability to do their work, but also make demands 
that can be challenging.  These relationships are between the researchers, the 
                                                        
89 For example, being able to gather information in funding round assessment panels or ethics 
committee reviews, and interviews with junior researchers. 
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institutions they work for, and the communities they work with.  I have categorised 
these experiences of the everyday as issues of, or related to: legitimacy, precarity, 
population/communities as raison d’être, practices and priorities, burnout, peer 
community as self-care and co-conspirator, silencing; and for Māori and Pasifika 
informants, the added factors of the “Brown Tick”, tokenism and extra burdens.90 
These everyday experiences are created by and maintain the ruling relations, that I 
argue, are characterised by neoliberal policies (in health and education) and the 
dominance of the biomedical perspective that ignores and constrains the work of 
these informants within the broader research environment.  
4.1. What is institutional ethnography? 
Institutional ethnography is a feminist, sociological methodology, developed by 
Dorothy Smith. Many have adopted the methodology (Campbell, 2002; Campbell et 
al., 2006; Hansen, Holmes, & Lindemann, 2013; Lund, 2012), but the theory was 
originally largely theorised by Smith (Smith, 1987, 1999, 2005). Institutional 
ethnographies begin with the experiences of people in their everyday/everynight 
setting91, to uncover the way generalised institutional discourses organise these 
experiences and actions through the medium of text (Campbell et al., 2006; Smith, 
1999, 2005). The institutional ethnographic method is used to focus on the 
discovery of ‘ruling relations’ that, through institutional documentation and 
processes, affect and control trans-local activities of actors in their 
everyday/everynight experiential context (Campbell et al., 2006; Smith, 1999, 
2005).  
What does this mean?  
Smith, writing within a Marxist and feminist tradition, makes the distinction 
between the ‘local’, which is the everyday of people’s lives, and the ‘extralocal’, 
which is the abstract position outside of the everyday experience. Extralocal is 
analogous with a ‘bird’s eye view’ perspective; a detached and objective position not 
taken by anyone in particular. To discover the ‘ruling relations,’ Smith’s 
                                                        
90 Each of these issues is defined and described in sections below.  
91 IE’s have been used in a multitude of settings from mothering, to academia, social-work, nursing, 
etc. where the setting of work can be at all times hence the everyday/everynight specification 
(Campbell et al., 2006; Smith, 1987). 
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methodology compels us to return to, or focus on, the local. In other words, the 
intention is to consider the standpoint92 of everyday experience (Campbell et al., 
2006; Smith, 1987, 1999). The ‘ruling relations’ are processes that objectify us, and 
through which we become part of a system that, not only directs our actions but is 
maintained by our very actions.  The extralocal is the position of the ‘ruling 
relations’ – an abstraction. She states: 
The ruling apparatus is that familiar complex of management, government 
administration, professions and intelligentsia, as well as the textually mediated 
discourses that coordinate and interpenetrate it. Its special capacity is the 
organisation of particular actual places, persons and events into generalised and 
abstracted modes vested in categorical systems, rules, laws and conceptual practices 
(D. E. Smith, 1987, p. 108).  
By attending to the local, we ground ourselves in the everyday of people’s lives and 
obtain a view that we cannot access otherwise. Starting from this locus, we gain 
direct access to the social organisation of our experienced world (Smith, 2005).  
While other sociological methodologies attempt to explain behaviours, understand 
feelings, or experiences; institutional ethnographies begin with people as they are in 
the world in order to explain “the social relations of society of which we are part, 
explaining an organisation that is not fully present in any one individual’s everyday 
experience”(Smith, 1987, p. 89). The purpose is beyond the experience.  Smith 
believed that methodologies within sociological practice and universities, in general, 
are part of the overall hegemonic discourse of capitalism, “promoting concepts, 
methodologies and relevances” (Smith, 2005, p. 29)  that are detached from the 
everyday, and embedded in their ongoing promotion. A consequence of 
capitalism’s93 social relations is the creation of circumstances within which 
individuals “become externalised as differentiated systems of relations”(Campbell et 
al., 2006, p. 17).   
                                                        
92 While her work can be described as a standpoint theory, it moves beyond Harding (Harding, 1987) 
and Hartstock (Hartsock, 1983), insofar as the standpoint is not “politically, economically or socially 
defined”, but rather utilises the subjective/objective dichotomy privileging the first (Smith, 2005) 
93 Smith writes about capitalism because that is the world she lives in.  It is also the type of society, I 
live in and those who took part in this study live in.  This discussion and methodology is not meant to 
involve a greater discussion of the worth of capitalism over any other political ideology, but one can 
criticise something without talking about the merits or failings of comparable others. 
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To understand the conditions outlined above, one has to take a different 
perspective. Using a sociological method that begins with people’s experience is 
crucial, but it does not end there. Smith writes:  
Locating the sociological problematic in the everyday world, does not mean confining 
the problematic to the everyday world. Indeed, as we shall see, it is essential that the 
everyday be seen as organised by social relations not observable from within it. (D. E. 
Smith, 1987) 
By locating our inquiry in the everyday, an understanding of others’ experience lets 
us see the way in which these very experiences are coordinated and organised. The 
experiences are the starting point of analysis, rather than the sole purpose. The 
experiences are used to identify the ruling relations; the social organisation of 
individual lives, where the latter’s participation in those very relations sustains this 
social organisation.  Individuals both experience the relations and sustain them. 
Smith states that “a mode of ruling has been created that transcends local 
particularities but at the same time only exists in them” (Smith, 1987, 2005). What 
one gains through an institutional ethnographic method is the description of 
peoples’ experience from those people directly, and subsequent analysis of those 
experiences using texts and discourses to understand how they are controlled. This 
approach provides the ability to see a thread of the ruling relations; the organisation 
and coordination of activities trans-locally within the dominant framework.  It is a 
“thread” because the overall discourses of ruling relations across all activities 
within a society are large and complex and this chapter focuses only on particular 
activities within a particular setting (DeVault, 2006). 
Institutional ethnography is not a comparative methodology; it does not compare 
experiences. This chapter makes no claims regarding the experience of researchers 
who work with general health research populations. Nor does an institutional 
ethnography explain the intentions of ruling relations, other than when their texts 
explicitly described them.  That is, the ethnographic analysis does not surmise from 
the collation of various texts and experiences, detailed motives where these are not 
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plain other than the overall organisation of activity within a capitalist, and in this 
case specifically, neoliberal94 society. 
4.2. Why Institutional Ethnography 
The purpose of an institutional ethnographic method is to try and understand how 
ruling relations organise the experiences of people, which they are to some extent 
unaware of, where this organising occurs through institutional texts and discourse.  
In this work, the purpose is to understand how the health research system (as it 
exists across universities, government and health systems) acts on and directs 
researchers working with marginalised groups. What views of marginalised 
population research emerge? Of interest here, is the “what”, the “where”, and the 
“how”.  Gaining this understanding is important as it makes it possible to grasp the 
production of knowledge for marginalised populations in NZ within a larger overall 
system. Understanding what work does and does not happen (and why), provides 
information to assess whether there is an injustice or problem of some kind. The 
work starts from the standpoint of those working with marginalised populations 
looking out to the system.   
I chose this methodology because of the preferencing of perspective in viewing the 
system. It will also become clear in this chapter that the emphasis of perspective 
resonates with that of the researchers working with marginalised populations. The 
informants in this study also on occasion choose to look out at society and the 
structures that affect the well-being of the populations they work with, rather than 
always looking from the outside-in; a view from society of the marginalised 
population itself.  
This complementarity between the philosophies of those whose environment and 
actions I wish to understand and the philosophical foundations of institutional 
ethnography makes this choice of methodology particularly germane for this part of 
the thesis.  
                                                        
94Neoliberalism is defined as a political theory (with accompanying practices and processes) that 
prefers a limited state whose sole role is to promote the free market and free trade where the ideal of 
the self-interested individual is promoted and  can thrive with private property and limited 
governance. The market itself does not require state intervention, it regulates itself and the 
successful individual is one who is competitive and enterprising in this environment. (Olsen & 
Peters, 2005; Roberts, 2007) 
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In this chapter I aim to provide a description of the experiences of a variety of 
senior researchers working with marginalised populations (the informants), 
followed by an analysis of the ruling relations that organise their research practice 
(everyday). This analysis described thematically uses as points of entry both 
informant experience and the texts that informants engage with in their everyday. 
These themes are then related to the ruling relations, theorised as systems formed 
in the biomedical tradition combined with neoliberal policy, that focus on 
performance (measured narrowly) and impact (largely measured economically and 
reputationally) (Ashcroft, 2006; Burrows, 2012; Docherty, 2014; Sayer, 2014). What 
is drawn out and then discussed in the next chapter (Chapter 5) is the epistemic 
injustice (Fricker, 1998, 2007a) that arises from these systems.  
4.3 The Problematic  
The ruling relations are organisations that co-produce the health research system in 
New Zealand for the informants in this study, who are senior researchers working 
with marginalised populations.  These organisations are governmental (both in 
health and education), but may also include non-governmental organisations 
(NGOs) and private companies. Organisations direct the informants’ actions through 
processes, documentation, and discourses, thereby creating the circumstances in 
which research is funded, approved, conducted, reported and utilised. To 
understand the ruling relations within this problematic, I describe the experiences 
of the informants which are used alongside literature and institutional texts to 
uncover the ruling relations and the influence the ruling relations exert on action.  
4.3.1. The Everyday for Researchers working with Marginalised Groups 
I provide a full account of the informants in Appendix C-1, including the inclusion 
criteria. Nevertheless, it is important to highlight several key factors: the majority of 
informants were female (10 of the 11); the group was ethnically varied (Pakeha 6, 
Māori 4, Pasifika 1); all the informants were senior researchers, and their research 
settings were mixed (university or NGOs; various employment conditions – 
permanent, contract, or a mix). The communities they worked with, and for, were 
Māori, Pasifika peoples, people with learning disabilities, youth, mental health and 
addiction service users. I have used the term communities for the populations these 
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researchers work with, but readers should consider this in a broad sense of the 
word.  Not all of our informants were “community researchers” in the typical sense 
that people might imagine. The group included a wide variety of practices, 
methodologies and philosophies. However, all our informants identified themselves 
as serving a “community”. For some, this was a very clear and particular community 
that they spent much time in; for others, it was a community conceived of as a group 
of people tied together through shared experiences, characteristics, and in these 
cases disadvantages. These latter researchers could work in multiple sub-
communities (geographically determined) of that larger community.  It is also by no 
means suggested here, that these populations represent the full breadth of 
disadvantaged populations in New Zealand. Nor, do I suggest, that researchers 
working within other communities with groups that may not be considered 
disadvantaged do not have some of the same experiences in their practice where it 
includes certain types of questioning and methods prevalent for those working with 
disadvantaged populations.   
The informant “everyday” might be a mixture of teaching, research, and service, in 
the university setting. In the non-university setting, the “everyday” might be but 
was not limited to, research and community liaison activities. All informants 
experienced visits to government ministries, NGOs, and interactions with their 
populations and communities. Relationships were important for all informants, not 
only within the institutions they belonged to and had to navigate, but more 
importantly, within the communities they served.  
4.3.1.1. Legitimacy  
Informants required different forms of legitimacy between the communities they 
work with and represent and the academy/government agencies they work for.  
Being part of academia is beneficial for the informants; it provides access to an 
intellectual community, time, and resources.  Academia provides a level of 
legitimacy to them as a researcher going out into the (public) world when engaging 
with government departments and organisations that directly affect their 
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communities.95  This legitimacy, within the academy, is performative96, but this 
performance can undermine the informants’ status or ability to engage in the 
communities with which they work. Marginalised individuals and communities can 
distrust figures of authority from government agencies and organisations, especially 
when the latter have historically treated their community poorly.  There is, 
therefore, an ongoing need to switch from one type of researcher mode to another 
where this shifts between the academic and community settings.  
I observed an illustrative example of this dynamic in a seminar given by a Māori 
woman97, whose role within the University was health researcher and more 
specifically epidemiologist. Her presentation outlined her involvement in a 
development project in her community, a suburb classed as lower socio-economic. 
The project itself involved community members as leaders in improving health and 
well-being for their area. Since the researcher’s department was related to the 
Medical School, fellow academics from the school attended her presentation. 
Importantly, members of the community leadership project also attended. Her 
tikanga98 was to bring food, which she justified to the audience, who should have 
acknowledged this but did not. Proper tikanga would have also been to introduce 
her and the community members in line with Māori protocols: no-one did this. In 
introducing her topic, she qualified her professionalism (spelling out her 
quantitative practice and experience) before describing the wearing of a “different 
kind of hat” for the community project. There was a sense she felt caught between 
the community members present and the academics in performing her identity and 
building legitimacy.  One felt she wanted to make clear to the academics in the room 
that her professional training and practice was rooted in quantitative methods in 
health, that her “normal” research practice was something more “robust”; because 
her description of the community work undertaken was pragmatic, openly 
emotional, and non-linear.  There was a risk that this way of presenting would 
                                                        
95 Those informants who were independent or based in other organisations had gained their 
legitimacy through qualifications earned in universities and had ties to universities, and had 
completed joint projects with universities early in their careers, to build a slightly different type of 
legitimacy. 
96 Performativity is defined as communication that not only communicates meaning but crafts 
identity in certain spaces(Butler, 2010) 
97 Not an informant (taken from Field notes) 
98 Māori custom and cultural practices. 
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change her identity within her academic community. Questions from the audience 
supported this interpretation, insofar as attendees asked her about funding, 
evaluation measures, and the like. The speaker provided evidence of small 
immediate benefits to the community, but the group had not undertaken any long 
term evaluation. Although the audience did not dismiss the so-called “soft 
outcomes” as such, many of the attendees were concerned with understanding how 
this process could be “operationalised”. In other words, how might these outcomes 
be validated or verified and then implemented? One audience member recognised 
and commented on the emotional labour the presenter had provided in the project 
and thanked her for her open manner in discussing work during the presentation.99 
The act of balancing legitimacy was also apparent in informants’ experiences of 
what their communities valued versus what the academy required of them to prove 
their ongoing validity and performance.  
Yes. Because I'm known in the community, those invitations to be involved around 
things come. Yeah, I think that we try to be collaborative. Again, or we are 
collaborative probably to our detriment. (…) That's a double-edged sword for us 
though because the people who assess my work are not going, "Hey, she's great. She's 
out there, and she's been for 20 years doing this stuff." They go, "She has not enough 
publications." (…) It's a double-edged sword. There would be barriers created, 
challenges created from working outside, but also working inside as well because I do 
believe that we wouldn't have the relationship we have with the community if I had 
been located in the university. (Informant 1) 
Performance measures specifically within the university (created by government) 
but also for funders focus on international recognition as a measure of research 
excellence.  This emphasis is evident in the goals of universities who reflect back in 
their strategy documents what governments measure them on.  For example, Otago 
University in its strategy document states that its Vision is to be “A research-led 
University with an international reputation for excellence”.100 The University of 
Auckland does not have a Vision statement, but its Mission statement, reads: “A 
research-led, international university, recognised for excellence in teaching, learning, 
                                                        
99 The project had been positive and negative. The community had suffered some losses during the 
time of the funding, which had been hard on the leaders of the project and the community itself. 
100 Available from: http://www.otago.ac.nz/about/official-documents/index.html  
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research, creative work, and administration, for the significance of its contributions to 
the advancement of knowledge and its commitment to serve its local, national and 
international communities”.101  At first glance, this seems somewhat more 
comprehensive and fairly focused, but on reviewing the strategy document, one 
finds that the measures for “High-quality research that benefits society” are around 
publication in peer-reviewed journals with international collaborations and 
successful funding applications.102 
While research excellence measures have multiple metrics that are easily 
quantified, the measure for connections to the community is singular – “Number of 
engaged alumni”.103 The actions listed under this measure include engagement with 
“key partners”, broadly defined across local government and community. This 
metric for community engagement would indicate that it is not measured 
meaningfully. Wright et al (2015) have found that this emphasis on internationally 
recognised impact can be detrimental to researchers working on the local level or 
with indigenous populations, as their work fails to garner the attention from 
overseas, that is required to meet performance targets within the institution 
(Wright, Curtis, Lucas, & Robertson, 2015). This type of performance measuring as a 
means of undermining and constricting informants’ work is repeated throughout 
various sections and is discussed further in section 4.4. 
Interestingly, informants were able to describe the gulf between the two locations 
of their work as both physical and philosophical. Many used the words “inside” and 
“outside” to delineate the difference in spaces for their work; “inside” the academy, 
“outside” in the community. 
Straight away, at that very onset, you're caught between two different worlds. One 
doesn't work for Māori and works for non-Māori, but you are having to go down that 
path because, at the moment, there is no alternative. It's not even about having an 
alternative; it's about complete lack of understanding.  (Informant 4) 
                                                        
101 Available from: https://www.auckland.ac.nz/en/about/the-university/mission-and-values.html  
102 Available from: https://www.auckland.ac.nz/en/about/the-university/official-
publications/strategic-plan.html 
103 Ibid 89. 
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To get funding, we have to talk about disparity and problems and deficits, yet as a 
[PROFESSION]104, as a [MARGINALISED GROUP] health person, as someone who 
works from a healthy [MARGINALISED GROUP] development philosophy, we're about 
building assets and creating a safer environment rather than taking a really 
individualist approach to healthcare. (Informant 7) 
This dislocation appears to stem from the role of academic as separate and 
separated from society and communities. Informants felt this separation in how 
they are asked to perform and measure their academic role leaving no space for 
their relationships and community-embedded work, but it is also apparent in the 
lack of community relationships academia has as a whole. Marginalised populations 
especially sit beyond the academy.  Gendron has described the former as the 
“construction of the academic performer,” where academic identity is intimately 
bound up with the ongoing (high impact) publication (Gendron, 2008) or what 
Burrows calls the “Quantified Academic” (Burrows, 2012). This performance and 
the continuous evidencing of it serves to constrain the academic within universities, 
but also constrains researchers external to universities, who must compete with 
university-based academics for funding and so must show the same ‘credentials’.   
The latter, the distrust of academia by marginalised communities, has been 
described by Linda Tuhiwai Smith (Smith, 1999) and others (Anderson & Solomon, 
2013; Guillemin et al., 2016; Robinson & Trochim, 2007) and is based on the after 
effects of colonising practices and discourses. Research practices of “researching on” 
communities rather than with or for them. Communities see researchers in 
government or commercial organisations as not having their (the 
community/population) best interests at heart. 
4.3.1.2. Precarity  
The precariat is a relatively new term, generally understood as the social underclass 
that suffers from high-level job insecurity and unpredictability, and lacks 
psychological and social welfare within the neoliberal state (Standing, 2011). The 
“Academic Precariat” is an ever increasing group of workers who work on non-
permanent research and teaching contracts (Brown, 2011; Reay, 2000). Their 
                                                        




insecurity exists because of the neoliberal policies in many countries in the Global 
North that create a scarcity of resources within academia, leading to greater 
competition, and market rather than public accountability (Brown, 2011; 
Butterwick & Dawson, 2005; Ivancheva, 2015).   
All but four participants had permanent, full-time academic positions. Despite this, 
there remained an underlying sense of precarity even though some participants 
held what are considered to be “senior” roles.  Across our sample, depending on the 
particular informant, this feeling of precarity was traceable to a constant 
restructuring of “non-profitable” academic departments, pressure to generate 
“revenue”, fixed-term employment in institutions with no guarantee of renewal, 
uncertain research funding environments and independent/private contracting. 
The current system measures outcomes based on commercialisation, cost-
effectiveness, and value-for-money given the current neoliberal zeitgeist within the 
academy/ government institutions adding to this employment insecurity. This 
background employment context contributed to the overall unease these 
researchers felt given the work they do is always seen methodologically and 
politically, as less valid because the focus is on smaller populations. While their 
work can potentially have a great impact for the target population and society as a 
whole, those assessing projects always ranked it as less of a priority when 
compared to projects or activities that bear a clear commercial impact, or larger 
population impact (Health Research Council: health significance105/impact rating, 
university: revenue, and commercialisation, governments: cost-effectiveness).   
This precarity is described in the literature and is especially pertinent for female 
academics, NZ-trained scholars, or those working on NZ issues (Wright et al., 2015) 
and contract staff (who interestingly are also often female) (Reay, 2000, 2004) 
working both within and outside academia.  
I don't actually have a contractual relationship with the university, because I cannot 
get funding, but I have little bits and pieces of the jobs they do for various 
                                                        
105 HRC rates its grants based on rationale of research, scientific method, track record and health 
significance, where health significance means that the application addresses a significant problem in 
NZ. An extra point is also given if the work can be classed as translational. 
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organisations, and I just have to accept that I'm not going to be a paid academic. 
(Informant 5) 
Informants who held permanent positions face other issues of precarity. 
Specifically, the pressure to continually publish in high impact journals when their 
philosophy was one of disseminating to their populations and stakeholders first, 
and the work they did publish was in lower impact journals because of its 
particularity. 
The practice that we would have is prioritising what I see as our responsibility or 
obligation back to the community. That's to our detriment at times because by the 
time you've done all of that reporting and plain language formats, (…) By that stage, 
we're having to look at other work and pick up other funding, so the academic writing, 
which should always occur, we're always falling behind on that. As I said, to our 
detriment, because that's what you're assessed on for the next grant, not how many 
people in the community that you're working in, have got to hear about this and might 
have learned something or changed their ways or the general practitioner might have 
got to hear about something that might be a different way of doing things. (Informant 
1) 
Informant commitment to work that did not fit neatly into the overall systems of 
measurement meant that they sacrificed their own time and status (seen in the 
comments by Informant 10 and 8 below). Arguably, this also hinders their practice, 
insofar as others within the academy may also be going over and above in their 
work, but it is recognised more readily in the measures of impact used. A somewhat 
circular problem occurs in that the lack of recognition of their work fails to support 
their activity, which in turn means they must take actions that further undermine 
their position to complete the activity, leading to a further lack of recognition. 
The community sector itself is really low resource. At least a third of the work I do is 
voluntary, you don't do community research in the sector I'm in without accepting 
that you would end up doing a lot more work to get a project done than might be paid 
on the contract. (Informant 10) 
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To be quite honest, one of the reasons I don't apply for a promotion, I've reached the 
top of the bar106 for [RESEARCH-BASED ACADEMIC POSITION]. There is no point. It is 
hard enough getting funding on my current salary. It just pushes your research grant 
further. I'm not in it for the promotion, it doesn't drive me any other way. What's the 
point in putting all the time and energy into a promotion, it's just going to make 
getting a research grant even harder. (Informant 8) 
An underlying insecurity of position is in and of itself stressful and arguably adds to 
the “burnout” phenomena discussed below (4.3.1.5). 
4.3.1.3. Population/Community as raison d’être 
All of the informants, in one way or another, either self-identified as an active 
member of a particular population or community (e.g. Māori or Pasifika), had family 
members who were part of a specific population or community, or had developed a 
deep connection with a population or community over time.  Their marginalised 
populations were these informants raison d’être in their research. Understandably, 
this meant the driving force for the informants in conducting their work, were 
direct outcomes for these groups. Informants’ research practice was defined by 
what worked best regarding achieving positive change rather than necessarily blue 
skies, commercially-, or reputationally-valuable work. This focus, of these 
researchers working with marginalised populations, was a positive aspect to their 
motivations, but they could also experience this aspect as great responsibility or 
burden. Consider the following from the researcher identified as Informant 8: 
You have a responsibility to the group, but I think it's also partly that the types of 
people who work with marginalised groups are there because they are really 
passionate about that group. That passion drives whatever you want to do. It's not just 
about responsibility. It's really, these are a group, I'm really concerned about. I'll do 
whatever it takes to make sure they get a voice. I think that's ... there's very few people 
who are working that I know of who are working with marginalised groups who are 
not really passionate about working with those groups. (Informant 8) 
                                                        
106 In many New Zealand tertiary institutions, academic roles have salaries situated within a band 
(i.e. minimum amount to maximum), where the top tier of this band is above a “bar”.  When 
employed staff are placed on the level in the band that is commensurate with their skills/experience, 
and the progress automatically through the band during their employment until they hit the “bar” at 
which stage they have to apply for a salary increase justifying why it is deserved. 
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Informants described how they often went over and above. Where institutions were 
unsupportive of activities that they thought were important for their communities, 
they would do the extra work in addition to the work they needed to do for 
organisational approval. This “over and above” could include extra time, out of 
pocket expenses, and sharing expertise for other purposes than research, amongst 
others things. Informant 7 said that: 
You do, do a lot more than you get paid for. (…) I don't know if other people have that 
same responsibility, but also expectation from their communities to do all that extra 
stuff. Because it is our community, because it's something that we're passionate about, 
we do give more because we feel there is this ethical and moral responsibility to do a 
good job and go above and beyond because it's your people. (Informant 7) 
The informants made it clear that the processes, at present, did not facilitate any 
opportunity to “give back” to the communities. And yet, sharing resources, giving 
back, and supporting their communities were things they felt very strongly about: 
Another key principle that I always use is as much as possible of the money that we 
have for that research should be spent in that community. As much as possible, can we 
employ people there either as translators or caterers, etc. being aware that managing 
confidentiality and all of those issues is not insurmountable and just needs extra care. 
(….) Everybody in the research machinery is earning money out of this, but the 
community whose information this comes from are expected to turn up for nothing 
when they are the poorest? (Informant 9) 
This awareness of the discrepancy between the money in the system and the money 
in the community is, I would argue, unique to this group.  Trying to support 
communities with research resources is challenging when ethics committees frown 
up practices that could be interpreted as coercive (payments) or create conflicts of 
interests (employing people in the community). Informants felt that coercion and 
conflicts of interest are manageable and that giving back was the greater ethical 
priority. 
Not only their time but often their intellectual work was something informants gave 
away for free, recognising that these actions put them at a disadvantage. In a 
competitive setting where institutions measure researchers on the academic 
identity, they craft and perform, sharing ideas and work is counterintuitive. The 
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feeling expressed by informants was that giving away ideas was necessary to make 
sure someone, even if not them, got the work done if it had the potential for positive 
change when they could not access funding or resources to do the job themselves. 
I think what happens is that as a researcher someone that's seen as having knowledge 
around this area that we give a lot away for nothing. We give a lot of ideas away. I sit 
at the moment in the [GOVERNMENT] working party, tell them a whole lot of stuff, 
give a whole lot of things that other researchers possibly wouldn't. For me, I'm sitting 
with a group of the community that I work in. And again, ethically there's a moral and 
ethical obligation to contribute in a way. (Informant 1) 
These informants described their communities as both the beginning and the end of 
their work; the place where it must start and where it needed to finish by reporting 
back and creating positive change.  This starting could be the co-production of ideas, 
or the buy-in/endorsement of ideas they as researchers had recognised were an 
issue. Communities were powerful motivators, but also could weigh heavily on 
participants. 
4.3.1.4. Practices and Priorities 
Informants working with vulnerable, marginalised and hard to reach populations or 
groups (both socially and geographically) not often considered by mainstream 
health research, prioritised and practised research differently.  Their starting point 
of inquiry was different and informants seemed to welcome practice innovation and 
were flexible and pragmatic in thinking about how to get the information required.  
However, this flexibility again puts them at a disadvantage within performance 
measurement exercises, as standardised practice is easily rated and recognised, 
innovative practice is controversial and harder to measure (Lõhkivi, Velbaum, & 
Eigi, 2013; Olsen & Peters, 2005; Roberts, 2007). For these senior researchers 
(informants), they did not view their pragmatism as a lower standard of theory or 
method; it was not an indication of a drop in standards, but rather included a 
broader range of methods and tools, and variations in their application. Informants 
also recognised that their connection to people meant sometimes they could not 
perform their researcher role or had to shift priorities in different moments of the 
work. For these informants their values, relationships and community connections 
122 
 
are paramount and therefore doing what needs to be done to achieve outcomes for 
the community is crucial. 
I guess that is one of the reasons for why we haven't had as much success around 
attracting health research funding in this area. Our philosophy is…and my personal 
philosophy is conducting research that keeps people at the centre of it, it keeps 
[MARGINALISED GROUP] at the centre of the research. That is contextualised around 
their lives and their situations and that will have some practical utility for either 
people themselves or the groups that work around them in terms of it could be 
families, it could be support workers, it could be health professionals. In order to 
change the situation. Transformational, really. (Informant 1) 
Well, it's an ethical thing. It's a really key ethical issue. If you were ... I don't know if 
other people have said this, (…) historically, when [MARGINALISED GROUP] have sort 
of been researched on, and people fly in and take their expertise, fly out and nothing 
happens, nothing changes or improves for them, that there is a term for that which is 
tarmac professor or researchers have even been called parasite people. There's 
traditional hostility to people doing research on [MARGINALISED GROUP]. I think if 
people are going to give you their time and expertise, therefore it is a partnership, 
therefore the dissemination that suits them has to be prioritised. Of course, it's a 
conflict in the university. (Informant 5) 
Informants thought quantitative and qualitative dichotomising and dogmatic 
attitudes were largely unhelpful. Through experience, they prioritised and utilised 
the methodology that best addressed the questions arising from community need. 
What was emphasised, however, was being explicit about the perspective from 
which they were undertaking any particular piece of research, rather than 
methodology, per se. In exploring this idea of perspective over methodology with 
informants, this was not explained as relativism, but rather, explained as, a 
recognition that all science and research practice contain values. Most of the group 
of informants made this point in reference to “other” researchers, those meant to be 
“objective”. In every discussion where it arose, the informants indicated that they 
are open about their values, their perspective, their “bias”, but wanted other 
researchers to be more honest about the values and perspectives they bring to their 




(….), it's just a tool, and you can indigenize and create quantitative methods, or deliver 
quantitative methods in a way that align quite closely with Kaupapa Māori 
approaches, which some people struggle with, but it's probably well more framed. 
(Informant 3)  
It's not whether you use quantitative or qualitative methods or perhaps if you believe 
in a constructivist or positivist perspective, but for me it's about "How do we put on 
the table what our values and our underpinning beliefs are?" because that is what is 
determining the questions that are asked and the analysis that we bring to it. (…) So 
this is where you're getting into values, and the whole idea of the objective researcher 
going into a population and being able to come out with some science is not something 
that I agree with at all. (Informant 9) 
That's the idea that we can't be these objective, neutral scientists who go into the 
community and somehow objectively measure something and then state this expert 
opinion about what works or this is what needs to happen. The idea we all have our 
own cultural age, gender, cultural, sort of lenses we bring to our work, we need to be 
aware of those. That impacts all parts of our practice, really. (…) Added to that, a 
[MARGINALISED GROUP] (…) aren't passive recipients of research or services that we 
might be evaluating. They're actually active participants. They have agency and they 
have the right to participate in decisions that affect them, but also to participate in the 
development of services for them. For me, that makes the voices of [MARGINALISED 
GROUP] central to actually both evaluating and developing services. (Informant 10)  
Arguably, informants’ work is much more transparent than that of traditional 
“objective” researchers because of their awareness of how their values influence 
their practice and their openness about this. Additionally, informants’ recognition 
that communities and participants also have agency and values, goes some way in 
explaining their commitment to being responsive to those they work with. This 
recognition is in contrast to researchers who may only see participants as “subjects” 
to be studied. 
There was a discourse that formulaic/standard research practices as described by 
guidelines or preferred by other researchers did not work in their settings where 
the participant pool itself was small and people lived in vulnerable and challenging 
situations. Conducting randomised controlled trials with vulnerable youth, or the 
learning disabled, for example, was not often able to be done in a way that would 
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ensure the results were meaningful, depending on the intervention that was 
necessary. Evident again was a pragmatism and consideration of their participants 
in getting the research done. 
I have to say that…, once you're actually out there, I mean I've done between 60 and 
70 focus groups and hundreds of interviews in multiple projects. And often with 
vulnerable [MARGINALISED GROUP] without families, including going into 
[MARGINALISED GROUP] prisons, schools, community groups. We were talking about 
this the other day, no research plan…, you have your plan written out and what you 
submit to the ethics committee and, of course, you're going to follow the ethics and 
that, but I have to tell you, that once you get out there and you're in the community, in 
order to make that project work, you really have to be iterative with it. You really have 
to be flexible and adaptable. (Informant 10) 
But maybe it's about the way that we approach people. Why can't we go to people's 
homes? Why can't we take bloods at their homes if they want? Why can't we do things 
that are slightly different and creative way that is actually about us making life easier 
for them rather than us making their lives really complicated? That comes from that 
whole medical model of, "We know best. You come here. We'll do this for you and you'll 
be grateful," kind of thing. (Informant 7) 
Responses indicated consideration for what would work best for participants rather 
than what would be easiest for them. Prioritising participant needs partly comes 
with an experience of what those needs might be.  For these informants who are 
senior researchers, they have developed knowledge of their community and its 
needs over time. Through this experience, informants have relationships which 
mean they can consult and discuss the best way to do things within a project before 
they begin. 
Informants described their research practice as collaborative. They shared with 
their peers and communities more than just the outcomes.  Benefits were also 
shared where possible, as well as information. There was recognition that well-




In little ways, I sort of could share a bit of research funding so they could go to 
conferences. Just little, you know it was a little bit in that respect, a respectful 
relationship, so that's sort of something I've developed. (Informant 5) 
I think yes. Speaking from the clinical trials where there is all the evidence that Māori 
that take part in a trial, the better it is for your overall health. For the Māori 
participating in the research in the [HEALTH CONDITION] trial or the [HEALTH 
CONDITION] trial, they really enjoyed the process. I think that is partly been because it 
has been Māori led. So it is about the relationships. It is about making sure people are 
getting good quality care. (Informant 2)   
Many informants spoke about their research participants valuing feeling heard in 
qualitative projects. Informants reported that for some participants taking part in 
research had been the first time they had been able to have conversations about 
certain aspects of their lives, and they saw this a positive experience. To make their 
populations/communities priorities for others, informants recognised the necessity 
of relationships with those who prioritised and funded research and services. These 
relationships were created through persistence and patience - waiting for the right 
opportunity. In addition to establishing relationships with peers by attending 
conferences, workshops, and meetings, the informants used these meetings as an 
opportunity to establish relationships with “decision-makers” in research and 
service structures. 
Practices and priorities as has been outlined here are a point of difference for our 
informants. There was a feeling amongst informants that the broader health 
research community sees certain methods as better than others, but for this group 
choosing the method that best suited the terrain was paramount.  Evidence-
generating gold standard methodologies were not always useful or practically 
possible.  These kinds of methodologies were often impossible to operationalise 
based on their small populations, spread geographically, or some groups’ capacities 
to comply and understand with trial protocols precisely.  Also, these methodologies 
test efficacy, and this was not always the issue in our informants’ settings.  While 
there is greater recognition in the literature of complexity in community settings 
that requires consideration when informing evidence-based practice (Fraser & 
Taylor, 2016; Trochim, Kane, Graham, & Pincus, 2011; Urban & Trochim, 2009), 
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informants did not necessarily feel this recognition in dealing with practice or 
research-based funders.  The need for appropriate methodological selection, 
according to context, was often articulated by informants. These researchers placed 
additional emphasis on questioning the implicit, value-laden perspective of the 
researcher in relation to the community.  This explicit seeking of perspective and 
power relations ties to their understandings of marginalisation and disadvantage as 
socially determined. 
4.3.1.5. Burnout  
Precarity, competing demands, the required performativity between spaces, the 
burden of the communities’ disadvantage, the extra time and work to do activities 
that their environment did not support could all lead to informants’ having a sense 
of resignation or total burnout. Burnout is the result of physical or mental 
exhaustion when workers (in any setting) are exposed to emotionally challenging 
situations (varying in intensity and frequency)(Lackritz, 2004). Burnout is often 
also related to moral distress which as a concept originated in the field of nursing 
but researchers have explored this in other settings (Epstein & Hamric, 2009; 
Ganske, 2010; Hamric, 2012).  Moral distress relates to feelings that arise in 
institutional environments that either actively or passively stop a person from 
doing the thing they feel is the morally right thing to do (Epstein & Hamric, 2009; 
Ganske, 2010). It is evident in this work so far that there is a clash between 
institutional environment and researchers working with marginalised populations 
in what is considered the right thing to do. For informants in this study, burnout led 
either to a complete time-out or a stepping back, to be able to engage in their work 
sustainably. Stepping back or out of the work could, however, be seen as an 
abandonment. Absence could be felt both by the person and by the community as a 
form of betrayal or a let-down.  
The other side of it, though if you're really passionate about something, you're 
engaging at a very emotional level, too, you are working a lot, you are doing a lot 
above and beyond. There are people who have to leave, simply for their own health 
and just to keep their own sanity. It's not necessarily everybody that comes into the 
field, stays in the field. It's not necessarily everyone that leaves the field is not 
passionate about the field. Part of it is about survival. (Informant 8) 
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The emotional component of working relationally and feeling that your research is 
necessary to creating social change for a marginalised or disadvantaged group was 
important to these researchers, but also contributed to their stress and burnout.  
Those participants who identified as Māori or Pasifika or had family members who 
were part of the community that their research was for especially felt this pressure. 
They had no way of “escaping” their perceived commitment in the same sense that 
researchers might who did not have family ties.  They could reduce workloads, but 
they could not remove themselves from the evidence of disadvantage their 
community faced. This recognition of particular pressure for some is not to say that 
other researchers working with marginalised populations did not experience strong 
emotions about their communities and pressures, but that it was qualitatively 
different. 
One informant who worked with a community who suffers a range of disadvantages, 
also discussed her need for professional support in her work to debrief, recognising 
that the conversations she was having with participants were impacting her 
emotionally.  She did not want to pull back from the work itself feeling committed to 
its goals, but saw that she also had to look after her well-being to practice 
sustainably.  
Burnout as a phenomenon makes sense for researchers (emotionally) committed to 
communities and therefore providing extra time and effort, while in a system that 
fails to support their activity and in some cases actively obstructs it. Their only 
obvious recourse is either withdrawal (voluntarily/involuntarily) or practices of 
self-care. 
4.3.1.6. Peer Community as Self-Care & Co-Conspirator  
Communities of practice were a location of support. These communities of practice 
were not necessarily located within the informant's university department, 
however, and might be spread across institutions and organisations (particularly 
when participants sat in larger departments). Those informants, who were in 
specialised units concerning their population’s health, valued the protected space 
both physically and philosophically. This space was felt as somewhere where one 
was “safe” but still challenged intellectually through peer critique and support. 
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People could have useful discussions without having to justify basic starting points.  
For those informants working outside of the university, their organisations were 
“specialised” to the population they served and so similar to specialised units in 
universities with sympathetic peers. 
Peers could also be members of the marginalised group community either as service 
providers, advocates or marginalised members themselves. People, who understood 
the informants’ position between “worlds” and could empathise with them, were 
necessary for debriefs, planning and problem-solving to overcome roadblocks and 
feel well in their work. 
There's just the relationships, the working with the people themselves, as supportive. 
(Informant 6) 
I think fabulous colleagues. People who you can sit with, who can encourage you, who 
can challenge you. (…) Having inspirational mentors, colleagues, people who you can 
say this stuff out loud with and debate and not feel stupid. You can explore.  
(Informant 8) 
Descriptions from informants regarding their everyday showed their 
marginalisation within the research system, through the dismissal of their views, 
relationships, connections, methodologies and knowledges. These marginalising 
actions meant that they sat apart from others within their organisations where the 
organisation’s focus was not disadvantaged populations. 
Being able to link with other researchers with particular expertise and build multi-
disciplinary teams is a supportive thing and stops us being marginalised, too. I think to 
make a real difference that [MARGINALISED GROUP] has to become part of wider, 
broader projects. But it’s often being dropped out. That says a lot about just how 
people are valued. You're a kind of non-person. (Informant 1) 
Large-scale meetings and conferences around the population of interest were felt to 
be helpful and invigorating for informants.  Some occurred annually, while others 
could be less frequent, and costs of attending could be prohibitive (some of these 
meetings provided funding for some attendees or were free). In these kinds of 
meetings, there was not a feeling of having to fight for the basic respect of their 
position, as could be the case in other settings. 
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Yeah, Hui Whakapiripiri was great, it’s so good on so many levels. It showcases the 
great variety of Māori researchers that we have and non-Māori researchers who are 
doing Māori research, to be honest. It's also an excellent opportunity for networking, 
collaborating, talking to the issues (…). What it does is it provides a safe space for us to 
do that in so that you're not actually fighting and arguing your case. Everyone is on 
the same waka so to speak. That has been good.  (Informant 4)  
However, those peer relationships can, much like the community, also act as a 
source of pressure. 
So the relationships that we had with each other in the field worked two ways. So one, 
we're all so passionate, we're all so hard working that we all kind of supported each 
other to be passionate and hard working. Which has its benefits, but it also has its 
disadvantages. If you work like that, you decide to step back, then what does it mean 
for those other people and that has implications. At the same time, with me being 
really clear to people that I'm just needing to have a work-life balance for a wee while, 
people are really supportive. (Informant 8) 
Informants were builders of networks. They valued and maintained complex, 
challenging but also nourishing relationships within their population and 
intellectual communities (and these could be overlapping). They worked hard on 
connecting to decision-makers at various levels to maintain dialogue and encourage 
understanding of their communities needs and the practices and support required 
to affect improvement. 
4.3.1.7. Māori and Pasifika – Brown Tick, Tokenism, & Extra Burdens107 
Issues for Māori or Pasifika researchers were slightly different from those of other 
informants and distinct from each other. Institutions have formalised processes to 
reflect the inclusion of Māori based on the Treaty, but also sometimes Pasifika based 
on their disadvantage in society. Institutions often have processes in place to 
support this inclusion in a variety of activities, but as an example, informants found 
that they were often added last minute to grant applications (“brown tick”) rather 
                                                        
107 Informants have been given different informant codes in this section to stop cross-reference with 
previous sections and potential identification. This is less of a worry for the Māori informants given 
there are a number of them and they openly speak about Māori issues, but is a concern for the 




than consulted about project design or implementation when inclusion was 
prescribed or implicitly encouraged. All informants who identified as Māori or 
Pasifika perceived tokenism in processes and described examples. Some informants 
explained that inclusion processes also had unintended consequences: their 
university service demands based on the terms of reference of committees108 
regarding representation, were much higher given their smaller numbers within the 
workforce. 
What meaningful partnership have you had when you put a brown face on your 
application? What power does the brown face have on that application? When we're 
often asked to provide brown ticks for people, and then when you have a voice, the 
power thing comes out. (Informant A) 
I guess one of the barriers we constantly get ourselves in, most departments at our 
university, we've got what we call a 40/40/20 split. 40% of our time is supposed to be 
allocated to teaching. 40% of our time is supposed to be allocated to research and 
20% of our time is supposed to be for service, but because we're the Māori department, 
we're always called on for things like Matariki109 or powhiri110 or whakatau111 or 
anything like that. Actually our service demands exceed that of our non-Māori 
departments. (Informant B) 
Informants recognised the importance of their representation and were encouraged 
by their inclusion, but it came at the cost of their other work – research and 
teaching.112 They also worried that some representation was not genuine. 
Committees could choose people for their compliance with those in power. Also, the 
opposite problem, those that were representative were not listened to if they did try 
and advocate for their community’s views. 
                                                        
108 Based on Treaty of Waitangi obligations Māori representation is required for many types of 
committee both within government and tertiary education institutions. This is also applies to 
working party type activities and consultation work. 
109 Matariki – Māori New Year (Matariki denotes a constellation that signals the beginning of a new 
year within Te Ao Māori). 
110 Powhiri – is a formal welcome protocol that can involve speeches and singing and is generally 
conducted on a Marae but is also used to welcome new cohorts or visiting groups to an institution or 
open a new institution. 
111 Whakatau – is a shortened version of Mihi Whakatau, which is a formal welcome speech, not 
conducted on the Marae, largely at universities or government buildings to welcome new staff or 
open new buildings, for example.  
112 And in practice, it was explained that this is more often at the cost of research, as teaching has 
fixed times and deadlines, where classes need to be provided, or assignments marked, whereas 
writing grants and publications were more easily delayed, and pushed aside under pressure. 
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But one of the things I worry about, about setting up those kinds of specific roles is 
they're often done as tokenism, the quality is not demanded of them and there's not 
enough accountability, because it's easier for the organisation to roll on and keep 
doing what it's doing, and we've got this docile Pasifika group that we're just sitting in 
the corner. (Informant C) 
Te Ao Māori (Māori World View) and Kaupapa Māori were distinctive philosophies 
for Māori researchers. Kaupapa Māori is actively promoted as the ideal for Māori 
research (Bishop, 1999; Smith, 2012; Smith, 2000). It is in different places described 
as a philosophy and in others as a methodology; anecdotally it is often referred to by 
non-Māori as akin to participatory action research.  This comparison, however, is a 
mistake and a conflation of method and philosophy. Participatory action research 
emphasises collaboration and transformative change in communities helping 
participants help themselves (Selener, 1997).  The emphasis is on a research 
method that enables this collaboration and change. Kaupapa Māori research, 
however, does not specify method in any way, but rather perspective.  A Kaupapa 
Māori approach could use any method; the key is in centring the Māori world view 
when using the method. Are the questions asked arising from a Māori perspective? 
Are methods used to address the questions appropriate in the Māori setting, what 
things need to be added/changed to make it so? Is data analysed within a Māori 
world view, and so on.  When people equate participatory action research with 
Kaupapa Māori, they are imagining participatory action research in a Māori 
community thought of as a collaborative and engaged practice. However, this is not 
the same thing, it is missing an underlying philosophy and commitment and is why 
some informants and other researchers feel non-Māori researchers have 
misunderstood Kaupapa Māori. Some informants felt that the incorporation of 
Kaupapa Māori in funding and ethical processes had meant that Kaupapa Māori as a 
source of resistance113 was being institutionalised and subverted and that these 
processes were redefining its meaning as a method, rather than a perspective and 
practice. 
                                                        
113 At its very core, Kaupapa Māori research demands a centring of the Māori world view, this means 
not that a specific method is used, but rather that the world is seen from the view of where Māori 
principles, practices, colonised history are taken as the norm, rather than the “minority”.  
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I use kaupapa Māori because it makes sense. I work with Māori, and when you look at 
Māori health inequities, you see that, by far, the biggest drivers for inequalities in 
health, stem back to privilege, racism, colonisation. You can add surface causes, but if 
you dig deep enough, you're getting back to those. I guess a way of reframing that and 
reclaiming that space, is to work within a Māori worldview, so you're centralising 
Māori or things Te Ao Māori114 as the worldview are now normalised. What this does 
is it enables you to actually turn the gaze on others (….) it’s akin to feminism in a way 
with women actually taking the reins and saying “we've been excluded or 
marginalised or invisible and "othered" in research, so we're actually going to turn the 
tables now." Kaupapa Māori's got a resistant movement, a little like that, but more 
than that, it's also making sure that your research makes sense to your informants and 
yourself, within your own local and cultural context (...). (Informant B) 
I think that's where people have got a bit confused around what kaupapa Māori is, 
and I think that some of the confusion comes from the HRC , itself, and the way it asks 
researchers to when applying for funding, to explain these things. (Informant  A)  
Within the current setting for research funding informants articulated that the 
ability to investigate perceived societal causes of disadvantage was challenging. A 
point that came up repeatedly was informants feeling a need to fight constantly for 
the appropriate viewpoint to analyse data.115 
You're looking at a cell, or a disease function process, or drug therapy, that's our 
answer to health, whereas, again your framing, whereas I'm looking at power, 
privilege, you know, disadvantage, racism, those are my interests, those are my drugs I 
want to explore, and that's not an RCT. (Informant A) 
I'm really grateful to have colleagues who are very politically supportive and 
encouraging of, for instance, we have a data access policy (…) and it's really making 
sure that any data, any questions, any research that we do is under this philosophy of 
looking through an equity lens, always of privileging Māori views, and trying to 
reframe things in a positive assets way. (Informant D) 
                                                        
114 Te Ao Māori – means “Māori world” which generally encompasses three main things: Te Reo 
Māori (the language), tikanga (protocols and practices) and the Treaty of Waitangi. However, more 
broadly it includes whānau, hapū, iwi (familial and tribal connections) and the Marae (the 
community focal point), whakapapa (genealogy) and Waahi Tapu (sites of importance) 
115 This viewpoint is important – for example, if looking at a big dataset regarding prevalence and 
from there trying to understand causal factors, your perceptions of the environment and culture will 
determine the factors you find relevant. 
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Asmar, Mercier & Page (2009) who interviewed Māori academics in New Zealand 
describe academic life for Māori academics as mixture of experiences (Asmar, 
Mercier & Page, 2009; Mercier, Asmar & Page, 2011). There is a coming together 
with other Māori (both staff and students), as well as educating and advocating for 
indigeneity within and external to the institution, and also an effort of educating 
others and fighting for space (Mercier, et al.,2011). This fighting for space and 
understanding or responsiveness to things Māori also came out in these interviews 
with informants (both Māori and Pasifika-identifying).  
When funding was earmarked by funders for Māori or Pasifika health specifically, 
this was seen as largely positive, but could also have undesirable effects.  
Earmarked funding meant that other researchers might perceive that “the problem” 
was fixed or addressed and that they, therefore, did not have to consider Māori or 
Pasifika peoples. It also meant that work to integrate desired thinking more globally 
was not occurring (i.e. all researchers considering their obligations under the Treaty 
meaningfully for instance). 
There's also some weaknesses associated with that, because what then happens is the 
resource is never enough, the rest of the organisation then defaults to say, "Well, the 
Pasifika stuff sits over there and we're not going to bother with it." Managing that 
interface is an important thing, but I would argue, that having that space is really a 
critically important thing to happen so that you find good capability that's able to 
front that and be credible, that you allocate some resources to it and that within the 
organisation there is an absolute commitment at the highest level to supporting and 
growing that. (Informant C) 
I agree, it's great having the Rangahau stream, I don't want to be arguing against 
that, it’s fantastic, I think, for Māori there needs to be a space for Māori in resourcing, 
but then, in saying that, the trouble with that, is that everyone's thinks Māori have 
that space, that is theirs, they operate within in it and we can get on with business as 
usual. You need a 2-pronged approach where Māori have that set space to be safe, to 
have the resources to develop as is their right under the Treaty, but also that needs to 
be integrated into mainstream society. At every level, health and education, in politics. 
I think it’s only when we've got that latter integration that we're going to be achieving 
anywhere near social equity. (Informant B) 
134 
 
Reports from informants showed that they had mixed feelings about funding 
applications that included a section requiring applicants to justify how their 
research would benefit Māori.  While informants agreed that it did make clear that 
research must be beneficial to all, in their experience these sections of grants could 
include “boilerplate” answers or the most tenuous of links to Māori health. 
Participants that had sat on evaluation panels for ethics review and funding 
reported a high variability in the quality of the explanations and their content. 
Value-laden, judgments of value, around a [BIOMEDICAL] experiments, which might 
lead to some amazing hormone, which might lead to the development of a new cancer 
drug, which might lead, therefore cancer is high in Māori, therefore it's got to be 
positive for Māori. To be fair, we're not getting access to the current therapy, so why 
on earth some new therapy that might come about 50 years away? How on earth are 
Māori going to benefit from that? (Informant A) 
Professor Tony Blakely, who is a prominent New Zealand researcher of the social 
determinants of health has said: “Reducing health inequalities requires 
interventions that work as well, if not better, among disadvantaged populations” 
(Blakely et al., 2011). This sentiment was also echoed in the National Health 
Committee document on Chronic Conditions examined in Chapter 2 (National 
Health Committee, n.d.-b). Informants articulated this very same idea that getting 
services and interventions right for the most vulnerable works for the least 
vulnerable. 
I think if you are doing intervention studies, where you are actually working with them 
to design an intervention and applying it across populations. Because we've always 
argued if you get it right for Māori, you'll get it right for everybody. (Informant E)   
As a whole if it's good for Māori, it's good for everyone philosophy, yeah. (Informant B)  
When you were talking about clinical trials, there is increasing evidence that the 
biology and genes of different ethnic peoples mean that we might respond differently 
to drugs, that we might respond differently to treatments or programs, and because of 
that, Māori may not be getting the best evidence for them, rather than the best 




For Pasifika, it was arguably harder to carve out their area of attention and funding, 
because as an immigrant population, they do not have redress to the Treaty. While 
many problems for Māori and Pasifika people are similar, there are also important 
differences in cultural practices, norms, and beliefs that influence health and well-
being. “Pasifika”, “Pacific Islander”, “Pacifica” are some of the words used as a 
naming term for what is a very diverse group.  There are a variety of languages, 
cultural practices and genetic factors that make up this group “Pasifika” that is 
rarely paid attention to when grouping them together based on a geographic region. 
Moreover, while this cultural conflation in itself is wrong, their health issues are 
often further conflated with those of Māori. 
Then next is Māori, which is absolutely correct, New Zealand is bi-cultural country in 
its origins and there are massive inequalities and these have had to be addressed. But 
the inequalities agenda is largely about Māori health. You see these titles all the time. 
Ethnic disparities and then the analysis is only by Māori, and you go, "Hmm." 
(Informant C)  
Informants reported being encouraged by the progress made in the appropriate 
inclusion of Māori (and to a lesser degree Pasifika) priorities, interests, and 
representation in education and health settings. Having said that, they feared that in 
some cases, formalised processes had replaced meaningful engagement and 
representation. These informants repeatedly mentioned issues of tokenism and 
inauthentic engagement, and this reflects discourse in the literature (Prussing & 
Newbury, 2016; Smith, 1999). Barry Smith116, in discussing ethics has said: “that 
what passes for acceptable engagement with Māori is largely ritualistic and of the 
tick-box variety” (Tolich & Smith, 2015). In the book, Smith describes observing 
ethics committees and finding little evidence of real thought and consideration for 
Māori, despite application forms explicitly promoting researchers to response to 
this (Tolich & Smith, 2015). Another specific example is the recent National Science 
Challenges117 in New Zealand. The government made clear statements regarding its 
commitment to Māori knowledge, but then failed to create a Māori-specific 
                                                        
116 This book is divided into two sections, Barry Smith leads the latter section on issues of Māori 
consultation and engagement. 
117 Science Challenges are a new investment strategy targeted by the government to key areas (after 




challenge and did not appear (at least initially) to embed Te Ao Māori within the 
created challenges, which was felt by Māori as a form of silencing (Prussing & 
Newbury, 2016).  Prussing and Newbury (2016) described this as “as a tactic by 
neoliberalizing states to simultaneously recognize culturally diverse agendas while 
also undercutting their practical impacts”. 
For these informants, their lives are intimately bound with their research area 
which added other aspects to their experience. Their research work impacts their 
whānau, their hapu, their iwi or their Pasifika communities and this meant that, 
unlike for other researchers who could separate their professional and personal 
lives, this was not necessarily the case for informants.118 
4.3.1.8. Silencing 
Silencing is a term that originates in discourse analysis.  It describes the imposition 
of one form of discourse upon another, making the latter conform, disappear or 
appear aberrant and undesired through positions of power in society (Thiesmeyer, 
2003).  Scholars have explored silencing in many areas of marginalisation 
(race/ethnicity, gender, disability, their intersections) and specific social contexts, 
but also in academia (to name a few: Gill, 2009; London, Downey, Romero-Canyas, 
Rattan, & Tyson, 2012; Moran, 1998). As mentioned throughout, for many 
informants, there was a feeling of being silenced by the various organisations 
involved in the research endeavour. Silencing could occur through the constant 
clash with processes that did not recognise their practice. Examples included ethics 
committees interpreting ethical principles in ways that seemed incongruous with 
their settings; funders dismissing their potential impact and methodologies; 
governments burying work that did not conform to their ‘message’; and universities 
using processes and structures that actively obstructed or ignored their practice. 
These processes served to communicate to the informants that they did not fit the 
norm; that what they wanted to do was not how things are done. Informants’ views 
on silencing were not only based on their experiences of undertaking research, but 
many of the informants due to their seniority had been members of ethics 
                                                        




committees, funding panel committees, and other forms of review groups and also 
drew on these experiences. 
Overwhelmingly, informants felt that both funding and publishing agencies were 
biomedically and quantitatively biased. Both failed to understand that other 
methodologies could be valid or necessary given the questions and size of the 
populations that were in focus.  
An example of that would be Health Research Council, [PANELS] half of whom are lay 
but it would also apply to the biomedical people there. They never question research 
projects that go forward that might have mitochondria or genetics or microscope or 
pathophysiology. They'll never question those types of projects, and yet they'll always 
question the Māori funded projects, particularly in words that they would see as quite 
loaded political terms such as sovereignty or Tino Rangatiratanga119 or Whānau 
Ora120. They would always dismiss that as being not science or not as valid as these 
other projects. Actually just because it has mitochondria in it doesn't mean it's good 
science either. You don't actually know enough to be able to say it is good science and 
this is not. (Informant 2)   
So there's a major biomedical bias.  A huge biomedical bias. (...) Then, sorry, I think it's 
both things, there's that, and then resources are not being distributed fairly because of 
that fundamental epistemological approach that they take, and the values that they 
bring. The values of the system and the values of the government are filtered down 
through the research processes. That's that positivist bias, there has to be an RCT, 
there's value in that, and that tells us something good, but it also tells us something 
bad when we don't have representation... so it can also do a lot of damage...and it's 
only one method, so why would we be restricting ourselves to one method? (Informant 
3)  
Not only is funding biased in the sense that it preferences certain epistemological 
approaches, but funders failed to understand the processes and costs involved with 
other approaches such as community-based research when they did look on them 
favourably.  The perception of informants was that funders assumed that grants 
                                                        
119 Used to mean “absolute sovereignty”; also the name of a flag. 
120 Is a government funded work programme.  The Whanau Ora approach is unique – it is a family-
centred wrap-around approach that considers multiple elements in promoting well-being (including 
education, health, housing, etc.). For more information, please see: 
https://www.tpk.govt.nz/en/whakamahia/whanau-ora/   
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related to a laboratory were justifiably expensive, but that they do not necessarily 
appreciate that engaging with a community can also be costly. 
It takes a lot more time. (…) I think our proposal would struggle even more if we put 
the real cost on it. That's what you actually end up doing, is you end up putting in for 
the amount that you consider is likely to get funded. If you put the real cost of that 
funding in, I think most people would run a mile. (Informant 6)  
This informant’s experience was similar to others in this study.   The short-changing 
of grant budgets to have a chance of receiving some funding, even if insufficient, 
contributes to the situation in which researchers for marginalised populations have 
to do extra unfunded work.  Informants justified this by stating their belief that if 
they did not undercost their work, then no research would occur, as they would 
receive no funding at all. It is a form of self-silencing in an environment where 
perceived silencing occurs and illustrates the ways in which ruling relations are 
both restrictive of but maintained by, those who live within the problematic.  
The use of informants’ work by government and service organisations was found to 
be frustrating because decision-makers dismissed it for not being “evidence” or 
because often its conclusions were uncomfortable for those making decisions. When 
researchers conduct research from a perspective that examines the causes of social 
disadvantage, the conclusions will necessarily be critical of society and 
governments. The subsequent recommendations to ameliorate the situation 
frequently require additional service provision or change to disadvantaging 
structures, which are complex and costly. For neoliberal inspired policy making, 
policy-makers will necessarily view conclusions that require more government 
intervention and are expensive (which the complex often also is)121 unfavourably. 
The issues for [MARGINALISED GROUP] are all about, not only do we not have 
capacity, we struggle with resources, but we don't have the leverage to not only get 
onto the research agenda but what happens when research is actually done? Is it 
valued? I had a lot of examples of our research where it's mainly commissioned by 
agencies. It shows them in a bad light because what do you think? We have gross 
                                                        
121 If not costly, complex interventions are often long-term.  Long-term intervention requires ongoing 
commitment and ongoing committed funding, which can again be seen as unfavourable by policy-
makers on short-term policy cycles. 
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inequalities because of these things. They get to not release the results. So I would 
argue really strongly that what we need to enable good research in this area is good 
public policy that says, "Taxpayer-funded research must be released publicly". 
(Informant 9) 
For informants, impact meant a positive change in the community or for the 
population. Informants’ perceptions of other researchers’ priorities for impact were 
economic or academic (reputation based on publications). As is explained later in 
this chapter, evidence of these impact priorities exists throughout the strategies and 
documentation created by organisations. Impact measurement was not 
unimportant to our informants, but how they measured impact was the crux of the 
issue. 
It becomes a bit of a pointless academic exercise if you're only doing the research in 
the field of [MARGINALISED GROUP] for other researchers in the field of 
[MARGINALISED GROUP]. (Informant 6) 
One of the things that I was very interested in was there is this whole mantra about 
evidence-based policy in practice, but when the processes which enable the generation 
of that evidence don't support that happening. You have a chicken and the egg process 
where there's no evidence for that policy, but our policy doesn't support the 
generation of that evidence so then we'll continue to have no policy. That is a 
marginalising process in itself, which I think is what your thesis is and what your 
research is getting to. (Informant 9) 
Problems of justifying impact were felt directly by the author, who during the time 
of this PhD aided in the submission of two grants.  The university process is such 
that one gains advice during the application process from a research advisor (this is 
the case in most universities).  These advisors are aware through experience and 
interactions with funders, what exactly it is that funders like to hear and what is 
more likely to get funding.  For both grants, the advice given was to emphasise how 
the work meant cost savings for governments in the long run given it was obvious 
they would not produce revenue.  Even if the link was somewhat esoteric: the 
advice was that pointing out an economic value to the work was more likely to yield 
success, than if the applicants placed emphasis on ethical implications. Regardless 
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of the fact that the work aimed at bettering certain stressful situations for either 
clinicians or the public; this alone would not be sufficient.122 
Some informants felt that this mismatch in impact evaluation was partly due to a 
lack of representation in decision-making, i.e. informants felt they had no voice or 
champion.123 Fair representation by community members or researchers on various 
panels was felt to be lacking, meaning that their communities did not have input in 
decision-making exercises. While Treaty obligations meant that government had 
embedded Māori representation on panels to some degree, the extent to which this 
representation had influence was not clear.  For most other groups representation 
was entirely lacking or involved stakeholder consultation. For representation to be 
effective in informing decisions but also in ensuring that decisions are found 
acceptable by communities, representation must be accurate, comprehensive and 
authentic (Hunter et al., 2016). In speaking to informants and reviewing 
documentation, this did not seem to be the case. 
I went to a presentation on disabilities recently, and a very simple principle is 
"Nothing About Us, Without Us." That's a really simple measure that I think ... I really 
argue strongly for that idea of governance that includes credible [MARGINALISED 
GROUP] representation... Not that they pick who they want and who is friendly. We 
need to have some processes where we say, "Here are the people who have done some 
work in this area who understand the complexity and can engage with researchers in 
a similar way." I used to see this on clinical guidelines groups and things all the time. 
Here's all these professors of medicine and sociology and anthropology, and here's a 
[MARGINALISED GROUP] community person. Tell me how we’re meant to have a 
sensible discussion here...(Informant 9) 
According to informants, ethics committees sometimes failed to recognise, their 
different types of practices, the different ways they practised, or the value of their 
research artefacts (products of research such as recordings, transcripts, narratives, 
photography, or art). Informants felt that biased preferences towards certain kinds 
of research were once again present. The exclusion of some research 
                                                        
122 Field notes 
123 A champion is someone who advocates for a particular group based on knowledge and expertise. 
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methodologies124 from certain forms of ethical review (discussed further in 4.3.2.) 
highlights the dismissal of the work conducted by some of our informants when 
compared to that of clinical research.  
The other thing about ethics is when I did my [RESEARCH], I wanted all the tapes to be 
archived, because this is our history. This is our taonga125. That was difficult for the 
ethics committee, but I had agreement, I think only one person who worked for the 
[GOVERNMENT] said no, she doesn't want to have hers archived. (Informant 5) 
Even at an ethical level, being on an Ethics Committee, all the lay members are always 
questioning the qualitative research. “What’s the point of this research it’s not going to 
make a difference”. Being able to have both experience in quant and qual, it is really 
good being able to say “we don't know that statistical research is going to make a 
difference either. We don't have power to have randomised controlled trials”, having 
enough knowledge to be able to argue at that level, having somebody there to be able 
to advocate those critiques. (Informant 2)   
But I have had to spend a lot of time and energy working with ethics committees to 
convince them that it isn't unethical to do this research.  (Informant 8) 
Informants described endeavours to build relationships with committees, to 
facilitate a more healthy understanding of their projects and ways of working. For 
these informants the fact that Health and Disability Ethics Committees and some 
University Ethics committees allowed applicants to attend the review of their 
application, which enabled them to answer any questions personally was very 
valuable. Being able to explain to committees, their practice, relationships, and the 
ways they navigate ethics in challenging situations, face-to-face ameliorated some of 
the issues created by forms that did not ask for nor allow space for these kinds of 
explanations.  
                                                        
124 While it is not worded this way, the perception in the research community is that Health and 
Disability Ethics Committees no longer review qualitative health research since the 2012 reforms. 
The guidelines state that any research that collects personal information from patients or carers in 
their capacity as such, should go through HDEC review. Anecdotally, people have described being 
told to go to another committee with this kind of work. Issues arise here for those organisations that 
are not tertiary education providers with access to their own ethics committees.   




Informants felt that data practices presented another possibility for silencing, both 
of themselves and their populations. Processes of generalisation within large 
datasets were likely to ignore lines of questioning that draw out issues for those 
that suffered marginalisation or disadvantage. Informants noticed a lack of 
discussion around what was happening in this “Big Data” space specifically about 
representation. 
For Māori, we've had data used on us in really damaging… and disempowering ways. I 
worry that people will take our data and do really disrespectful stuff with it. We have 
no control over what happens to it once it becomes open access. On the other hand, I 
think people keep data and not having access to data can be also a form of quieting 
and not letting our voices be heard.  (Informant 7) 
My heart always starts racing a lot faster about open datasets and big datasets, 
however, when I said my heart starts racing, it’s because they are so open to abuse and 
mismanagement, and that really concerns me. We know that people use data 
incorrectly. We know that data can be used to spin...whatever purpose you want it to 
spin. So that worries me, about big data, bringing that back to the participant worries 
me because I have collected that data and I have made a promise to them that this is 
how it will work, so that's about my integrity and my relationship with that 
participant. That deeply concerns me. (Informant 8) 
Some researchers had direct experience with or were aware of Kaitiaki groups 
(described in Chapter 3, and discussed further in Chapter 7).  Informants perceived 
these groups managing data on behalf of populations as positive but also stated that 
this would not be possible were it not for the institutional backing of those groups 
providing them with authority. Informants were not data-sharing adverse, insofar 
as they perceived the benefits of sharing collected data in reducing the burden of 
research participation on their communities.  Their emphasis, however, was on 
appropriate management, where they saw this as having their marginalised 
communities’ best interests at heart first and foremost. Given their experience of 
various actors’ lack of consideration for their populations in the research 
environment, their anxieties regarding data practices were understandable. 
Informants also spoke about the dismissive or inconsistent attitudes adopted by 
various funding committees toward their research topics. The same was true of 
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decisions regarding the setting of priorities. The reported inconsistent atmosphere 
appeared to be attributable to the lack of expertise on the committees, meaning that 
a single member, by virtue of possessing a strong voice, may disproportionately 
influence the overall decision-making—an issue that often arises with constant 
membership changes.126 Dismissiveness was related to the ways in which inclusion 
was talked about and described in strategies, but then no-one ensured inclusive 
practices at the ground level. 
 (…) Unless you've got someone there. It showed me a lot about how much time, and 
attention is paid if that's not your field and how easily [EXAMPLE OF REVERSAL OF 
SCORE BASED ON CHAMPION ON THE COMMITTEE] For me, that was one of my 
moments when I went, there’s no point really. (Informant 1) 
Just thinking when you’re saying the barriers…at the political level, I was just thinking 
about the National Science Challenges, we were interested, or concerned, is probably a 
better word. As Māori researchers, when they determined what the [RESEARCH 
AREAS] were going to be, there was no Māori side, [RESEARCH AREA]. We would be 
incorporated into one of these other ones. I feel like it was another way that we were 
cut out of the decision-making. Our knowledge wasn't validated. (Informant 2)    
The informants’ experiences reveal how senior researchers working with 
marginalised populations are themselves marginalised and silenced in a system 
they feel undervalues their work and the population they do that work for.  
Nevertheless, over time they have successfully learned to navigate this system, such 
that, despite the obstacles, they can secure (limited) funding and publish their 
research as experts in their respective fields.  How ruling relations explain this 
experience is the next part of this chapter. 
4.4. The Ruling Relations for Researchers working with Marginalised Groups 
The informant experiences resonate with those of other researchers examining the 
academic environment who have stated that these institutional systems and 
processes, “make us feel silenced, confused and sometimes angry” (Butterwick & 
Dawson, 2005). Butterwick and Dawson (2005) are only describing work the 
                                                        
126 Field notes- departmental meetings on funding and HRC funding and panel review processes.  
Those who sat on panels at these meetings and those of our informants who sat on panels have 
described this aspect of panel review. This is of course not discussed at HRC roadshow meetings. 
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neoliberal university structure. I have presented here a specific view of the health 
research structure including researchers who sit outside of the university; the 
practices of research within the university influences those outside of it. 
Researchers outside academia must compete for limited funding on criteria 
established by those within academia and government. Using these experiences of 
informants, along with institutional texts and discourses, I now aim to “understand 
the exercise of power and the maintenance of hierarchies of privilege and 
subordination” within the research system (Butterwick & Dawson, 2005). 
This chapter has repeatedly alluded to the way in which researchers as actors in the 
system generate knowledge and evidence. As explained in Chapter 1, the use of the 
term evidence signals the designation given to this word by Sackett et al.,(Sackett, 
Rosenberg, Gray, Haynes, & Richardson, 1996) as information of a certain kind, 
based on narrowly defined robustness. Knowledge has been used to denote 
information generated by research practices seen as less robust and beginning with 
a specified viewpoint or perspective.127 It is argued that neoliberal policies that have 
pushed for a knowledge economy (Department of Labour, n.d.)  and fostered 
managerialism within the health and university system, alongside a traditionally 
biomedically focused health research system and this has created a specific 
environment. A knowledge economy is one that shifts its focus from production to 
information. It is an economy that relies on the value of information and ideas and 
their trade, rather than manufacturing and products. Managerialism is an ideology 
that propounds that anything managers can manage any system (no matter how 
specific or complex) according to good management principles rather than any 
specific specialist knowledge of an area. Managerialism removes the power from 
workers, society, specialists, and so on and places all power in a management class, 
who run all organisations on principles related to efficiency and standardisation.  
Marketisation is when something previously provided as a public good becomes 
open to market principles, such as supply and demand.  These three factors 
combined, the knowledge economy, managerialism and marketisation, create an 
environment in which measurement, standardisation, efficiency and economic value 
                                                        
127 Evidence is now used in more than the evidence-based medicine domain and so is broader than 
Sackett’s original definition, but arguably still denotes a certain kind of information.  Evidence 
generating research rarely discusses perspective or viewpoint and this will be discussed further in 
Chapter 5.  
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are paramount. This is an environment that preferences certain information 
generating activities, excluding and diminishing those that do not fit the 
marketisation of education, health, and research itself. This environment and its 
effects on information gathering are the ruling relations of health research in NZ. 
These ruling relations create the situation of precarity, silencing, and burnout 
discussed above, and our informants try to manage this environment through 
relationships (with peers, decision-makers, and their communities/populations) 
and practice flexibility. 
4.4.1. Knowledge Economy, Marketisation, and Managerialism in Health and 
Education 
The New Zealand Education Act of 1989 which sets out the role and definition of 
universities, is typically Humboldtian in its description (Ministry of Education, 
1989). Part of the Humboldtian ideal of the university, described by Humboldt in 
the late 19th century, was that of autonomy from the state despite receiving state 
funding (Habermas & Blazek, 1987).128 The legislation sets forth the following 
characteristics as those a University should have:  
(i) they are primarily concerned with more advanced learning, the principal aim 
being to develop intellectual independence 
(ii) their research and teaching are closely interdependent and most of their teaching 
is done by people who are active in advancing knowledge: 
(iii) they meet international standards of research and teaching: 
(iv) they are a repository of knowledge and expertise: 
(v) they accept a role as critic and conscience of society; and 
(b) 
that— 
  (iii) 
a university is characterised by a wide diversity of teaching and research, especially at 
a higher level, that maintains, advances, disseminates, and assists the application of, 
knowledge, develops intellectual independence, and promotes community learning 
(Ministry of Education, 1989)129 
 
On the website for New Zealand Universities created in 2012, the following is 
appended to this section of the Education Act:  
                                                        
128 His model also included a holistic conception of education across disciplines and a unity between 
research and teaching within the institution.  
129 Points (b-i, b-ii and b-iv referred to other educational institutions) 
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“Universities are a vital part of modern society and are important not just for 
teaching but also for research and the development of society as a whole.  As 
centres of research excellence they play an important role in economic 
transformation and development130.”(Universities New Zealand - Te Pōkai 
Tara, n.d.) 
This shift to include “economic transformation and development” is arguably 
attributable to reforms in New Zealand which began in the late 1990s/early 2000s 
and persisted for the remainder of the decade.  At the end of the 1990s, politicians 
argued that to transform the economy, New Zealand required a better-qualified 
populace (Shore, 2010a, 2010b). Reforms were put in place (by a then Labour party 
government) to facilitate increased access to university education to a larger 
proportion of the population (Shore, 2010a, 2010b) to achieve this better-educated 
society.  This opening of access began New Zealand’s ‘knowledge society’.  A 
knowledge society is one where knowledge is shared/dispersed throughout the 
society, the system flattens the previous hierarchy of knowers. A knowledge society 
is necessary for a knowledge economy, as workers are no longer the creators of 
things, but of ideas (David & Foray, 2002). During this period the university 
maintained relative autonomy, but on the pretext that the allotment of extra funding 
would ensure more New Zealanders gained access to undergraduate education 
(Shore, 2010a, 2010b).  Outside the university, society witnessed an erosion of New 
Zealand’s Keynesian welfare state131 in the early 1980s in response to the 
emergence of free market economics. Education largely managed to remain 
unscathed (in the 80s, early 90s) but eventually also came under the purview of 
neoliberal policies which had become mainstream and normalised (Shore, 2010a, 
2010b). The knowledge society moved to a “knowledge economy” along with 
international trends, and in 2008 a new National government came into power 
(Department of Labour, n.d.; Shore, 2010a, 2010b). The knowledge economy 
focused on highly skilled production and occupations (rather than low skilled 
                                                        
130 My emphasis. 
131 New Zealand is often referred to as the birthplace of the welfare state. The country chose to follow 
a Keynesian model (mixed model of private/government intervention with more of the later in times 
of recession) and implemented a socially democratic model that include state housing, welfare, 
public education and the like. This continued up until mid-80s when a Labour government began to 
advance the neoliberal agenda (Kelsey, 2015). 
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manufacturing or agriculture) and relied on universities to produce both skilled 
staff and innovation (Department of Labour, n.d.; Olsen & Peters, 2005). Within this 
environment, the emphasis was on courses with clear employment outcomes, 
efforts focused on the commercialisation of research, and an auditing culture 
repeatedly reviewing performance and value-for-money was introduced 
(Department of Labour, n.d.; Olsen & Peters, 2005; Shore, 2010a, 2010b). Thus, the 
marketization of the University. 
Examples of this marketization within universities are their innovation centres (all 
universities in our list Appendix C-1 had these centres). These centres represent 
concentrated infrastructure, staffing, and resources, aimed at creating economic 
benefit from university-led research and innovation. Consider the University of 
Otago’s “Innovation Centre.” It is self-described as a resource for “commercialisation 
of intellectual property”132.  Auckland University’s “Uniservices” describes itself as a 
“matchmaker” between researchers and companies.133 The innovation pages at 
Massey University are a lone exception in that they make comprehensive reference 
to outputs other than (international) commercialisation (although these are most 
prominent), listing projects that include the well-being of refugees and children 
living in higher socioeconomic deprivation.134 The University Commercialisation 
Offices of New Zealand (UCONZ) further support these innovation centres by 
bringing the centres together with industry partners both nationally and 
internationally to build relationships.135 
NZ university websites, reference support services, funding, and metrics, for 
innovations that lead to economic benefits. None have centres or clear support 
structures for engaging with the community or addressing inequalities.   
The relationship between the university and the local community is visible only 
insofar as some universities have student-led volunteer groups, publicly accessible 
seminars, or outreach activities that take place in a community for future student 
recruitment or placement. The term disadvantage appears concerning the recruiting 
                                                        
132 See: http://www.otago.ac.nz/centre-for-innovation/index.html  
133 See: http://www.uniservices.co.nz/  
134 See: http://www.massey.ac.nz/massey/initiatives/innovation/areas-of-interest/areas-of-
interest_home.cfm (Health and Well-being and Society are those of interest). 
135 http://www.universitiesnz.ac.nz/why-universities-matter/commercialisation  
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of, and supporting of, students from disadvantaged communities (identified as 
Māori or Pasifika). However, the latter is also to some degree an economic strategy 
given that higher Māori and Pasifika enrollment and success rates result in higher 
levels of funding from the Tertiary Education Commission.136 Some individual 
departments within institutions may develop community connections and outreach 
activities, but these relationships are established based on staff champions, rather 
than through university mandate.  While university strategies and mission 
statements may make reference to communities, dedicated resources are not 
allotted to the same extent (if at all) in the way that they are for “innovation” or not 
so that it is easily identifiable. 
Governmental emphasis on a knowledge economy has led to a change in the 
universities’ funding mix. This funding mix between government (40%) and 
external sources (remaining 60% a mixture of student fees, research income, and 
trading)137 means that the university has less secure financial foundations and ones 
that are arguably open to easier privatisation. This funding dynamic also means that 
knowledge production within academia is now more dependent on economic 
drivers that determine student enrollment (i.e. student uptake falls for courses that 
do not lead to work within the knowledge economy) and government priorities for 
research and innovation. There is an erosion of this ideal of independent 
institutions positioned outside of the state and the market for the benefit of society 
put forward by Humboldt and articulated in Haldane principle.138 There is still some 
evidence of university staff fulfilling their role as “critic and conscience” of society 
when they speak out on alcohol and smoking regulation, climate change, the Trans-
Pacific Partnership Agreement or other government policies. However, there are 
arguments in the literature and on university campuses that a certain risk 
adverseness to playing the role of government critic is growing within tertiary 
education as governments reduce funding (Bridgman, 2007; Harland, Tidswell, 
Everett, Hale, & Pickering, 2010).  
                                                        
136 See: http://www.tec.govt.nz/Funding/Fund-finder/Equity-Funding/Funding-Requirements-and-
Rates/ Limited funding is also available for students with disabilities but this is far less than that 
provided for Māori or Pasifika students. 
137 See: http://www.universitiesnz.ac.nz/nz-university-system  




One way that neoliberal policies enact this power over universities is performance 
measurement and a focus on instrumentalism (Ashcroft, 2006; Bridgman, 2007; 
Cupples & Pawson, 2012; Harland et al., 2010; S. Wright et al., 2015).  
4.4.1.1. Metrics & Excellence 
Marketisation refers to the application of market principles to typically, non-
market-based institutions (Reiners, 2014). The marketisation of the university 
arises through the creation of competition in an environment of scarce resources 
(Brown, 2011; Reiners, 2014). Managerialism reinforces this marketisation in the 
University, much like in the marketised NZ health system. It manifests in the 
introduction of private sector practices into the public sector (Teelken, 2012), 
practices that are target-driven and business-orientated. There are more and 
repeated bureaucratic and administrative tasks. These tasks ensure the 
quantification and measurement of performance and output (Brown, 2011; Reiners, 
2014; Teelken, 2012).  
Performance measures are, at best, simplistic. Such measures zero in on easily 
measurable outputs. At worst, they focus on the international and commercial 
(Wright et al., 2015).  All of these metrics place our informants at a disadvantage, 
especially those whose work focuses on the local, the complex (regarding 
measurement) and the transformative for minorities within society.  A continuing 
thread traceable in government documentation related to research, both within the 
health sector and university sector, is its status as ‘world class’. In New Zealand, the 
Performance-Based Research Fund (PBRF) aims to assess research quality and 
impact based on the submission of individual researcher portfolios within 
departments at universities and polytechnics on a six-year cycle.139 The measure 
“world-class” is evident in New Zealand’s research performance exercise (PBRF), 
but also in health research strategy documentation (Ministry of Health, 2016), in the 
HRC documentation140, and individual university strategy documents which 
naturally align with those of external funders and auditors.  An obvious example of 
                                                        
139 The Performance Based Research Fund is much like exercises in Australia (ERA) and the UK 
(REF), it is an auditing exercise to allocate funding based on performance measures around research.  
140 The HRC’s Research to Action report from 2015 is particularly interesting 
(http://www.hrc.govt.nz/sites/default/files/Research%20to%20Action%20-
%20HRC%20IIR%202015.pdf) but other documents including their Annual Reports and current 
documentation around the “Strategic Refresh” they are undergoing are of interest. 
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what the government emphasises is in the HRC Annual Report of 2015.  The 
outcome measures, on which the HRC had to report to government for the year 
were:  
o Outcome 1: New knowledge, solutions, and innovations are created 
for health 
o Outcome 2: The health system is improved through research evidence 
and innovation 
o Outcome 3: The best clinicians and researchers are attracted, 
supported, and retained within New Zealand 
o Outcome 4: The impact, responsiveness, and uptake of health 
research is increased (Health Research Council, 2015). 
 
A quick search of the document finds 12 references to commercial benefits/outputs, 
22 references to economic growth, revenue, or savings and just one reference to 
inequities (no mention of vulnerable populations, inequalities or disadvantage). The 
document discusses Māori and Pasifika populations and workforces throughout, 
and as previously mentioned there are specific funding streams and career awards 
for these populations from the HRC, but Māori and Pasifika communities are not the 
only ones suffering health inequities in NZ.  The reduction of inequities is not a 
prevalent discussion within the documentation of the main funder of health 
research in NZ with the task of funding research that benefits NZ society (Health 
Research Council, n.d.).    Of the four specific priorities the report outlines for the 
HRC dictated by the Minister of Health, two are mostly focused on innovation and 
economic gain (Health Research Council, 2015).141 
 
A marketised university requires efficiency in production to be successful within the 
market. Researchers working with disadvantaged populations undertake projects 
that affect small groups, take a long-term view, and produce little revenue. 
Researchers working with minority populations may link with international 
researchers, publish in international journals, speak at international conferences, 
and the like, but those journals have lower impact factors and the communities they 
link with internationally are much like their local ones, small and marginalised 
                                                        
141 The other two focus on translation of research into practice and research workforce development. 
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within their local system.  Research evaluation exercises and the environment of 
competition support more biomedical and laboratory-based sciences (Lõhkivi et al., 
2013; S. Wright et al., 2015). Evaluation favours biomedical/lab-based work 
because research that is formulaic (has clear rules and standards) is more easily 
measurable, and scrutinised (Lõhkivi et al., 2013).  
 
Research that is iterative, that uses community-based practice methods, 
participatory action research frameworks, or health research that utilises 
sociological methods with non-traditional paradigms for quantitative methods are 
not as easily evaluated.  The continual audit/performance processes in an 
environment of competition can distort the research endeavour; academics within 
the institution assimilate their practice to the “path of least resistance” that will 
more easily get published, funded, cited (Karmaeva, 2016; Lund, 2012). To state this 
more directly, the perception (and reality) of what is likely to get funded and 
published, changes what research is put forward for publication and funding. The 
informants spoke of a level of pragmatism in “playing the game” to be able to 
sustain activity. Interestingly, they also indicated that they often perform acts of 
subversion. This subversion was doing what was necessary to be funded or 
approved, then using the resources in the way that would satisfy the needs within 
their community work. During the question period of a recent conference 
presentation142 about empowerment for health promotion, a discussion ensued 
regarding the contradiction of utilising deficit discourse to gain access to funding. 
How can this be reconciled to empowerment approaches that were the purpose of 
seeking funding? A researcher confidently opined that in her country (from the 
Global North), funders are aware that what researchers write in a grant application 
and what work the research team actually undertakes in a severely disadvantaged 
community, were two different things. The implication was that everyone was 
happy as long they could tick their boxes – i.e. the researcher could achieve 
outcomes that she and the community felt were meaningful, and the funder could 
tick off that they had funded research in line with the measures against which they 
reviewed applications.  
                                                        
142 “A proactive model for empowering women for health promotion: Utilising Anne Donchin’s 





It was also clear from informants that relationships and stakeholder engagement 
were key to their work and meaningful outcomes.  These kinds of activities, 
however, are difficult to quantify and so are not recognised in performance 
measures. The lack of support for relationships and community building means that 
a researcher that values this kind of interaction for their work (and in fact, sees it as 
crucial), must rely on the benevolence of their department to allow time for this, or 
must do it outside of their employment time. Furthermore, any researchers who 
subscribe to a philosophy of collaborative partnership or co-production143 in their 
research practice, find this almost impossible to do within a university setting. Co-
production is the shared ownership of a project and its outcomes, and yet no 
process within the health research system allows for, or supports this, not funding, 
ethics review, or publishing. For reasons of research governance, each project must 
have a primary investigator. For purposes of publication and funding, each project 
must designate a primary author or primary investigator. The language used in 
most processes does not allow for a team philosophy or co-ownership.144 
 
In summary, the marketization of the university has created an environment in 
which funding is scarce; managerialism is rampant, and continuing performance 
measurement exercises are the norm. The impact of research is not measured 
robustly beyond funding and international recognition (based on publication and 
citation metrics).  For this group or researchers, this meant that they were in a 
competitive environment, in which many of the measures of success were stacked 
against them. Impact especially was incongruent with their setting.  For our 
informants, the impact was at the community level or the policy level. The 
Performance-Based Research Fund (PBRF) does not recognise this kind of impact in 
a way that equates with the impact other researchers may have. Efforts in NZ have 
been made in the continual editing of the PBRF criteria to acknowledge broader 
forms of impact, but they remain second rate measures. The lack of broader impact 
                                                        
143 These kind of research practices see partners in the community as co-investigator or team 
members; for co-production especially, systems and processes are difficult as this model wants to 
remove the hierarchy of team members, i.e. everyone contributes, no-one is a leader. 
144 Researchers can have a team philosophy regardless, but much work then needs to be done with 
the co-producer to explain that processes require something, that is at odds with the philosophy 
being used.  
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measures is partly because these types of impact are harder to measure, so they 
normally do not count as highly within assessments, nor do they contribute to 
performance measurement in general. 
 
4.4.2. Biomedical Bias 
Evidence-based medicine (EBM) has begun to influence all manner of domains: 
evidence-based practice, evidence-based decision-making, evidence-based nursing, 
evidence-based implementation, to name a few. This expansion from what was 
originally a clinical, epidemiological method that aimed to improve clinical decision-
making (Chalmers, Dickersin, & Chalmers, 1992; Cochrane, 1989) to the foundation 
of decision-making across health, social services, education and policy is 
problematic.145 This spread of EBM occurs in parallel with the rise of neoliberal 
policies that favour measurement and standardisation described above. As such, 
EBM is the perfect tool for the job. EBM within the health system allows a clear 
focus on efficiency and standardisation. The majority of work done by our 
informants was not ranked highly within an EBM hierarchy of evidence.  
 
EBM and a biomedical focus are not the same thing but they are closely related.  
Both privilege reductivist views of causality and health (Dowd, 2011; Solomon, 
2006, 2015; Vandenbroucke, Broadbent, & Pearce, 2016) The biopsychosocial 
model, Te Whare Tapa Whā146, patient-centered care, and other such resources 
have been introduced over time to allow a greater depth of understanding of health.  
However, while they are taught in medical curricula and referenced in government 
documentation, there are those that question to what degree they are understood 
and practised, again a kind of tokenism is seen (Bechtel & Ness, 2010; Bensing, 
2000; Berwick, 2009; Kreindler, 2015). 
 
                                                        
145 In New Zealand, the Ministry of Social Development now uses randomised controlled trial 
methodologies for social welfare interventions in order to generate best evidence prior to making 
decisions.  In some cases the trial design has been questioned (application of EBM principles without, 
methodological know-how) Their “Early Start” project or “Project K” available from their website are 
examples: https://msd.govt.nz/   




A biomedical and EBM bias in the health and health research system can be seen 
most strikingly in its documentation that both explicitly and implicitly directs 
readers or applicants to what the systems consider more valid. An example of this is 
the Health and Disability Ethics Committees discussed earlier in this chapter.  These 
ethics committees refer applicants to two sets of guidelines, one specifically for 
“intervention studies,” and one for “observational studies, which includes audits and 
other related activities” (NEAC, 2012a, 2012b).  The guidelines only mention 
qualitative methods once: 
While these Guidelines may be useful for investigators conducting other forms of 
non-intervention study, such as qualitative and social science research, note that 
those studies use distinct methods that may raise separate ethical issues.” 
 
“They may raise separate ethical issues”, but the document does not state where 
researchers can find guidance on what these issues might be or how committees 
and researchers should handle them. Nor is any mention made of non-biomedical 
research methods within the health setting. In 2012, the NZ government began a 
reform of the HDECs due to the perception that NZ was not providing a welcoming 
environment for clinical trials and therefore losing out on an important source of 
revenue. It was at this time that the government cut certain forms of research from 
the review process.147 This narrowing of the HDEC remit for ethical review meant 
that those organisations conducting health research outside of the university who 
lack their own ethics committee, and who are not funded by the HRC and not 
classified as clinical/observational research, have no recourse for ethical review.  
Also, in devising the online application system, the format and content of questions 
and permissions focus almost solely on the biomedical.148 These changes have a 
                                                        
147 Interestingly the submissions for the Parliamentary review were mixed between pharmaceutical 
companies, university health researchers (of varying types) and concerned citizens. Their concerns 
were around processing time, but their suggestion was that review was robust, but resourcing 
insufficient (this from commercial and university submitters). Ambiguity around Māori consultation 
processes were raised and problems with projects that required multiple committee approvals.  
Changes that were implemented did not clearly map to these concerns: the narrowing of the scope of 
the committee, an electronic submission process, narrowing of committee membership, and 
shortening of processing time, as well as an explicit removal of review of scientific validity, and 
formal ethical process for accessing New Zealand bloodspot cards for secondary research. (Tolich & 
Smith, 2015) 
148 Even though some qualitative work can be reviewed by an ethics committee, filling in the 




silencing effect; it sends a message to those conducting certain types of research 
about what their value is in the system. 
 
Application forms (ethics, funding) in many settings are not flexibly designed to 
accommodate different kinds of research.  By this, I mean, that while there are 
spaces within these forms for researchers to describe their work, explanatory notes 
provided are biomedically-focussed, or section headings align with biomedical 
practice rather than other more mixed or iterative practices.  Iterative practices 
especially are disadvantaged in a system that does not deal with flexibility. This lack 
of flexibility can be directly connected back to managerialism – auditing, 
bureaucracy, and the like require conformity to pre-established standards and 
ideals for system efficiency. 
 
This emphasis on the biomedical, the evidence-based, the commercial or 
economically beneficial, naturally disadvantages those looking at marginalised 
populations because the issues for these populations are largely not biomedical. 
Instead, the issues are social and complex. The methods to address these kinds of 
issues are rarely RCTs. The interventions researchers working with marginalised 
populations create, are unlikely to generate commercial revenue.  Some 
interventions might be more clinical (pharmaceutical, medical), but most will fall 
within issues of access, intervention or delivery. 
 
Not only are the marginalised disadvantaged through circumstances in society, but 
research that would improve their situations is itself marginalised by systems that 




4. 5. Summary  
Institutional ethnographic practice in New Zealand is rare and while work exploring 
the effects of neoliberalism and performance measurement on the academy (and 
more specifically women) exists (Cupples & Pawson, 2012; Lõhkivi et al., 2013; 
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London et al., 2012; Reay, 2000; Reiners, 2014; Shore, 2010a; Teelken, 2012; Wylie, 
2011) my work here extends these analyses to understand how the health research 
system works for researchers that affect health inequity. 
More specifically, in this chapter, I described the ruling relations of health research 
for those working with marginalised populations and their experiences.  The 
tensions of support and stress from the communities informants work with, and the 
organisations they work for are distinct.  Informants enjoyed their work and gained 
satisfaction from it. For many, their work as a researcher expands to advocate and 
champion for the populations they serve.  The burden of this role is evident in the 
barriers that these researchers overcome and address when conducting research 
within systems that neither privilege their population of interest or recognise their 
questions (and the means of answering them) as valid or important research 
practice. These systems are a part of the ruling relations that, within a neoliberal 
framework, direct academic pursuits towards the free market with a biomedical 
bias.  There is a commodification of research (and teaching) as processes of product 
creation for economic benefit within a knowledge economy.  
Teaching has not been part of this enquiry because not all informants were within 
tertiary institutions.  The knowledge economy commodifies teaching through the 
valuing of courses that generate the most revenue and the devaluing of courses that 
conversely do not.  The commodification of teaching impacts the informants by 
creating both some of the precarity they felt and some of the burnout (where 
teaching commitments add to their workload burden).  It is also the case that given 
the premise of research informed teaching (that universities are mandated to 
address by legislation), that where diverse research is not occurring or is silenced, 
teaching becomes and is limited in what it conveys to students.  Further work in this 
area is required. 
Within this theory of the ruling relations, those working specifically with 
populations that suffer injustice, are themselves disadvantaged by not only focusing 
on a group that rarely leads to any form of economic benefit but a group that fails to 
participate in the neoliberal ideal of a self-regulating market that creates well-being 
for the self-interested individual.  Also, the constant emphasis on the biomedical 
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and evidence-based health research practices fail as epistemologies to address the 
full scope of health knowledge and as such fail to address all health research 
questions, specifically those pertaining to the marginalised and disadvantaged.  
I posit that this failing is an epistemic injustice for the researchers working with 
marginalised populations, insofar as their knowledge and knowledge practices are 
devalued or silenced within the larger health research system. This original 
application of epistemic injustice will be explored further in the next chapter where 





Chapter 5: Epistemic injustice, research practice, evidence and decision-
making 
“A wise man proportions his belief to the evidence.” 
David Hume 
 
“Scientific standards themselves are always already actively politically engaged, whether or 




The previous chapter finished with the claim that epistemic injustice occurs for 
researchers working with marginalised populations (and the populations 
themselves). This chapter must now explore this assertion. To that end, I explain 
epistemic injustice, an unfair dismissal or failure to recognise certain knowers and 
certain types of knowledge as valid using measures of rational authority and 
credibility (Fricker, 1998).  I link this in part to the research environment which is 
dominated by a biomedical bias and evidence-based standards (Chapter 4). 
Evidence-based medicine (EBM) has become the status-quo model for decision-
making across health services and health policy settings.   
The history and rationale of EBM are explained, including the hierarchy of evidence. 
The hierarchy of evidence is used to evaluate and classify information. I explain the 
assumptions that underpin this evaluation and some critiques of EBM, are put 
forward.  Based on the findings of Chapter 2 and 4, I then make the novel claim that 
our health research environment and the dominant EBM framework create 
epistemic injustice for marginalised population researchers. This injustice is 
achieved by denying researchers working with marginalised populations rational 
authority and credibility. I explain that this occurs through the concepts of 
objectivity and generalisability used in the health research environment. I conclude 
by considering possible solutions to this problem of epistemic injustice. 
5.1. What is epistemic injustice?  
Miranda Fricker explains epistemic injustice as a dismissal of or failure to recognise 
certain “knowers and knowledges” enacted through social power of either agents or 
structures, passively or actively (Fricker, 2007). There is a here an epistemic 
injustice for both the marginalised population and for the researchers who work 
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with marginalised populations. Epistemic injustice could be said to occur for 
marginalised populations in that their cultural, or social, or gendered149 experiences 
and needs are missing from the dominant discourse of health and largely ignored in 
considerations regarding health. They are, in other words, invisible. Fricker calls 
this a hermeneutic injustice (Fricker, 2007).  A hermeneutical injustice is one of 
communication, where a person/group lacks access to a significant part of their 
social experiences, because of socially dominant ways of interpreting and 
communicating (Fricker, 2007; Medina, 2012). 
Therefore, in undertaking research that focuses on experiences and conditions that 
the dominant health research culture does not recognise as significant or different 
from those of the general population, marginalised population researchers start 
from a point that is already deemed less valuable within that dominant discourse.  
However, the discussion in this chapter focuses on the direct dismissal of 
knowledge generated by researchers working with marginalised populations rather 
than the hermeneutic injustice experienced by the populations themselves. For an 
epistemic injustice to occur at the level of knowledge creators or knowers150, one 
has first to understand that the definition of knower is someone who possesses both 
rational authority (competence and trustworthiness) and credibility (ability to be 
believed to have rational authority)(Fricker, 1998).  Rational authority is recognised 
when we consider the knower to be someone who tells the truth (trustworthiness) 
and has the right way of determining it (competence); credibility occurs when we 
recognise that a knower has rational authority based on socially determined 
characteristics or consistent external confirmation of knowledge claims (Fricker, 
1998).  
5.1.1. Epistemic injustice within the Aotearoa New Zealand health research 
environment 
The research environment as a structure enacts social power that discredits both 
aspects of rational authority and credibility required for a marginalised population 
researcher to be a knower.  In Chapter 4, marginalised population researchers 
                                                        
149 This could be any axis of potential discrimination or marginalisation and as mentioned earlier can 
also be the intersection of multiple axes of discrimination or marginalisation. 
150 Fricker calls these informants, but given our use of informants in Chapter 5 in line with the 
ethnographic method, it was felt that using an alternative term would be clearer. 
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appeared to have differing perspectives from other health researchers and/or 
methodologies and pay attention to different phenomena in the world.  They may, 
for example, use a traditional quantitative method, but apply it to mapping the 
social causes of phenomena, where the dominant framework is focussed on the 
behaviour of individuals. Alternatively, they may have a ‘traditional’ perspective of 
the individual but use ‘non-traditional’ methodologies, such as participatory action 
research. They may have both a ‘non-traditional’ perspective and methodology.  The 
fact that they are delineated here as ‘non-traditional’, and this conveys a shared 
understanding to the reader evidences a certain dominance of perspective within 
the health research environment. These interests, perspectives, and methodologies 
are either altogether dismissed, or ranked lower within the health research 
knowledge environment that currently exists. Their dismissal is partly created by 
the privileging of “objective” priorities and perspectives in health knowledge 
creation, and also partly due to the “positivistic” standard by which we assess 
healthcare research methodologies.  
Within the academic environment, given the forces described in Chapter 4, there is a 
tendency to favour research that generates either government interest, 
international acclaim or has a commercial output/economic benefit. As was 
explained in Chapter 4, researchers working with marginalised populations conduct 
a range of research using qualitative, quantitative, and mixed methods. Their work 
ranged from small, interventional studies to larger descriptive studies, 
observational studies, including various exploratory and theoretical research; all 
focused on distinct and small populations.  Research of this type does not generate 
commercial outcomes (it may generate economic outcomes, i.e. cost savings, but 
these are often comparatively small). Research of this type rarely attracts 
international acclaim and when it does, it is generally within a small international 
community dedicated to an equally small and specific area. Government interest is 
mixed (as described below). Therefore, the work of marginalised population 
researchers, with the knowledge they create, is less valued and less valuable within 
the greater health research environment. Researchers working with marginalised 
populations create work that fails to conform to the standards of evidence and value 
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that exist in the system.151  They fail to meet these standards in part because of the 
perspectives they start from (credibility/rational authority), in part based on the 
devaluing of methods they use (rational authority), and in part based on the greater 
systems lack of interest in their topics and populations (credibility).  
5.1.2. Epistemic injustice within the government evidence environment 
Government research use is applied. It has a purpose and therefore must meet 
criteria to qualify as a specific kind of information. Sometimes research is 
commissioned by the government to fill an information gap; sometimes 
governments use research information already in existence and sift it through an 
evidence evaluation framework to use that which fills their information gap.152 The 
government health sector mostly uses evidence assessment frameworks adapted 
from evidence-based medicine’s hierarchy of evidence (GRADE Working Group, 
n.d.) with a strong focus on RCTs.153 It will become clear in this chapter that the 
work of our informants and other researchers working with marginalised 
populations is often outright ignored because it fails to meet the criteria established 
by evidence evaluation frameworks. 
This dismissal of research completed with marginalised populations creates or 
contributes to the injustice of health inequity by excluding information relevant to 
those that decisions may apply to, failing to also address their needs. 
5.1.3. Epistemic injustice and its relation to health inequity 
As outlined in Chapter 1, health inequity is a complex phenomenon with many 
contributing factors, including the social determinants of health. The fact that the 
groups that suffer inequity are also the groups, least well represented in clinical 
trials and health research would seem to be a contributing factor given that 
information from these activities informs services, clinical guidelines, and policy, in 
an evidence-based decision-making environment (Chapter 2). 
                                                        
151 Biomedical knowledge that is patentable or in some way commercialisable is also valuable in the 
system, but the work done with marginalised populations is hardly ever this type of work. 
152 Funding bodies value the kinds of research that are seen as valuable within the system. So 
research conducted outside of government interest is still to some degree aiming for these same 
standards (if not aiming for reputational impact or commercial output). 
153 As we saw in Chapter 3, the GRADE framework is often used – a tool that rates evidence 
robustness and relevance to question under consideration.  
162 
 
The disadvantages caused by invisibility in health research minimally have two 
negative aspects: 
1) Issues of interest, clinical measures (from diagnostic trials for example.), 
well-being measures, quality of life measures, and the like may be less 
generalisable to you, i.e. the problems focussed on may not apply to you 
or are measured in a way that does not accurately address your need or 
context. 
2) Research outcomes are less likely to apply to you – therefore the 
projected health outcomes are undetermined, i.e. they may be less 
successful, or not successful at all, and in some cases, they may be 
harmful.154  
 
Research used as a source of evidence for service and priority decision-making does 
not include work that is representative of issues within marginalised populations. 
This exclusion of certain work is in part due to the dominance of one perspective of 
health and the privileging of particular priorities and methodologies to explore 
health. The priorities, perspectives, and methodologies are described as “objective” 
and therefore fair. To explore this further, I now clarify terms. 
5.2. Research, evidence and their evaluation 
The terms “knowledge” and “evidence” have been used in very distinct ways within 
this thesis155.   
Knowledge and evidence are precise terms when used in the philosophical 
literature. Philosophy of Science, which is a philosophical branch that deals with the 
nature of truth and knowing, has a rich history of theories that attempt to designate 
these terms and their meanings.156 This philosophical usage of the words is not 
quite how I am using them here. While my focus is epistemological: what counts as 
                                                        
154 Remember in Chapter 3, one of the causes of injury for Pasifika peoples was adverse reaction to 
medication not resulting from misuse. It is just as plausible that service design or delivery evidence 
could be less applicable based on cultural issues or socio-economic issues, for example, where these 
were not considered in the research. 
155 In Chapter 1, we described this as a distinction between knowledge generated from research and 
evidence as it was defined by Sackett within the EBM framework, this is now made somewhat more 
clear. 
156 Philosophy of Science occupies itself with the definitions of science and knowledge and covers 
theories that are reductionist, positivist, constructionist, coherentist, etc.  
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knowledge, what counts as evidence; this only applies to the specific environment of 
health and health research. Rather than the weightier question of what are the 
requisite conditions to count anything in any context as being true or as knowledge. 
It is, therefore, important to make clear how I am using them in this chapter.  
5.2.1. Definitions 
In this specific context of the relationship between health research and health 
inequity, I am using “knowledge” to denote information generated by health 
research not classified as evidence.157  Knowledge is “knowledge about” something.  
Knowledge can be produced using the full range of research methods about the full 
scope of health research topics. Information is classed as knowledge when created 
within the standards of the particular methodology used, i.e. there are different 
methodologies, but each provides a different kind of “knowledge about” something. 
Whether the information is knowledge or not is decided based on whether it 
adheres to internal standards within a given methodological framework. The 
community of knowers then accepts that framework as knowledge-producing.158   
Evidence is being used here as a term to denote that information classified as 
vigorously arrived at within the dominant evaluation framework, i.e. information 
arrived at in the right way to inform questions in a very specific way.  Evidence is 
“evidence for” something (within this thesis). This evaluation of information 
predominantly measures methodologies against each other, rather measuring 
internal consistency within a methodological standard (i.e. this methodology 
provides better “evidence for” something than that one). Evaluation of 
methodological rigour for any given piece of evidence occurs after the evaluation of 
whether it is the right kind of methodology in the first place (i.e. we pick RCTs over 
case studies before we determine whether the RCT was well-conducted).  
It is also important to note that “evidence” is evidence even if not yet used, i.e. 
something that would be evaluated highly within the epistemological framework is 
still “evidence for” even if not yet explicitly used within a decision-making exercise. 
                                                        
157 Knowledge in its more traditional sense can be gained through experience or deduction, of course, 
but for the purposes of this chapter, it is being specified as above in the context of the health research 
environment. 
158 In effect within this thesis for the purpose of making distinctions between the information created 
by different kinds of researchers, I’m using the following system: evidence, is knowledge that is rated 
as valuable, knowledge is research/information that is rated as valid research, but not evidence.  
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Governments, academia, and industry generate evidence (Figure 19).  
 
Figure 19 - Research Drivers & Evidence Sources159 
Evidence is used largely by governments for decision-making (based on the working 
definition within this chapter), but also of course by industry and academia for 
particular kinds of activities (for example product creation, product marketing, or 
research planning). The focus here is on evidence used by governments, 
nevertheless acknowledging that industry and academia have overlapping roles 
within these activities and all three are mutually influencing.  
It is important to understand the how of “evidence-based” decision making whether 
for clinical guidelines, or in service, or policy design, to see how this affects 
knowledge generation. To do this, we must understand the emergence of evidence-
based medicine, its original goals, how it is now employed, some contemporary 
critiques generally, and then more specifically regarding health inequity. 
 
 
5.3. Why do we need evidence? 
                                                        
159 Circles overlap unevenly as the relationships between these three entities are not balanced.  
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Decision-makers use evidence in multiple ways (Figure 20).  Not only does it inform 
the question to be addressed (scoping of the problem), it helps set parameters, 
finding potential solutions and choosing between those solutions (Majone, 1989).   
 
Figure 20 - Information for Decision-Making160  
Evidence in decision-making can come in many forms (Figure 20).  Data is the data 
collected by government agencies or researchers in establishing the size of a 
problem (epidemiology) or the use/costs of services (cost-benefit analysis/cost-
utility analysis). Various government organisations and services collect this data for 
purposes unrelated to a particular research problem (for example services record-
keeping or the census). Although it can be created specifically to answer a question 
(national surveys, such as those for health or mental health), and then used by 
government agencies or researchers to quantify issues. 
Research results provide a range of information, yet research that delivers 
“evidence” is ranked highest with regards to soundness (as explained in 5.4.3. 
below).  Research can offer information that helps us understand a problem, as well 
                                                        
160 This diagram represents decision-making at the policy and service design level not the patient-
clinician level, where evidence-based decision-making specifically states that patient values be 
included (how they can be is not clear, and is discussed further in this chapter). 
Scope  - Do I have all the kinds of information I need? 
Accuracy - Is the information correct? 










as showing the efficacy of potential solutions.161  Expert opinion is used in 
combination with data and research and is relied on more heavily where research 
evidence is lacking. Expert opinion provides a link between practice and theory 
(Baker, Lovell, & Harris, 2006; Majone, 1989; Orton, Lloyd-Williams, Taylor-
Robinson, O’Flaherty, & Capewell, 2011) in an ideal setting.   It is the accumulation 
of relevant experience and knowledge. What is important to all decision-making is 
whether or not these sources of information are comprehensive, accurate and 
relevant (Cartwright, Goldfinch, & Howick, 2009; Hunter et al., 2016; K. Oliver et al., 
2014; Wye et al., 2015). Inequities in health research, evidence of which was found 
in Chapter 2, lead to inequities in decision-making (also found in Chapter 2), which 
in turn lead to policy, provision, and services that are not response to those that 
suffer health inequities.  
In many government decision-making settings, not all the necessary information 
relevant to a problem or decision or a solution is available. Ideally, most of the 
questions one would want answers to are listed below (Table 15): 
Table 15 - Information required for decision-making 
 What is the size and nature of the problem?  
o How many people does it affect? 
o Which people does it affect? 
o How does it affect those people? 
 What are the key contributing factors to the problem? 
o What are medical factors contributing to the problem? 
o Are there other factors contributing to the problem? 
 What is the impact of the problem? 
o What is the impact on individuals and their families? 
o What is the impact on communities and society? 
o What is the impact on the health systems and services? 
 What solutions can address the problem? 
o What can prevent the problem? 
                                                        
161 The distinction between efficacy and effectiveness is one of internal/external validity, i.e. 
something is efficacious if it is shown to work within a controlled environment, something is 
effective, if it has a high probability that it will work in the real world, based on evaluation or trials 
mimicking the real environment. Internal and external validity are described further in 5.4.4. 
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o What can treat the problem? 
 Which solutions address the problem best considering all factors, where 
factors are: 
o biomedical, 
o individual acceptability, 
o social acceptability, 
o health system feasibility (financial, practical, political, etc.)? 
 
All of this information must come from data, research, or expert opinion.  The 
information sourced must be as complete as possible, relevant to the posed 
questions, and accurate to provide the best possible support for decision-making.162 
5.3.1. The Evaluation of Information 
For the system to work, we need to know how to evaluate the cogency of 
information relevant to our questions.  Current evaluations use a ranking system 
that assesses information based on one-dimension:  accuracy. This system defines 
accuracy narrowly as the ability of a methodology to make valid claims about the 
cause and effect of a particular course of action. Decision-makers informally assess 
the completeness and relevancy in the picking-and-choosing of information 
(Cartwright et al., 2009; Majone, 1989). This evaluation applies across a range of 
decision-making but originated in EBM. 
The argument for the use of evidence in decision-making is that it serves to increase 
fairness and efficiency by making decisions that are based on “objective” evidence to 
ensure best outcomes for given situations (Bluhm, 2005; Borgerson, 2009; Buetow, 
Upshur, Miles, & Loughlin, 2006; Timmermans & Mauck, 2005). The question is, 
however, whether the evidence determines the decision, and whether the evidence 
generated is truly objective. Both the assumption of objectivity and the assumed 
connection of objectivity to fairness are taken up in this chapter, but first an 
explanation of evidence-based medicine. 
                                                        
162 It is important to note here, that the literature is clear that best use of research in decision-making 
currently does not occur.  What is important for the argument here however is not whether research 
is used optimally, but that the value of research is determined by the degree to which it is “useful” 
and for our researchers specifically the reference for usefulness is government decision-making. 
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5.4. What is evidence-based medicine & evidence-based decision-
making? 
5.4.1. What is it? 
Evidence-based medicine is the evolution of clinical epidemiology, which came 
about in the late 1940s early 1950s (Burch, 2009).  Post World War II, physicians on 
both sides of the Atlantic (Archibald Cochrane, UK (Cochrane, 1989) and Austin 
Bradford-Hill, USA (A. B. Hill, 1965)) were making efforts to make medical decisions 
dependent upon evidence rather than individual clinical experience, beliefs, or 
clinical judgement (Burch, 2009). These efforts led to the creation of the formal 
randomised controlled trial and called for a greater use of their results in decision-
making.  This work continued throughout the 1960s and 1970s in an environment 
where communicable diseases were the raison d’être of medical research.  Evidence-
based decision-making was introduced in the 1980s by Eddy to ensure that policy 
and guidelines were tied to appropriate evidence (Eddy, 2011). The term itself, 
however, arose at McMaster University in the early 1990s from a student of Daniel 
Sackett’s (Rogers & Ballantyne, 2009; Sur & Dahm, 2011), although Sackett’s 
definition is the most commonly known (from 1996): 
Evidence-based medicine, (…), is the conscientious, explicit and judicious use 
of current best evidence in making decisions about the care of individual 
patients. (Sackett et al., 1996) 
Sackett’s definition did receive some criticisms for failing to consider other 
elements in decision-making and was later revised to include clinical expertise and 
patient values: 
(…) a systematic approach to clinical problem-solving which allows the 
integration of the best available research evidence with clinical expertise and 
patient values. (Sackett, Richardson, Rosenberg, & Haynes, 2000) 
 
 
5.4.2. What does it claim?  
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The reason EBM in part163 became popular is that it resonates, i.e. the idea that 
matters of health should be decided by robustly gathered evidence rather than mere 
opinion, was attractive to many.  It implied a level of fairness and objectivity that 
would nullify waste or discrimination – decisions could be made based on, good, 
solid facts (Rogers, 2004a; Sackett et al., 1996). Everyone, regardless of age, gender, 
sex, or colour, should receive the same treatment for the same condition, while 
equally, nobody ought to get a treatment that is ineffective (causing personal, public 
and financial costs). These were laudable goals. No discrimination, no waste, a 
system that guarantees fair and efficient healthcare.  
The problem is that EBM oversells what it can deliver. The evaluative framework 
used does not necessarily fulfil its mandate and it is not clear that objectivity is by 
default fair. I investigate these assumptions further below, but first, it is necessary 
to explain some of the constituent parts of EBM and decision-making. 
5.4.3. Hierarchy of Evidence 
To determine what qualifies as “best available evidence”, EBM endorses a hierarchy 
of evidence.  The hierarchy of evidence rests on the premises that not all evidence is 
equal and that some forms of evidence are more robust than others. Variance in 
robustness is due to the ability of a method to isolate a causal connection between 
the effect measured and the intervention, while simultaneously removing bias 
(Lewis & Warlow, 2004; Sibbald & Roland, 1998).  The hierarchy moves up and 
down a range of methodologies. The least robust methods are at the base: basic 
science, expert opinion, case studies, and case series. Methods attributed to the peak 
are RCTs and meta-analyses/systematic reviews (Figure 21) (SUNY Downstate, 
n.d.).  Systematic reviews and RCTs are rated the highest within this hierarchy, 
because proponents of EBM believe that these methodologies, when conducted 
proplerly, are robust enough to remove the likelihood of bias and confounding 
factors (for RCTS through practices such as randomisation and blinding and 
controlling for placebo-effect)(Lewis & Warlow, 2004; Sackett et al., 2000; Sibbald & 
                                                        
163 EBM fits well with the overall managerialism in the health system discussed in Chapter 4. 
Benchmarking, auditing, standardisation, etc. occurs more readily in an environment with guidelines 
and prediction models. It is also fair to say that it was not broadly popular and accepted - clinicians 
objecting particularly to the prescription of decision-making. 
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Roland, 1998).  Various statistical analyses are additionally used to minimise 
unwanted effects further. 
The ranking (Figure 21) emerges clinically and in policy settings, as seen in Chapter 
2 (e.g. the GRADE tool or similar adaptations conflate levels, but keep overall 
framework, i.e. A-D grades). 
 
 
Figure 21 - Hierarchy of Evidence 
5.4.4. Internal versus External Validity  
Researchers are asked to pay attention to internal and external validity when 
conducting an RCT. Internal validity describes how accurately the trial can assess 
whether the cause and effect relationship between intervention and outcome is 
valid; external validity describes how well the trial can map to real life situations, i.e. 
be generalizable (Louis & Shapiro, 1983).  As many confounding factors as possible 
and bias need to be removed from the trial protocol to improve internal validity.  
Researchers remove confounding factors and bias by using randomisation, blinding, 
and controlling as many of the conditions in which the trial operates as possible. 
Researchers may also consider excluding subjects who are likely to have other 
factors that will influence the outcome of the study. Improving external validity 
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requires almost the opposite strategy, as the truer the trial protocol maps to real 
world conditions and actual patients, the better.  Good internal validity conveys high 
scientific rigour, whereas good external validity conveys high clinical applicability.  
Ideally, a trial should aim to get some form of equilibrium between internal and 
external validity, so that if the results are positive, statements can be made both 
about the effectiveness of the intervention (internal validity), as well as its 
applicability/acceptability in the real world (external validity). Where a trial does 
not reach a balance between internal validity and external validity, researchers 
should undertake successive trials moving from internal validity to external validity 
(i.e. later stages of Phase1-5 research, (Portney & Watkins, 2015)). In other words, a 
researcher may begin with perfectly controlled conditions, and then move to RCTs 
in more “real-world” settings with the same intervention. To capture the “real-
world” setting, researchers use such methods or analyses as Intention-to-Treat 
(analysis uses all participants’ data including those participants who withdrew or 
discontinued the trial) or pragmatic protocols (clinician researchers assigned 
participants to intervention arms or control arms based on participant 
characteristics, similar to clinical decision-making in the typical clinician-patient 
scenario).  
When applying the evidence hierarchy, internal validity is taken above external 
validity, at least implicitly, during the assessment of methodologies. Those with less 
confounding factors are ranked higher than those with confounding factors, those 
things that make a trial more externally valid are often confounding.  No extra work 
is done in the ranking level of trials to distinguish, for example, between two trials 
that are both conducted rigorously but with different degrees of external validity. 
Explanatory trials (higher degree of internal validity) are more prevalent than 
pragmatic trials (greater degree of external validity) in the literature (Borgerson, 
2013; Schwartz & Lellouch, 2009).  Prevalence of one type of validity over the other 
means that decision-making must rely on internally valid, but less externally valid 
evidence most of the time. 
5.4.5. Generalisability 
One of the claims of EBM is that gold standard RCTs produce generalizable evidence 
(Rothwell, 2005). If researchers undertake trials with sufficient samples and use 
172 
 
robust methods (i.e. blinding, randomisation.), then this means that the results of 
those trials will successfully transfer to the general public. Blinding removes 
investigator and participant bias; if neither the investigators nor the participants 
know which intervention the patients are receiving, then this piece of knowledge 
cannot have an effect on the intervention. Randomisation removes the ability of 
investigators to assign those more likely to show significant change within the trial 
to the intervention arm.  Cohort size and characteristics (inclusion/exclusion 
criteria) are used to account for potential confounding factors based on participant 
variables.  
With this in mind, it is not clear that the current assumptions of generalisability are 
in fact valid. I explore this further below (5.4.6.1). 
5.4.6. Problems with Evidence-Based Frameworks  
EBM and evidence-based decision-making is now widespread and mostly seen as 
“best practice” across many disciplines. Government agencies responsible for social 
welfare or education, for example, conduct RCTs when assessing new initiatives.164 
Third sector organisations incorporate these EBM-based methodologies in their 
justification for ongoing funding (Samson et al., 2015). The justification of dominant 
practices by way of evidence-based rhetoric attempts a sleight of hand. When we 
say something is evidence-based, it evokes the idea of objectivity (and fairness) 
derived from facts (seen as value neutral). Value is always seen as subjective, and 
therefore prone to prejudice and bias, whereas we treat facts (whether correctly or 
not) as immune to prejudice and bias (Douglas, 2007). However, despite intentions, 
EBM decision-making processes remain value-laden. The ruse of evidence-based 
rhetoric masks values that are embedded within this framework.   
5.4.6.1. EBM & Evidence-Based Decision-Making – The Assumptions 
The definition of EBM is laden with epistemological presuppositions and these are 
inextricable from the intentions of the model.  In this section, these assumptions are 
shown to be problematic, but even if they were not, the definition itself still fails 
because of the difference between its conception and implementation. 
                                                        
164 Ibid 135 
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Decision-makers in health source evidence from robustly conducted clinical trials or 
systematic reviews (an analysed collection of clinical trials). Decision-making also 
includes Cost-Benefit or Cost-Effectiveness Analyses (CBA/CEA).  I focus here for 
now solely on evidence related to interventions (and therefore traditional EBM), 
because evidence regarding interventions is part of what is used in these kinds of 
economic analyses.165 They are generally conducted using a mixture of government 
service or economic data and intervention evidence.  A discussion about the 
measures of effectiveness or benefits, etc. will be included later in this chapter.  
The information gained from a positive clinical trial rests on some key factors. In the 
clinical trial setting, a result is deemed to be positive when: 
a. A significant change is detected between the intervention group and 
the control group, where that significant change is determined by a 
difference in outcomes measures and decided to be a result of the 
intervention rather than mere chance (based on statistical 
probability). 
i. The “power calculation” is a fundamental element of these 
statistical tools. It tells triallists the number of people required 
in each group to be able to establish a statistically significant 
difference between groups on the chosen outcome measure 
scale. 
ii. A statistically significant change can be measured in multiple 
ways. It can be purely physical (the difference between anti-
inflammatory markers pre- and post-intervention for 
example), clinical (difference in swelling pre- and post-
intervention, for instance), or patient-focused (Minimally 
Important Clinical Difference (MICD) in pain, for example).  
b. Generalisability is the assumption that if a trial has the correct 
number of people in it then the results will be generalisable to the 
population. This is because the sample, by sheer numbers alone, will 
have a diversity of variables, that cannot be controlled for within the 
                                                        




trial, meaning that a positive result should mostly translate to the 
diversity of variables present in the population. 
i. Sample size is where representation is considered (or not). For 
example, if as a researcher, I know that an equal number of 
men and women suffer from the condition I have an 
intervention for, then I should aim to recruit a proportionate 
sample of each within my trial cohort to be truly generalizable 
to the disease population (and conduct a subgroup analysis). 
Prevalent variables such as gender, or variables of interest 
such disease-related variables (blood pressure or BMI for 
example)) are controlled for and included in the analysis. 
 
So a trial result is positive and reliable, where a researcher detects a significant 
clinical difference between intervention group and control group, based on robust 
design in a generalisable sample, where the researcher has considered relevant 
variables. 
Decision-making using health research and clinical trial data is assumed to be fair 
because it does not take into account specific characteristics of trial participants; it 
is ostensibly fair because it is methodologically “blind”166 to the differences in 
people.  Paradoxically, this so-called blindness is precisely what is unfair.  Full 
recognition of the disadvantages or complexities of some groups is necessary to 
provide them with good health outcomes, part of that begins with research. Not only 
that but this “blindness” is a myth - to say it is objective is to assume that 
representation was fair in the first place. If we consider the lack of representation of 
various minorities in trials then actually, trial data, baseline data, outcome data, all 
of it is far from objective167, it is skewed and skewed to the dominant group in 
society. Outcome measures have been determined using skewed populations, not 
only for biomedical parameters but also when considering what outcomes to value 
(Berger et al., 2009; Graham, 1992; Heiat, Gross, & Krumholz, 2002; Pearce et al., 
2004; Rogers, 2004b; Rogers & Ballantyne, 2009; Sharpe, 2002).  
                                                        
166 “blind” is the terminology generally used within EBM and would not be a terminology I would use 
in other circumstances  
167 These non-objective measures once set are used within the health system and the research 
environment, compounding the problem. 
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 5.4.6.1.1 Assumption 1: Evidence generation is objective 
Objectivity is assumed a solution to different kinds of bias. First a counter to 
favouritism or prejudice in selecting priorities and second, a counter to bias in 
science, where those conducting research either consciously or unconsciously skew 
the results of a piece of work to their preferred outcome. These are two very 
different considerations.  One concerns justice, while the second is an issue of best 
practices in research.  
Objectivity, as a tool of justice at the deliberative level (what is a priority), is 
discussed further below (5.7.1.2. and in the next chapter). Here it is important to 
note, that values determine the various key factors of any given project.  What kind 
of intervention is chosen to test, how it should be delivered, what an outcome is, 
how it is measured, are all questions that involve a particular perspective or 
position.  Researchers are mainly designing evidence-generating activities in a 
biomedical setting with little input from patients, families, and communities. What 
we often refer to as the objective or neutral position, is, in fact, the tacitly accepted 
values and practices of a socially (i.e. morally) dominant group (Harding, 2006; 
Haslanger & Haslanger, 2012). When researchers in a socially dominant group talk 
about objectivity, they are talking about removing their personal preferences, not 
letting their emotions or feelings cloud their judgment. They are not talking about 
suspending their particular social position from influencing the decisions made 
during a given evidence-generating activity. It is this latter that would be truly 
objective, but arguably quite impossible (Haslanger & Haslanger, 2012). The only 
way therefore to be “neutral” is to consider and include multiple perspectives as a 
form of equalising any particular bias. Actions to remove this type of bias are not 
discussed, reviewed, or promoted within the EBM framework.168 
 
5.4.6.1.2. Assumption 2: Evidence is Generalisable  
Generalisability is only assumed when trials meet certain requirements.  These 
requirements are based largely on external validity measures (internal validity tests 
                                                        
168 It is discussed in evidence-based decision-making exercises to a degree through the inclusion of 
“lay people” or stakeholder groups in the process. However, there is no explicit recognition of this 
point, rather a softer recognition that people should be included in decisions that affect them (these 
people are not always very representative as is noted in Chapter 4).  
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tell us whether we can trust an outcome; external validity tells us whether it will 
work outside of the trial). It is generalizable if: 
 The delivery method was similar or identical to that used in the clinical 
setting 
 The sample was either appropriately sized or specific (sample included 
suitable subgroupings mirroring real-world disease population). 
 
Literature (Graham, 1992; Heiat et al., 2002; Rogers, 2004b; Rogers & Ballantyne, 
2009; Sharpe, 2002)  and the work done in Chapter 2  indicates that  researchers 
choose samples based on size to eliminate “noise” (noise, defined as interference 
from uncontrolled variables), rather than specifications based on disease-
population (not that this does not also happen).   
The underlying problem is the assumption that blindness to difference can solve 
matters of representation.  In the current system, problems of diversity in the 
population for the outcome are solved by volume rather than degree, that is, large 
trial cohorts rather than specific trial cohorts. If we consider any one person, he or 
she has some factors that influence their health (Figure 22). Factors vary in the 
degree to which they affect health depending on the health problem169 (in this 
Figure 22, they are broadly balanced, with the biomedical being somewhat bigger 







                                                        
169 Some health problems like appendicitis for example have very little influence from other factors, 

















Figure 22 - Factors influencing health 
Typically in a clinical trial, cohort numbers are used to overemphasise the factor of 
interest and to minimise the other factors (variables) (Figure 23). Considering the 
figure seen below, if the purpose of a trial is to intervene on, and measure a 
biomedical factor, by using a large cohort the central factor (biomedical) becomes 
more prominent, while the other factors– in theory – are thought to become less 
confounding (Figure 23). 
 
Figure 23 - Factor of interest magnified within larger cohorts that dilute other factors 
One issue here is that regardless of size, trial cohorts tend to be largely homogenous 
(Graham, 1992; Rogers, 2004a; Rogers & Ballantyne, 2009; Symonds et al., 2012). 
Furthermore, they also represent the “best of patients” insofar as people enrolling 
in trials are often more motivated with flexible circumstances (i.e. can fit trial visits 
in), which makes them more likely to successfully comply with intervention 
requirements than the group representing the general disease population. This 
phenomenon is not unrecognised (Blakely & Woodward, 1999; Phillips, 2003).  The 
health research community is well aware that trial effects should be considered as 
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ideal with drop off expected in the ‘general’ population (Liang, 2007).  What 
remains unconsidered is that the spread of “drop off” falls much more heavily on 
those who are already marginalised based on their heterogeneity, based on age, 
ethnicity, complexity, or disadvantage, because they are the least like the 
“generalizable” sample and have to account for more complexity.   
The literature also shows that delivery methods used in trials are often unlike those 
used in the clinical setting. In fact, as was mentioned earlier, trial stages 
theoretically could move from internal to external validity to ensure generalisability 
to negate this issue.  Phased testing of this kind moves from mechanistic 
disease/intervention understanding and testing, through to intervention/delivery 
testing. However, again literature would indicate that the majority of work done and 
funded in the clinical trials space prefers practices that test internal validity over 
those that test external validity(Schwartz & Lellouch, 2009).  
The attention paid to internal validity over external validity is in part based on a 
reductionism that focuses solely on the intervention-outcome mechanism of a trial 
and nothing else. An RCT itself does not tell you, if you designed your intervention 
appropriately for the setting in which patients will later receive it. It does not tell 
you whether the intervention is acceptable to those who have the disease. It does 
not tell you why something worked or failed, neither biomedically or subjectively.  
In addition to ignoring all the factors that our informants deemed to be important 
(see Chapter 4), RCTs also ignore factors such as pathophysiological explanations 
(Ashcroft, 2004; Solomon, 2015).   
In essence, RCTs ignore confounding factors to ensure that the results are “clean” 
because there is recognition that these factors play a part in outcomes, but no work 
is done to address these very factors when translating results to the real world, 
where they matter in achieving outcomes. Between the trial situation and the 
practice situation, there is an information gap regarding complexity (of situation, of 
patient, of system) that researchers and decision-makers are not addressing.  
At present, policy-makers and health providers are expected to address this 
complexity gap in practice.  The only recourse they have to do this is through 
experience (trial and error) and information-sharing (about trial and error).  Little 
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research or evidence is provided to help them consider interventions in the contexts 
in which they may have to apply them.170 The missing complexity might be, for 
instance, multi-morbidity, where the patient has multiple conditions at once, and 
various interventions for their conditions may be contraindicated or require careful 
management. It might be cultural: the patient has beliefs that mean the clinician 
cannot provide the intervention as designed in the trial in the same way. There are 
many variations of complexity than can be imagined, but it is apparent that 
marginalised groups will almost always include some variation of complexity based 
on their “difference” to the general population. The majority of researchers who 
work with marginalised populations recognise this essential complexity in their 
identification of problems, in their connection to communities when deciding 
courses of action, and in their selection of methods used to evince the best 
information within the given circumstances.  
5.4.6.2. Critiques of EBM  
Despite the influence of EBM, there are vocal opponents. Criticisms are either 
philosophical or practical.  The former, take issue with either the hierarchy of 
evidence or the very way in which EBM is meant to influence decision-making at the 
clinical level, rejecting the dominance of evidence, over other considerations such as 
clinical expertise and patient values. The latter believe that within the current 
environment that entails high volumes of information (but with a narrow range) 
and poorly created information (through fraud, time/funding constraints, or 
incompetence), it is impossible to parse evidence usefully.  
 
 
5.4.6.2.1. Philosophical Critiques 
EBM works together with such things as prediction rules, or scoring tools, to create 
standardisation (Niessen, Grijseels, & Rutten, 2000; Pronovost et al., 2006; 
Timmermans & Berg, 2010). Standardisation implies fairness and consistency. 
Robust evidence leads to essential relationships: if x, then y. Thus, for all situations 
                                                        
170 Some of course do exist. 
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of x, we will always, for all people do y.171  A counter-argument against this is that x 
is not always so very alike and therefore, “when y” will require more input.  As 
noted earlier in this chapter, arguments for the incorporation of clinical expertise 
and patient values were made so forcefully, that they revised the definition of EBM.  
Second, critics of EBM have pointed out that the clearest results come from the 
simplest trials, trials that ask simple questions within homogenous populations 
(Rogers & Ballantyne, 2009; Sharpe, 2002). A preference for simplicity returns us to 
our discussion of internal validity versus external validity but requires that we 
extend it. It is, therefore, better for those conducting trials to keep a trial simple, by 
paying more attention to internal validity than external validity since the latter 
requires the management of many confounding factors.  It is also better to avoid 
multi-factorial solutions or questions in complex health conditions/contexts. This 
avoidance of complexity is because the ability to isolate a causal mechanism within 
a trial format is hindered significantly when either the cause (intervention) creates 
too much “noise,” or the environment in which the cause takes place is already too 
noisy. Remembering that, because EBM largely ignores pathophysiological (or 
other) reasoning (Ashcroft, 2004; Solomon, 2015), it has no way of assessing what 
might be influencing the cause-effect mechanism.  It can only indicate when it has 
been successful, unsuccessful, or that the results are unclear.  Some argue that this 
is why RCTs are entirely unsuitable for social interventions because social 
interventions are more likely to be multifactorial and in complex environments 
(Jackson & Waters, 2005; Rychetnik, Frommer, Hawe, & Shiell, 2002; Slowther, 
Ford, & Schofield, 2004). 
Complexity either in the cause or the effect environment dilutes information in such 
a way as to make clear statements impossible. EBM, therefore, is a limited tool in 
creating evidence. Once again, it is clear that it fails to address complexity and it 
does this philosophically.172 
                                                        
171 There are exceptions in practice based on the degree to which “y” is likely to be successful for a 
particular patient, in a particular situation at a given time – but this is not based on evidence. 
172 There are other philosophical objections to EBM based on how it views both doctors and patients 
within the decision-making process, but these are not important to our discussion here at the level of 
research. For a selection of these views, please see (Buetow, Upshur, Miles, & Loughlin, 2006; Hay et 
al., 2008; Tonelli, 2006) 
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 5.4.6.2.2. Practical Critiques 
Clinical trials are very expensive because overseeing the provision of a new 
intervention and monitoring people receiving the intervention (or an alternative) 
requires a lot of resources. Resource constraints mean two things: first, trials run 
for shorter periods of time than would be ideal for assessing outcomes. Second, only 
trials that attract someone to fund the activity happen.  
 
Industry and academia are the dominant players in clinical trial activity 
(governments, usually contract one or the other to do their trials). They are often 
carried out in environments that are time-poor and resource limited.  Funding 
sources can create significant bias, not only in what work is chosen to be done but 
also in the outcomes reported from that work (Goldacre, 2012). 
 
It is critical to draw attention to the “best available evidence” phrasing used in the 
definition of EBM. Most often, people discussing EBM focus on “best” in this 
definition. However, it is essential that we not to overlook “available.” Decision-
makers, health professionals, and researchers are not able to review evidence for all 
options when ranking evidence that informs decision-making. Rather, pertinent are 
those options that have evidence and more accurately, published evidence. It can 
also be said, that within the ranking system, where we know of other interventions 
but have no highly ranked evidence, our final decision is unlikely to recommend 
that option.  
Therefore, decision-making is dependent on a selection of positive evidence 
available in the literature on selection of interventions.  Of course, no situation 
would exist where we have all the available evidence, for all possible options, on any 
particular topic. If we consider reports of poor research practices, and biased 
publishing (Bosch, 2014; Elliott, 2010; Fanelli, 2010; Fang, Steen, & Casadevall, 
2012; Goldacre, 2012; Jones et al., 2013; Simes, 1986; Trinquart, Ioannidis, 
Chatellier, & Ravaud, 2014), then evidence-based decision-making starts to look 
much less robust given this informational base.173 
                                                        
173 Trial data fraud, post-trial outcome selection (i.e. secondary outcome if more significant), positive 
publication bias, etc. – these things come to light only when someone points them out, but with the 
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5.6. What are the alternatives? 
What I have shown so far in the discussion of evidence is: 
a) The health research environment values research that either has an 
economic impact (through economic output or policy/service savings), has 
(international) reputational impact, or can be classified as evidence (for 
policy/service decision-making). 
b) Evidence in these situations is defined using the Evidence-Based-Medicine 
framework of ranking (the hierarchy of evidence). 
c) The hierarchy of evidence ranks methodologies against each other based on 
their ability to determine cause and effect for a given intervention.  
d) Evidence-based practices make claims to: 
i. Objectivity, which I have argued, fails based on chosen topics of 
interest, and the tacit perspectives that influence the choice of 
interventions, measures, and outcomes. 
ii. Generalisability, which I have argued fails, based on widespread 
practices of homogenous trial cohort recruitment (which is likely to 
be based on drivers in the research environment such as publication 
pressures, amongst others).  
e) Researchers working with marginalised population do not generate research 
classed as valuable because it is rarely of a commercial nature, lacks an 
international audience (impact), and is not classed as evidence. 
i. Their work fails to be classed as evidence since it does not meet the 
standards of generalisability or objectivity.  
 
Researchers working with marginalised populations suffer an epistemic injustice in 
that the model used for assessing research as evidence (largely) excludes their 
work.  Their work is not valuable in the other ways available to researchers as 
described in Chapter 4 (commercial/economic or international value).174 The 
epistemic injustice occurs because objectivity and generalisability establish rational 
authority within the health research environment, and researchers that do not 
                                                                                                                                                                    
sheer volume of work being published now, discovery often lags behind, meaning decision-making 
activities can occur with faulty information without knowing it.  
174 Which can be the case for other researchers who do not generate “evidence” in this sense, if we 
think of geneticists or historians for example.  
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abide by the epistemic claims that structure this environment, fail to establish 
credibility.  
 
Any evidence framework will need to recognise and address the complexity 
discussed thus far to amend this injustice.   
5.7. Integrating complexity 
Complexity describes the various factors associated with individuals that influence 
their ability to benefit from an intervention. Assessing issues of complexity include, 
but are not limited to, normative judgments. What you pay attention to, and how 
you pay attention to it, is based on what you think is the right thing to do - what is 
fair.  
 
So what a researcher first chooses to research is itself a value judgment, and I 
discuss this further below.  However, once a researcher decides what to research, 
other issues of justice arise. Complexity increases in the health research 
environment as you move from pilot work through to implementation and 
evaluation work (Figure 24).  
 
Figure 24 - Research stages and complexity 
 
In Figure 24, the diagram uses stages that combine various other models that exist 
such as Phases 1-5 or Translational Research’s staged model (Committee to Review 
the Clinical and Translational Science Awards Program at the National Center for Advancing 
Translational Sciences, 2013) to illustrate the pathway of research while indicating 
the degree of complexity along the pathway. Here interventions can be 
pharmaceutical or behavioural, where lab studies/pilot work are exploratory or 
safety tests that test the basic assumptions; efficacy trials test whether it works; 
effectiveness trials test whether it works in the real world setting and better/worse 
184 
 
than other interventions; and finally health service research covers a range of 
implementation and evaluation work happening both in the health system and the 
NGO setting relating to health and intervention outcomes, or service evaluation. 
Evidence can be generated at any given stage without completing all five; it is just 
evidence of a different kind. Community researchers would likely conflate these 
stages (i.e. 1&2 together, or 2&3 together) for the kind of work they do and it would 
be called different things at each stage. 
In the current environment, complexity generally and specifically as it relates to 
marginalised populations is mostly considered outside of the research process.  
Complexity, if discussed at all, takes place during decision-making, at policy level, 
service level, or at the doctor-patient level (Figure 25) 
 
Figure 25 - Current practice for considering complexity 
One way to add complexity into the research-evidence pathway is to incorporate it 
at critical stages.  Adding complexity in this way includes recommendations to 
incorporate stakeholders or focus group input at design points of the research-to-
evidence pathway to ensure appropriate decisions in both research design and 




Figure 26 - Incorporating complexity 
For the researchers interviewed in Chapter 4, the incorporation of complexity was 
unnecessary since it was entirely embedded. There was no separation, no critical 
points at which it could be considered since for them it was simply the process itself 
(Figure 27). 
 
Figure 27 - Researchers working marginalised populations - Complexity and Research Practice 
All of our informants in Chapter 4 practised research where their point of focus was 
always the marginalised group and how their position was affected by the larger 
system. This positioning was the case regardless of methodology or question, i.e. a 
researcher may have been investigating a very typical quantitative epidemiological 
question of cardiovascular disease-related death as an example, but the researcher 
did it from the position of a particular group, with an interest in bettering the 
situation for that group. The analysis was conducted considering the group’s culture 
(i.e. does death at a certain age, mean something different than at another age for 





This paying attention needs to be more widely adopted for interventions to benefit 
those marginalised populations, but what does this require?   
5.7.1. Change of Epistemology or Change of Values? 
The proceeding sections have argued: 
• Evidence generation includes values/bias 
• Evidence evaluation includes values/bias 
• These values/biases currently favour the majority and do not consider 
marginalised populations 
Evidence-based decision-making is said to be fair because decisions are made based 
on the facts of the matter (evidence). If, however, as has been argued, the facts are 
heavily weighted in favour of one group over another, then this is the very opposite 
of fair. How do we resolve this issue? There are two potential ways of addressing it: 
1) A shift in the evaluation framework – what we consider to be the right type 
of evidence (and means of generating it) 
2) A shift in justice theory – what we consider is important and fair 
5.7.1.1. Evidence 
It is not clear that a total and fundamental epistemic shift is needed, such that 
everyone should conform to a feminist-inspired standpoint theory175, for example 
(Harding, 1987).  Rather the issue is one of deciding “what is evidence” within the 
health research environment, and that an epistemological pluralism could provide a 
more thorough picture in making decisions. To broaden our informational base, we 
require a different evaluation framework for evidence. 
 
Some scholars have called for the hierarchy of evidence to be fundamentally 
revised. Walach has suggested a circular approach, that is, that there are multiple 
types of information required to decide whether an intervention both works and is 
appropriate (Walach, Falkenberg, Fønnebø, Lewith, & Jonas, 2006).  Other 
suggestions include a web, again suggesting the connection of multiple 
                                                        




strands/kinds of evidence supporting each other (much like a Quinian web176) 
(Bluhm, 2005; Sehon & Stanley, 2003).  I agree with these calls for a broader 
inclusion of information types into the evidence definition to provide a better 
foundation for decision-making. 
 
There are, however, two more things to consider: 
1) Evaluation of research within its particular methodological framework 
2) Evaluation of different research within a decision-making exercise. 
The first point is a distinction made earlier in the chapter, namely that something 
can be knowledge only if it meets internal methodological standards.  We must 
establish that a piece of work meets these standards before we can count that piece 
of work as evidence. The second point applies to the evaluation of knowledge as 
evidence within the decision-making setting. If we consider Table 16, certain kinds 
of information are more pertinent to different aspects of this list.  It, therefore, 
makes much more sense to evaluate information about the question we are asking 
and the methodological rigour. 
5.7.1.2. Justice  
Theories of justice provide us with the means of establishing what we think is fair in 
providing and relating to our fellow humans. In health, what we believe is fair 
underpins all decision-making, insofar as we make decisions in line with beliefs 
about what is the “right” thing to do, and then direct our enquiries based on this. 
Two things create injustice, as has been argued in this chapter: 
1) What we consider evidence when decision-making177 
2) What we think is fair as the goal of decision-making 
 
To change how we generate and evaluate evidence, I believe we have to change 
what we deem to be fair in the decision-making process. By doing this, the effects 
flow on to how we conduct research, based on what we then need to pay attention 
                                                        
176 Quine argued for a holism in epistemology based on an ontological relativism – the web, meaning 
that each belief was dependent on others, no single belief of any kind being able to stand alone 
(Putnam, 2002). 
177 Where our evaluation framework to judge evidence always excludes information of a certain kind 
that pertains to a certain people/groups. 
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to in exploring issues. This shift in what we consider and how we measure fair is 
crucial to make change and a novel solution to a long-standing problem. 
If we consider it necessary to improve the situation of disadvantaged/ marginalised 
populations in health, then the information we require for decision-making must 
incorporate appropriate evidence concerning these groups. To have these facts, we 
have to include them in our research processes. 
To do this, a Capabilities Approach (CA), which focuses on the capabilities a person 
requires to achieve their desired functioning (Sen, 1992), explicitly opts for the very 
opposite of the blindness I have described here.  It is a person-centered approach 
that values intrinsic goods (well-being and freedom) and uses democratic public 
deliberation to arrive at priorities (i.e. a set of capabilities) (discussed more fully in 
the next Chapter). By setting what capabilities are relevant and necessary and then 
ensuring that ALL people meet them, we can address the health research aspect of 
health inequities in two ways: 
1) We can take stock on where inequities exist at a population level and set 
priorities accordingly (top-down approach) both for health services and 
research within a capabilities framework (much like the UN Health 
Development use of capabilities). 
2) We can also deliberate on what capabilities are necessary to flourish 
within the health service context and then embed these capabilities not 
only in services but also in research processes. For example health 
literacy, self-advocacy (meant in its broadest sense to incorporate 
family/whānau), peer support perhaps.  (Bottom-up approach)   
 
What does this mean for health research and clinical trial research?  
Evidence to inform decisions around health inequity will sometimes be of the 
clinical trial kind and sometimes be of methodologically different kind. Quantitative 
methods are a measure of magnitude, whether this is the size of an effect, the 
number of people or the rate of change, for example. Qualitative methods explore 
people's understandings/ opinions about/experiences of "something" so that 
researchers can better understand that "something".  Both of these things are 
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necessary for addressing health issues.  These methods are complementary, and 
questions roll from one to the other in dealing with an issue.  
The epistemological paradigms within which they sit can also be varied. Whether 
one adopts a positivist paradigm or a social constructionist paradigm, reflects 
something about the knowledge you generate, but not whether you generated it 
appropriately. The information from different paradigms tells us different things 
about the world and can inform decision-making in various ways.  It is, for example, 
not inconceivable to imagine a decision-making process regarding public health 
interventions for smoking that included biomedical evidence relating to the efficacy 
of a particular nicotine patch and a grounded theory approach to understanding 
teenage self-image in rural towns related to smoking. Both of these pieces of 
information from varying epistemological frameworks can provide useful 
information in deciding how to implement a nicotine patch intervention for 
teenagers in the rural setting. What counts in the assessment of whether that 
information is useful, whether we can say it is evidence, are the internal standards 
of the method rather than an external ranking of different methods against each 
other.  We must tease apart the conflation of methodological rigour with objectivity 
associated with EBM.   
Not only is a diversity of methods necessary, but also a diversity of research 
populations is required to make sure that we make decisions based on information 
that applies to the actual disease population.  We cannot design interventions that 
work well amongst the disadvantaged if we do not include them in the research 
itself, as well as the discussions about what might work in the first place, not to 
mention what counts as “working” (i.e. measures of benefits and harms).  
In the next chapter, we explore further how the capabilities approach might be used 
to direct our inquiries in a fairer manner to all groups within the population 
5.8. Summary  
In this chapter, I argued that evidence-based decision-making creates an epistemic 
injustice for marginalised population researchers and inadvertently disadvantages 
marginalised populations due to the privileging of an objective viewpoint 
considered fair, but blind to difference (and therefore varying need).  I explained 
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that evidence-based decision-making promotes the idea of fairness based on 
objectivity and generalisability. Researchers working with marginalised populations 
are transparent about their values and their work is directed to a specific group, 
meaning that they do not meet the EBM measures of objectivity and generalisability 
and so are dismissed as knowers within the dominant culture. I then argued that 
EBM’s definitions and standards related to objectivity and generalisability are 
inaccurate and rarely achieved in research that currently counts as evidence. From 
here I showed that there is a need to for appropriate information to feed into 
decision-making, for decision-making to be fair and that includes a recognition of 
complexity, which EBM practices fail to incorporate. Reform is therefore required. 
Various forms of epistemologies can generate different kinds of evidence; I 
therefore argue rather than adopt a new epistemology across all evidence-based 
decision-making a change in focus through a theory of justice (Capabilities 
Approach) that requires an informational base more responsive to inequity for its 
evaluative space would allow a broader acceptance of evidence types and 





Chapter 6 – Justice Framework as a Horizon of Significance 
“It is manifest that the actual availability of information can affect the possibility of using 
specific moral approaches.” 
Amartya Sen (Dewey Lectures, 1984) 
 
Sen’s point above lies at the heart of this thesis.  The argument here has been that 
disadvantage is created by what information we pay attention to and use to make 
decisions. Information available in the health decision-making environment (from 
research and data) provides us with a limited base from which to make fair 
decisions.  Therefore, people in the system make decisions with a certain moral 
approach178, which the system further reinforces through information-gathering 
exercises, creating a mutually supporting narrow field of justice and inquiry. As 
such, the only way to reform the system is to explicitly reformulate what is fair, 
which requires a new informational base, thus driving the circular relationship 
between justice and evidence in the health research environment into a broader 
cycle. 
 
In a system that focuses on a very distinct idea of evidence (as discussed in Chapter 
5) and cost-benefit or cost-utility analyses, those who lack representation in either 
the evidence or analyses will necessarily lose out.  The current decision-making 
system in New Zealand relies on ad hoc methods to address considerations of social 
value or justice.  The majority of information considered in these decision-making 
exercises is clinical and/or economic in nature and fails to represent the complex 
picture of society accurately.  It is poorly representative in two distinct ways: 
evidence of effectiveness is not generalizable to marginalised populations, but more 
importantly, measures of burden, risk, and benefit, are not generalizable to 
marginalised populations.   
 
To understand why this is the case, first I explain some of the ways in which 
resources are distributed within NZ’s health system, how they reinforce what 
information is used to make resource decisions, and how decision-makers consider 
                                                        
178 It is hard to say what comes first in this relationship, obviously when gathering information we do 
so with the intention of addressing something we find significant therefore we already start from a 
particular point of view, but what is clear, is that once the relationship between values/justice and 
information/evidence begins, it does create a somewhat mutually-reinforcing closed system.  
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health inequity or marginalised groups. I then make a distinctive move, by 
discussing informational bases and theories of justice that determine them.  Sen 
(2009) articulated that all theories of justice rely on an evaluative space that 
requires an information base. That is, to weigh what is fair, first requires 
identification of the thing that is important to equalise or maximise (utility, primary 
goods, capabilities for example) and then requires information about how different 
actions will affect the thing of importance (Sen, 2009).   
 
 I introduce Sen’s Capabilities Approach (CA) as a potential solution to this problem, 
including its key elements: intrinsic value (well-being and freedom), person-
centeredness, and public deliberation; and its relationship to social choice theory 
(Sen, 1992). I then discuss what information would be necessary to implement a CA 
in the NZ system (stating that research is required to fill this gap) and what benefits 
this would have while outlining some possible limitations of this approach.  
6.1. Decision-making for health inequity in NZ 
Chapter 1 argued that New Zealand has committed itself to the goal of health equity 
and that the government has made some progress in reducing health disparities, 
especially within Māori communities. However, there is still considerable work to 
be done, some of which is currently being undone (Human Rights Commission NZ, 
n.d). Prioritisation decisions in health affect health inequity, not only through access 
to services but to the kinds of services prioritised and funded over others. Priorities 
in the health system directly change priorities in the research funding system. This 
connection is evident in research data regarding rheumatic fever and rheumatic 
heart disease discussed in Chapter 2. During 2006-2010, before a raised awareness 
of the impact of rheumatic fever on Māori communities (especially), there was a 
single research grant related to this disease awarded. In 2011, 2012, and 2013, 
there was one grant per year. While these figures may appear insignificant given 
rheumatic fever affects a small group of a minority population, moving from one 
grant in five years before national discussion of the issue up to one grant per year 
post-discussion is noteworthy.179 Increased attention on rheumatic fever and its 
                                                        
179 It is difficult to do this kind of analysis with other diseases that are less specifically focused, i.e. 
rheumatic fever is seen as a problem that largely affects Māori or Pasifika people. Other government 
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outcomes was not a result of decision-making processes (i.e. it did not become a 
priority through the ranking systems currently used) but was rather directly 
achieved through advocacy, as was emphasised earlier. 
6.1.1. Health budget distribution   
VoteHealth is the budget managed by New Zealand’s Ministry of Health (provided 
by Treasury) to fund the country’s health and disability services. The Treasury 
distributes this money to the Ministry of Health who distributes it further across the 
health system, including to PHARMAC180, the twenty regional district health boards 
(DHBs)181, and national disability and maternity services. (Ministry of Health, n.d.-l). 
A description of the different ways the Ministry of Health distributes these funds is 
useful to understand what information the Ministry uses and what considerations it 
makes. 
6.1.1.1. Allocation to District Health Boards and Primary Health Organisations 
The Ministry of Health distributes funding to DHBs and Primary Health 
Organisations (PHOs) (who are responsible for subsidising primary care visits with 
a private GP) based on two different models, which both employ some of the same 
assumptions.  
For DHBs, the “population-based funding formula” is used to distribute the health 
funding allocation to each DHB.  This formula takes into account age, ethnicity, sex, 
NZ deprivation index, rurality and an adjustment for unmet need, all based on 
historical data (Ministry of Health, n.d.-i). Therefore, if the DHB has a greater degree 
of deprivation, rurality, populations that are ageing or diverse, it receives more 
funding because these factors correlate with a higher level of service need.  
PHOs work on an enrolled capitation model.  A capitation model distributes funds to 
primary healthcare practices based on the number of people enrolled at said 
                                                                                                                                                                    
priorities remain relatively stable over blocks of time, and so picking out another example of this 
kind either for the wider population or for a specific minority is not possible. 
180 NZ’s Pharmaceutical Management Agency – responsible for the funding/subsidising of various 
medications and some medical devices. It undertakes health technology assessments in deciding 
what should be funded and negotiates with pharmaceutical companies to get the best possible prices, 
to ensure the budget provides as much as possible. www.pharmac.govt.nz  
181 District Health Boards are responsible for tertiary and secondary care, but also distribute funding 
to Primary Health Organisations who in turn distribute funding (based on a capitation formula) and 
support to private general practitioners providing primary care. District Health Boards also contract 
community services from private suppliers and non-governmental organisations.  
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practice. Therefore to receive subsidised primary care, people who live in NZ must 
register with a general practitioner of their choice.182 A patient is eligible to receive 
greater subsidies should they have a defined high need (determined at an 
appointment and applied for by the general practitioner to the PHO). The capitation 
formula is used by DHBs and their related PHOs to distribute money at the level of 
primary care for enrolled patients.  This capitation formula distributes partly 
according to weighted demographics (age, sex, ethnicity, deprivation, rurality), 
some according to need (Higher-User, CarePlus (for multimorbidity)), and then 
further funding can be shared for health promotion activities (Ministry of Health, 
2016b).183 Explaining the capitation-based funding model, the Ministry explains 
weightings in the following: 
In general, people need more care when they are very young and as they get older. 
Women in their child-bearing years tend to need services more frequently than men. 
The formula for calculating capitation payments takes into account the demographic 
make-up of the population (Ministry of Health, n.d.-b). 
The weightings provide more for Māori and Pasifika patients, more for those living 
in social deprivation, and more still, for Māori or Pasifika living in higher social 








Table 16 - Services to Improve Access for High Need Groups (Ministry of Health, 2016b) 
                                                        
182 General practitioners are private and set their own fees, however these are generally similar 
between individual practices for purposes of competition in the market. 
183 There are additional capitation rates for children, certain management activities, and vaccine 




Health inequities are addressed at the highest level of resource allocation by 
demographic-stipulated need, i.e. subgroups within the population of a particular 
demographic ‘kind’ generally, suffer poorer health (or are more expensive – e.g. 
pregnant women). Therefore, a higher degree of funding is required to cover that 
population. The information used here is historical demographic data and historical 
service utilisation data.184 
6.1.1.2. Allocation decisions between services and interventions 
Health technology assessments are the general tool by which governments decide 
whether it will be worthwhile to fund a particular service or intervention (what 
“worthwhile” means is discussed below). It also allows for a comparison of the 
relative merits and disadvantages of different kinds of interventions used for the 
same conditions. These prioritisation exercises use a mixture of need/benefit cost 
analysis or social value information. For example, PHARMAC, which is the most 
prominent agency making funding decisions in a formulated way,185 has different 
                                                        
184 Remembering that PHOs distribute money based on enrolled patients. Information about low-
service users (for which there is some extra funding) is minimal and largely old. 
185 The National Health Committee referred to in Chapter 2 has been disestablished, this means that 
there is no centre of expertise in the MoH for HTA but rather that this is spread throughout the 
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types of criterion subjected to its considerations. PHARMAC lists its assessment 
criteria as clinical, economic and commercial (‘Making funding decisions | 
PHARMAC’, n.d.). The clinical criteria cover aspects related to the effectiveness of a 
drug, the evidence that exists to support it, the alternative options, and the size of 
the affected population. The economic criteria measure cost-benefit analysis type 
assessments using quality-adjusted life years (QALYs) and disability-adjusted life 
years (DALYs).186 “Commercial” refers to PHARMAC’s ability to negotiate drug 
prices with large pharmaceutical companies on account of being a conduit for 
injecting pharmaceuticals into the health system (i.e. people can pay privately to 
have other medications in NZ, but PHARMAC provides all publically funded or 
subsided medications). PHARMAC has also implemented something called “Factors 
for Consideration” which reference five distinct dimensions: need, health benefit, 
costs and savings, and suitability (‘Making funding decisions | PHARMAC’, n.d.). 
These are relatively self-explanatory, except suitability, which captures the non-
clinical aspects of the medicine under consideration and what impacts it might have 
on outcomes.  
Once a draft decision has been made on a drug (or device), PHARMAC posts this 
document on their website and allows a period of submissions from not only 
clinicians but also the general public. It is worth noting, however, that PHARMAC 
does not promote these publications widely, so unless there already exists a 
particular interest, through which one is aware that a consultation is open (i.e. by 
checking their webpage regularly), then it remains unlikely that these submissions 
will generate broad interest or response. Based on PHARMAC’s website, the 
informational base that supports their decision-making is primarily demographic, 
service utilisation data, clinical research, and economic data.  
6.1.1.3. Allocation decisions within a given service or intervention 
Health providers make service allocation decisions also using cost-benefit analyses 
calculations. However they also use “clinical priority assessment criteria” for 
                                                                                                                                                                    
ministry with differing departments either undertaking HTA independently or contracting private 
companies or academics to do this work.  
186 QALYs and DALYs are economic tools used to quantify burden of disease (mortality and 
morbidity) in a dollar amount based on quality of life measures and overall life expectancy.  They are 




decision-making on a case-by-case basis where they have established a threshold to 
receive care (i.e. based on limitations of resourcing). These tools are developed 
nationally but not exclusively, as some regions create their own. They are intended 
to help public sector clinicians evaluate a patient for a particular type of 
intervention, such as surgery or fertility treatment, for instance.  Clinicians and 
stakeholders decide the tool using a Delphi process,187 and use five categories to 
determine priority scores: “pain, personal functional limitation, social limitation, 
potential to benefit from operation and consequences of delay” (Gillett, Peek, & 
Herbison, 2012). Each of these categories is weighted differently and has a variety 
of criteria to help determine the score. The users of the tool determine a threshold 
above which the intervention is offered, based on knowledge of what is possible 
with the resources available – i.e. it rations. The information used here is a mixture 
of service funding data, clinical expertise, including reference to the evidence-base, 
and some explicitly normative considerations around the social limitation. These 
tools have been criticised, not only for their rationing but because it fails to account 
for specialist bias when scoring a patient.188 They also suffer access issues for those 
who are subject to health inequity (Dew et al., 2005; McLeod, Dew, et al., 2004; 
McLeod, Morgan, et al., 2004). 
6.1.2. Information used in Health Resourcing Decisions 
The above outlines what information is being used to make distribution decisions: 
1) Need -  based on population-level demographic data and retrospective 
health data 
2) Clinical information – such as effectiveness and ability to benefit 
3) Cost-effectiveness using estimated QALYs and DALYs referenced to NZ 
demographics and service use data 
4) Social values – vaguely determined about the impact on 
family/communities (as seen in PHARMAC) or social limitations (as seen 
in CPAC).  
                                                        
187 Some have included a consumer representative, but in the mid-2000s rather than use a Delphi 
method and discussion, CPACs were created using 1000minds (a software programme) where those 
taking part are asked to rank statements against each other in order to determine 
preferences/weightings.  For more information, see: https://www.1000minds.com/ 
188 That is, as a rationing tool, it can be used unfairly, as a surgeon can score one patient differently 
than another, even if their need is the same, based on preference, or what is called the “squeaky 
wheel” problem (some patients are better at complaining than others). 
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The limitations of information collection mean that these are the best measures we 
currently have to assess need and distribute funding appropriately (within the 
current framework).  However, when we explicitly consider marginalised groups, it 
becomes apparent that the following problems emerge: 
1) Service utilisation data – shown in Chapter 2 to be problematic based on use 
and accuracy of data; therefore is non-representative.  
2) Clinical information is mostly prevalence and efficacy information based on 
research data, which again in Chapter 2, was seen to be non-representative 
3) Cost-effectiveness data using QALYs and DALYs which have long been 
contested on their applicability to subgroups of the population – so non-
representative189  
4) Social values are those of participating decision-makers, if decision-makers 
are not representative, then social values are unlikely to be. 
 
These decision-making practices and their informational base focus on a fair 
distribution of goods (health services), or maximisation of clinical outcomes based 
on a distribution of goods (where health is determined by clinical predictions of 
benefit).  It fails to consider the conversion of goods into actual well-being (i.e. the 
focus is on the distribution of goods or a form of utility).  
I now explore how these practices relate to theories of justice, what informational 
bases different theories of justice have and the problem of goods conversion further. 
6.2 Foci of current models 
Sen argues that all theories of justice aim to equalise some factor of importance, 
whether it is primary goods, utility, or freedom. (Sen, 2011). The overarching theory 
of justice used within our health system is a distributive one (in a Rawlsian form  
(Rawls, 2001)), where the aim is to distribute goods fairly amongst all, taking into 
account the position of the worst off in allocating resources at the highest level (that 
is in distributing it across the entire system).  The currents system uses a modified 
                                                        
189 Various work exists on this front considering equity, disability, etc., for a selection see: (Bevan & 
Hollinghurst, 2003; Brock, 2004; Chamberlain, 1985; Starfield, 2001) 
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or weak utilitarianism190 combined with a distributive model when allocating 
limited access to resources at the lower level (that is within the system for specific 
services).191  Utilitarianism seeks to maximise utility for the majority in any given 
decision, where utility is often defined as a well-being or happiness.  It is weak in 
this system because, in some cases, decisions take particular account of inequity in 
maximising utility (i.e. decision-makers may choose a slightly less maximising 
option if it improves equity, rather than just the option that maximises utility 
ideally). 
 
   Focus of Distributive Model                                                                                                          Focus of Utilitarian Model 
 
Figure 28 - Points of Measurement & Distribution at Present 
Neither of these foci (Figure 28) ensures well-being.  For example, if the municipal 
council of a small, impoverished town could provide its citizens with seeds for 
vegetable growing, it might reasonably allocate larger families with more seeds. 
However, a family’s ability to grow vegetables and be nourished by them depends 
on a network of factors, such as land available to them, material resources required 
for nurturing the vegetables, time to tend to the vegetables, and basic levels of 
knowledge about vegetable growing.  In principle, the distribution process was fair, 
as the council gave those with the greatest need more. This provision did not 
necessarily ensure well-being. Over time, families may psychologically adapt to 
being undernourished to the extent that they may well rate their well-being 
relatively well, despite being undernourished. Similarly, they might even report 
high well-being from receiving a significant amount of seeds, even though they are 
unable to use them for nourishment. Thus, this stark example highlights that, in 
                                                        
190 Utilitarianism in this sense – greatest benefit to the greatest number based on QALYs/DALYs as 
measure of utility. 
191 This discussion is limited to the distributive and utilitarian justice models as these are most 
pertinent in the NZ setting. While a libertarian/rights-based approach could also be justified, it is less 








trying to distribute seeds based on distributive or utility measures, we still fail to 
address the problem of undernourishment and the effect had on a person’s life. 
 
Sen calls this a conversion problem (Sen, 1992, 1999). It is this space of conversion 
(i.e. receiving a “good” and converting it to well-being) that is the proper site for 
evaluation.  Theories of justice that distribute resources “fairly” or maximise utility 
are not capable of capturing whether people are better off or ensuring those with 
the most need are better off.  
6.3. What is the Capabilities Approach?  
In the last section, I described the view of health and resource allocation as one 
focused on resources and utility. Attention was given to the way they fail to 
efficiently and justly address problems of both health and health inequity. 
Here I describe the Capabilities Approach (CA) to resolve the issue of conversion by 
focusing on a person’s capabilities to “achieve functionings they value and have 
reason to value” (Alkire, 2005). What is of particular importance in a CA is the focus 
on individuals, intrinsic goods (freedom and well-being) and public deliberation (in 
determining what capabilities are valuable) and the implications for the required 
informational base, which I will show links us back to Chapter 5 and the need for 
more diverse information. 
6.3.1. Capabilities and Functioning 
Capabilities are those things that we need to achieve valuable functionings. That is, 
capabilities are the factors required to turn a resource into functioning, where the 
desired functioning is one an individual values and has reason to value (Alkire, 
2005; Robeyns, 2005; Sen, 1992, 1999). “Functionings” are things we want to do 
with our lives, whether it is to nourish ourselves or to read, or to be politically 
engaged, perhaps have a career. Sen and Alkire describe functionings as a capability 
set - like a menu that opens up possible functionings, from which I can then achieve 
those I desire (Alkire, 2005; Sen, 1992).  Capabilities are functionings that people 
have real access to, and functionings are those they choose to achieve. Converting 
resources into functionings depends on factors that limit one’s capabilities. These 
can be personal factors that are physiological or social in nature.  For example, a 
valued functioning might be walking in the park. My capability to achieve that 
201 
 
functioning will depend on whether I am capable of walking very far, whether I live 
in a society where a female-identifying person can walk in the park, whether I have 
access to a park (i.e. it may have an entry fee, that is prohibitive for those on my 
income, or requires transport costs to get there).  Sen’s focus is on the real 
opportunities people have access to, not just the nominal opportunities they have 
access to (Sen, 1992). To take another example, I might live in a country with free 
Wi-Fi for all, but if I do not have access to a computer or smartphone, then the 
opportunity of Wi-Fi (and the further functionings this entails) is closed to me 
(Figure 29).  
 
 
Figure 29 - Points of focus within CA for distribution 
One of the unique things about the CA is that it combines well-being and agency, 
whereas utilitarianism focuses on well-being, and Rawls begins with agency as the 
starting point for the distributive model in determining the principles (Rawls, 2001; 
Robeyns, 2005; Sen, 1985). 192 Sen argues that theories that focus only on one aspect 
i.e. well-being or agency, are missing relevant information (Sen, 1985, 2011). Both 
well-being and agency are important in determining whether someone is a leading a 
good life (Sen, 1985, 2011).193 Importantly, though, well-being and agency cannot 
be conflated. There are times when increased agency could negatively impact on 
well-being and vice-versa (Sen, 1985).  Sen illustrates why well-being and agency 
are both important factors for assessing justice and equality if we consider two 
people who are starving, where one starves due to lack of access to food and the 
other due to religious commitment (Sen, 1985, 1992, 1999).  The former is both 
lacking in well-being and has little opportunity to rectify it; he has diminished 
agency in what he can choose and achieve. The person starving for religious reasons 
                                                        
192 In Rawls “Original Position”, rational beings objectively decide the principles of a fair society 
without knowing what position they may have in that society (Rawls, 2001)  
193 Sen sees freedom as both a factor of well-being or agency (i.e. you can have agency freedom or 
well-being freedom or both) (Sen, 1985) 
Resource Capability Functioning Utility 
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has a different set of opportunities available to him despite his similar state of well-
being. This difference between the two cases is important. 
To then evaluate capabilities and opportunities people have access to, the 
functionings people have reason to value must be determined. For Sen, public 
discourse and democratic processes are used to decide these (Alkire & Black, 1997; 
Robeyns, 2006; Sen, 1992, 1999). Through consultative processes that determines 
what functionings are important to people, considering those who have access to 
the least functionings first, one can arrive at information required to make fair 
decisions. A real world example best illustrates this practice.  
Burchardt and Vizard aimed to use a capability approach to monitor human rights 
in Britain (Burchardt & Vizard, 2011).  To do this, they decided that four ‘building 
blocks’ were necessary: 
1) they focussed on substantive freedoms and opportunities (i.e. those things 
people could actually do);  
2) the evaluation had to include: functionings (what people were doing), 
treatment (what discrimination/challenges people faced in society), and 
autonomy (people’s choice and control);  
3) they disaggregated population data by subgroups to move away from the 
generic to the specific, and  
4) through public consultation, they determined a capability list using the 
human rights framework as a starter for discussions (Burchardt & Vizard, 
2011).  
Through this, they have created a sophisticated evaluation matrix requiring a broad 
informational base (indicators determined through consultation) to conduct 
monitoring. Both the capabilities list and the indicators in assessments were 
informed by deliberative processes (Burchardt & Vizard, 2011), meaning criteria 
and measures are relevant and representational. Monitoring using CA is now being 
implemented to measure human rights in this instance; it requires ongoing research 
in refining metrics and seeking means to access the information needed. This 
project illustrates the need to create an entirely new informational base to use this 
particular evaluative framework. It also shows that to implement both the 
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framework and determine the base consultation is required.  In making decisions 
between capabilities to prioritise there will necessarily be times where options 
come into conflict.  It is, therefore, necessary to consider how decision-makers can 
resolve these.  
6.3.2. Weighing up conflicts 
Sen’s CA uses Kenneth Arrow’s Social Choice theory as a framework for combining 
various people’s deliberatively decided capabilities into a collective decision for 
priority setting (Arrow, 2012).  What this does is allow a ranking without 
specifications of weights, i.e. rather than saying this is valuable to this degree and 
we should weigh it accordingly, people stipulate that they prefer x, over y, and y 
over z for example. Different people may rank these in a variety of ways, but a 
collective decision based on rankings of compared options is possible without 
assigning specific weights to specific options.  Preference ranking and compromise 
is counterintuitive to most of our current practices and the place where most people 
struggle with the CA in practice. Our society is set up on a social contract theory 
approach where much is seen as a zero-sum game: for someone to benefit someone 
has to lose out.  An adversarial position, where someone has to lose out, does not 
necessarily have to be the case within a social choice theory framework, where 
people may agree through rankings of an outcome that they do not agree on 
directly.194  
For example, I might prefer apples to oranges and oranges over grapes.  Judith may 
prefer oranges over grapes and grapes over apples.  Moreover, Sally may like 
mangoes over oranges and oranges over grapes.  We can provide everyone with 
oranges, and no-one specifically loses out, although Judith will be happier than Sally 
or I.  This, of course, is a very basic example that does not take into account 
outcomes (i.e. what the various fruit achieves) or well-being at all and does not 
consider need. This example does illustrate that there is an option for improving 
everyone’s situation through preference ranking rather than a distribution based on 
weightings of particular elements or factors against each other.  
                                                        
194 Extensive work has been done by Jennifer Prah Ruger to outline how conflicts within these 
situations can be ameliorated using the incompletely theorised arguments approach. She shows that 
it is possible to combine conflicting preferences into a satisfactory solution (Ruger, 2010). 
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If we consider this in health, most discussions about redistribution of funding 
within the system focus on the fact that someone has to lose out.  However, it is not 
clear that that has to be the case if we work within a capabilities model.  It may be 
the case that some people do not receive additional benefits that they currently 
receive, while others begin to equal out, but it is not necessarily true that some 
people would be worse off.  Designing and choosing interventions that work for the 
groups currently disadvantaged does not necessarily entail a lack of responsiveness 
to those for whom the current system is sufficient. It is also worth noting that the 
current system is not necessarily that responsive to the “general” public, but that 
due to the relative advantages they have access to they can overcome this lack of 
responsiveness. After all, trial cohorts do not map to the variety of people that make 
up the general population any more than they do to the people who are the focus 
here. As a woman in her late 30s, there would be little evidence that pertains to me 
in the system based on the literature referenced in Chapter 1, 2, and 5. 
6.4. Capabilities Approach in Health and Health Research  
So far we have discussed the CA in very broad terms.  Often when used overseas, in 
developing countries, for example, it is used to focus on the very minimum of things 
required to achieve functioning, food, water, shelter, education, and so on. 
Alternatively, as was shown in the example above, to evaluate a particular aspect of 
society. It is important now to focus on health and health research specifically.  
If the assumption that the health research system influences the health system (and 
vice versa) is correct, then to implement a CA requires action in the health system as 
well as the health research system. Considering the health system first, if we were to 
use the CA as an evaluative framework in health in NZ, we would need to: 
1) Establish a capability set of interest in health through deliberative practices, 
where these deliberations include membership more strongly weighted to 
those who currently suffer health inequity.195 
2) Take stock of the degree to which inequalities in this capability set exists (i.e. 
where are the gaps, how big are they) at present. 
3) Devise measures for assessing and monitoring them. 
                                                        
195 This is the high level capability set; it is conceivable that within different conditions or situations 




Implementing the CA would require better processes for public involvement and 
deliberation between the Ministry of Health and the populace. It also means that the 
priorities the Ministry of Health sets will be somewhat different, i.e. they focus first 
on equalising health for everyone and then on improving health beyond that.196  
 
There are two levels at which capabilities sets needs to be determined.  Firstly, the 
set of capabilities (related to health) that are required to achieve functioning in 
everyday life.  Secondly, the set of capabilities required to convert health services 
into health functionings.  One addresses the overall relationship health has to well-
being, the other addresses how people benefit from the health services that 
governments provide.   
This first level: these are the capabilities needed to achieve functioning determined 
as being healthy – these may include mobility, or pain-free living, longevity, or 
quality of life. They could be any number of things, but this would need to be 
determined in public deliberation and mapped to conditions, i.e. if people see these 
things as most valuable, which conditions hinder them, which services support 
them, and how do we prioritise them. It is possible that the public deliberation 
would result in a similar set of priorities as currently exists, but these current 
priorities are not openly discussed and become contentious whenever the public 
contests a funding decision.197 It is also possible that different groups within the 
population prioritise different things such as quality of life over longevity or vice 
versa, and some flexibility within the system for recognising that is necessary. The 
NZ population currently engages in these discussions on a case-by-case basis based 
on advocacy and the ability of a group to get attention for an issue. Completing, this 
process within CA framework would mean that the public have an open  
deliberation (and have ongoing input) facilitated by governments who then set 
priorities which were informed by these processes. Furthermore, in this type of CA 
process, the voices of those who currently suffer health inequity are explicitly 
                                                        
196 This is somewhat controversial given the reference to neoliberal policies in the last chapter, but 
could be justified under the NZ Public Health and Disability Act (NZ Public Health & Disability Act, 
2000) 
197 Examples of this can be seen in New Zealand around PHARMAC decisions for cancer drugs 
(Herceptin and Ecluzimab both caused public backlash) and surgery access.  
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considered in contrast to the present where the only input is from those who have 
well-developed voices in the civic and market square. 
For the latter, i.e. the capabilities required to achieve functionings within a given 
health service type. One would imagine that such things as transport, health literacy, 
self-advocacy, cultural and religious recognition, and so on, may come up on this list, 
as those things that hinder a person’s ability to convert a health intervention into a 
positive outcome. Once these are determined, however, they can be embedded in 
health services and in the design of new interventions that researchers investigate. 
The informational base required to address these capabilities must be particularly 
responsive to those who have a capabilities deficit, i.e. current measures fail to 
capture much more than very basic differences between groups and the accuracy 
can be called into question (as was shown in 6.1.). 
6.4.1. Health Research Priorities and Practice 
Again there are two ways in which a CA framework affects health research.  One is 
the needs of the health system for information to answer its questions, the 
redefining of the informational base described above. The second is in the actual 
practice and prioritisation of health research itself.   
A CA focused health system would require a different informational base. This 
informational base would include some of the traditional elements, but would 
additionally need to understand what things people value and what things help 
them achieve the things they value.  
For health research, this would mean there are three distinct domains of 
information required to proceed: 
1) Capability preferences 
2) Capability gaps 
3) Interventions/supports/contexts that help people achieve capabilities 
 
These will require different methodological approaches to determine them and will 
need close connections with people (and specifically people who suffer 
disadvantage) to set relevant frames of inquiry and measurement. 
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This connection to people is worth noting for other reasons.  Both Māori, Pasifika 
and the disability movement have made strong calls for self-determination (Tino 
Rangatiratanga)(Bickenbach, 2013; Bishop, 1999; Cobb, Lehmann, Newman-
Gonchar, & Alwell, 2009; Field, Martin, Miller, Ward, & Wehmeyer, 1998; McDougall, 
Evans, & Baldwin, 2010; Smith, 2000). A CA allows this to occur through the 
stipulation of person-centered (and deliberated) valuable functionings and 
measures.  Person-centered care is described as the goal for providing successful 
healthcare to people and a CA that explicitly promotes this would seem beneficial 
(Entwistle & Watt, 2013).  
Another benefit of the CA is that it allows recognition of the various factors that 
constitute health capability, i.e. the social determinants of health.  A CA opens 
broader avenues for investigation and supports the Health in All Policies approach 
promoted by the World Health Organization.198 
At the research prioritisation level, there is a requirement for more public 
involvement in decision-making. In part, this can come from prioritisation at the 
health service level, but it can also come from direct participation in the setting of 
priorities at the research level.  One could imagine for instance the HRC creating a 
public or patient panel to inform their investment stream priorities. Models exist 
overseas of public involvement in research priority setting such as the Patient 
Centred Outcomes Research Institute199 in the USA or the James Lind Alliance200 in 
the UK, both of which use public input to inform research goals and activities. The 
National Institute of Health Research (NIHR) in the UK also has extensive processes 
for including the public, patients and carers in setting research priorities, informing 
research design, taking part as researchers in research and being participants in 
research.201  These organisations have ways for the public, patients and 
stakeholders to have direct input into what research is done and how it is done.  At 
present in New Zealand this kind of involvement is dependent on individual 
researchers and their philosophies, and it would be fair to say that while these 
                                                        
198 Health in All Policies recognises that the social determinants of health play a real role in the health 
of populations and as such health policy alone cannot affect health outcomes. For more information 
see: http://who.int/social_determinants/publications/health-policies-manual/en/  
199 For more information see: http://www.pcori.org/  
200 For more information see: http://www.jla.nihr.ac.uk/about-the-james-lind-alliance/  
201 For more information: http://www.nihr.ac.uk/patients-and-public/opportunities/  
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organisations exist in other countries they are not necessarily a model of how all 
relevant health research related activity is occurring in those countries.  By 
explicitly underpinning health, health services and health research with a CA 
framework, it is hoped this kind of activity would be seen as necessary rather than 
desirable.  
6.4.1.1. Project Level 
At the individual project level, a CA also requires some changes.  Researchers need 
to consider within any given project, patient-informed priorities and outcome 
measures (to achieve full functioning in the service setting; a conversion of resource 
into outcome), as well as what capabilities, are required to take part in research. 
Many of the informants described in Chapter 5 begin with their populations, they 
start from what their communities consider issues.  A CA framework would support 
other researchers to recognise this need to consider populations and appropriate 
measures from the beginning and acknowledge those researchers already working 
in this way.  
Consider, for example, Outcome Measures in Rheumatology (OMERACT).202  Before 
their consultation with patients, OMERACT focused on a core set of outcome 
measures that did not include fatigue.   The measures focused mostly on pain and 
joint swelling. OMERACT and others promoted these measures as those that 
researchers should be using in clinical trials as the most relevant and to gain the 
most from combining data from various trials.  Once OMERACT began consulting 
with patients, however, they found that patients worried most about fatigue rather 
than those in the core set (Kirwan et al., 2003) and so fatigue measures were added 
to the core set.  Trials often do not include patient-focused measures in their 
outcomes measures (i.e. just clinical measures), and this is problematic when 
deciding what things are worth implementing to achieve patient well-being 
(Wieseler et al., 2013). 
Another aspect related to this would be to develop more patient-relevant measures 
such as the Patient-Specific Functional Scale (PSFS) (Nicholas, Hefford, & Tumilty, 
2012).  This tool asks patients within a physiotherapist appointment to list three (or 
                                                        
202 OMERACT is a group that focuses on rheumatology research, specifically outcome measures in 
rheumatology research. See: http://www.med.uottawa.ca/research/omeract./about/about.html  
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more) activities that they would normally do but cannot do due to their 
injury/illness and rate them as to their current ability to perform them. Patients 
then repeat this exercise at the end of treatment.  The PSFS is the perfect tool within 
a CA, in that it focuses on a person’s ability to achieve functionings they value (and 
the effects of treatment on that functioning). More of these kinds of measures and 
tools would ensure that health services and treatments provide patients with 
meaningful outcomes. 
These kinds of measures could also be included in health data systems along with 
typical measures such as blood pressure if designed in a manner that makes 
reporting simple. The utilitsation of this kind of data alongside typical biomedical 
data would go some way in providing a broader range of information in decision-
making.  This kind of data would provide both decision-makers with the real world 
outcomes for patients aside from changes in a specific clinical measure.  
Research systems at the highest level (priorities and funding) and the project level 
would need to reconsider practices in light of the informational base required for 
CA framework decisions in health. 
6.5. Limitations 
The CA is an incomplete theory of justice and as such requires analytical support on 
a number of fronts. These gaps can create avenues for distortion. The weighing of 
different factors as discussed earlier is still somewhat underdeveloped but is 
possible to implement (Fukuda-Parr, 2011).  One could imagine a CA-distributive 
hybrid model – that is a system where the point of focus is capabilities but another 
system is used to ensure their effective weighing/distribution.203  Using key 
elements of the CA such as public deliberation and person-centeredness combined 
with the distributive model, which focuses on procedural fairness in combination 
with CA evaluative framework may be useful for ethical decision-making, i.e. 
capabilities/functionings are the evaluative space, rather than goods, and public 
deliberation is used to inform the ground rules of distributive decision-making.  
                                                        
203 Other hybrids or models of CA have been suggested by Ruger (Ruger, 2010) and Ventakapuram 




Secondly, Sen’s CA relies on extensive and extended processes of public consultation 
and deliberation. These kinds of discussion exercises are fraught with practical 
issues. Issues include: 
a) upskilling of both those leading the discussions and those involved as 
representatives in the discussion needs to occur, if meaningful outcomes are 
to be achieved 
b) some form of infrastructure and system development for ongoing dialogue 
and relationship building to reduce costs and improve knowledge acquisition 
and transfer 
c) ensuring transparency and meaningful representation (i.e. for 
representation to be meaningful it needs to be authentic, comprehensive and 
accurate to the community and people it represents (Hunter et al., 2016)).  
 
People are already using the CA in development settings (Sen, 1999; Venkatapuram, 
2013) and other discrete projects, and so it is not too theoretical for a practical 
setting.  What is important is to ensure those using CA retain the key concepts of 
intrinsic goods (i.e. a focus on the interconnected goals of well-being and freedom), 
public deliberation, and person-centredness in whatever way they operationalise 
CA. 
6.6. Summary 
In this chapter, I described the distribution of funding within the NZ health system 
and what information is used to decide that funding.  I argued that the information 
used was lacking and contributes to the epistemic injustice for marginalised 
researchers and inequity suffered by marginalised populations described earlier in 
the thesis.  I have then argued that the introduction of a CA in the NZ health 
decision-making environment and the health research system would be useful in 
addressing the health inequity and the epistemic injustice that occurs within that 
environment for researchers working with marginalised populations.   
The CA is helpful because it focuses our attention first on those that are not 
achieving their full functionings (i.e. the most disadvantaged). The informational 
base the CA requires to evaluate justice requires a broader set of information, and 
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there is an emphasis on intrinsic goods, person-centeredness, public discussion and 
participation.  Not only that, but it can help reform our systems both on the larger 
scale, by making explicit the link between other social policy areas and health, and 
the smallest scale, in conducting research in a way that is patient/participant 





Chapter 7: Implications 
“I may not have gone where I intended to go, but I think I ended up where I needed to be” 
Douglas Adams 
7.1. The Story so Far 
This work began with the intuition that one of the many causes of health inequity 
was the invisibility of marginalised populations in health research, both within 
research studies and across all research activity.  The literature supported this 
intuition of a lack of representation as was shown in Chapter 1. It was, however, 
necessary to also verify this within the NZ health research environment. Adequate 
representation of various marginalised groups in research that informs decision-
making is lacking.  Novel work exploring this across trial registries, ethics 
committee records, and health funding records indicated this was the case (Chapter 
2). While some projects specifically aimed to address health inequity or the social 
determinants of health, or even distinct populations, the magnitude of this work, 
appeared to be out of balance with the size of the marginalised populations and 
their need (Curtis et al., 2015; S. Hill et al., 2010, 2013; Leeder & Dominello, 2005; 
Linton et al., 2011; McCormack et al., 2012; Meredith, Sarfati, Ikeda, & Blakely, 2012; 
Ministry of Health, 2013; Talamaivao et al., 2010; Waldon, 2003).204  Lack of 
inclusion means we are not discovering or creating knowledge that can help us 
address the health of these marginalised populations and the disparities they face. It 
also means decisions currently made by the health system and health researchers 
are based on limited information.  I found evidence of this limitation based on a lack 
of representation of marginalised populations in a review of health guidelines for 
the major causes of morbidity and mortality for marginalised groups available from 
the Ministry of Health and in decision-making exercises that were publicly available 
from the National Health Committee and PHARMAC.   What this work shows is that 
there is a lack of representation not only in the research itself, but in the use of 
information from research that informs decisions, and in the decision-making.  
 
To understand the reasons for this disparity, I undertook further work.  First, I 
conducted a survey of ethics committees in NZ who review the majority of research 
that would likely make its way into decision-making.  In NZ, National Ethics 
                                                        
204 Remembering only three particular marginalised groups were investigated here and that others 
are likely to be less well represented. 
213 
 
Advisory Committee (NEAC) guidelines make very wide-ranging claims about 
justice, including reference to representation and health inequity among others 
(NEAC, 2012a, 2012b).  These documents are in place to guide both researchers and 
committees in their considerations of justice.  I wanted to understand how ethics 
committees felt about justice requirements given justice is not apparent in the 
research activity reviewed in this thesis, despite clear statements about justice in 
the guidelines.   
 
I, therefore, surveyed committees to ask what they thought of the definition of 
justice, whether they thought applicants addressed the various elements of justice 
described in the guidelines and what their responses were to applications that did 
not address them.  Did they make recommendations, or if not, did they feel like they 
could?  The survey also asked about certain practices in the literature described as 
being likely to aid health inequity improvements (big data, open data, collaborative 
partnerships and stakeholder engagement). The initial thought in undertaking this 
work was that with a wide-reaching definition of justice available in the guidelines, 
an ability to enforce this might be lacking. I based this presumed inability to enforce 
justice on the conjecture that if applicants were not embedding the idea of justice 
provided in the guidelines in their projects, then projects that fell short would likely 
require changes that had resource implications.  Such changes were likely to be 
contested based on funding and time pressures. Alternatively, reasons for the lack 
of justice in the research environment could be that applicants addressed justice in 
applications, but in practice fall short; or ethics committees could disagree with the 
definitions. While this enquiry was the first of this kind in NZ, unfortunately, the 
response to the survey was low, and so results cannot be considered representative.   
From those participants who did provide input and comment, some points of 
interest were found.   
 
There appeared to be an ambiguity of what justice (specifically around health 
inequity) should look like in ethics review, other than when it was definitively laid 
out in regards to Treaty obligations.  Even where justice was a detailed requirement 
for Māori populations, the survey respondents noted tokenism and a lack of real 
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engagement, which is supported by informants reports in Chapter 4 and the 
literature (Hudson & Russell, 2009; Tolich & Smith, 2015). 
 
I further asked respondents about practices that in the literature have been 
suggested as ways to either ameliorate the burden of research participation on 
communities and especially vulnerable communities, fill knowledge gaps where 
information is lacking, or ensure that researchers and decision-makers included.  
 
Answers to questions regarding big data showed that those participants that 
responded felt that it could be useful in improving health inequity, but that there 
were many things to be considered in dealing with the data sensitively and that 
ethics committees were not necessarily equipped to do this.  Big data practices are 
powering ahead in NZ with initiatives such as Statistics New Zealand’s Integrated 
Data Infrastructure and the HRC funded programme “Burden of Disease 
Epidemiology, Equity and Cost-Effectiveness Programme (BODE³)” to name but two, 
using large datasets and integrating them together.205  As previously mentioned, 
worries about data privacy, safety and ownership are rife both here and 
internationally, but for marginalised groups specifically the question of power is 
crucial (Bollier & Firestone,2010; Boyd & Crawford, 2012).  By this I mean, who 
decides the questions being asked of data and who interprets the data, with what 
perspective and with what outcome in mind? These are points discussed further 
below (7.2.3). 
 
Responses to open data were more mixed with some favouring these practices and 
others reporting that they did not believe people should be made to share data. 
Open data in contrast to big data is that collected by researchers.  Concerns from 
respondents were largely in consideration of the researcher and their potential loss 
of intellectual property, rather than towards either participants from whom 
researchers collected the data or communities that future analysis of the data might 
impact. In Chapter 4, talking with informants a Māori participant described one of a 
                                                        
205 Stats NZ IDI available at:  http://www.stats.govt.nz/browse_for_stats/snapshots-of-




few Kaitiaki206 groups that manage a research data set, deciding and guiding how 
others may access it. These Kaitiaki groups exist for a number of datasets (both 
from research and government services), the National Kaitiaki Group being the 
most well-known.207  This group governs Māori women’s cervical smear data, which 
is part of the national cervical screening registry in NZ (i.e. all cervical smear results 
are forwarded to the registry) ensuring that researcher’s use of this data is 
responsive to Māori and Māori women and does not impact them negatively.  It is 
more accurate to describe this kind of management as semi-open and whether this 
should be the model for all research data sets or only those affecting populations 
that face marginalisation is something to be considered. Data management and 
ownership is discussed further in 7.2.3. 
 
Respondents agreed in principle that both collaborative partnerships and 
stakeholder engagement were positive and necessary models of conducting 
research but did see that they were potentially, ethically challenging. A CA to health 
and health research would require more of this type of work, based on the need for 
direct input on the prioritisation of capabilities required for functioning (discussed 
further in 7.2). It would therefore, seem that researchers and ethics committees will 
require support to be able to undertake and review such practices appropriately. 
 
The next step was to move from ethics committees to the research environment 
itself. Does the research environment promote the inclusion of marginalised 
populations in research and marginalised populations’ research in general? I 
therefore, spoke to those working with marginalised populations, this again is a first 
in Aotearoa New Zealand (others have spoken to Māori academics as described in 
Chapter 4; Asmar et al.,2009; Mercier et al.,2011).  What is it like being a 
marginalised population researcher? What work gets done and why?  I used an 
institutional ethnographic method to explore this.  This feminist sociological 
method starts from the experiences of people in their everyday lives and uses these 
                                                        
206 “Kaitiaki” translated means guardian and while this traditionally may have been associated with 
the land in this context it means guardianship over the data collected. This serves to both ensure that 
future users use it with appropriate consideration to Māori, but also provides participants with 
peace-of-mind about their data and its future use. 




experiences as entry points, in combination with institutional texts, to understand 
the ruling relations in the given problematic (the health research environment in 
NZ) (Smith, 1987).  I found that these researchers and their populations suffered an 
injustice within a health research environment governed by neoliberal policies and 
a biomedical bias: the ruling relations.  These ruling relations were evident in the 
way different kinds of research was valued and supported.  This environment 
impacted on our informants through the way people thought about health problems 
and their solutions in NZ when making decisions about policies and services.  The 
environment also impacted on these researchers through the prioritisation of 
research, i.e. what was more advantageous within the system to conduct, given 
pressures for international recognition or economic benefit and continuous 
performance measurement requirements.  The researchers working with 
marginalised populations in this study are distinguishable from other health 
researchers by their ties to specific communities and populations; these ties often 
being personal. They utilised various methods but did so with an emphasis on small 
groups and with a perspective that recognised the social processes that created 
their populations’ disadvantage.  Their practice was at odds with what the ruling 
relations valued regarding answers and ways at arriving at them. I explained this 
was an epistemic injustice. 
 
An epistemic injustice, as theorised by Miranda Fricker, is one where a dominant 
group denies members of another group the status of knowers and dismisses their 
knowledge.  The definition of “knower” is someone who possesses both rational 
authority and credibility.  This work is the first to make a connection between the 
health research environment and researchers working with marginalised 
populations positing that the health research environment in NZ creates an 
epistemic injustice for these researchers.  I argued that the system denies these 
researchers working with marginalised populations both rational authority and 
credibility within exercises that evaluate research and evidence.  These researchers 
are denied the definition of “knower” by the system because they are upfront about 
their perspective (one of empowering their disadvantage community) when 
undertaking research and their commitment to a particular group. The system sees 
this avowal by these researchers as a bias that undermines their knowledge because 
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this knowledge creation lacks objectivity and generalisability.  The biomedical and 
evidence environment is one that privileges objectivity and generalisability.   
 
I then argued that the concept of objectivity prized within the health research and 
decision-making environment was first, a conflation between the objectivity of 
values and objectivity within the scientific method for those within the dominant 
paradigm; and secondly, was a misunderstanding of objectivity’s relationship to 
ensuring fairness.  I explained these problems of objectivity by showing that there 
are a variety of values always present within research.  Regardless of these values, 
however, what was important was an internal objectivity208 within the method 
regarding standards of rigour when determining the significance of a piece of 
information.  Points of interest, outcome measures and the like are always chosen 
within a particular normative framework.  Removing bias within a study for the 
purposes of generating robust information (or evidence) was not in the selection of 
a measurement, but in measuring the world against that dimension, if the original 
selection of measures was clearly explained within a normative framework (making 
it clear what the biases are). Therefore, to address the problem does not require a 
privileging of one epistemology over another but recognition of the kinds of 
information multiple epistemologies provide, along with attention to 
methodological rigour within individual research projects, and explicit statements 
of perspectives in the assessment of knowledge and evidence.  
 
I argue that the best position in decision-making is one where one has this diversity 
of evidence from different methodologies and normative viewpoints. This diversity 
only occurs in a pluralistic epistemological environment.  However, to ensure the 
marginalised are considered appropriately in a pluralistic epistemological 
environment, a theory of justice that robustly underpins this environment is 
necessary. This theory of justice must privilege the perspectives of those with the 
least power.  
 
                                                        
208 Of course, objectivity makes little sense at all within some qualitative methodologies, but even 
within these methodologies, reference is made to rigour, and subjectivity within a project either has 
to be clearly explained separately or as part of the analysis. 
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To that end, the Capabilities Approach (CA) is explained and suggested as the 
appropriate framework for justice in the health research and health decision-
making environment. The CA is rarely discussed in the NZ setting. While NZ 
geographers and community activists have explored the CA as a way to make sense 
of well-being in policy discussions or consider post-neoliberal models of society 
(Larner & Craig, 2005; Fleuret & Atkinson, 2007) little else exists that directly 
applies CA to health in the NZ setting.  The CA is an evaluative framework of justice 
that aims to equalise capabilities as means of achieving functionings one values and 
has reason to value (Alkire, 2005; Sen, 1992).  These capabilities and functionings 
are prioritised through public discourse but focus on those populations where a gap 
in capabilities exists. I explained Sen’s CA, and its key elements for this argument – 
person-centeredness, intrinsic goods (rather than instrumental goods) and public 
deliberation (for capability definitions and priority setting) before arguing why 
Sen’s approach was the most suited to creating our pluralistic epistemological 
environment and ensuring an appropriate focus on health inequity.  
7.2. Where to with the next? 
7.2.1. Research activity – prioritisation and representation 
Our systems for ranking and evaluating research require review. The lack of 
representation found in Chapter 2 is a direct result of the systems described in 
Chapter 4. These systems create both demand and supply issues.   
The demand issue arises in a system that privileges work that does not include or 
seek to improve the lives of marginalised populations. This privileging means that 
the kinds of research done by people like the informants in Chapter 4 are less 
“desirable” within the existing research systems.  This desirability is in part based 
on the outcomes not being “valuable” and in part based on the perception that 
problems they address are not “significant” enough (where significance is either 
international acclaim or economic outcomes).    
The supply issue is in part created by the demand issue (i.e. fewer people seek to do 
work for which there is less demand) but is also created through the current 
funding and research support mechanisms failing to fund and support the work in 
these areas adequately.  General clinical trials lack representation because within 
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the timelines and funding available it is more realistic to pick the easiest population 
to recruit rather than the most relevant (which might require outreach activities, 
more time, more research locations, and so on). Specific research for these 
communities currently is often of a methodological type that is judged to cost less 
and therefore research funders rarely fund work that may be expensive in this area 
without extensive justification.209 The structures and mechanisms that review and 
support research activity rarely recognise other forms of undertaking research that 
include co-production or iterative processes.210 This lack of recognition means work 
done for marginalised groups is either done within a narrow field of “what will a 
research funder fund” or is done outside of the research system and with little 
recognition of the work.  
This interrelated demand and supply issue requires concerted efforts and strategies 
to counteract it.  General promotion of inclusion will not fix these problems. I say 
this based on the evidence of current inclusion of Māori, despite the degree of 
discourse that occurs about Māori as the Tangata Whenua, to whom we have special 
obligations based on the Treaty. Universities and the health system include cultural 
workshops or cultural competence training, there is the stipulation in research to 
consult with Māori, there is specific funding for Māori, and yet a lack of 
representation was still found (Chapter 2). Further work is required to understand 
the best way to use a CA to appropriately modify the research environment to foster 
greater recognition of marginalised groups in relevant research and promote more 
research for these groups to address health inequity. Factors in the research 
environment that require considerations are:  
1) The Performance-Based Research Fund (PBRF) 
2) Health Research Council funding  
3) Tertiary Education Infrastructure and Support  
4) Ethics Committee review (discussed in 7.2.4. below)  
                                                        
209 Unlike justifications for other expensive research that can generally convince a reviewer of the 
need for an expensive laboratory or piece of equipment, researchers working with marginalised 
groups generally have to convince reviewers to fund more time and travel, which reviewers with 
limited experiences of working with marginalised populations can easily dismiss or reduce (i.e. it can 
be done with less visits or trips, etc., where as they rarely edit a budget for equipment – recommend 
different/cheaper equipment for example). 
210 University and ethics systems struggle to deal with projects of this kind for funding, ethics 




7.2.1.1. The Performance-Based Research Fund (PBRF) 
I explained in Chapter 4, as with other international research performance 
measuring exercises, the PBRF aims to assess research quality and impact based on 
the submission of individual researcher portfolios within departments at 
universities and polytechnics. These portfolios211 are then used along with research 
degree completions (i.e. Masters and PhDs) to distribute money to universities and 
polytechnics based on their research performance.  Some have argued that these 
kinds of exercises (along with funding mechanisms) create the “publish or perish” 
culture, which fosters stress and pressures, that lead to less than ideal research 
practices (Ashcroft, 2006; Fanelli, 2010; Gendron, 2008; Herndon, 2016; Ivancheva, 
2015; Lund, 2012; S. Wright et al., 2015).  Again, what a metric focuses on drives 
behaviours. If we, therefore, want to change behaviours we have to improve our 
metrics or what they mean.212 More radically, we could abolish the system of 
measurement altogether, if one reads blogs or Twitter this discussion is happening 
almost constantly between academics and has led to research largely on the adverse 
effects of measurement exercises such as PBRF mentioned in Chapter 4 (Ashcroft, 
2006; Ivancheva, 2015; Reay, 2004; Waitere, Wright, Tremaine, Brown, & Pausé, 
2011; Waitere et al., 2011).213  
 
What is especially interesting with the PBRF is that its goals are broader than 
unidimensional publication impact. If one looks back at the Working Party Report 
from 2002 published just before the first measurement exercise occurred in 2003 in 
NZ, it clearly states that impact should be broader than publication. The purpose of 
the fund goes beyond ensuring quality in research in the simplest terms to also 
recognise the support of students into research, and broader dissemination of work 
beyond academia, including references to diversity and community (TEC, 2002). 
One is asked to include a lot more in a portfolio than just publications and their 
citations. The metrics created for portfolio evaluation, however, mainly focus on 
                                                        
211 Individual researcher scores are private, departments receive a public ranking. Researchers 
receive their scores, as well as various layers of management within the institution.  
212 Recognising of course that a metric is only ever an indicator of behaviour and that people can 
“cheat” the system, and for some it will not affect their behaviours at all. 
213 The London School of Economics has a number of blogposts relating to research impact and 
performance measurement for example. 
221 
 
outputs, funding and academic reputation (measured in multiple ways), but these 
latter two are somewhat dependent on outputs (TEC, 2013).214 An interesting 
exercise beyond the scope of this project would be to assess portfolios elements 
separately to determine whether publications are a stronger indicator of 
performance than funding and academic reputation (i.e. would people score higher 
based on one element over another, or are they generally even across all three 
domains) . It would also be interesting to compare the content of curricular 
documents from different institutions considering staff PBRF scores, i.e. does the 
PBRF actually ensure that teaching is research-led (as stated in its goals). Both of 
these projects would be difficult to gain ethical approval for (given the private 
status of individual scores) and neither solves the problem of measuring impact and 
quality, but they would provide a better understanding of the current system and 
whether it is meeting its goals. 
 
For health inequity specifically, recognition of community impact of research 
applications would be useful.  Recognition of community impact is worthwhile 
beyond the health sphere, in helping communities and institutions come together. 
While universities should be aiming for impact on the global stage, they should also 
be trying to make a direct local impact.215 A measurement of this is likely to be 
difficult, proven through narratives rather than numbers in some cases; although as 
discussed in Chapter 6 patient and community specified outcomes could be 
developed. As I tried to argue in Chapters 5 and 6, picking something to value 
because it is the easiest to measure, does not necessarily provide the best outcomes. 
Measuring something purely in a narrative form may not be useful, but the 
combination of quantitative/standard metrics and other non-traditional signs of 




                                                        
214 That is  you do not get invited to speak at conferences if you are not widely published, you fail to 
attract funding if you have not published in the area your seeking funding for, etc. 
215 Later revisions of PBRF for the 2018 evaluation have introduced a recognition of broader impact, 
but it remains to be seen, how this will score in relation to other more traditional forms of 
impact.(TEC, 2016)  
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7.2.1.2. Health Research Council Funding 
The Health Research Council of New Zealand as New Zealand’s primary health 
research funder must do more to address health inequity.216  While funding of 
career awards for Māori and Pasifika were vital and necessary, as well as the 
funding of Hui Whakapiripiri (Annual Conference), some other processes require 
review.  
For example, I raised in Chapter 3 and 4, that sections in applications that require 
applicants to address their project’s “responsiveness to Māori” are often seen to be 
completed perfunctorily or in a tokenistic fashion. The research community and 
funders (especially HRC) need to have further discussion about what are valuable 
indicators of genuine engagement and consideration217 and how reviewers should 
deal with applications that do not meet these indicators.  The development of a 
more suitable scoring framework within applications and with weightings that 
reflect the importance of different elements is needed.  A scoring framework would 
require some research to ensure metrics measured desired behaviours (one issue, 
of course, being that forms only ever provide a proxy of the engagement rather than 
the knowledge of the relationships itself) and testing of weightings to ensure the 
sought outcomes. 
Similarly, the HRC must either revise the definition of the current Health 
Significance score that grants receive based on their impact on the health of New 
Zealanders or add a further score for health inequity. Currently, applications can 
score highly across all other domains, but due to addressing the needs of a small 
population receive a very low health significance score and therefore not get 
funded.  If revision is not possible, a second score reflecting health inequity is 
required to balance out when a grant addresses significant issues for small but 
marginalised populations. This health inequity score would have to be 
appropriately weighted against health significance to achieve the desired 
                                                        
216 I made reference to the Haldane principles in early chapters, which as a simple translation is one 
of academic freedom. It could be argued, that a move to focus on inequity is inhibiting to academic 
freedom. I of course, disagree; I think this would be no different than the current limits on academic 
freedom within a resource-constrained environment.  
217 I would suspect that these are known by senior Māori reviewers already, but their current ability 
to critique or score poor responses is limited.  
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outcome.218 Again, any revisions to include an appropriate response to health 
inequity would require some work to investigate appropriate metrics and 
weightings. 




1) Health and Well-being 
2) Improving Outcomes for Acute and Chronic Conditions In New 
Zealand 
20% 3) Health Service Delivery 
10% 4) Rangahau Hauora Māori 
 
Anecdotally, there is discussion at HRC workshops that streams 3) and 4) are 
constantly undersubscribed, and yet arguably this is where a lot of the work 
regarding health inequity could be improved.  Matters of health inequity are often, 
but not always, matters of service access and delivery, rather than the biomedical 
aspects of the intervention (although this can also be the case) (Devaux, 2013; Hill 
et al., 2013; Mladovsky & Bâ, 2016; O’Connor, 2011; The uneven playing field: ethnic 
inequalities in cancer outcomes in NZ, Sarfati, 2013). It would, therefore, seem that a 
greater balance across these funds could be called for (with an explicit statement 
regarding inequity) or it may be more useful to disregard these existing categories 
and begin again.  
Categories such as Exploratory, Descriptive, and Interventional220 could be argued 
for as more useful, as long as the scoring of applications in each took appropriate 
account of responsiveness to Māori and health inequity. Alternatively, these three 
categories plus the current 4) Rangahau Haora Māori could be maintained, but 4) 
could be modified slightly to only fund Māori-led research as a natural progression 
                                                        
218 It would be useful to explore whether a separate score would create more representation both 
within and across studies, which I suspect might be the case rather than just changing the criteria for 
health significance (i.e. from great impact on health of New Zealanders, to equity improving or large 
impact).  
219 This information is in the general guidelines for 2016/2017, available from: 
http://www.hrc.govt.nz/news-and-publications/publications/investment-signals  
220 This is by no means a final list, Evaluative for example could also be included, but this would be 
decided in consultation. 
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from the career awards for further development. These changes to funding 
mechanisms require some thought and modelling and require rigorous consultation 
with stakeholders (where consultation membership favours those stakeholders 
who represent the interests of those who suffer inequity). 
Funding panels must become more diverse both regarding methodological 
expertise221, but also regarding the interests they represent. Our current primary 
funding mechanism in New Zealand does not address health inequity appropriately. 
If we were to change to a CA framework then, capability deficits would be apparent, 
and funding mechanisms would have to concentrate on these.  An emphasis on 
capability deficits would require changes to both the weightings funders give to 
various factors when reviewing a grant and the way they divide the money between 
areas of importance. 
 
Lastly as mentioned in Chapter 6, a CA framework would require input from public 
and marginalised groups in research. As I suggested, models such as the PCORI, the 
James Lind Alliance or the NIHR show that public involvement in decision-making is 
not only possible but beneficial.  It would seem that the Health Research Council of 
New Zealand would be the obvious place from which to organise or support these 
activities given its status as New Zealand’s main health research funder.  
Alternatively, the Ministry of Health may be better suited and could use such an 
infrastructure for questions beyond health research, in deciding other priorities in 
service planning or policy activities. 
7.2.1.3. Tertiary Education Infrastructure and Support 
As we saw in Chapter 4, tertiary institutions provide little in the way of support for 
community outreach and fail to recognise activities by their staff that do this despite 
the lack of support.  A CA framework could be used to make tertiary institutions 
directly show their influence and impact on the capabilities of communities locally, 
nationally and globally. We should not dismiss international acclaim for research, 
but we must balance this acclaim with other impact if we want to address health 
inequity. Some Polytechnics are better at this than universities, because of their 
                                                        
221 Fieldnotes from a HRC funding workshops with input from a previous panel member, discussed 
one panel as having four biostatisticians and one qualitative researcher for example. A diversity of 
experts, including those who undertake economic analyses, etc. would seem more appropriate. 
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previous applied focus rather than research focus. It requires the building of 
relationships with communities, discussing need, and attempting to address it.222 
This relationship building with communities prior to any specific projects would 
make the practice of research with marginalised groups potentially less challenging. 
Relationship building requires funding prioritisation within the institutions, and for 
that to be successful, again more work is needed to understand what kind of models 
and systems might be useful.223 
7.2.2. Research practice – What questions? What answers? 
I argued in Chapter 5 that a pluralistic epistemological environment was necessary 
as we require various information from diverse perspectives to ensure appropriate 
consideration of those who have the least capabilities. It is still necessary to 
understand purely physiological processes such as mechanotransduction224 for 
example, which requires lab-based methods and little in the way of consultation and 
outreach.  Nevertheless, at the same time, if I were wanting to trial an intervention 
for balance (the processes of balance being ones that involve 
mechanotransduction), then I need to talk to people who suffer the particular 
balance problem to design a responsive intervention before beginning my work and 
throughout it. Designing and testing of the intervention will require a variety of 
methodologies to provide the information necessary to know that it works, how it 
works, and that it works for people in the real world. Every single researcher cannot 
be an expert in a variety of methodologies, and so the multidisciplinary team 
approach is an obvious one (and one already promoted to some extent).   
 
Part of this “talking to people” is ensuring appropriate consideration, choice of 
questions and metrics and so forth, which can only happen if there is real 
representational participation in decision-making (as argued in Chapter 6). 
Designing infrastructure within universities that supported participatory decision-
                                                        
222 See for example: Otago Polytechnic http://www.op.ac.nz/about-us/governance-and-
management/our-partnerships/ or Unitec http://www.unitec.ac.nz/about-us/our-
partnerships/community  
223 New Zealand can learn from international examples of these and adapt. It must be said of course, 
that various institutions have varying relationships with their local iwi and marae (meetinghouse) 
and so some community relationships exist. They also exist sometimes through student placement 
programmes in the community in health programmes, but these need to be strengthened and 
supported in the same way that innovation is currently supported.  
224 Process by which cells transfer mechanical stimulation into a biochemical response. 
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making at the macro- and micro-levels225 would be helpful.  This infrastructure 
could then support researcher relationship-building with communities, as currently 
exists for commercial and innovation activities.   
 
Importantly, we also need to consider a different way of supporting research in 
various forms as informing evidence-based medicine and decision-making. Of 
course, these discussions are already happening and have been for some time along 
with the critiques of EBM discussed in Chapter 5.  Calls for science-based medicine 
(broadening the base), as well as the development by GRADE of an evaluative 
approach for qualitative research and Cochrane’s inclusion of qualitative method 
tools,  are positive examples of moves towards a different way of recognising 
valuable information.   
 
There is discussion now in policy circles226 of “post-normal” science (Funtowicz & 
Ravetz, 1993) and the need to incorporate different kinds of methods and 
information into decision-making. However, my experience of these discussions to 
date have shown them to be still relatively STEM-focused (as the “hard sciences”), 
and when people do mention social sciences (as the “soft sciences”), they only refer 
to them when discussing big data (so the work is still quantitative).  These 
discussions focus on the difference in the types of questions now posed that need 
answers and on multidisciplinary teams and scientists as “knowledge brokers”, 
where these are defined as experts who present the evidence available objectively 
(Gluckman, 2016).  Where these developments may lead is not yet clear, but it 
would seem that they are likely to continue as is without a powerful impetus to 
focus on health inequity.  
 
In a tight funding environment, in a small country where minority populations live 
spread across a vast geographical area, it would make sense for institutions to 
                                                        
225 This distinction is between individual project level and programme or research strategy level. 
226 Peter Gluckman (Chief Scientific Advisor) travelled the country in 2016 discussing this “Post-
normal” science at universities, which contrasts to the first meeting of Global Science Advice in 
Policy, which I attended in 2014 and was STEM based and the meeting itself completely lacked 
diversity (which was questioned in the sessions and tweeted about), so there is some progress. 
However it was also clearly stated that in this new era knowledge brokers (objective presenters of 




collaborate more.  The current systems, again, do not support this collaboration, 
fostering competition instead. Further work, to discover better ways of ensuring 
research excellence without creating an environment that undermines useful 
practices, is needed. 
7.2.3. Data  
I mentioned in Chapter 3 and Chapter 4, the literature references to big data and 
health inequity.  These come in two forms.  Firstly, data already existent in systems 
if it were to be combined, could provide answers to questions, for which there has 
been no funding or no practical way of collecting data in the past (Bollier & 
Firestone, 2010; Lohr, 2012; Raghupathi & Raghupathi, 2014).  Where this may fall 
short, as also mentioned in Chapter 5, is the service utilisation of marginalised 
communities, i.e. if they use services less, records about them will only provide an 
incomplete picture.  In addition, even where service utilisation data might provide 
some information, if data classification is poor and inaccurate, then this information 
source is likely to be more harmful than useful.  In using this data, we come across 
the problem of questions asked and measures used.  If those using the data only 
consider marginalised groups within the larger questions investigated in the data, 
then answers are unlikely to apply.  There is a risk of the marginalised becoming 
invisible within big data as they currently do in the research and decision-making 
setting. The Kaitiaki groups mentioned earlier would seem to be a well-functioning 
model for Māori data.  How do we consider this for other groups? Any solution will 
need to provide two things: 1) a means of ensuring that the way data is combined 
and analysed considers those who suffer the most disadvantage first and foremost, 
and 2) conveys to research participants or service users that information they have 
provided is being used by researchers in their best interests.  
Secondly, the call from Ben Goldacre for the collection of new research data at the 
point of care which (Goldacre, 2012) also existed in the literature beforehand in 
slightly different forms such as evidence-farming (Hay et al., 2008), again comes 
down to service utilisation.  Collecting data at the point of care means people could 
do research in the clinical setting for such things as comparative trials (testing 
effectiveness where evidence exist for efficacy). Goldacre suggested this for 
pharmaceutical research, but there is here also the opportunity to create 
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deconstructed RCTs, i.e. a collection of n=1 like trials based on a set protocol and 
with specified outcome measures collected across national clinics, where patients 
meet criteria for the trial.  The trial protocol would need to be some form of AB trial 
design (i.e. ABA, or ABAB)227 to ensure treatment efficacy in the patient, while also 
providing data to be collated with other single-patient data sets.   There are 
advantages to this, insofar as that while service utilisation for marginalised groups 
is lower than majority groups, it is higher than trial participation. Therefore, this 
data use would at least provide more information than currently available. It allows 
for a much more externally valid form of data collection: standard point of care.  
Moreover, one could conceivably add adjunct research to collect other data using 
other methods (such as qualitative methods) to assess differences in responders 
and non-responders. 
Disadvantages include the possibility of greater distrust in the health services based 
on the breaking down of the separation between therapy and research.  This 
separation was created based on past transgressions of clinicians experimenting on 
patients without their knowledge. Clinician transgression is a particularly poignant 
topic in New Zealand where Dr Green conducted research using women with 
abnormal cervical smears without their knowledge (Manning, 2009). Some of these 
women died, and it would be fair to say it was not immediately recognised or 
addressed by the medical establishment of the time.  Green’s actions and the 
establishment’s response led to the Cartwright Inquiry in NZ.  It is from this inquiry 
that the government established NZ’s ethical review system and in so doing made 
clear that research required ethical approval and patient informed consent.   In 
tying research closer to clinical practice, two things would be necessary: a) ethical 
approval of trial protocols for clinical practice; and b) some form of public 
consciousness raising to avoid the fear of being ‘experimented’on.  This latter needs 
efforts to educate the public that much trial and error already occurs in medical 
practice, in finding the right intervention for the right person (i.e. consider current 
                                                        
227 A or B designate receiving the treatment or not receiving the treatment. Typical N=1 trials, have a 
period of taking measures prior to intervention/ during intervention, or during intervention/after 
interventions. Depending on the type of illness or intervention, one can explore more robust testing 
methods, for example where the intervention is trialled (A), removed (B), and trialled again (A) to 




polypharmacy, self-management interventions for smoking, diabetes, or mental 
health issues). This type of research would only introduce a process to formalise 
that regular course of action and by doing so make it rigorous, ensuring the right 
information is used to make decisions. 
Open data is a movement asking for researchers to share their results openly as 
soon as they are available.  The argument here is that often this data is publicly 
funded and so should be publicly shared. Sharing of data improves transparency, 
reduces research fraud, and should reduce waste by allowing people to use different 
datasets for questions they have without having first to collect the same data, 
someone else has already collected (Doshi, Groves, & Loder, 2014; Gurstein, 2011; 
Molloy, 2011; Saito & Gill, 2014). It also means that decision-makers can use all 
relevant information in their deliberations, rather than all information published in 
a journal.  
Objections to this do exist.  Those researchers who work in resource-limited 
funding environments worry that if they are made to make their data accessible 
after collection and primary analysis that someone in a higher resource setting may 
trump them on future secondary analyses.  They see data ownership solely in 
regards to their rights, i.e. it is their intellectual property and labour. They own that 
data. I think this is, in part, is a sign of the environment in which they conduct 
research and the measures by which we review performance. Changes to what 
counts as having an impact (i.e. substantially used datasets versus widely cited 
publications) and how a researcher’s reputation is built, directly thwart the idea of 
the researcher as “seeker of truth”.  If collaboration and discovery were more 
lauded rather than individual status, then this could balance these instincts and 
objections somewhat. In many fields, it is also the case that it is somewhat archaic to 
discuss research as if it was the result of one person’s thinking, even though we 
refer to it in that kind of way.  After all, for the basic sciences, there are often huge 
research teams, in social sciences, this can also be the case. Researchers in academia 
also have to remember that all of their time is publicly funded.228  Issues of data 
                                                        
228 As is noted in the Appendices related to Chapter 2, I have made the unanalysed datasets from my 
research available to all.  The information shared was already publicly available, but in a 
cumbersome fashion, through sharing the collated information in a usable format, this work may 
help someone else in future. 
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analysis such as those raised above for big data, could similarly be managed with 
Kaitiaki groups or the like. Participants would need to be made aware of what 
taking part in a trial means in terms of the data collected and its future use. Making 
sure these various mechanisms are sufficient and participants are appropriately 
informed requires oversight. 
7.2.4. Ethics Committees 
An obvious question here would be “What is the role of the ethics committee?”, and 
others have debated this (Holm, 2016; Moore & Donnelly, 2015; Schaefer, 2016).  
Their discussion focused on whether the role of committees was “code-consistent 
review” that involved no ethical deliberation (i.e. rule-following)(Moore & Donnelly, 
2015), a denial of this view suggesting their role is ethical deliberation (Holm, 
2016), or the hybrid – their role is ethical deliberation in applying the rules 
(Schaefer, 2016). I am inclined to agree with Holm and Schaefer that more occurs 
than basic code-consistent review. However, I do not think that this is what the 
issue is here, based on the findings in Chapter 3.   
 
In my view, the question is one of ethical authority.  It is not whether committees 
take part in ethical deliberation or code-consistent review, but the fact that the 
current tasks of ethics committees are both ethical consideration of standards in 
relation to codes and code-consistent review, at the one point of review. To state 
this more clearly: ethics committees are tasked with both setting and maintaining 
standards of ethical practice and enforcing those standards at the one point of 
reviewing an application. Each committee when it decides whether a certain 
practice sufficiently meets their conception of informed consent as prescribed in the 
guidelines, for example, is deciding a standard, but they are each doing this 
independently. This one-point of contact229 for both standard setting and reviewing 
seems wrong to me.  
 
Incorporating ethical practice into a project happens at the design phase, not at the 
application stage. If the role of committees is to approve a piece of work that meets 
                                                        
229 One could argue that standards are set over multiple reviews, i.e. that most researchers will apply 
for ethics more than once and share their experience with other researchers, so that standards are 
spread through an academic “osmosis” type phenomenon.  
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the agreed standards (which requires more than a code-consistent review), then we 
need some other body that first sets those standards, provides other information on 
what meets those standards and promotes them. Considering work in Chapter 3, 
what is just research practice, what are the key elements and how should 
committees assess it? Who is promoting what the standards of just research 
practice are?230 The promotion of justice as a fundamental principle in research is 
not at all evident.   Generic guidelines exist and are available. They underpin all 
committee guidelines. However, what I think is needed is ongoing support material 
regarding topics, such as “things to consider when managing consent in context ‘x’”, 
or “ethical recruitment in the clinic setting”, for example. The body that oversaw 
this would also have to have some authority with institutions so that they could 
easily disseminate and encourage the use of material. These resources would then 
also be available to ethics committees. In NZ, the obvious choices for this would 
either be the National Ethics Advisory Committee, the Health Research Council 
Ethics Committee or the Royal Society of New Zealand (in recognition that more 
research occurs than just health research). The former is preferable as any work in 
this area should cover more than accredited committees231. This body could then set 
and disseminate the standards for “justice” or innovative research practices such as 
photovoice methodologies232, or working with the learning disabled (based on 
consultation).  
 
This norm or standard setting should not sit with individual ethics committees (i.e. 
it would then be disparate between committees).  Currently, it does with each 
committee making these decisions in their review practices (and precedent setting). 
What informs these norms and standards are usually academics publishing papers 
of an ethical practice or conundrum. Committees use these and their knowledge of 
legislation or research experience to make decisions. For example, committees 
assessing big data practices might consider legislation and international research 
                                                        
230 If these were set, then funding bodies and institutions would have to take note of them. 
231 NEAC does create advisory documents occasionally across a broader domain then just health 
research. And the Health Research Council was directly responsible for the creation of Te Ara Tika 
for Māori research. The idea here is for something more active. 
232 Photovoice methodologies are those that use participants taking photos and discussing those 
images as research data.  These kind of projects are often ethically fraught in relation to the various 
consents that might be needed in taking and using, and sharing images.  
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literature. This use of information in decision-making is by no means systematic or 
comprehensive. Ethics Committees in NZ do not meet each other regularly 233 other 
than when Chairs or members attend conferences or the like, so dissemination and 
standard setting between committees occurs sporadically. 
 
There is a here a gap that requires filling beyond the ethics committee itself in 
setting standards, promoting them, providing training and ensuring committees and 
research organisations meet them. This task again needs funding support for the 
body tasked with doing this work.234  
 
7.3. The Good and the Bad 
The three studies completed within this thesis and the theoretical argument made 
are limited but novel with the NZ environment.    
The survey of representation in research activity in public records while being the 
first of its kind in New Zealand was restricted insofar as the sources themselves 
were limited.  I wrote about this in 2013 when conducting the review (Tumilty, 
2013) suggesting that a national database of research activity would be useful not 
only for purposes such as my own, but more generally for researchers, clinicians, 
government policy-makers, and the general public.  The records used had errors, 
were incomplete, provided limited information and did not exist in a way that 
searching or analysis was easily possible.  This lack of information means that NZ 
decision-makers in various situations (research or the health system), can quantify 
activity in its simplest forms (numbers of applications, numbers of grants and 
dollars spent, types of grants) but cannot analyse it meaningfully to plan activities 
and fill strategic gaps. My work here shows that in research activity representation 
was extremely poor (less than 5% combined) between 2006-2013, for three groups, 
one of whom are Tangata Whenua. It also shows that inclusion of research related 
to these three groups in a selection of clinical guidelines (for diseases of 
importance) and in health technology assessments/decision-making documents 
that were publically available (PHARMAC and National Health Committee) was also 
                                                        
233 HDECs Chairs communicate and individual Chairs may informally communicate with each other, 
but no formalised mechanism of ethics committee communication exists. 
234 It should be noted, that if this were the case, then this would move committees further to either 
Schaefer’s conception of them or Moore’s and away from Holm’s. 
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extremely poor. Others have done a more detailed analysis of one related aspect of 
this part of the work – Jull and colleagues went through ethics records and analysed 
how many were registered with a clinical trial registry (Currie & Jull, 2012; Jull et 
al., 2005). Heather Came reviewed public health documentation between 2009 and 
2011 for inclusion of Māori scholarship (Came, 2012, 2014), which my work here 
has extended, finding a similar lack of inclusion. Other groups have sought evidence 
of representation within specific countries or conditions (Berger et al., 2009; 
Graham, 1992; Heiat et al., 2002; Sharpe, 2002; Symonds et al., 2012).  
My work is the first of its kind to seek representation in NZ across multiple sources 
about the representation of marginalised groups and sets a baseline for future 
inquiries. With greater time, funding and technological skill, a cross comparison of 
sources to create a “master list” of research activity that pulled data from websites 
for ongoing updates would be possible in a format that could be shared online for 
open use by anyone. The creation of this resource was not possible within the 
parameters of this study. However, it was important for me as researcher who 
believes in an open scholarly community to share my data and so raw data related 
to Chapter 2 is available on figshare235 (address links are included in the relevant 
sections of the Appendices).  
The survey of ethics committees did not reach an adequate response rate and focus 
groups would have been more productive, especially given participant feedback.  
The survey was also too long and should have remained focused on the questions 
related only to justice. There is relatively little research work done with ethics 
committees in New Zealand.  As referred to earlier, Gillett has commented on the 
reforms of 2012 (Gillett & Douglass, 2012) and some commentaries exist regarding 
these reforms.  Moore has commented on the role of committees as discussed above, 
but not in the particular NZ context (Moore & Donnelly, 2015). Pieper and Thomson 
from Australia have written theoretically on justice in ethics review in the 
Australian context of the National Statement (Pieper & Thomson, 2013). Others 
have questioned specific practices of NZ ethics committee about children and youth 
(Allen, 2009; Powell & Smith, 2006), and ethical review and methods have been 
                                                        
235 www.figshare.com is an open repository for the sharing of research artefacts, whether it is data, 
reports, figures, etc.w 
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described for Māori by Māori (Hudson, 2004, 2009; Hudson & Russell, 2009; 
Hudson, Milne, Reynolds, Russell, & Smith, 2010) 
By far the most work done on the New Zealand ethics environment has been 
undertaken by Tolich; and more recently Tolich and Smith, both Chairs of HDEC 
committees pre-2012 and still very prominent in the ethics review space in New 
Zealand (Tolich & Smith, 2015).  Aside from this book, Tolich has in collaboration 
with other authors written numerous papers on specific elements of ethics review 
in NZ (Gremillion, Tolich, & Bathurst, 2015; Tolich et al., 2016; Tolich, 2002, 2015; 
Tolich & Fitzgerald, 2006). He has also written with other committee members 
about an unorthodox committee he founded to fill an ethics gap post the 2012 ethic 
committee reforms (Flanagan & Tumilty, 2015; Marlowe & Tolich, 2015; Tolich & 
Marlowe, 2016).  None of this work has addressed justice in ethics review 
specifically. 
My work here was the first attempt in the NZ context to consider ethics committee 
review of justice. It was obviously limited in what it provides in relation to the 
thesis due to the low response rate, but what it does do, is provide valuable 
information to researchers in how to approach committees for their views in future.  
I also think it provides motivation to explore: 
a) The practice of ethical review in New Zealand. What are ethics committee 
assessing exactly? Is it purely risk assessment, as was suggested? I would 
think not, but this requires investigation. 
b) Big Data Ethics – what do we need to do, whose responsibility should it be, 
what is currently happening, who “owns” data, and so forth?  Big data 
activity is rising, and ethics committees require support and information to 
deal with this.  
c) Research regarding the relationship between information provided in 
applications and desired behaviours, i.e. whether applications are the best 
indicator of desired practice. If not, what novel forms of ethics review could 
we institute instead? There are those who think that ethics review requires a 
total reform, thinking about it in new and dynamic ways (van den Hoonaard 
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& Hamilton, 2016). To do this well more information and discussion is 
required. 
d) The relationship between committee membership, committee guidelines and 
review outcomes. Some work in this area has been done236, but not 
extensively and not in the New Zealand context.  
 
An institutional ethnographic method is a rare tool in NZ – Ellen Pence, would be its 
most prominent advocate here (Pence 2001; Edleson 2010).237  It is the only piece 
of work speaking to researchers working with people who suffer health inequities 
in New Zealand. Work in the UK has included researchers and advocates and their 
views regarding health inequalities research (Smith & Garthwaite, 2015).  There are 
projects (referenced throughout this thesis) on people’s perspectives of the PBRF or 
Māori research practice, but my work here is original in that it examines a group of 
researchers and their experiences within the research system and specifically those 
working with marginalised populations. As this thesis was nearing submission, 
work from the assessment of the UK’s Research Evaluation Framework (REF), 
similar to NZ’s PBRF, was published and also drew conclusions regarding the 
discrimination of women, ethnic minorities, and people with declared disabilities 
within the process, as well as the focus on marketisation (some positives were also 
noted)(Stern, 2016). What this work adds to these kinds of findings, is that not only 
are marginalised researchers disadvantaged, but researchers working with 
marginalised populations are, too.  And in fact, that researchers working with 
marginalised populations are often themselves those marginalised researchers in 
the first place. There is here a compounding of their discrimination in the system.  
 
Further work, would seek to talk to junior academics in this area and understand 
how they experience the research system. Also, it would be interesting to speak to 
those who started in this area and did not continue, although their recruitment 
would likely be very challenging.  
 
                                                        
236 For example see: (Dal-Ré, Espada, & Ortega, 1999; Savulescu, Chalmers, & Blunt, 1996; Stark, 
2012) 
237 Pence is known for immensely valuable work in domestic abuse and violence against women and 
children.  She has sadly passed away. 
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The theoretical thinking in this thesis sought to connect epistemology and justice 
more explicitly. While every first year philosophy student can recite “no is from an 
ought”, fewer are aware of Putnam’s work on fact/value entanglement 
(incorporating Sen’s early economics) (Putnam, 2002) and feminist thought in 
Philosophy of Science (Harding, 2006; Harding, 1987, 1991; Hartsock, 1983; 
Haslanger & Haslanger, 2012; Smith, 1999).  These works provide valuable entry 
points to reform evidence-based medicine, which has long been criticised ( Buetow, 
2008; Buetow & Kenealy, 2000; Buetow et al., 2006; Cartwright, 2010, 2011, 2013; 
Greenhalgh, Howick, Maskrey, & for the Evidence Based Medicine Renaissance 
Group, 2014; Greenhalgh, 2012; Greenhalgh, Snow, Ryan, Rees, & Salisbury, 2015; 
Hay et al., 2008; Hunter, 1998; Kerridge, Carter, & Lipworth, 2008; Rogers, 2004b; 
Rogers & Ballantyne, 2009; Tonelli, 2006), but is still prominent, partly based on the 
idea that impartiality equals fairness.  I have proposed that embedding the CA that 
stresses intrinsic goods (rather than instrumental goods), person-centredness, and 
public participation may go some way to transforming knowledge generation 
exercises, by explicitly linking them to people and outcomes, changing the variety of 
questions that can be asked and answered. 
The work done here shows that if we use an evaluative framework (the CA) that 
makes explicit reference to its informational base, we can more clearly link values 
and facts and engage with them in public deliberation and discussion. This explicit 
linking of fact and value in the health system and health research space provides a 
new avenue for addressing inequities. The connection of the CA to evidence-
generation allows for explicit arguments for the connection with research 
populations at the beginning of research activities and throughout.  While public 
involvement in research decision-making happens in some places around the world, 
it is by no means standard practice globally or locally in NZ.  A CA would help to 
provide a voice to these populations in health research, and it is my feeling that the 
NZ government should also incorporate it at the service and policy level. Health 
research is not sufficient to address health inequity but it is necessary to address 




I sought to understand the representation of marginalised populations in research 
and the systems that use that research.  I found a lack of representation to be 
indicated and then set out to understand why.  This involved surveying ethics 
committees in NZ to find out how they consider justice in their reviews (defined as 
both representation and fair distribution of risks/benefits).  This survey, while not 
reaching a response rate to draw conclusions, provided interesting information for 
discussion. I then used an institutional ethnographic method to understand the 
research environment for researchers who work with marginalised populations to 
determine whether there were factors in the research environment that created this 
lack of representation.  I found that an epistemic injustice occurs for researchers 
working with marginalised populations, insofar as neoliberal health and educational 
policies, and a bias towards the biomedical in health research means that their work 
is rarely rated as evidence or as valuable.  
From here, I argued that the policy and service exercises of rating research as 
evidence, influence what work people in the research setting perceive as valuable. 
Our method for evaluating research as evidence was found to be lacking: it focusses 
too narrowly on efficacy, thus excluding other work that could provide useful 
information for decision-making. Our evaluative framework also fails to determine 
the quality of efficacy in relation to connections with real world settings. I then 
argued that this dominant epistemology restricts our ability to make ethical 
decisions, by limiting the information with which we make them.  
Based on this limitation, I introduced Sen’s CA as an evaluative framework that 
focuses on well-being and freedom in an important way.  I explained the CA with its 
focus on the capabilities people need to achieve functionings they value and have 
reason to value. By focusing on intrinsic rather than instrumental goods, 
incorporating public deliberation in determining capabilities, and actual 
achievement of well-being and freedoms, the CA requires a broader informational 
base. This informational base supports the pluralistic epistemological environment 
argued for in Chapter 5 and does so while involving public engagement.  
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Development of prioritisation tools, consultation/engagement infrastructure, 
evidence matrices238, as well a reform of ethical review and research evaluation are 
needed, but a CA framework in the health decision-making setting and the health 
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Appendix A: Health Research Funding data 
Health Research Council funding data is available on their website.  This list is not complete, 
as those investigators who do not wish to have their grants added to the website 
(embargoed) for commercial or sensitive reasons can choose to do so.  I am also aware of 
some grants that were not asked to be kept from the site, which were not in the list based 
on my previous professional roles in research administration. Therefore the data from this 
website is incomplete. However, it is suggested only marginally so. 
Methodology 
Annual reports’ (in PDF/Word format) include tables of applications.  I copied tables from 
documents and then converted them to Excel. These were then searched using multiple 
methods: 
1) Electronic search using “Find” option in Excel searching for terminology related to 
Māori (Māori, Māori, whenua, kaupapa, whanau, Whānau Ora,  nga*, whan*, 
whak*,*ori , tanga*), Pasifika (Pacific*, Pasifik*, Samoa*, Tonga*, Fiji*, Cook*, Niue*, 
Kiri*) and Learning Disability (intellectual, learning, Down*, Prada*, fetal*, 
disability) groups. These provided lists that were then scrutinised for those that 
pertained to our groups (i.e. some results with *ori or fetal* were not related our 
case groups, but these were then excluded).  A fourth group was created  that 
included those projects related to equity or that involved two of our groups or that 
included studies that relate to rheumatic fever which has been a particular health 
issue for Māori and Pasifika children and adults.  These terms included: equity, 
disparity, rheum*, equality, determinants.  This was completed by the primary 
investigator. 
2) Additionally, manual checking (i.e. checking in each item in the list) was completed 
by the primary investigator and an external checker (medically trained).  Filtering 
of titles was thrice-checked by the author on three separate occasions each multiple 
days apart, and by the external checker (medically trained). The principle of charity 
was used between checkers and searches, insofar as the largest list was taken as the 
final list. 
3) All titles that were an acronym rather than a title such as “SPRINT Trial” or that 
were considered ambiguous in the larger list were searched online to check the 
nature of the study before being included or excluded.  
A full dataset (without analysis) has been posted openly for future use by others in the 
spirit of collaboration and collegiality.  This data is available from www.figshare.com 
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Tumilty, Emma (2016): Health Research Council of New Zealand Funding 2006-
2013 (Open).xlsx. figshare. 
https://dx.doi.org/10.6084/m9.figshare.2062068.v2  
  Māori 
  Pasifika 
  Learning Disability 
  
Equity or Multiple case 
groups 
  
Year Title Investigator Organisation/Institution Amount ($) Duration 
(mnths) 
2009 Exploring whanau based 
strategies and communication 
employed to reduce violence 
Mere Balzer Te Runanga o Kirikiriroa 
Charitable Trust 
$4,000 3 
2013 The Tangata Whenua and 
Tangata Tiriti of the New 
Zealand coalition to end 
homelessness: National 
Homelessness Strategy 
Hulita Tauveli University of Auckland $5,000 10 
2012 Māori housing-related 
potentially avoidable 
hospitalisation in Waitemata 
DHB 
Zarah Allport University of Auckland  $5,000 4 
2012 The use of rongoa in 
contemporary physiotherapy 
practise: An exploratory study 
Kelly Gray AUT University  $5,000 3 
2012 Māori conceptions of health in 
ultimate relationships: An 
exploration of health and 
intimacy 
Pita King University of Waikato $5,000 3 
2012 Indigenous women, problem 
gambling and the care of their 
children: A literature review 
Patricia Grogan AUT University $5,000 3 
2013 Māori and palliative care Diane Koti Massey University $5,000 2 
2013 Literature review of cultural 
safety pertaining to foot-care 
with Māori 
Cynthia Otene AUT University $5,000 2 
2009 Resilient Whanau: Well-being 
through innovation and 
traditional practice 
Tania Ruana Te Hauora O Turanganui a 
Kiwa Ltd 
$10,000 3 
2011 Sport as a forum for capacity 
building and self-
determination in Indigenous 
communities 
Renei Ngawati AUT University  $11,600 36 
2011 How do different populations 
define Whānau Ora?  
Te Moana 
Rolleston 
Massey University $11,600 18 
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2010 Porirua Harbour and the 
relationship to Tangata 
Whenua - Working towards a 
healthy built environment 
Stephen Kenny HRC $11,873 13 




Massey University $11,970 12 
2011 He Kura Aro Huango: Primary 
Schools & Māori Children with 
Asthma - A Pilot 
Anne Webster Tu Kotahi Māori Asthmas 
Trust 
$11,997 7 
2012 A Kaupapa Māori approach to 
Cardiac Risk Reduction 
Josephine 
Church 
The Cardiac Clinic $12,000 12 
2013 Supporting Māori 
tamariki/whanau with chronic 
asthmas: A health literacy 
approach 
Maraea Nathan Tu Kotahi Māori Asthma 
Trust 
$12,000 6 
2011 Ngaitai Papkainga Toiora: 
Sustainable Housing 
Development for Ngaitai 
Whanau 
Leah Redstone Ngaitai Iwi Authority $12,000 6 
2006 He Arorangi Whakamua - A 
Ngati hauiti tobacco control 
intervention 
Gillian Pirikahu Whakauae Research 
Services 
$12,000 6 
2009 Mauri Ora Growing healthy 







2007 Exploring resiliency factors for 
prevention and management 




AUT University  $13,900 12 





Massey University $15,600 12 
2008 Why are mental health services 
failing Māori homeless 
Diana Johnson University of Waikato $16,066 12 




AUT University $17,600 24 
2009 Ko taku iwi tuaroa tena: Key 
factors in decision-making on 




Tumana Research Services $32,315 4 
2013 The secret happiness: 
Narratives from Māori elders in 
the Bay of Plenty 
Marama 
McDonald 
University of Auckland $37,303 12 
2007 Oranga Kaumatua - Taranaki William 
Edwards 
Massey University $47,627 24 
2006 Workplace safety for Māori 
nurses 
Victoria Simon Massey University $50,690 18 
2011 SICK TO DEATH: Māori Access 
to Quality Healthcare in 




2011 The impact of whakapapa 
exchange on the therapeutic 
alliance in therapy with Māori 
clients 
Arna Mitchell Massey University  $65,550 24 
2007 A Māori-centred inquiry into 
health governance: Māori 
directors on DHBs 
Joy Panoho Massey University $65,740 30 
2006 Kia  ngawari ki te awatea: a 
psychological journey toward 




Massey University $66,039 32 
2006 Whanau bioethical decision-
making - genetic disorders and 
Māori Health 
Hope Tuapara Massey University $74,650 24 
2012 Collaboration with and for 




University of Otago $80,278 36 
2012 A Māori-centred grounded 
theory study of Māori with 
addiction and related problems 
Maria Baker Massey University  $85,050 48 
2006 Insulin resistance & Māori 
health - repeated measures 
study 
Isaac Warbrick Massey University $95,050 36 
2008 Pilot intervention study to 
improve the oral health of 
rangatahi in Taranaki 
Kate Morgaine University of Otago  $100,000 36 
2008 Māori with disabilities and 
their whanau navigating 
complex support systems 
Adelaide Collins Māori Development 
Research Centre 
$100,000 36 
2006 Acceptable child/adolescent 
Mental Health Services for 
New Zealand Māori 
Kahu 
McClintock 
University of Auckland $101,050 36 
2006 Māori and Indigenous health 
initiatives: blood-borne viral 
and sexually transmitted 
infections 
Mera Penehira University of Waikato $102,550 47 
2010 He Kaakano ahau I ruia mai I 
Rangaiaatea: engaging Māori 
in Child an Adolescent Mental 
Health Services 
Pikihuia Pomare University of Auckland $104,738 36 
2010 Whānau Ora: Māori 
motherhood, cultural identity, 
and mental well-being 
Reena Kainamu University of Auckland $107,602 36 
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2011 Whakapapa: An Interpretation 
of Indigenous Theory for 
Postvention of Suicide for 
Whanau Māori Experiencing 
Whakamomori 
Pania Renati University of Waikato $108,095 36 
2013 Whanau kopepe: Young Māori 
parents experiences of raising 
a family 
Felicity Ware Massey University $108,402 36 
2013 Māori elders resilience and 
arthritis: Measuring home 
health outcomes 
Sharon Awatere Massey University $109,500 36 
2013 Kaupapa Māori evaluation of 
health literacy appropriate CVD 
intervention 
Teah Carlson Massey University $109,500 36 
2013 Taku aroha ki ngā tai e 
ngunguru e ra: Transforming 
the Māori health cancer 
workforce 
Monica Koia Massey University $110,050 36 
2012 Ngaitai well-being indicators: 
Measuring iwi health outcomes 
Jodi Porter Massey University  $110,050 36 
2008 Parenting patterns of Māori 
women who have experienced 
domestic violence trauma 
Alayne Hall AUT University $113,050 52 
2008 Māori Whanau participation in 
mental health service delivery 
Louise Ihimaera Massey University $114,497 24 
2006 Older Māori and medication: 




Massey University $120,519 24 
2009 Whanau Māori & mental 
health: Snapshots of strengths, 
resilience & recovery 
Mere Balzer Te Runanga o Kirikiriroa 
Charitable Trust 
$132,483 18 
2010 EGFR testing for Māori patients 
with non-small-cell lung cancer 
Lesley Batten Massey University $143,868 12 
2008 Monitoring sexually 
transmitted infections among 
Māori in the Bay of Plenty 
Clive Aspin University of Waikato $144,267 12 
2009 Developing Sleep Services that 




Massey University $145,561 12 
2008 Whānau Ora cardiovascular 
risk assessment and 
management - a feasibility 
study 
Tania Riddell University of Auckland $146,002 12 
2012 Feasibility of an exercise 
programme to reduce smoking 
during pregnancy among Māori 
Ralph Maddison University of Auckland  $149,985 12 
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2010 Mental health and substance 
abuse disorders among 
Rangatahi Māori offenders 
Tai Kake Victoria University $149,999 12 
2011 Haua Mana Māori Leigh Hale University of Otago $151,790 12 
2006 Cognitive behavioural therapy 
for depression with Māori 
tangata whaiora 
Simon Bennett Massey University $191,858 39 
2006 Partnership: refocusing 
successful interventions for 
Māori deaf/hearing impaired 
children 
Kirsten Smiler Victoria Link Limited $196,923 36 
2008 Measuring Whanau - Research 
methods to capture whanau 
realities 
Fiona Cram Katoa Ltd $200,000 12 
2007 A best practice package: early 
intervention for whanau 
violence 
Erana Cooper University of Auckland $229,575 37 
2011 Rangatahi Sexual and 
Reproductive Health Research 
Lynne Russell 
(Pere) 
Victoria University $244,360 24 
2010 Mauri Ora - Growing healthy 




Tuhoe Education Authority 
Charitable Trust 
$247,743 21 
2008 Parental attitudes to HPV 




University of Otago  $249,538 12 
2011 Māori health literacy and 
communication in palliative 






2013 Whanau Pakari: A multi-
disciplinary intervention for 
children with weight issues 
Yvonne 
Anderson 
University of Auckland $250,000 48 
2007 Quality of public hospital care 




University of Otago $250,311 61 
2006 Hauora practice led 




Massey University $256,063 36 
2009 Oral health research priorities 
for Māori 
Bridget Robson University of Otago $257,124 13 
2007 He mokopuna, he taonga: 
Health and well-being of 
grandparents raising 
mokopuna 
Cherryl Smith Te Atawhai o Te Ao $265,045 44 
2010 Māori priorities for life stage 




Massey University $270,000 19 
2008 Research priorities identified 
by Māori with disabilities and 
their whanau 





2006 Health, cultural and social 
experience of Māori affected 
by chemical related illness 
Cherryl Smith Te Runanga o Ngati Apa $275,625 36 
2011 Palliative care, health literacy, 
Māori communities and health 
services 
Jacquie Kidd Auckland Uni Services Ltd 
& University of Auckland 
$290,002 12 
2008 The socioeconomic factors 
associated with food security 
and physical activity for Māori 
Charles 
Waldegrave 
The Family Centre $291,107 19 
2011 Nga ara hou: New pathways 
toward Whānau Ora for 
incarcerated Māori women 
Lily George Massey University  $293,948 36 
2011 Mauri Tangata: Re-Positioning 
Māori resistance and well-
being in Sexual and 
Reproductive Health Policy and 
Service Provision 
Mera Penehira University of Waikato $296,297 36 
2011 Oranga niho me nga tangata 
whaiora 
John Broughton University of Otago $303,540 12 
2010 Tangata-centered Huntington's 
disease research: Partnership 
between Indigenous 
community and biomedical 
science 
Melanie Cheung University of Waikato $305,780 36 
2007 Nursing and Māori patient 
outcomes 
Denise Wilson Massey University $311,620 15 
2009 Whakaoranga Whanau: 
Whanau Resilience 
Mason Durie Massey University $313,000 24 
2008 Moe tike, moe pai: Advancing 




Massey University $321,740 41 
2010 Tomo mai, Responsive Child 
and Adolescent Mental Health 




Te Rau Matatini $322,034 36 
2012 Ka puāwa ngā kōhungahunga 
turi: The early development of 
Māori deaf children 
Kirsten Smiler Victoria University  $330,734 36 
2012 Huarahi rongoa ka a ngai 
tatou: Māori views on rongoa 
Māori and primary health 
Glenis Mark Whakauae Research 
Service 
$333,273 36 
2012 Huarahi rongā ki a ngai tātou: 
Māori views o rongā 
(traditional medicine and 
practices) 
Glenis Mark Whakauae Research 
Service 
$333,273 36 
2011 Nga Pou Wahine: A kaupapa 
wahine intervention 
addressing gambling misuse 
Laurie Morrison AUT University  $334,761 38 




2012 Exploring the practical 
applications of Matakite 
(unusual perception) 
understandings in health 
provision 
Ronald Ngata University of Waikato $339,407 36 
2010 Kia Ngawari: Investigating 




University of Waikato $341,433 36 
2009 Facilitating whanau resilience 
through Māori primary 
healthcare intervention 
Heather Gifford Whakauae Research 
Services (Te Maru o 
Ruahine Trust) 
$349,734 24 
2008 Te Tomokanga: a model for 
facilitating bicultural health 




Inst. Of Environmental 
Science & Research Ltd 
$350,000 18 
2013 Te Maramatanga: How 
education positively affects 
Māori health over time 
Reremoana 
Theodore 
University of Otago $354,512 36 





AUT University $375,234 36 
2010 Health research and services: 
Localising the interface 




Massey University $388,626 40 
2007 Growing up kapo Māori: 
Whanau, identity, cultural well-
being and health 
Nancy Higgins Donald Beasley Institute $389,589 24 
2007 Kei ruka kei raro: Māori health 
experiences and perspectives 
Emma Wyeth University of Otago $400,774 58 
2006 Health measurement and 
knowledge translation for 




AUT University $417,189 18 
2009 Growing up kapo Māori: 
Accessing paediatric 
ophthalmology services 
Nancy Higgins Ngati Kapo O Aotearoa Inc. $501,216 24 
2008 Interventional study on 




University of Auckland $555,895 30 




Massey University $574,465 36 
2008 Enhancing food security and 
physical activity for Māori, 




Auckland Uni Services Ltd $599,000 24 
2010 Racism as a health 
determinant: implications for 
Māori health and inequalities 
Ricci Harris University of Otago $600,032 36 
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2007 Pukapuka Hauora: Parents' 
knowledge of preventing and 
treating their child's asthmas 
Bernadette 
Jones 
University of Otago $624,415 24 
2007 He kakano: Māori views and 
experiences of fertility, 
reproduction, and ART 
Paul Reynolds Te Atawhai o Te Ao $656,062 36 
2013 Māori health identities: 
Affecting and driving health 
Helen Moewaka 
Barnes 
Massey University $666,299 36 
2008 Nga Tohu o te Ora: traditional 
Māori wellness outcome 
measures 
Maui Hudson Inst. Of Environmental 
Science & Research Ltd 
$699,370 36 
2007 Determining the contaminant 
health risk of kai moana, kai 
roto, and kai awa 
Ngaire Phillips National Institute of Water 
and Atmosphere Research 
$705,786 36 
2008 Wahine Hauora - Inequalities 




University of Otago  $707,474 30 
2012 Best Health for Māori: Te Hoe 




Massey University $786,852 36 
2011 Culturally appropriate end of 
life care for Māori 
Maureen 
Holdaway 
Massey University $803,763 36 
2008 Stomach Cancer in Māori Lis Ellison-
Loschmann 
Massey University $951,381 60 
2011 Can Better Surveillance 
Prevent Liver Cancer and 




Auckland District Health 
Board 
$964,393 30 
2011 Supporting the Traditional 
Rongoa Practice in 
Contemporary Healthcare 
Settings 
Amohia Boulton Te Maruo Ruahine Trust & 
Whakauae Research For 
Māori Health and 
Development 
$1,023,301 36 
2011 Marae Food Gardens: Health 
and Well-being through the 
Urban Marae in Tamaki 
Makaurau 
Rhys Jones University of Auckland $1,165,597 36 
2009 Wahine Hauora: reducing 
barriers to care for pregnant 
mums and their whanau 
Beverley 
Lawton 
University of Otago $1,179,945 48 
2013 Pakeketanga: Living and dying 
in advanced age 
Merryn Gott University of Auckland $1,191,255 36 
2012 Diabetes - The Impact of 
Maternal Care Disparities on 
Māori Mothers and Infants 
Beverley 
Lawton 
University of Otago $1,192,365 36 
2013 He kura: Asthmas support for 
Māori tamariki at school 
Bernadette 
Jones 
University of Otago $1,199,064 36 
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2010 Addressing barriers to care for 
young pregnant Māori women 
and their infants 
Beverly Lawton University of Otago $1,199,936 36 
2013 Preventable Māori mortality Andrew Sporle University of Auckland $1,199,945 36 
2006 The Māori community heart 
study 
Suzanne Pitama University of Otago $1,919,504 60 
2007 Programme Extension: Te 
Pumanawa Hauora 
Mason Durie Massey University $2,345,384 36 
2009 He Kainga Oranga/Community 





University of Otago $2,966,584 36 
2012 He Kainga Oranga/Community 






University of Otago $3,749,138 36 
2011 He Kokonga Whare: Māori 
Intergenerational Trauma and 
Healing 
Paul Reynolds Independent Māori 
Institute for Environment 
and Health: Te Atawhai o 
te Ao 
$4,728,200 60 
2013 A joint Auckland and 
Waitemata District Health 
Board Pacific Demographic and 
Health Status Report 
Zarah Allport University of Auckland $5,000 2 
2012 Cook Island Adolescent 
perception and behaviour of 
alcohol use in Auckland  
Tupuna Mataio University of Auckland $5,000 3 
2013 A review of community 
development initiatives for the 
prevention of self-harm 
behaviour amongst Pacific 
youth in New Zealand  
Synthia Dash University of Auckland $5,000 2 
2012 The effects on breast cancer in 
Pacific women and cancer 
survival rates in regions with 
most Pacific Island residents 
Sara Samuela  University of Otago $5,000 3 
2013 A literature review on the 
health profile of Tuvaluans 
living in New Zealand 
Saneta Manoa University of Auckland $5,000 2 




University of Otago $5,000 3 
2013 Pacific health models: Do they 
fit?  
Mayor Mataio University of Auckland $5,000 2 
2013 Barriers to Pacific women 
breastfeeding in the 





University of Auckland $5,000 2 
2013 The role of culture in Pacific 
suicide prevention 
Luarell King University of Otago $5,000 2 
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2013 Vaevae manava and food 
secruity in Tongan 
communities: A way forward 
Litiuingi Ahio AUT University $5,000 2 
2013 Literature review of nutritional 
issues amongst pregnant 
Pacific women in New Zealand 
from ages 15-40 years 
Heimata 
Herman 
University of Auckland $5,000 2 
2013 Stepping Forward: A needs 
analysis addressing gaps in 
knowledge in regards to family 
violence amongst Pacific 




University of Auckland $5,000 2 
2013 Stepping Forward: A needs 
analysis addressing gaps in 
knowledge in regards to family 
violence amongst Pacific 




University of Auckland $5,000 2 
2012 Identifying risk factors 
associated with Pacific suicide 
in New Zealand  
Eliza Puna University of Auckland  $5,000 3 
2013 Exploring mental health and 
suicide amongst Cook 
Islanders: A review of the 
literature 
Eliza Puna University of Auckland $5,000 10 
2013 Pacific smoking cessation 
services: Will they be enough 
to help us research Smokefree 
2025 goal 
Athena Tapu AUT University $5,000 2 
2012 The Canterbury Earthquake: 
Impact of Pacific Health 
Provision 
Ashalyna Noa University of Canterbury $5,000 3 
2013 Depression amongst Tongan 
(New Zealand born) 
Afu Taufa University of Auckland $5,000 2 
2012 Going Local: Impact of 
sustainable development 
policies on health in Rarotonga 
Rochelle 
Newport 
University of Auckland $18,253 12 
2012 Diabetes: Impact on work, 




University of Auckland $18,253 12 
2006 Samoans and Disability Study Nite Fuamatu Massey University $101,550 36 
2013 Substance use amongst 
Samoan youth in New Zealand 
Helen Tanielu University of Auckland $105,896 36 
2013 Promoting health literacy to 




Victoria University $110,555 36 
2012 Pacific Men's Health and Well-
being; The Case of Niue and 
the Cook Islands 
Vili Nosa University of Auckland $150,000 36 
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2012 Suicide prevention for Pacific 
youth in New Zealand: Pacific 
Community Solutions 
Jemaima Tiatia Auckland Uni Services Ltd $289,437 20 
2008 Exploring Samoan women's 
attitudes towards antenatal 




Victoria University $303,331 36 
2013 Arterial function, vitamin D and 
cardiovascular disease in 
Pacific peoples 
John Sluyter University of Auckland $387,195 48 
2007 Strengthening Career 
Pathways: A Pacific Health 
Programme of Research 
Billie Harbidge Auckland Uni Services 
Ltd/University of Auckland 
$570,000 29 
2012 A lifestyle intervention model 
to address obesity and type 2 
diabetes in Pacific 
Ofa Dewes Auckland Uni Services Ltd $594,434 24 
2010 Pacific Islands Families Study: 
Hearing Status of 11-year-olds 
(PIF:HS) 
Philip Schluter AUT University $732,717 24 
2011 Pacific Health Outcomes: 




Pacific Perspectives Ltd $897,303 16 
2008 Transnationalism in Pacific 
health through the lens of TB 
Judith Littlejohn University of Auckland $1,411,510 36 
2010 New Zealand law on the 
sterilisations of intellectually 
disabled girls and women 
Amelda Schrenk University of Waikato $5,000 3 
2006 Examination of the outcomes 
of resettlement of residents 
from Kimberly Centre: Phase 
Two 
Anne Bray Donald Beasley Institute $540,033 24 
2006 Evaluation of Intersectorial 
Disability Needs Assessment 
and Service Coordination 
Trials: 3-month extension 
Anne Bray Donald Beasley Institute $54,248 3 
2006 In search of the molecular 
basis of mental retardation 
Armaz Aschrafi Massey University $138,350 36 
2009 Communication intervention 
for adults with intellectual 
disability 
Jeff Sigafoos Victoria University $150,000 12 
2007 Working in intellectual 
disability services: Staff 
retention and turnover 
Nancy Higgins Donald Beasley Institute $1,137,610 36 
2009 Reducing inequalities in the 
Primary Health Sector 
Lynda Hare-
Rangitauira 
Western Bay of Plenty PHO $4,000 2 
2013 Cultural perspectives on 
hearing and hearing aids 




University of Auckland $5,000 2 
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2012 Racism and its link with body 
size 
Rhiannon Jones University of Otago $5,000 3 
2013 Acceptability and access to 




University of Auckland $148,730 30 
2010 Can we reduce Māori and 
Pacific School children's 
hospitalisations to Pakeha 
rates 
Diana Lennon University of Auckland $149,883 12 
2009 Studying eye diseases of Māori, 
Pacific, and the elderly using 
animal models 
Monica Acosta University of Auckland  $150,000 36 
2009 What motivates Māori, Pacific 
and Low SEC users of tobacco 
to stop smoking?  
Marewa Glover Auckland Uni Services Ltd $217,000 12 
2010 Ethnic and socioeconomic 
differences in pandemic 
influenza infection in New 
Zealand 
Michael Baker University of Otago $229,323 12 
2012 Translating best practice to 
reduce equity gaps in 
immunisation 
Nikki Turner University of Auckland $444,809 24 
2009 Inequalities in cervical cancer 
survival in New Zealand 
Lis Ellison-
Loschmann 
Massey University $665,198 36 
2007 Equity in prescription 
medicines use 
Pauline Norris University of Otago $911,503 36 
2006 Cancer trends: Ethnic and 
socio-economic trends in 
cancer incidence and survival  
Tony Blakely University of Otago $924,356 36 
2010 Whiti Te Ra: Bronchiolitis 
Disparities among Māori and 
Pacific children 
Tristram Ingham University of Otago $1,146,720 36 
2011 Whiti Te Ra: The Contribution 
of Housing Conditions to 
Bronchiolitis Disparities 
Tristram Ingham University of Otago $1,157,725 36 
2008 Programme Extension: Health 
Inequalities Research 
Programme (HIRP) 




Appendix A-1: Trial Registry Data 
Trial Registry Data across the various trial databases comes in different formats, and each 
trial document has a long trial record.  I do not provide a list here of the trials included as 
once each electronic search engine provided results based on the search strategies 
described in the chapter, trial registrations were printed and kept as paper records. 
I then hand-searched these paper records for statistical descriptions, 
prospective/retrospective registration and study results/publication descriptions. This 
searching was repeated multiple times by the author, but not double-checked by a second, 
given that definitions were clear (i.e. prospective or retrospective inclusion is a line within 
the trial record and is in no way ambiguous).  
Where study results or publications were listed, these were also searched electronically and 
then printed and attached to the paper registration record. I searched study results and 
papers for references to demographics and ethnicity data.  
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Appendix A-2: Health and Disability Ethics Committee Data 
New Zealand Health and Disability Ethics Committee provide their annual reports including 
a list of all reviewed applications on their website.  
Methodology 
I converted  tables of applications in Annual reports’ (in PDF/Word format) into Excel. 
These were then searched using multiple methods: 
4) Electronic search using “Find” option in Excel searching for terminology related to 
Māori (Māori, Māori, whenua, kaupapa, whanau, Whānau Ora,  nga*, whan*, 
whak*,*ori , tanga*), Pasifika (Pacific*, Pasifik*, Samoa*, Tonga*, Fiji*, Cook*, Niue*, 
Kiri*) and Learning Disability (intellectual, learning, Down*, Prada*, fetal*, 
disability) groups. These provided lists that were then scrutinised for those that 
pertained to our groups (i.e. some results with *ori or fetal* were not related our 
case groups, but these were then excluded).  A fourth group was created that 
included those projects related to equity or that involved two of our groups or that 
included studies that relate to rheumatic fever which has been a particular health 
issue for Māori and Pasifika children and adults.  These terms included: equity, 
disparity, rheum*, equality, determinants.  This was completed by the primary 
investigator. 
5) Additionally, manual checking (i.e. checking in each item in the list) was completed 
by the primary investigator and an external checker (medically trained).  Filtering 
of titles was thrice-checked by the author on three separate occasions each multiple 
days apart, and by the external checker (medically trained). The principle of charity 
was used between checkers and searches, insofar as the largest list was used as the 
final list. 
6) All titles that were an acronym rather than a title such as “SPRINT Trial” or that 
were considered ambiguous in the larger list were searched online to check the 
nature of the study before being included or excluded.  
A full dataset (without analysis) has been posted openly for future use by others in the 
spirit of collaboration and collegiality.  It is available from www.figshare.com 






  Māori 
  Pasifika 
  Learning Disability 
  
Equity or Multiple case 
groups 
 
Project Key  Short title Co-ordinating 
Investigator 
Study status 
12/CEN/6 Could local 'Aunties' facilitate 
better Māori pregnancy 
outcomes? 
Dr. Marewa Glover Approve 
13/NTB/15 Intergenerational 
Communication Practices and 




13/NTB/4 Thyrotoxicosis in Māori Dr. Jade Tamatea Approve 
13/CEN/138 Te Waiata a Hinetitama Dr Debra Tepora 
Emery 
Approve 
13/STH/187 Filaggrin mutations in atopic 




12/CEN/18 Whanau-Ora – whanau-
centred engagement and 
provision 
Mrs. Te Moana 
Campbell-Knowles 
Approve 
12/CEN/32 Te Kete Tuatea Ms Kirikowhai 
Mikaere 
Approve 





12/NTA/62 The Māori and Assessment Of 
Renal Impairment (MĀORI) 
Study 
Dr. Curtis Walker Approve 
12/NTB/32 Incentives to stop smoking 
among pregnant Māori women 
Dr. Marewa Glover Approve 
12/NTB/5 Diabetes: The impact of 
maternal care disparities on 
Māori mothers 
Prof Peter Larsen Approve 
NTX/12/05/047 Ngā Waiata O Tāne 
Whakapiripiri: music, mental 
health, and healing in a Māori 





NTX/12/EXP/084 Palliative care, health literacy, 
Māori communities and health 
services 
Dr. Sue Crengle Approved 
NTX/12/EXP/116 Korero Mai E Te Whanau – 
Whanau stories of 
engagement, innovation and 
integration. PIS/Cons V#2, 
31/05/12 
Ms. Moana Eruera Approved 






NTY/12/04/027 The Hua Oranga: A Māori 






outcome service application 
NTY/12/05/033 HRC 11/793 He Kokonga 
Whare: Māori 
intergenerational trauma and 
healing 
Dr. Paul Reynolds Approved 
NTY/12/06/052 Māori experiences of bipolar 
affective disorder and 





NTY/12/EXP/007 Change in patient scores 
following arthroplasty surgery: 
are there any differences 
between Māori and non-
Māori? A registry-based cohort 
study. 
Neal Singleton Approved 
MEC/12/03/031 Mouri Whakapapa: 
Repositioning Māori resistance 
and well-being in sexual and 
reproductive health policy and 
service provision 
Ms. Mera Penehira Approved 
MEC/12/EXP/038 Health literacy: and the 
prevention and early detection 
of gout; prevention and 
treatment of skin infections in 
Māori children, and the 
screening and management of 
gestational diabetes 
Ms. Susan Reid Approved 
MEC/12/EXP/050 Palliative care, health literacy, 
Māori communities, and health 
services 
Dr. Jacquie Kidd Approved 
MEC/12/EXP/066 The Wahakura: A qualitative 
study of the flax bassinet as a 
safe infant sleeping 
environment for Māori 
Dr. Sally Abel Approved 
URA/12/03/007 Whaia Te Waimarino: The 
experiences of Māori who may 
use Psycho-Oncology Services 
Dr. John Waldon Approved 
NTY/12/06/054 Aunty Whakahaere Hapunga 
Initiative (AWHI): Could local 
‘aunties’ facilitate better Māori 
pregnancy outcomes? 
Dr. Marewa Glover Closed 
CEN/11/03/014  Culturally Appropriate End of 




CEN/11/11/059 Whakatirotirohia nga korero a 
te Māori mau atu ki te 
whakatakotoranga whakaaro 
petipeti - Exploring Māori 
input decision-making on 
gambling 
Dr. Nicole Coupe Approved 
MEC/11/EXP/079 Māori women's experiences of 
healthcare in the pregnancy, 
birth and postpartum periods. 
Maria Baker Approved 
MEC/11/EXP/084 The perspectives of speech 
language therapists on 
working in communication 




MEC/11/EXP/099 Palliative Care, Health Literacy, 
Māori Communities and 




MEC/11/EXP/129 What Are The Challenges 
Faced by Māori Rural Health 
Nurses in Accessing 





MEC/11/EXP/132 Trends in Genital Wart 
National Sentinel Surveillance 
Data for Māori and Non-Māori 
Following The Introduction of 
Quadrivalent Human 
Papilloma Virus Vaccination in 
New Zealand 
Dr. Kerry Sexton Approved 
NTX/11/04/022 Nutritional well-being of Māori 
living to advanced age:  kai ora 
me to noho a te kaumatua 
Māori: PIS/Cons V# 27/4/11 
Mr. Eruera Maxted Approved 
NTX/11/05/034 Kaumatua Well-being study: 
Supporting whanau 
aspirations of Whānau Ora: 
PIS/Cons V#2, 26/05/11 
Mr. John Waldon Approved 
NTX/11/09/082 The evaluation of anatomical 
and biomechanical parameters 
of the feet in Māori with 
diabetes: a feasibility study:   




NTX/11/EXP/197 Reducing and preventing 
violence in tamariki Māori 
Dr. Stacey Byers Approved 
NTX/11/EXP/207 Te kete o wananga: What are 
the beliefs, intentions, needs, 
and capabilities of Māori 
participation in lifestyle 
programmes to improve 
metabolic health from a rural 
community? PIS/Cons V#2, 
25/11/11 
Dr. Geoff Kira Approved 
NTX/11/EXP/208 Reducing and preventing 
violence in taitamariki Māori 
intimate partner relationships 
in the context of their whanau, 
hapu and iwi. PIS/Cons v#1, 
3/8/2011 
Ms. Terry Dobbs Approved 
NTX/11/EXP/261 Exploring the end of life 
experiences of Māori and non-
Māori living to advanced old 
age in Aotearoa, New Zealand:  
a study to identify research 




NTX/11/EXP/308 WERO:  Whanau End smoking 
Regional Whānau Ora 
Challenge 
Dr. Marewa Glover Approved 
NTY/11/05/057 Tangata-centred Huntington’s 
disease research: partnership 





NTY/11/06/067 Why do Māori Women in 
Taupo Have a Low Cervical 






NTY/11/08/085 Māori Health Literacy and 
Communication in Palliative 




NTY/11/EXP/054 Negotiating Māori Kaumatua 
'Space' in Ageing Healthcare in 
Aotearoa New Zealand: Ka tae 
au ki taku Kaumatuatanga ma 
wai au e tiaki? (Who will look 
after me when I grow old?) 
Ms. Marie Were Approved 
URB/11/07/021 Te Hoe Nuku Roa: Best Health 
for Māori: Nelson Marlborough 




MEC/11/03/024 Impacts of Gambling for Māori 
Families and Communities: A 
Strengths-Based Approach to 
Achieving Whānau Ora 
Ms. Mere Balzer Approved 
NTX/11/09/086 Ko tōu Manawa, ko tōku 
Manawa ka ora: Pain and 
suffering through Māori Eyes. 




NTX/11/EXP/116 Exploring mental health 
service users' sensory 
experiences during 
participation in Kapa haka: 
PIS/Cons V#4 
Ms. Tania Hollands Approved 
CEN/11/11/057 Tipping Points:  The 
Relationship between Māori 
Youth Workforce Participation 
and Mental Health  
Professor Linda 
Smith 
Approved Subject to 
Conditions 
NTY/11/11/107 A 12 week, Kaupapa Māori, 
comprehensive cardiac risk 
reduction programme that 
specialises in exercise  and 




Approved Subject to 
Conditions 
LRS/11/12/059 Māori Child Maltreatment: A 
Way Forward: He Ara 
Whakamua 
Ms. Helen Harte Deferred 
CEN/11/EXP/075 Stocktake and Profile of Māori 








Evaluating the process within 
the Whānau Ora System for the 
National Hauora Coalition 
Mr. Antony 
Raymont 
Ethical approval not 
required 
NTY/11/EXP/041 Comparison of complications 
following lower limb 
arthroplasty between Māori     
and non-Māori. 
Mr. Dawson Muir Ethical approval not 
required 




Ethical approval not 
required 
MEC/10/001/EXP He Kura Aro Huangō: How are 
primary schools responding to 
the needs of Māori children 
with Asthma? 
Bernadette Jones Approved 
MEC/10/01/011 Māori deaf children and their 
whānau: A study of the nature 
Kirsten Smiler Approved 
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and impacts of early 
intervention 
MEC/10/026/EXP Developing Mahi Oranga - a 
Māori-specific measure of 
occupational well-being 
Ms. Lisa Stewart Approved 
MEC/10/05/042 Te Tomo mai, Responsive 
Child and Adolescent Mental 





MEC/10/050/EXP Racism as a health 
determinant: implications for 
Māori health and inequalities 
Dr. Ricci Harris Approved 
MEC/10/060/EXP Te whakapunanga me te 
whakaita i ngā tāngata 
whaiora Māori - Towards 
understanding seclusion and 




MEC/10/10/106 Ngā Tohu o te Ora: Traditional 
Māori Wellness Outcome 
Measures – Stage two of 
MEC/08/08/098 
Mr. Maui Hudson Approved 
CEN/10/09/041 Central Corneal Thickness in a 
Māori Population in Hawke’s 
Bay 
Dr. Alex Buller Approved Subject to 
Conditions 
CEN/10/02/10 The Type, Grade, Stage at 
Diagnosis, and Survival Rates 
in Endometrial Cancers in new 










CEN/10/05/018 Within the Current Primary 
Healthcare System How Easy is 
It for Registered Nurses 
Employed by Māori Healthcare 
Providers to Work in a Holistic  
Way with People with Type 2 
Diabetes 
Ms. Liz Day Approved 
CEN/10/07/024 The Effect of An Acute Bout of 
Exercise on Smoking 
Withdrawal Symptoms 
(craving) in Māori 
Dr. James Faulkner Approved 
CEN/10/09/036 Wahine Hauora : Reducing 
Barriers to Care for Pregnant 





CEN/10/09/040 A Feasibility Study of EGFR 
Testing for Māori Patients with 
Non-Small-Cell Lung Cancer 
(HRC Ref ID: 10/675) 
Lesley Batten Approved 
CEN/10/EXP/01 A Needs Assessment to 
Identify if Specific Kai 
Preparation and Cooking Skills 
is a barrier to Healthy Eating 
for Adult Māori with Diabetes 
or at Risk of Diabetes, 
Principally Enrolled in Valley 
PHO and A resident in 




CEN/10/EXP/04 Use of Public and Private 
Health Services by Māori and 
Non-Māori women: An audit of 





CEN/10/EXP/05 Facilitating Whanau Resilience 





MEC/10/072/EXP He Kakano: Māori views and 
experiences of fertility, 
reproduction, and ART - a 





MEC/10/082/EXP Well Child/ Tamariki Ora 
Nursing: Who are the Māori 
Health Provider Well Child/ 
Tamariki Ora registered 
nurses and what are their 
experiences in delivering a 
Well Child/ Tamariki Ora 
program to Tamariki Māori 




NTX/10/07/063 He Kakano ahau i ruia mai i 
Rangiatea:  engaging Māori in 
child and adolescent mental 





NTY/10/06/056 Critical Success Factors in 
Kaupapa Māori AOD 
residential treatment: Māori 
Youth Perspectives.  
Dr. Ria Schroder Approved 
NTY/10/06/059 VerifyNow Assessment of 
Māori Platelet Inhibition 
Relative to European New 
Zealanders. (VAMPIRE).  
Dr. Gerard Devlin Approved 
NTY/10/EXP/052 An examination of research 
carried out by the Mental 
Health Foundation on the 
subject of the over 
representation of Māori people 




NTY/10/EXP/095 Toiora: Conceptualisation and 
measurement for iwi and 
Māori communities. 
Ms. Jodi Porter Approved 
URA/10/11/074 A community-based 
participatory approach to 
diabetes education for 
Christchurch Māori 
Ms. Alison Farmer Approved 
URA/10/EXP/041 What is the cost? Estimating 
the economic costs of Māori: 
Non-Māori child health 












NTY/10/04/034 He whakamarama rua I te 
wairangi o te hinengaro: At the 
interface – A bicultural 




MEC/10/088/EXP A feasibility study of EGFR 
testing for Māori patients with 
non-small-cell lung cancer 
Mr. Christopher 
Drury 
Approved Subject to 
Conditions 
NTX/10/11/117 Oral health promotion services 
for young Māori pregnant 
women in the Whangaroa 
Health Services region 
Professor Jeffrey 
T.F. Watts 
Approved Subject to 
Conditions 
NTX/10/12/129 The secret to happiness - 
narratives from Māori elders 
in the Bay of Plenty 
Ms. Marama 
McDonald 
Approved Subject to 
Conditions 
NTY/10/12/101 The experiences of Māori with 
aphasia and their whanau. 
Ms. Karen 
McLellan 
Approved Subject to 
Conditions 
URB/10/11/047 Tupu Ake: Developing a 
kaupapa Māori definition of 
resiliency for rangatahi in 
Taranaki 
Ms. Bry Kopu Approved Subject to 
Conditions 
NTY/10/10/081 Rites of Passage: 
Strengthening the capacity of 
Māori communities to support 
whanau aspirations for 
Whānau Ora. 
Mere Balzer Ethical approval not 
required 
NTY/09/03/027 Oranga Tāne Māori. Mr. Wayne 
Johnstone 
Approved 
CEN/09/05/030 A   Kaupapa    Māori qualitative 
investigatory study into the 
origins of domestic violence 
within the whanau of Taranaki 
Dr. Janice Wenn Approved 
CEN/09/09/068 Wahine Hauora: Reducing 
Barriers to care for Pregnant 




CEN/09/11/085 Māori Adaptation of an Ultra-
Brief Intervention for Common 





CEN/09/32/EXP Identifying pathways that 
support Māori access of 
Psycho- Oncology services 
within MidCentral DHB region 
Julie Beckett Approved 
CEN/09/55/EXP Health Professionals 
Experience Delivering Asthma 




LRS/09/10/044 Perspectives on the ethical and 
practical issues of prenatal 
alcohol use screening for 
indigenous females: Māori and 
Native American Indian 




The acceptability of cystisine 
by Māori people that smoke 
Dr. Marewa Glover Approved 
NTY/09/01/003 A pilot study to test the 
effectiveness of a 
Computerised CBT resource 
for Māori adolescents 
experiencing mild to moderate 
depressive disorder. 
Matthew Shepherd Approved 
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NTY/09/02/009 An Evaluation of the Rangatahi 
Māori Sexual and Reproductive 
Health Strategy for Hamilton: 
The “Rangatahi         Realising 
Potential” Project. 
Ms. Naina Watene Approved 
NTY/09/05/045 Acceptance of a computer-
based heart imagery 
programme in the exploration 
of beliefs about   heart   failure   
and 
adherence to symptom 
management among Māori  
Ms.   Eva   Rose 
Morunga 
Approved 
NTY/09/08/069 Improving Access for Māori to 
Palliative Care Services in Te 
Tai Tokerau/Northland. 
Ms. Liane Penney Approved 
NTY/09/09/091 A randomised controlled trial 
of a family–centred tobacco 
control program about 
environmental tobacco smoke 
(ETS) to reduce respiratory 
illness in Māori infants. 
Dr.  Natalie Walker Approved 
NTY/09/10/104 Kia Ngawari: Investigating 
Palliative Care of Māori and 
their Whanau. 
Dr. Tess Moeke- 
Maxwell 
Approved 
NTY/09/59/EXP The 'Potential Benefit' of Māori 
Models of Health/Practice              
in Forensic Psychiatry 
Inpatient Settings. "What is the 
level of knowledge and 
experience of Māori Models of 
health/practice in acute 
Forensic Psychiatric inpatient 
setting of Ward 33 of the 
Henry Rongomau Bennett 
Centre, Waikato? 
Mr. Taipu Moana Approved 
URA/09/10/071 Exploring the experiences of 
Māori patients and whanau 
living with chronic kidney 
disease (CKD) within the CDHB 
Tania Huria Approved 
NTY/09/09/093 “Te Kaponga” – Whanau Māori 
and Mental Health: Snapshots 
of Strengths, Resiliency and 
Recovery. 
Mere Balzer Approved Subject to 
Conditions 
NTY/09/11/110 Evaluation of breastfeeding 
support services for Māori 
whanau in Te Tai Tokerau. 
Ms. Amber Logan-
Riley 
Approved Subject to 
Conditions 
NTY/09/10/106 Mauri Ora    –    growing 
healthy tamariki (children), 
whanau (families) and hapu 





Subject to Conditions 
NTY/09/12/121 Resilient Whanau: Well-being 
through innovation and 





CEN/08/06/026 Supporting whanau as carers – 
a project to determine the 
support needs for Māori caring 
for loved ones dying at home 
Ms. Dianne Keip Approved 
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from cancer in the Hawke's 
Bay. 
CEN/08/09/049 The experience of urban Māori 
women and perceived delay in 
accessing women's healthcare 
in Aotearoa New Zealand: an 
exploratory study. 
Beverley Parton Approved 
CEN/08/11/058 Identification and description 
of the barriers and facilitators 
for Māori in maintaining 
healthy lifestyle changes using 
a Kaupapa Māori research 
framework. 
Christine Kerr Approved 
MEC08/03/031 Research priorities by Māori 





MEC/08/09/102 Stomach cancer in Māori Dr Lis Ellison-
Loschmann 
Approved 
NTX/08/03/017 Engagement pathways for 
Māori in mental health 
services at Auckland District 
Health Board: PIS/Cons V#2, 
25/03/08 
Mr. Tom Ruakere Approved 
NTX/08/97/EXP Monitoring sexually-
transmitted infections among 
Māori in the Bay of Plenty 
Dr. Clive Aspin Approved 
NTX/08/98/EXP Impact on Māori clients and 
their family/whanau who have 
end stage renal failure and 
receive haemodialysis, and 
who live in rural areas of 
Northland: PIS/Cons V#2, 
7/10/08 
Ms. Shih Li-Chin Approved 
NTY/08/02/012 Characteristics of non-
alcohol/drug users, 
particularly non-drinking (or 
non-problem-drinking and 
non-smoking) Māori 




NTY/08/05/048 An investigation into the lung 
cancer management pathways 
for Māori in Northland 
Ms. Amber Riley Approved 
NTY/08/05/050 The impact of oranga niho on 
quality of life of rangatahi 
Māori aged between 16 years 
and 18 years who reside 
within the Waikato rohe of 
Tainui 
Assoc Prof John 
Broughton 
Approved 
NTY/08/20/EXP Kaupapa Māori advanced 
nurse practitioner (KMAN) 




URA/08/08/053 Te Pounamu: a study to 
explore the acceptability of a 
Māori explanatory model of 
mental well-being for 
rangatahi and their whanau in 
a Kaupapa Māori mental health 




URA/08/12/EXP The quality of public hospital 
care for Māori and New 
Zealand Europeans in 




URB/08/08/034 Te Hoe NukuRoa: best health 




NTX/08/09/084 Te Tomokanga: a model for 
facilitating bicultural health 
policy and programme 





CEN/08/09/044 Wahine hauora – inequalities 
in uterine cancer: exploring 




LRS/08/08/036 Whakawhirinakitanga Ahua: 
exploring an iwi model of 




MEC/08/04/048 He Kakano: Māori views and 
experiences of fertility, 
reproduction, and ART 
Dr. Paul Reynolds Approved 
MEC/08/09/098 Ngā Tohu o te Ora: traditional 
Māori wellness outcome 
measures 
Maui Hudson Approved 
NTX/08/11/113 Māori whanau experiences of 
neonatal intensive care 
services 
Dr. Jenny Lee Approved subject to 
conditions 






Approved subject to 
conditions 
MEC/08/04/041 Does cross-sectoral 
collaboration hold the key to 
Māori achieving their 
environmental goals?  Using 
mahinga kai as the vehicle for 
exploring opportunities 
Dr. Gail Tipa Ethical approval not 
required 
MEC/08/04/040 Clinical characteristics of 





MEC/07/02/028 He Puawaitanga mo te Mana o 
te Whanau: Mental healthcare 
‘responsiveness’ to Māori 
Louise Ihimaera Approved 
MEC/07/04/050 Health measurement and 
knowledge translation for 
improved Māori health 
outcomes. 
Ms. Liane Penney Approved 
MEC/07/08/110 Growing up Kapo Māori: 
whanau, identity, cultural well-
being and health. 
Dr. Nancy Higgins Approved 
NTX/07/07/075 Barriers and enablers for 
Māori experiencing the 
colorectal cancer pathway 
from diagnosis to treatment 
through the Waikato Cancer 
Ms. Kay Berryman Approved 
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Services, Waikato Hospital: 
PIS/Cons V#2, 5/09/07. 




Ms. Liane Penney Approved 
NTY/07/07/072 A pilot study of the impact of 
oranga niho on quality of life of 
rangatahi Māori. 
Assoc Prof John 
Broughton 
Approved 
CEN/07/03/015 Health, cultural and social 
experiences of Māori affected 
by chemical-related illness. 
Dr. Cherryl Smith Approved 
NTX/07/11/115 Survey of SIDS-related infant 
care practices in Māori 
families. 
Dr. David Tipene- 
Leach 
Approved subject to 
conditions 
CEN/07/07/048 Pukapuka Hauora: Māori 
parents’ experiences managing 
a child with asthma. 
Bernadette Jones Approved 
LRS/07/04/007 The principles of Māori 
directed practice and 
development. The 
development of a tikanga 
Māori informed community 
development evaluation 
framework. 
Mr. Anaru Eketone Approved 
CEN/06/02/006 Older Māori and medication 
management, regulation and 
facilitation: characteristics, 
influences, indicators and 
attitudes of medication taking 





CEN/06/02/009 Cognitive behavioural therapy 
(CBT) in Aotearoa: CBT for 
depression with Māori tangata 
whaiora 
Dr. Simon Bennett Approved 
CEN/06/06/058 A community-based health 
needs assessment of the oral 
health needs of Māori mothers 
enrolled with a Wellington-




CEN/06/10/085 A cultural approach to music 
therapy in New Zealand: a 
Māori perspective 
Dennis Kahui Approved 




•      defines cultural based 
experiences in the 
environment that can be used 
as a preventative intervention 
to enhance Māori health and 
well-being 
•      develops tools to assess 
the effect of different types of 
Dr. Gail Tipa Approved 
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cultural based experiences in 
the environment on Māori 
health and well-being 
•      develops a framework for 
applying the tool and 
collecting data about health 
outcomes for Māori resulting 
from application of such an 
intervention. 
MEC/06/01/008 Māori women’s access to the 
national cervical screening 
pathway and Breastscreen 
Aotearoa screening pathways 
Ms. Nicole Coupe Approved 
MEC/06/02/010 Te Tomokanga, acceptable 
child/ adolescent mental 
health services for New 
Zealand Māori 
Kahu McClintock Approved 
MEC/06/03/026 The Māori community heart 
study 
Suzanne Pitama Approved 
MEC/06/10/113 A formative investigation of 
the impacts of gambling, 
including problem gambling, 
on Māori communities, 
whanau/hapu/iwi: a national 
Māori collaborative approach 
Naina Watene Approved 
MEC/06/10/125 Organisational pre-requisites 
to fund, implement, and 
sustain a Māori health 





NTX/06/17/CPD The burden of renal disease in 
Māori with diabetes in South 
Auckland. 
Dr. Mark Marshall Approved 
NTY/06/08/072 Evaluation of Manaaki 






NTY/06/11/115 Community-based medical 
education: benefits and 
drawbacks from students, PGY 
1 HOs (house officers), 
teaching GPs, practice staff and 
Māori and non- Māori patients 
Dr. Tana Fishman Approved 
MEC/06/03/019 The role of resiliency in 
responding to blood-borne 
viral and sexually transmitted 
infections in indigenous 
communities 
Dr. Clive Aspin Approved 
CEN/06/05/035 The experiences of a group of 
rangatahi Māori with 
psychosis during the Tuakiri o 
te Tangata programme 
Ms Menetta 
TeAonui 
Approved subject to 
conditions 
MEC/06/07/069 Upper gastrointestinal cancer 
in Māori and non-Māori 
Dr. Lis Ellison- 
Loschmann 




NTY/06/12/130 He Kete Korero: Māori health 
researcher and provider views 
on Kaupapa Māori and 
validation frameworks 
Dr. Leonie Pihama Approved subject to 
conditions 
NTY/06/11/123 Does cardiovascular 
rehabilitation improve the 
quality of life for Māori? 
Ms. Helen Wihongi Approved subject to 
conditions 
MEC/06/10/130 Health measurement and 
knowledge translation for 
improved Māori health 
outcomes 
Dr. Robyn Manuel Deferred 
NTY/06/04/027 Outcome evaluation of the 
centre for continuing 
education’s iwi and Māori 
community initiatives project 




Ethical approval not 
required 





CEN/05/09/070 Reliability of diagnoses of 
schizophrenia in Māori and 
non-Māori pilot study 
Dr. Tai Kake Approved 
LRS/05/02/001 Inheritance of type 2 diabetes 
in the Parata Whanau 
Miss Emma Wyeth Approved 
MEC/05/03/036 Raranga Whatumanawa: 
Research services on mental 
injury in survivors of sexual 
abuse: diagnosis and 
rehabilitation guidelines 
Cheryl Wooley Approved 
MEC/05/06/072 Identifying barriers to car 
driver licensing among Māori 
Dr. Dorothy Begg Approved 
MEC/05/11/156 Cognition and 
Psychopathology in Māori 
diagnosed with Schizophrenia: 
follow-up study 
Dr. Anna Bashford Approved 
MEC/05/12/174 Rakaipaaka Health and 
Ancestry Study 
Dr. Rod A Lea Approved 
NTX/05/05/048 Depression and Māori: 
experiences regarding 
antidepressant medication: a 






NTY/05/02/009 A proposal for Foreign Studies 
Fellowship: a Brown 
University – University of 
Auckland co-operative pilot 
investigation of the 
traditional/western medicine 
interface in contraceptive 





NTY/05/03/011 The best of both worlds? An 
exploration of the relationship 
between kaupapa Māori and 
participatory action research 
















NTY/05/10/077 Ko taku iwi tuaroa tena – key 
factors in decision-making 





NTY/05/12/100 To improve our understanding 
of tangata whaiora Māori and 
whanau needs from mental 
health inpatient services when 
acutely unwell. This project 
aims to identify factors that 
contribute to better outcomes 
for Māori when admitted to Te 
Whetu Tawera (TWT), 
Auckland City Adult Inpatient 
Mental Health, Auckland 
District Health Board (ADHB). 
Ms. Julie Maria 
Wharewera- Mika 
Approved 
URA/05/10/122 Marlborough Māori experience 
in accessing mental health 
services via primary 
healthcare: an exploratory 
study 
Lorraine Eade Approved 
URA/05/11/145 A profile of Māori engaged 
with opiate substitution 




URA/05/11/147 Māori consumers perspectives 
on genetic research 
Suzanne Pitama Approved 
URA/05/11/149 The design, implementation, 
and evaluation of a heart 
disease and diabetes education 





URB/05/08/102 Tissue bank: investigation into 
possible biological reasons for 
the discrepancy in cancer 
survival of Māori vs non-Māori 
in New Zealand 
Dr. Gabi Dachs Approved 
URB/05/10/136 Resilient indigenous health 
workforce networks: 




Approved subject to 
conditions 
NTX/05/03/023 Māori cardiac and stroke 
rehabilitation study 
Ms. Helen Wihongi Completed 
CEN/05/02/007 Nga Mokai Whānau Ora Mr. Denis O'Reilly Deferred 
MEC/05/09/118 (Retrospective review) Māori 
and assisted human 
reproduction: an exploratory 
study 
Dr. Marewa Glover Deferred 
URA/05/08/088 Māori and physical activity in 
Marlborough: part 2 of the 
research project carried out 
for Maata Waka ki Wairau Inc. 
Ms. Melissa Love Ethical approval not 
required 




Transferred to M/C 
committee 
13/CEN/51 Promoting health literacy on 






to improve health outcomes 
for Samoan people 
13/STH/75 TALANOA Samoa Dr. Vili Nosa Approve 
13/NTA/12 PIF:CYP Professor Janis 
Paterson 
Approve 
12/CEN/73 Pilot Study: Metabolic Growth 
and Development of Pacific 
Children 
Dr. Edward Saafi Approve 





NTX/12/EXP/092 Malaeola – Pacific family 





NTY/12/EXP/009 The perceived barriers to 
following dietary advice in 
Pacific Island women with 
diabetes in pregnancy, in the 





CEN/11/03/011 Validation of the WHO Alcohol 
Smoking Substance 
Involvement Screening Test 





CEN/11/EXP/005 Pacific Peoples and Their 





MEC/11/02/018 Pacific mental health services: 
Improving service 
responsiveness to meet the 




MEC/11/EXP/062 Primary Care for Pacific People 





NTX/11/02/006 A pilot study: Pacific peoples' 
awareness and understanding 
of rheumatic fever: PIS/Cons 
V#2, 15/03/11 
Ms. Nancy Naea Approved 
NTY/11/03/031 Gapatiaga i le maliu: examining 
customs and cultural practices 
that support Samoan men and 
their aiga through 
bereavement. 
Mr Byron Malaela 
Sotiata Seiuli 
Approved 
NTY/11/06/066 The experience of depression 
in the Tokelauan culture 
Dr. Iain Loan Approved 
NTY/11/EXP/061 Online Mental Health 





CEN/10/EXP/27 Exploring if Samoan men make 
any lifestyle changes following 





LRS/10/11/059 Infertility in Samoa and its 
relationship to chlamydial 
infection 
Professor Philip C 
Hill 
Approved Subject to 
Conditions 
NTX/10/12/124 Suicidal behaviours and 
ideation amongst Samoan 
people:  the journey towards 





NTX/10/EXP/058 The epidemiology of rheumatic 




Approved subject to 
conditions 
CEN/10/EXP/17 HEHA  Community Action 
Project: A Case Study of how 
HEHA was Implemented 
Among Pacific Communities in 
the Hutt Valley 
Ms. Milli Burnette Approved 
MEC/10/055/EXP Developing a Pacific mental 





NTX/10/10/100 A prospective randomised 
controlled, open two-group, 
one-year feasibility trial of 
personal trainer facilitated 
individually tailored gym 
based structured resistance 
exercise programme, in 
comparison to usual care for 
Pacific adults diagnosed with 





URB/10/10/037 Pacific people and non-
financial factors 
influencing access to 
mainstream general practice 
services 
Dr. Lynley Cook Approved 
NTY/10/11/092 Pacific Islands Families Study: 
Hearing Status of 11-year-olds 
(PIF: HS) 
Dr. Janis Paterson Approved Subject to 
Conditions 
CEN/09/10/076 Community reintegration of 
Male Pacific Prisoners with 
Mental Health Issues : A Public 
Health Perspective 
Mr. Sione Feki Approved 
NTY/09/09/083 Quality Of Life Amongst Pacific 
People Living With 
Type 2 Diabetes Mellitus In 
New Zealand. 
Ms. Claire O'Brien Approved Subject to 
Conditions 
NTX/09/13/EXP 
Evaluation of the Enua Ola 
Pacific Community HEHA 
Project: PIS/Cons V#1 
30/1/09 
Dr. Janet Clinton Re-confirmed 
MEC/08/07/076 Transnationals in Pacific 
health through the lens of 
tuberculosis 
Dr. Judith Littleton Approved 
MEC/08/61/EXP Consumers with chronic 
conditions and chronic 
conditions and care: 





NTX/08/04/034 A profile of traditional Pacific 
tattooing in New Zealand 
Dr. Leti Lima Approved 
NTX/08/09/087 Qualitative study of older 
Pacific informal caregivers of a 
child or young person with a 
chronic illness or disability: 
PIS/Cons V#4, 15/10/08 





NTX/08/16/EXP Adherence to medication: data 
analysis of two Pacific general 
practices 
Dr. John Kennelly Approved 
NTX/08/17/EXP Adherence to medication in a 
Pacific general practice: 
qualitative review and nurse-
led intervention 
Dr. Kuinileti Chang 
Wai 
Approved 





NTY/08/04/027 Factors that support 
abstinence or responsible 
alcohol consumption amongst 





NTY/08/04/035 Pacific Islands families study: 




NTY/08/04/037 Process mapping with families 
of Pacific mental health 
consumers in a community 




CEN/08/05/025 How do Samoan people with 
type 2 diabetes mellitus who 
need insulin for good 
glycaemic control, come to 






MEC/08/09/103 Exploring Samoan women’s 
attitudes towards antenatal 





NTX/08/05/044 Validation of the Edinburgh 
postnatal depression scale as a 
screening tool for postnatal 
depression in Samoan and 
Tongan women: PIS/Cons V#3, 
17/06/08 
Dr. Alec J Ekeroma Approved 
NTY/08/29/EXP An innovative approach to the 
treatment of subcutaneous 
panniculitis-like T-cell 
lymphoma in Polynesian 
patients with cyclosporine 
achieves excellent outcomes in 
comparison to those treated at 
the Mayo clinic 
Dr. Jovina Goh Approved 
NTX/08/09/088 An evaluation of a pictorial 
childhood asthma medication 
plans for supporting asthma 




Approved subject to 
conditions 
NTY/08/12/119 The core Pacific Islands 
families study: towards 
adolescence (PIF: TA) 
Dr. Janis Paterson Approved Subject to 
Conditions 
NTY/08/12/118 Pacific Island families study: 
nutrition, body size and 
physical activity of 9-year-old 
children (PIF:NBS-2) 
Dr. Janis Paterson Approved Subject to 
Conditions 
NTX/08/78/EXP Project to scope Pacific matua 
advisory capacities within 
Dr. Tamasailau 
Suaalii-Sauni 





CEN/07/06/039 Skin and wound management 
in the homes of Pacific children 





NTX/07/05/031 Use of the Case-finding and 
Help Assessment Tool (CHAT) 
to assess mental health and 
violence issues in Pacific 
populations in Auckland: 
Questionnaire and PIS/Cons 
V#2, 24/05/07: Cons for 




NTX/07/05/050 Health of Pacific children: 
environmental and nutritional 
determinants (Healthy End): 




NTX/07/28/EXP Evaluation of the Pacific 
Islands Heartbeat’s health 
promoting churches health 
promotion programme. 
Dr. Janet Clinton Approved 
NTX/07/32/EXP Evaluation of the Auckland 
Pacific community project: 
PIS/Cons V 23/03/07. 
Dr. Janet Clinton Approved 
NTX/07/76/EXP Pacific Island community 
support workers role in 
mental health services 
(ADHB). 
Siosinita Alofi Approved 
NTY/07/05/048 An exploratory study of factors 
that influence the retention of 
Pacific health professionals 
working in Pacific community 
health providers and primary 





NTY/07/22/EXP Review of the setup and 
rationale for the ‘Malaga a le 





NTY/07/87/EXP A review of Pacific cultural 
formulation tools utilised by 
WDHB for cultural assessment 
work alongside DSMIV cultural 
assessment statements – 




NTY/07/23/EXP Audit of the ‘Matalafi Matrix’ 
cultural formulation tool in 





CEN/07/08/054 The SPIRIT study: South 
Pacific Islanders resist 
diabetes with intense 
resistance training: a 
randomised controlled trial. 
William Sukala Approved subject to 
conditions 
MEC/07/11/161 Development of a provider 
self- evaluation tool for Pacific 
alcohol and other drug (AOD) 
Dr. Tamasailau 
Suaalii-Sauni 





NTY/07/07/085 How do attitudes, beliefs, and 
perceptions of Tongan asthma 
patients in Auckland influence 
access to primary healthcare? 
Ms. Tenisia Hager Approved 
CEN/06/17/CPD Pacific youth health 
perspectives 
Ana Fonua Approved 
NTY/06/02/006 Samoans and disabilities study Mr. Nite Imakulata 
Fuamatu 
Approved 
NTY/06/11/121 Pacific smoking cessation: 
exploring issues to increase 
the quit rate of Pacific smokers 




URA/06/02/016 Evaluation of pilot Pacific 
community project 
Chris Mene Approved 
LRS/06/09/034 Monitoring antibiotic 
resistance in Samoa 
Ms. Pauline Norris Approved subject to 
conditions 
NTY/06/11/117 Cook Island community 
leaders talk about their 
community’s determinants of 
health 
Mr. John Natua Approved subject to 
conditions 
NTY/06/10/096 Exploring Pacific attitudes to 
food, food consumption, 





NTX/06/03/021 Dimensions of the 
nasolacrimal duct by 
computed tomography in 





MEC/05/05/061 The development of a self-
assessment tool for use by 
Pacific providers 
Dr. Gail Robinson Approved 
NTX/05/04/032 Process evaluation of a 
framework for services to 
assess a range of Pacific 
service models of care within 
the Pacific alcohol and other 
drugs (AOD) sector: PIS/Cons 
V#2, 26/4/05 
Dr. Gail Robinson Approved 
NTX/05/05/044 Why Pacific patients do not 
attend (‘DNA’) outpatient 
clinics in the Counties 
Manukau District Health Board 





NTX/05/09/122 Fijian Indian patients’ 
understanding on diabetes; 
how they self-manage and 
their views on a culturally 
tailored educational 
intervention: PIS/Cons V#4, 
7/11/05 
Ms. Faieza Ali Approved 
NTX/05/12/159 Pacific Islands families: 
nutrition and body size of six-
year-old Pacific children 
(PIF:NBS): PIS/Cons V#2, 





NTX/05/03/016 An observational study of the 
impact of long-acting 
risperidone microspheres in 
Māori and Pacific people with 
schizophrenia and related 
psychotic disorders: ADHB 
PIS/Cons V#4, 26/9/05: 
Wai/C-M DHB IS/Cons V.5, 
27/1/06 
Dr. Wayne Miles Approved 
CEN/05/12/097 Effects of ‘back migration’ on 
atopic markers and asthma 
symptoms in Tokelauans: a 
pilot study 
Dr. Robert Siebers Approved subject to 
conditions 
MEC/05/10/127 Learning communities. 
Searching for 'Pacific" 
solutions: a community-based 
intervention project to 




Approved subject to 
conditions 
13/CEN/45 Executive Functioning, Social 
Cognition and Adaptive 
Behaviour in Children with 
Fetal Alcohol Spectrum 
Disorders (FASD) 
Ms. Andi Crawford Approve 
13/NTA/74 Music therapy to support the 
well-being of young people 
with intellectual disability 
Dr. Daphne J. 
Rickson 
Approve 
13/NTB/34 Advance Care Planning and 
Intellectual Disability 
Ms. S Brandford Approve 
13/NTB/85 A screening study to identify 
adult and adolescent 
individuals with Down 
Syndrome for eligibility to 
participate in a future Drug 




13/STH/94 Cervical and Breast Screening 






Relationship education and 
intellectual disability 
Ms. Cate Shields Approve 
URA/12/06/022 Developing a legal system 
responsive to the needs to 





MEC/11/EXP/127 The Mental Healthcare of 
People With a Dual Disability 
of Mental Illness and 
Intellectual Disability: A 
Comparative Study of the 
Mental Health Inpatient 
Experience of People with Dual 
Disability, Carers, and Nurses 
Mrs. Chris Taua Approved 
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NTX/11/EXP/152 A comparison of the 
differences with fitness to 
stand trial between mentally 
disordered and intellectually 
disabled defendants within the 
New Zealand Criminal Justice 
System 
Dr. Joseph Allan 
Sakdalan 
Approved 
NTX/11/EXP/272 Audit of children with Down 
Syndrome and sleep 
disordered breathing - use and 
acceptability of CPAP 
Ms. Amy Doherty Approved 
URA/11/02/004 Aging with an intellectual 
disability in New Zealand: 
Experiences, perspectives, and 
future planning for individuals 
living with family/whanau 
Ms. Henrietta Trip Approved 
URA/11/08/045 Prevention of falls for adults 
with intellectual disability 
(PROFAID)  
Dr. Leigh Hale Approved 
URB/11/EXP/035 Local impact of antenatal 
screening for Down Syndrome 
and other conditions on 
diagnosis and outcomes in a 
Fetal Medicine Centre 
Dr. Rosemary Reid Approved 
CEN/11/02/04 Pilot Study to Assess Nocturnal 
Sleep Duration in Children 
with Prader-Willi Syndrome 
and Normal Controls, and 
relationship to Daytime 
Activity 
Dr. Shiree Gibbs Approved 
CEN/11/EXP/090 A better understanding of the 
deaths of people with 
intellectual disability.  
Dr. Stuart Todd Ethical approval not 
required 
MEC/11/EXP/031 An audit of New Zealand's 
intellectual disability specialty 
in-patients units: focusing on 
antipsychotic medication use 
Ms. Sarah Moana 
Skipper 
Ethical approval not 
required 
NTY/11/EXP/022 10-year trends in Down 
Syndrome diagnosis in 
Auckland 
Dr. Karena de 
Souza 
Ethical approval not 
required 
MEC/10/086/EXP CCS Disability Action: Article 
19 Project 
Mr Paul Milner Approved Subject to 
Conditions 
MEC/10/030/EXP The Incidence of Down 
Syndrome in NZ Pacific Births 




NTX/10/04/029 Constructing the lives of 'care 
recipients' under the 
Intellectual Disability 
(Compulsory Care and 
Rehabilitation) Act 2003:  a 
discourse analysis: PIS/Cons 
V#4, 24/05/10 
Ms. Amanda Smith Approved 
NTY/10/EXP/071 Improved Health Outcomes for 
Ageing People with Intellectual 
Disability Pilot. 
Dr John Parsons Ethical approval not 
required 
LRS/09/10/040 Assessment of central GABA-B 
function in subjects with Down 






LRS/09/11/052 Assessment of cognitive 





NTY/09/06/048 Acquisition of 
periodontopathic bacteria in 




URA/09/04/029 Living with Diabetes and 
intellectual disability: Self-
management practices 
Dr. Lisa Whitehead Approved 
URA/09/06/040 The use of oral health services 
by adults with Intellectual 
disability who required a 
general anaesthetic for dental 
treatment over a five-year 
period in Christchurch, and the 
perceptions of their guardians 
and support people relating to 





MEC/08/10/118 Access to ACC for people with 
pre-existing disabilities 
(physical, blind/ vision 
impaired and intellectual) 
Sally Duckworth Approved 
NTX/08/10/093 Body composition in children 
and young persons with Down 
syndrome: comparison of 
DEXA, bioelectrical impedance 
analysis, and anthropometry: 
PIS/Cons V#2, 11/08 
Dr. Sarah Loveday Approved 
NTY/08/24/EXP Suitability of actuarial and 
structured professional 
judgment risk assessment 
measures for the regional 
forensic intellectual disability 
service of the Waikato DHB 
Mr. Chris Floyd Approved 
URA/08/06/EXP Prenatal detection rate and 
outcome of Downs Syndrome 
pregnancies in Canterbury 
1991–2007 
Dr. Nigel Anderson Approved 
CEN/07/07/050 Exploration of nurses’ 
experiences of using a pre-
admission pack for people 
with intellectual disabilities in 
the Day of Surgery Department 
of Palmerston North Hospital. 
Dina Cole Ethical approval not 
required 
NTY/07/40/EXP Five-year trends in Down 
Syndrome diagnosis in 
Auckland. 
Dr. Yvonne Lake Ethical approval not 
required 
LRS/07/11/042 Transforming notions of 
disability – a qualitative 
evaluation of the joint IHC/CCS 
“Our stories” community 
education project. 
Dr. Nancy Higgins Approved 
LRS/07/06/EXP Prevalence of chronic 
conditions causing 
developmental disability in 
children in the province of 
Otago and the assessment of 
their service provisions. 
Muhammed 





MEC/07/05/070 Incidence of and risk factors 
for falls in adults with 
intellectual disability: a pilot 
study. 
Dr. Leigh Hale Approved 
MEC/07/50/EXP Working in intellectual 
disability services.  Phase I: 
staff retention and turnover. 
Dr. Nancy Higgins Approved 
NTY/07/06/063 Pilot testing new measures of 
a) quality of care and b) 
quality of life for people with 
intellectual and physical 





LRS/07/05/021 A case study on the use of the 
levonorgestrel intrauterine 
device (Mirena) in an 
adolescent with an intellectual 
disability. 
Dr. Helen Paterson Completed 
CEN/06/06/044 The lived experience of 
supporting a family member 
with an intellectual disability 
who is dying in a community 
setting: an interpretive 
analysis of family member’s 
accounts 
Ms. Susan Marlow Approved 
LRS/06/02/001 Preventing falls in people with 
intellectual disability: an 
innovative clinical placement 
combining theory, practice and 
research 
Dr. Leigh Hale Approved 
NTX/06/09/114 Core affect and its role in the 
maintenance of subjective 
well-being of people with 
intellectual disability: 
PIS/Cons V#1, 18/09/06. 
Ms. Kathleen Jane 
Martindale 
Approved 
URA/06/07/045 Responding to the mental 
health needs of people with an 
intellectual disability: a pilot 
education programme for 
nurses 
Dr. Caroline Mohr Approved 
URB/06/08/058 Exploring counseling for 
clients with a mild intellectual 





CEN/06/07/072 Analysing inter-agency activity 
– a case study examining the 
relationship between a health 
and education state sector that 
provides services for children 
with special needs 
Carlene Receveur Ethical approval not 
required 
URB/05/05/059 Impact of the use of the 
functional health assessment 
tool (TFHAT) by direct-care 
staff on the interface between 
people with an intellectual 
disability and their general 
practitioner 
Ms. Henrietta Trip Approved 
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MEC/05/12/164 Peer abuse in group homes for 
adults with intellectual 
disabilities 
Dr. Anne Bray Approved subject to 
conditions 
13/CEN/79 The composition of breast milk 
according to different 
ethnicities of individuals living 
in New Zealand 
Dr. Christine Butts Approve 
13/NTA/185 Innate Immune Defects in 





13/NTB/36 Cultural Adaptation of the QPS 
Battery and GICS 
Ms. Karen Hayman Approve 
13/CEN/202 Transforming & Healing 









13/STH/57 Genetic background of 





13/STH/189 The Familial Rheumatic Heart 
Disease Study 
Dr. Nigel Wilson Approve 
12/NTA/91 Impact of a promotional DVD 
on bowel screening uptake for 




12/NTB/22 A whanau approach to health 
and well-being 
Dr. Anna Rolleston Approve 
12/NTA/9 TAK875 in Asia Pacific 
Subjects with Type 2 Diabetes 
Dr. John Baker Approve 
NTY/12/02/017 The management of metastatic 
prostate cancer in high health 




MEC/12/EXP/046 National retrospective audit of 
perinatal outcomes including 
Caesarean section, NICU 
admission, readmission and 
mortality in relation to 





URB/12/EXP/020 Normal range of 
exophthalmometric values and 
interobserver variations 
across various ethnic and age 
groups 
Dr. Kathleeya n 
Stang-Veldhouse 
Approved 
NTY/12/06/050 Incredible years specialist 
service – an evaluation of the 
efficacy of adding a manualised 
enhancement service to 
improve outcomes for high-
risk families/ whanau 
attending the incredible years 
parent programme 
Ms. Dianne Lees Approved 
MEC/12/EXP/003 Examination of the 
experiences of older people 
with dementia and their 
family/whanau/caregivers and 
staff during admission to an 
acute hospital unit 
Dr. Kay de Vries Approved 
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NTX/12/EXP/017 Ethnic differences in creatinine 
generation in South Auckland 
peritoneal dialysis patients 
Ms. Tina Sun Approved 
NTX/12/EXP/034 To examine the prevalence of 
HLA DQ2/DQ8 positivity 
among different ethnicities 
particularly Asian extracts 
from HLA DQ2/DQ8 tissue 
typing 
Dr. John Hsiang Approved 
NTY/12/EXP/022 How can the costs of providing 
care for family and whanau 
within a palliative care context 




Ethical approval not 
required 
NTY/12/EXP/005 A retrospective observational 
study on growth discordancy 




Ethical approval not 
required 
CEN/11/EXP/022 Healthcare provider's 
perspective of the effect of 
stigma and cultural values on 
reporting an incident of 
exposure to patient's blood 
and body fluid in NZ" 
Mr. Moazzam Zaidi Approved 
CEN/11/EXP/024 Teaching the Generalisable 
Skills of Cultural Competency: 
A New Educational 
Intervention in NZ 
Ms. Katy Thomas Approved 
MEC/11/02/016 Determining whether the 
paraplegin haplotype which is 
thought to be causing 
hereditary spastic paraplegia 





MEC/11/EXP/094 The Impact of Ethnicity on 
Maternal Serum Markers for 
Aneuploidy Screening in Māori 




MEC/11/EXP/125 Questionnaire Study: "Whanau 
opinion on tamariki 




NTX/11/EXP/062 Improving support for 
families/whanau of clients 
post stroke (phase two):  
longitudinal study of 
experiences of family/whanau 
members 
Dr. Dianne Roy Approved 
NTX/11/EXP/117 Family/Whanau involvement 
in goal setting and 
rehabilitation outcomes: 
PIS/Cons V#1, 7/06/11 
Ms. Jamie Taylor Approved 
NTX/11/EXP/204 Indexing integration of health 
and social services for young 
children in Tairawhiti 2:  




NTX/11/EXP/225 Incidence of melanoma in 
Māori and Pacific Island 
population in the Counties 
Tien Ming Lim Approved 
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Manukau District Health Board 
area in Auckland, New Zealand 
NTX/11/EXP/252 Evaluation of 'Tomorrow's 
Clinical Leaders' - a leadership 
training programme for Māori 
nurses and midwives 
Julian King Approved 
NTX/11/EXP/315 Growing Our Own:  Using a 
sector partnership model to 
build the Māori and Pacific 
Health workforce in Aotearoa 
New Zealand 
Jenna Clarke Approved 
NTY/11/08/084 Articulating cultural practice 





NTY/11/EXP/053 "The usefulness of a cultural 
framework to guide treatment 
for people with 
Methamphetamine Problems - 
Clinical Perspectives" 
Ms. Peti Murray Approved 
CEN/11/09/054 Whanau Pakari : A Multi-
Disciplinary Intervention 
Programme for Child and 




MEC/11/EXP/022 What do family / whanau of 
people with mental health and 
addiction issues think about 
smoke-free mental health and 
addiction services?: A 




MEC/11/EXP/061 Research Question: How is 
decision-making by whanau 
altered when the birth plan is 
repeat caesarean section? 
Dr. Patricia Boyd Approved 
NTX/11/EXP/143 Managing cultural diversity in 
CMDHB a key driver for 
effective service delivery 
Rachna Sudhakar Approved 
NTX/11/EXP/033 Surveys to evaluate the 
effectiveness of a change in the 
pain management protocol for 
Intramuscular Penicillin 
injections for children, 
adolescents and young adults 




NTX/11/12/113 Evaluation of an Innovative 
Sleep Intervention for The 
Prevention of Sudden 
Unexpected Death in Infancy in 
a cohort of Māori and Pacific 




Approved Subject to 
Conditions 
NTX/11/EXP/301 "It's not just about heart 
failure":  optimising the 
Primary Healthcare (Practice 
Nurse) role as a Navigator in 
supporting patients with 
multiple long-term conditions 








CEN/10/EXP/32 Analysing discourse in 
intercultural health settings: 






NTX/10/03/020 Evaluation of Waitemata DHB 
child disability service project 
for culturally and linguistically 




LRS/10/07/029 Association of ethnicity and 
levator ani muscle elasticity 
with avulsion injury following 
vaginal delivery 
Dr. Vivien Wong Approved 
MEC/10/008/EXP Implementing the Rheumatic 
Fever Guidelines:  Identifying 





NTX/10/EXP/009 Acute predict: evaluation of 
differences in incidence & 
method of revascularisation by 
ethnicity in patients with acute 
coronary syndromes 
Dr. Andrew Martin Approved 
NTX/10/EXP/038 Epidemiology of pharyngeal 
group A streptococcus in acute 
rheumatic fever household 
contacts in Auckland, 2008-
2009 
Dr. Brigid O'Brien Approved 
NTX/10/EXP/100 The epidemiology of rheumatic 





NTX/10/EXP/133 Development of an ethnicity 
data audit tool for primary 
healthcare; PIS/Cons V#2, 
5/8/10 
Dr. Dale Bramley Approved 
NTY/10/02/013 A cross-sectional observational 
study of the timing and pattern 
of emergence of permanent 
teeth in children of different 
ethnic origin between the ages 




NTY/10/10/078 The adult legacy of Acute 
Rheumatic Fever; Rheumatic 
Heart Disease and its 
complications in the Eastern 
Bay of Plenty 2000 – 2009. 
Dr. John Malcolm Approved 
NTY/10/EXP/090 Abdominal aortic aneurysm 
survival trends  and ethnicity 




NTY/10/03/018 Congenital Hypothyroidism 
Screening – Are we preserving 
Intellectual Function? 
Dr. Paul Hofman Approved Subject to 
Conditions 
MEC/10/093/EXP Compliance with CPAP in 
obstructive sleep aponea: 
effects of ethnicity and 








NTY/10/EXP/004 A descriptive observational 
study to determine if there are 
any differences in ethnicity of 
individuals presenting to 
Auckland City Hospital late 
after stroke (greater than 24 
hours after symptom onset) in 
comparison to individuals 
presenting to hospital early 
after stroke (less than 24 
hours after symptom onset) 
during 2009.  
Ms. Anna McRae Ethical approval not 
required 
NTX/10/09/097 Can we reduce Māori and 
Pacific School Children's 
hospitalisations to Pakeha 





NTX/10/EXP/067 Screening for kidney disease 
amongst family/whanau of 
people with stage 4 or 5 
advanced kidney disease 
Dr. John Collins Approved 
NTX/10/EXP/071 Improving support for 
families/whanau of clients 
post CVA/stroke:  a 
longitudinal study 
Dr. Dianne Roy Approved 
NTY/10/04/040 Patients’ and their 
whanau/families’ perspectives 
of hospital care on one hospital 
ward in one District Health 
Board.  
Dr. Elizabeth Finn Approved 
NTY/10/EXP/025 Understanding the perceptions 
of Māori and Pacific Island 
parents towards childhood 
immunisations. 
Mr. Liesje Donkin Approved 







NTY/10/EXP/045 Complications related to 
Obesity in THJR and TKJR in 
Māori and Pacific Island 
population at Counties 
Manukau DHB between June 
1999 and June 2005. 
Dr. Simon Kim Approved Subject to 
Conditions 
URA/10/EXP/068 Examining ethnic differences 
in psychiatric inpatient care in 
Māori and non-Māori patients 
diagnosed with Schizophrenia 





of echocardiographic diagnosis 
of rheumatic heart disease 
Dr. Nigel Wilson Approved 
NTX/09/152/E 
XP 
The epidemiology of rheumatic 







Analysis of ethnic variation of 
breast size in correlation to 
BMI in Auckland 
Mr. David Moss Approved 
NTX/09/179/E 
XP 
The impact of ethnicity and 








Transposition of the Great 
Arteries: Incidence and 
Ethnicity 
Dr. Tom Gentles Approved 
NTX/09/84/EX P 
Ethnic differences in the 
duration of untreated 
psychosis and referral patterns 
in patients presenting to an 
early psychosis intervention 
team 
Dr. Ian Soosay Approved 
CEN/09/11/091 The Effect of Ethnicity, 
Socioeconomic Status, Health 
Literacy and Self- Efficacy on 
Compliance to Continuous 
Positive Airway Pressure 
Therapy for Obstructive Sleep 
Apnoea 
Jessie Bakker Approved 
NTY/09/10/099 Cross-cultural communication 
with patients in the hospital 
setting. 
Dr.  Jeremy 
Rossaak 
Approved Subject to 
Conditions 
NTY/09/113/EXP Epidemiology of Rheumatic 
Heart Disease in New Zealand 
children and Young adults 
1994- 2008. 
Dr. Rachael Webb Approved Subject to 
Conditions 
NTY/09/90/EXP Morbidity of New Zealand 
Children admitted to the 
Paediatric Cardiology Unit 
with Acute Rheumatic Fever or 
Rheumatic Heart Disease over 
a 2 year period. 
Dr. Nigel Wilson Approved 
Subject to Conditions 
NTX/09/156/E 
XP 
A 10-year review of outcomes 
for surgical treatment of 
development dysplasia of hips 
between patients of European 
origin and Māori/Pacific 





Task one: exploring the voices 
of parents and whanau, 
increasing our understanding 
of families' experiences by 
listening to families involved 
in paediatrics palliative care  
Ms. Erin Gaab Approved 
NTY/09/06/055 Understanding barriers to 
accessing immunisation for 
whanau/families who are 
referred to the Outreach 
Immunisation Service as being 
overdue for immunisation. 
Dr. Nikki Turner Approved 
URB/09/02/001 
START Evaluation – Is  
Involving caregiver and 
family/whanau an effective 
treatment strategy to reduce 
sexual abuse symptomology 
and what evidence exists of 
dissociative symptomology 







Whanau/Family and Health 
Professionals' Perspectives on 
Paediatric end-of-life care 
planning at Starship Children's 
health: PIS/Cons V#2, 
06/09/2009 
Ms. Jess Jamieson Approved  
MEC/08/01/004 Investigation of biological 
factors in colon tumours from 
cancer patients self-identified 
as Māori, Pacific Islander, and 
New Zealand European in New 
Zealand 
Assoc Prof John 
Koea 
Approved 
MEC/8/04/051 The socioeconomic factors 
associated with food security 
and physical activity for Māori 




NTX/08/94/EXP Clinical presentation of 
nasopharyngeal carcinoma: is 
there a fundamental biological 
difference in the pattern of 
presentation between Asians 
and Pacific Islanders 
(including Māori)? 
Mr. Louis Lao Approved 
CEN/08/06/EXP An exploratory study 
investigating the acquisition of 
'cultural competence' at the 
organisational level to enable 
delivery of culturally safe 
services in the mental health 
sector. 
Miss Naomi Aporo Approved 
NTX/08/120/EXP Improving the quality of 




NTY/08/21/EXP The influence of cultural 
background on health beliefs 
and condition management in 




MEC/07/38/EXP Family/whanau views on 





NTY/07/07/086 A best practice package: early 
intervention for whanau 
violence (Phase I). 
Erana Cooper Approved 
NTX/07/12/127 Exploring the culture of safety 
in the influence of nursing 
leadership in the 
contemporary healthcare 
organisation in New Zealand 
(pilot study): PIS/Cons V#4, 
1/08. 
Ms. Deborah Rowe Approved 
URA/07/04/030 An exploration of the 
relationship between culture 
and fatigue for people living 
with chronic obstructive 
pulmonary disease. 
Ruth Haynes Approved 
329 
 
CEN/07/04/020 Characterisation of plaque 
development in Māori, Pacific, 
and NZ European children 
with high caries and without 
caries by analysing the 
microbiota of plaque 
microcosm biofilms grown in a 
laboratory-based artificial 
mouth plaque culture system 




Approved subject to 
conditions 
NTX/07/06/053 A randomised trial of 
adjunction intensive 
psychological, dietary and 
cultural management versus 
standard guidelines based care 
to maximise weight loss 
among high-risk subjects with 
type 2 diabetes mellitus and 
morbid obesity treated with 
bariatric surgery. Protocol 
V#1, 25/05/07: 
Protocol/amendment V#2 
23/11/07 + Questionnaires: 
Prot. Synopsis V#3, 11/01/08: 
PIS/Cons V#4, 11/01/08. 
Dr. Brandon Orr- 
Walker 
Approved 
CEN/07/24/EXP The cultural, age and injury 
demographics of clients using 
the Back Institute (TBI) at each 
of their Wellington clinics and 
how did the clients find out 
about TBI services. 
Alec Beresford Completed 
MEC/07/01/011 Acute rheumatic fever and 
household crowding in New 
Zealand. 
Richard Jaine Approved 
NTY/07/52/EXP Outcomes of valve surgery for 
rheumatic heart disease in 
children: 1990–2005. Phase 
one: retrospective review. 
Dr. Rachel Webb Approved 
NTX/06/24/CPD Nutrition labels: 
understanding and use by 
ethnicity and income in New 
Zealand: PIS V#2, 13/12/06, 
Survey V#3, 20/12/06. 
Dr. Cliona Ni 
Mhurchu 
Approved 
NTY/06/03/017 Prevalence of neuroleptic-
induced movement disorders 
in psychotic patients within 
Northland DHB: ethnic 
variation 
Hossam Mahmoud Approved 
URB/06/10/078 Tissue bank: Is there a 
molecular link between cancer 
and metabolic syndrome to 
explain ethnic disparities in 
cancer survival in New Zealand 
Dr. Gabi Dachs Approved 
MEC/06/01/007 Determinants of inequalities in 
breast cancer survival 
Dr Mona Jeffreys Deferred 
LRS/06/09/033 A New Zealand experience of 
men in a bi-cultural 
therapeutic community 
Karl Meyer Approved 
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NTY/06/05/032 Individualised growth 
assessment in different ethnic 
groups: an observational 
ultrasound study of fetal 
growth 
Dr. GK Parry Approved 
MEC/06/06/063 Whakanui Orana: using the 
New Zealand Disability 
Strategy as a framework for 
strategic policy development 





NTY/06/12/140 Ethnic women’s experience of 







MEC/05/03/039 Improving stroke recovery for 





NTX/05/02/010 An intervention for changing 
symptom perceptions of 
European and Māori women 




MEC/05/06/069 Differential colon cancer 
survival by ethnicity in New 
Zealand 
Diana Sarfati Approved 
MEC/05/07/082 SoFIE-PRIMARY CARE: 
structure of primary care, 




MEC/05/07/085 Unequal Treatment – the role 
of health services 
Bridget Robson Approved 
NTX/05/11/141 The influence of demographic 
factors, injury severity and 
fatigue on post-traumatic brain 
injury employment outcome in 
a New Zealand population: 




CEN/05/03/CPD Assessing response to the free 
heart check campaign in Māori 
and Pacific men over 35: what 
are the barriers to care? 
Adnan Bilgrami Completed 
NTY/05/10/079 Public health and integration 
of first nations at the time of 






Ethical approval not 
required 
NTX/05/07/081 An evaluation of four 
community service 
organisations in Tai Tokerau 
(Northland) New Zealand: 
PIS/Cons V#2, 21/7/05 
Ms. Tina Darkins Approved 
NTX/05/10/129 The EASAP study: evaluation 
of asthma in a South Auckland 
population. Diagnosing asthma 
accurately and assessing 
severity in a South Auckland 
population of asthmatics – do a 
range of investigations 







research environment have 
clinical relevance and lead in 
turn to better management? 
PIS/Cons V#2, 18/10/05 
NTX/05/10/140 Accommodation needs and 
preferences for 
consumers/tangata whai ora 
of mental health services: 





NTY/05/11/083 Bridging the gap: multicultural 





MEC/05/03/031 Rheumatic fever monitoring in 
New Zealand 
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Appendix B-1: Survey questions 
(The questions provided below come from a pdf created by the electronic survey 
platform, this PDF includes awkward page breaks hat do not reflect how the survey 




























































































































































Appendix C-1: Institutional Ethnography - Methods  
An institutional ethnographic method collects information from informants, texts, and 
experiences in the field and brings these together to understand the “ruling relations” 
guiding actions of varying people translocally through textual and discursive media 
(Campbell et al., 2006; Smith, 2005).  
In using this institutional ethnographic method, I interviewed 11 participants (see sampling 
below), gathered texts from universities, ethics committees, the Performance Based 
Research Fund239 website, and research funders (see list below) and took field notes (2014-
2016). Field notes reflected my experiences in research administration, research 
governance and research practice at the University of Otago and Otago Polytechnic 
campuses.  
Ethics and Māori Consultation 
I completed the University of Otago Ngāi Tahu Research Committee process for Māori 
consultation.  The committee responded and gave approval (Appendix C) with a comment 
regarding the collection of ethnicity data and reporting back findings, which I agreed to 
positively. The Otago University Ethics Committee (Human) approved the project 
(Appendix C). 
Sample  
I used purposive and snowball sampling in this project. People who undertook health 
research with groups who identified as Māori, Pasifika, LGBTQ, or who worked with groups 
who had learning disabilities, mental health issues, youth health issues, drug and alcohol 
addiction, or researchers working on the social determinants of health and who met one or 
more criteria for seniority were invited to take part by email and the email included a 
request to pass this on to other suitable researchers. Seniority was defined as: 
- Position in university of Senior Research Fellow/Senior Lecturer or higher 
- Evidence of multiple grant success, including one from the main funder or 
equivalent 
- Publication record  
- 10+years practical experience 
- Role as “research expert” on government or NGO committee 
                                                        
239 A research evaluation exercise in New Zealand tied to funding, similar to the Research Excellence 
Framework (REF) in the United Kingdom and the Excellence in Research for Australia (ERA), in 
Australia. All three measure research performance against metrics (largely to do with publications, 
citations and research funding) and distribute government funding based on scores. 
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This selection of inclusion criteria meant that informants  were experienced researchers 
working with marginalised populations who had had some success. The reasoning for this 
being, that success would equal, firstly more exposure to and involvement with the various 
entities that are involved in the health research system with ongoing relationships created 
through funding contracts and producing outputs related to those contracts. Secondly, a 
degree of savviness about how to navigate that system, i.e. an awareness of what is needed 
to get results. Thirdly, a length of time in which they may have seen changes occur within 
the system. This exclusion of more novice researchers misses views of how engaging with 
the system as an early career researcher for marginalised groups may further explicate the 
ruling relations in this context and further work in this area is needed. Thirteen researchers 
responded eleven of whom were interviewed (the two not interviewed, were due to time 
and one self-identifying an unsuitability).  As can be seen from the table below (Table 17), 
these participants were researchers who worked with Māori, Pasifika, youth, mental health 
and addictions, and people with learning disabilities. Participants who worked with LGBTQ 













































                                                        
240 It is of note, that New Zealand is an extremely small research community.  For some of these 
groups there are only a handful of researchers who met the criteria and so this may have been 









Table 17 - Sampling Summary 
Those interviewed were overwhelmingly women.  The majority worked at a university and 
had more than ten years’ experience.  Those who did not work for a university worked 
either within a charitable organisation or were self-employed contractors working for 
NGOs and government bodies.  Seven were in permanent positions (both full and part-time) 
and four worked in fixed-term or contract-based roles (both full- and part-time). The 
participants identified in some cases as researchers for more than one marginalised group 
(i.e. youth and mental health or Māori & Youth), which reflects the intersectionality of 
disadvantage.  
Texts 
In addition to talking to researchers who work with marginalised groups, I utilised the 
following websites and texts: 
1) Health Research Council New Zealand 
a. Website (www.hrc.govt.nz ) 
b. Statement of Intent (2010-2013) 
c. Investment Signals 
d. Annual Reports (2006-2013) 
e. HRC Strategic Plan (2008-2013) 
2) National Ethics Advisory Committee 
a. Website (www.neac.govt.nz ) 
b. Māori Research Ethics (2012) 
c. Streamlined Guidelines for Interventional and Observational Studies (2012) 
3) Health and Disability Ethics Committee  
a. Website (http://ethics.health.govt.nz/ ) 
b. Standard Operating Procedures 
c. Parliamentary review and submissions 
4) University websites and documentation (with health research activity) 
a. Otago University (www.otago.ac.nz) 
b. Auckland University (www.auckland.ac.nz ) 
c. Waikato University (www.waikato.ac.nz ) 
d. Victoria University (www.victoria.ac.nz ) 
e. Massey University (www.massey.ac.nz ) 
f. Auckland University of Technology (www.aut.ac.nz ) 
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5) Government Ministry and Offices’ websites and documentation 
a. Tertiary Education Commission – Performance-Based Research Funding 
http://www.tec.govt.nz/Funding/Fund-finder/Performance-Based-
Research-Fund-PBRF-/  
b. Ministry of Health (www.moh.govt.nz ) 
c. Ministry of Social Development (www.msd.govt.nz ) 
d. Office for Disability Issues (www.odi.govt.nz)  
e. Accident Compensation Corporation (Government-owned) (www.acc.co.nz ) 
f. PHARMAC (www.pharmac.govt.nz)  




Experiences and Perspective 
I identify as a Pakeha, female migrant who has gained New Zealand citizenship. I am a 
developing intersectional feminist with broad professional and personal interests in social 
justice and activism.   Before my PhD enrollment and then during my studies, I had 
employment in various health research administration (research administrator), 
governance (ethics committee member and Vice-Chair), and assistance (research assistant 
and assistant research fellow) roles across Otago University and Otago Polytechnic in 
Dunedin. I took field notes of my attendance at various seminars, funding roadshows, 
workshops and interactions with research governance structures. I also wrote reflections 
on how my professional experience has informed and guided my research and determined 
my perspective in reviewing transcripts and documentation, to be able to utilise this within 
the analysis. My point of view naturally sides with that of the participants, given my 
experiences within the health research system. 
Analysis 
To begin the analysis, I read interview transcripts alongside interview notes written 
immediately after each interview reflecting on the conversation. These notes had also been 
added to after I transcribed each interview, providing another point in time to consider 
nuance and meaning. I sought descriptions of informants’ experiences of practice in 
interviews that were rich enough to be used to analyse the conditions in which they 
occurred.  I then searched these experiences or entry points to the problematic for 
similarities and differences between participants. From here, I scrutinised these groupings 
of experiences alongside relevant institutional texts, which led back to transcripts for 
further experiences and back to the texts (as a reflexive process). This back and forth is the 
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two-level process of the institutional ethnography; the first level being the accessing of 
experience, the second being the examination of that experience beyond the personal 
within the context of the institutional environment (Campbell, 2002). I discussed the 
categorisation and analysis for coherence with supervisors. From the relationship between 
the categories of experience to the conditions in which they were created based on the 
interviews, texts, personal experience, fieldwork, and literature, I formulated a theory of 
ruling relations within the framework Dorothy Smith created (Campbell et al., 2006; Smith, 
2005).   
 
